
<html lang="en"     class="pb-page"  data-request-id="c4560877-a5c8-4f72-98f4-3a7aeba420d0"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;article:article:10.1021/acs.jmedchem.6b01774;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text;issue:issue:10.1021/jmcmar.2017.60.issue-7"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="First Bispecific Inhibitors of the Epidermal Growth Factor Receptor Kinase and the NF-κB Activity As Novel Anticancer Agents" /></meta><meta name="dc.Creator" content="Mostafa M.  Hamed" /></meta><meta name="dc.Creator" content="Sarah S.  Darwish" /></meta><meta name="dc.Creator" content="Jennifer  Herrmann" /></meta><meta name="dc.Creator" content="Ashraf H.  Abadi" /></meta><meta name="dc.Creator" content="Matthias  Engel" /></meta><meta name="dc.Description" content="The activation of the NF-κB transcription factor is a major adaptive response induced upon treatment with EGFR kinase inhibitors, leading to the emergence of resistance in nonsmall cell lung cancer..." /></meta><meta name="Description" content="The activation of the NF-κB transcription factor is a major adaptive response induced upon treatment with EGFR kinase inhibitors, leading to the emergence of resistance in nonsmall cell lung cancer..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="March 28, 2017" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.6b01774" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2017 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.6b01774" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.6b01774" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.6b01774" /></link>
        
    
    

<title>First Bispecific Inhibitors of the Epidermal Growth Factor Receptor Kinase and the NF-κB Activity As Novel Anticancer Agents | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.6b01774" /></meta><meta property="og:title" content="First Bispecific Inhibitors of the Epidermal Growth Factor Receptor Kinase and the NF-κB Activity As Novel Anticancer Agents" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01774/20170407/images/large/jm-2016-01774z_0016.jpeg" /></meta><meta property="og:description" content="The activation of the NF-κB transcription factor is a major adaptive response induced upon treatment with EGFR kinase inhibitors, leading to the emergence of resistance in nonsmall cell lung cancer and other tumor types. To suppress this survival mechanism, we developed new thiourea quinazoline derivatives that are dual inhibitors of both EGFR kinase and the NF-κB activity. Optimization of the hit compound, identified in a NF-κB reporter gene assay, led to compound 9b, exhibiting a cellular IC50 for NF-κB inhibition of 0.3 μM while retaining a potent EGFR kinase inhibition (IC50 = 60 nM). The dual inhibitors showed a higher potency than gefitinib to inhibit cell growth of EGFR-overexpressing tumor cell lines in vitro and in a xenograft model in vivo, while no signs of toxicity were observed. An investigation of the molecular mechanism of NF-κB suppression revealed that the dual inhibitors depleted the transcriptional coactivator CREB-binding protein from the NF-κB complex in the nucleus." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.6b01774"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.6b01774">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.6b01774&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.6b01774&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.6b01774&amp;href=/doi/10.1021/acs.jmedchem.6b01774" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2017</span><span class="cit-fg-volume">, 60</span><span class="cit-fg-issue">, 7</span><span class="cit-fg-pageRange">, 2853-2868</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/60/7" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.6b00326" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.6b01805" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">First Bispecific Inhibitors of the Epidermal Growth Factor Receptor Kinase and the NF-κB Activity As Novel Anticancer Agents</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Mostafa+M.++Hamed">Mostafa M. Hamed</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Sarah+S.++Darwish">Sarah S. Darwish</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jennifer++Herrmann">Jennifer Herrmann</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Ashraf+H.++Abadi">Ashraf H. Abadi</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Matthias++Engel">Matthias Engel</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>∥</sup></span><span class="loa-info-orcid"><a href="http://orcid.org/0000-0001-5065-8634" title="Orcid link"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img></a></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-symbol">†</span> <span class="aff-text">Pharmaceutical and Medicinal Chemistry, Campus C2.3, and Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), Saarland University, Campus E8.1, D-66123 Saarbrücken, Germany</span></div><div class="aff-info" id="aff2"><span class="aff-symbol">‡</span> <span class="aff-text">Department of Pharmaceutical Chemistry, Faculty of Pharmacy and Biotechnology, German University in Cairo, Cairo 11835, Egypt</span></div><div class="aff-info" id="aff3"><span class="aff-symbol">§</span> <span class="aff-text">Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), Campus E8.1, D-66123 Saarbrücken, Germany</span></div><div class="aff-info" id="aff4"><span class="aff-symbol">∥</span> <span class="aff-text">Pharmaceutical and Medicinal Chemistry, Saarland University, Campus C2.3, D-66123 Saarbrücken, Germany</span></div><div class="corresp-info"><strong>*</strong>Phone: +49 681 302 70312. Fax: +49 681 302 70308. E-mail: <a href="/cdn-cgi/l/email-protection#0568642b606b62606945687d2b706b6c287664647769646b612b6160"><span class="__cf_email__" data-cfemail="7e131f501b10191b123e1306500b1017530d1f1f0c121f101a501a1b">[email protected]</span></a></div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.6b01774&amp;href=/doi/10.1021%2Facs.jmedchem.6b01774" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2017</span></span><span class="cit-volume">, 60</span><span class="cit-issue">, 7</span><span class="cit-pageRange">, 2853–2868</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">March 14, 2017</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>8 December 2016</li><li><span class="item_label"><b>Published</b> online</span>28 March 2017</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 13 April 2017</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.6b01774" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.6b01774</a></div><div class="article_header-article-copyright"><strong>Copyright © 2017 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D2853%26pageCount%3D16%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DMostafa%2BM.%2BHamed%252C%2BSarah%2BS.%2BDarwish%252C%2BJennifer%2BHerrmann%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D60%26issueNum%3D7%26contentID%3Dacs.jmedchem.6b01774%26title%3DFirst%2BBispecific%2BInhibitors%2Bof%2Bthe%2BEpidermal%2BGrowth%2BFactor%2BReceptor%2BKinase%2Band%2Bthe%2BNF-%25CE%25BAB%2BActivity%2BAs%2BNovel%2BAnticancer%2BAgents%26numPages%3D16%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D2868%26publicationDate%3DApril%2B2017">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.6b01774"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">1431</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">14</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.6b01774" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;First Bispecific Inhibitors of the Epidermal Growth Factor Receptor Kinase and the NF-κB Activity As Novel Anticancer Agents&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Mostafa&quot;,&quot;last_name&quot;:&quot;M. Hamed&quot;},{&quot;first_name&quot;:&quot;Sarah&quot;,&quot;last_name&quot;:&quot;S. Darwish&quot;},{&quot;first_name&quot;:&quot;Jennifer&quot;,&quot;last_name&quot;:&quot;Herrmann&quot;},{&quot;first_name&quot;:&quot;Ashraf&quot;,&quot;last_name&quot;:&quot;H. Abadi&quot;},{&quot;first_name&quot;:&quot;Matthias&quot;,&quot;last_name&quot;:&quot;Engel&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2017&quot;,&quot;month&quot;:&quot;03&quot;,&quot;day&quot;:&quot;28&quot;,&quot;issue&quot;:&quot;7&quot;,&quot;volume&quot;:&quot;60&quot;,&quot;pages&quot;:&quot;2853-2868&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.6b01774&quot;},&quot;abstract&quot;:&quot;The activation of the NF-κB transcription factor is a major adaptive response induced upon treatment with EGFR kinase inhibitors, leading to the emergence of resistance in nonsmall cell lung cancer and other tumor types. To suppress this survival mechanism, we developed new thiourea quinazoline derivatives that are dual inhibitors of both EGFR kinase and the NF-κB activity. Optimization of the hit compound, identified in a NF-κB reporter gene assay, led to compound 9b, exhibiting a cellular IC50 for NF-κB inhibition of 0.3 μM while retaining a potent EGFR kinase inhibition (IC50 = 60 nM). The dual inhibitors showed a higher potency than gefitinib to inhibit cell growth of EGFR-overexpressing tumor cell lines in vitro and in a xenograft model in vivo, while no signs of toxicity were observed. An investigation of the molecular mechanism of NF-κB suppression revealed that the dual inhibitors depleted the transcriptional coactivator CREB-binding protein from the NF-κB complex in the nucleus.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.6b01774&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.6b01774" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.6b01774&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.6b01774" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.6b01774&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.6b01774" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.6b01774&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.6b01774&amp;href=/doi/10.1021/acs.jmedchem.6b01774" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.6b01774" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.6b01774" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (3 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.6b01774&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.6b01774%26sid%3Dliteratum%253Aachs%26pmid%3D28291344%26genre%3Darticle%26aulast%3DHamed%26date%3D2017%26atitle%3DFirst%2BBispecific%2BInhibitors%2Bof%2Bthe%2BEpidermal%2BGrowth%2BFactor%2BReceptor%2BKinase%2Band%2Bthe%2BNF-%25CE%25BAB%2BActivity%2BAs%2BNovel%2BAnticancer%2BAgents%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D60%26issue%3D7%26spage%3D2853%26epage%3D2868%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=290896" title="Cells">Cells</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=291793" title="Inhibition">Inhibition</a>,</li><li><a href="/action/doSearch?ConceptID=291788" title="Reaction products">Reaction products</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/60/7" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/jmcmar.2017.60.issue-7/20170413/jmcmar.2017.60.issue-7.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01774/20170407/images/medium/jm-2016-01774z_0016.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01774/20170407/images/large/jm-2016-01774z_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01774&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">The activation of the NF-κB transcription factor is a major adaptive response induced upon treatment with EGFR kinase inhibitors, leading to the emergence of resistance in nonsmall cell lung cancer and other tumor types. To suppress this survival mechanism, we developed new thiourea quinazoline derivatives that are dual inhibitors of both EGFR kinase and the NF-κB activity. Optimization of the hit compound, identified in a NF-κB reporter gene assay, led to compound <b>9b</b>, exhibiting a cellular IC<sub>50</sub> for NF-κB inhibition of 0.3 μM while retaining a potent EGFR kinase inhibition (IC<sub>50</sub> = 60 nM). The dual inhibitors showed a higher potency than gefitinib to inhibit cell growth of EGFR-overexpressing tumor cell lines in vitro and in a xenograft model in vivo, while no signs of toxicity were observed. An investigation of the molecular mechanism of NF-κB suppression revealed that the dual inhibitors depleted the transcriptional coactivator CREB-binding protein from the NF-κB complex in the nucleus.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i1">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_04520" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_04520" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Inhibition of the epidermal growth factor (EGF) receptor kinase-mediated signaling is a well-established strategy for the treatment of advanced stage nonsmall cell lung cancer (NSCLC). EGFR was found to be overexpressed in about 62% of NSCLC cases, which correlated with a poor prognosis.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> However, in most cases, the clinically used EGFR kinase inhibitors, such as gefitinib and erlotinib, are only effective if the tumor cells harbor specific activating EGFR mutations which appear to preserve the ligand-dependency of receptor activation but alter the pattern of downstream signaling.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> These EGFR mutations include mainly small in-frame deletions in exon 19, or the single point mutation L858R,<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> and are found in ∼10–50% of NSCLC patients, depending on the ethnicity and the tumor subtype.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> Of those, about 75% show a response to the small molecule inhibitors compared to ∼10% in the wild-type case.<a onclick="showRef(event, 'ref2 ref3'); return false;" href="javascript:void(0);" class="ref ref2 ref3">(2, 3)</a> Hence, only a minor proportion of lung cancer patients can actually profit from the treatment with EGFR inhibitors.</div><div class="NLM_p">In addition, tumors showing an initial response to treatment with EGFR inhibitors often become resistant due to acquisition of a mutation in the ATP binding pocket of EGFR (T790M), which mainly decreases the <i>K</i><sub>m</sub> for ATP, thus out-competing the binding of gefitinib.<a onclick="showRef(event, 'ref2 ref4'); return false;" href="javascript:void(0);" class="ref ref2 ref4">(2, 4)</a> Alternatively, tumor cells might activate distinct pro-survival signaling pathways, as exemplified by the amplification of MET in lung cancers treated with EGFR inhibitors.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a></div><div class="NLM_p">Triple-negative breast cancer was considered another potential indication for EGFR kinase inhibitors because they are not amenable to endocrine or ErbB2 (HER2)-directed therapies,<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> while they overexpress EGFR kinase, paralleling the loss of estrogen receptor dependency.<a onclick="showRef(event, 'ref7 ref8'); return false;" href="javascript:void(0);" class="ref ref7 ref8">(7, 8)</a> However, inhibition of EGFR by gefitinib or erlotinib showed low efficacy in arresting tumor cell growth at the cell line level, e.g., using triple-negative MDA-MB-231 cells,<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> and results from clinical trials were disappointing.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> Nonetheless, cell line studies showed that besides EGFR overexpression, the transcription factor NF-κB becomes constitutively active in ER-negative breast cancer cells, thus ensuring cell survival in spite of EGFR inhibition. Indeed, some evidence suggested that an additive or synergistic effect could be expected from a simultaneous inhibition of both EGFR kinase and the NF-kB pathway in triple-negative breast cancer cells.<a onclick="showRef(event, 'ref11 ref12'); return false;" href="javascript:void(0);" class="ref ref11 ref12">(11, 12)</a> Notably, a crucial role of NF-κB in ensuring cell survival was also reported for other tumor types that overexpress EGFR kinase, in particular lung tumors but also head and neck squamous cell carcinomas (reviewed in ref <a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">13</a>). Using lung cancer cell lines, a large siRNA screen identified the NF-κB pathway activity as a key factor that determined the sensitivity toward EGFR inhibitors. In the same study, knockdown of several components of the NF-κB pathway enhanced cell death induced by EGFR inhibition.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> These findings were further validated in EGFR-dependent tumor models, confirming that the activation of NF-κB signaling conferred resistance to EGFR inhibitors and, conversely, that NF-κB knockdown enhanced sensitivity to the latter.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> Furthermore, it was recently shown that in EGFR-mutant lung adenocarcinoma from patients, initial EGFR inhibitor treatment led to a rapid engagement of NF-κB signaling, which promoted tumor cell survival and residual disease.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> In this study, direct pharmacologic NF-κB inhibition prevented the EGFR inhibitor-induced adaptive response, thus suppressing the emergence of EGFR inhibitor therapy resistance in several NSCLC models and in a patient-derived xenograft in vivo. These findings demonstrated that NF-κB activation is a critical adaptive survival mechanism engaged by EGFR oncogene inhibition and provided a rationale for EGFR and NF-κB coinhibition to eliminate residual disease and to extend the duration of patient responses.</div><div class="NLM_p last">While coadministration of antitumor therapeutics is a common strategy in several current cancer trials and has proven to be beneficial in some cases, toxic side effects could increase by the number of different agents.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> Moreover, the individual pharmacokinetic properties render it difficult to deliver effective amounts of multiple therapeutics to the tumor cells in a concerted manner to achieve maximum efficacy. Therefore, it would be a major advantage to combine the desired pharmacological activities in a single agent in order to simultaneously suppress the synergistic EGFR and NF-κB signaling pathways at the same time. In the following, we describe the development of dual inhibitors of EGFR kinase and the NF-κB transcriptional activity based on the 4-aminophenylquinazoline scaffold, followed by an investigation of the mechanism of NF-κB suppression. Eventually, we provide first evidence for the efficacy of the novel anticancer agents in vivo.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_70388" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_70388" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i3" class="anchor-spacer"></div><h3 class="article-section__title" id="_i3"> Identification of Hits Displaying Dual EGFR and NF-κB Inhibitory Activity</h3><div class="NLM_p">With respect to EGFR kinase inhibition, it was known from previous studies that the 4-aminophenylquinazoline motif is both essential and sufficient to mediate strong inhibition of the kinase in the nM range.<a onclick="showRef(event, 'ref17 ref18'); return false;" href="javascript:void(0);" class="ref ref17 ref18">(17, 18)</a> On the other hand, the 6- and 7-positions of the quinazoline scaffold offered possibilities for substitutions without strongly compromising the EGFR-directed potency because these positions pointed toward the outside of the ATP binding pocket (compare e.g., PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2ITY">2ITY</a>). Of note, the quinazoline heterocycle was successfully used as a scaffold for the synthesis of potent inhibitors for a range of enzymes besides protein kinases, including endothelin converting enzyme,<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> thymidylate synthase,<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> trypanothione reductase,<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> phosphodiesterases,<a onclick="showRef(event, 'ref22 ref23'); return false;" href="javascript:void(0);" class="ref ref22 ref23">(22, 23)</a> glucocerebrosidase,<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> and G9a-like protein lysine methyltransferase.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> Hence, the quinazoline system can be considered a “privileged scaffold” according to Evans et al.,<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> thus potentially suitable to serve as an affinity anchor in inhibitors of diverse enzymes, without evidence of promiscuous binding. Thus, there was some chance that new 4-aminophenylquinazoline derivatives, which are likely to retain EGFR inhibitory properties, would also inhibit one of the steps in the NF-κB activation cascade. Accordingly, a set of appropriate derivatives was prepared by us, supplemented by compounds from previous studies<a onclick="showRef(event, 'ref27 ref28'); return false;" href="javascript:void(0);" class="ref ref27 ref28">(27, 28)</a> and screened for inhibitory activity on the NF-κB activation pathway using a luciferase-based reporter gene assay. The compounds selected for the screening included derivatives with variable substitutions at the <i>N</i><sup>4</sup>-position of the aminoquinazoline nucleus, such as haloanilines, alkylanilines, sulfonamide containing anilines, and alicyclic amines (<b>I</b>-<b>II</b> in <a class="ref internalNav" href="#cht1" aria-label="Chart 1">Chart 1</a>). Another set of compounds featured at the 6-position different combinations of linkers, potentially acting as a H-bond donor/acceptor pair, as well as aliphatic or (hetero)aromatic moieties which may be accommodated in potential hydrophobic binding pockets of new target proteins. In this compound set, <i>m</i>-bromoaniline was kept constant at position 4. The linker types connecting different substituents (R in <b>III</b>-<b>VI</b>, <a class="ref internalNav" href="#cht1" aria-label="Chart 1">Chart 1</a>) to the quinazoline nucleus comprised imine (<b>III</b>), amide (I<b>V</b>), amino alkyl amide (<b>V</b>), and thiourea (<b>VI</b>) groups (<a class="ref internalNav" href="#cht1" aria-label="Chart 1">Chart 1</a>; the structures of all screened compounds are shown in <a class="ref internalNav" href="#notes-1" aria-label="Chart S1">Chart S1</a>, Supporting Information).</div><figure id="cht1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Chart 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01774/20170407/images/medium/jm-2016-01774z_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01774/20170407/images/large/jm-2016-01774z_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Chart 1. General Structures of the Quinazoline Derivatives Selected for Screening Towards the NF-κB Inhibitory Activity</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01774/20170407/images/large/jm-2016-01774z_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01774&amp;id=cht1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The reporter gene assay was performed using the lymphoma cell line U937. Because of its origin from tissue macrophages,<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> this cell line responds with a strong activation of the NF-κB pathway after stimulation by LPS or TNFα. Inhibition of any of the essential components of the conserved classical (canonical) NF-κB pathway would be expected to result in a decrease of the final luciferase activity-based read out. Moreover, it was of importance that the U937 lymphoma cell type lacks expression of EGFR, thus excluding any interference due to the intrinsic EGFR inhibitory activity of the compounds.</div><div class="NLM_p">Indeed, screening of the 4-substituted quinazoline derivatives at 10 μM led to the identification of several compounds which suppressed the NF-κB reporter gene activity in U937 cells at variable degrees (<a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>; IC<sub>50</sub>s were calculated for the compounds showing more than 80% inhibition). The most potent hit was the benzylthiourea derivative <b>VIa</b>, exhibiting almost 100% reduction of the luciferase read out (<a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>). In comparison, the reference compound gefitinib showed a considerably weaker inhibition of about 50% at 10 μM, suggesting that the structural variations had created a significant inhibitory activity on the NF-κB pathway. Importantly, <b>VIa</b> still retained a nM potency with respect to EGFR inhibition, although it was about four times reduced compared to gefitinib (<a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>). It is worth mentioning that 4-phenethylaminoquinazoline derivatives were previously reported to inhibit the NF-κB activation in Jurkat cells,<a onclick="showRef(event, 'ref30 ref31'); return false;" href="javascript:void(0);" class="ref ref30 ref31">(30, 31)</a> however, the substitution pattern and the obtained SAR were different; in particular, an ethylene spacer between the quinazoline C(4) amino function and the phenyl ring was essential for NF-κB inhibition, which would be incompatible with EGFR kinase inhibition.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> In contrast, the 4-aniline analogue was inactive toward NF-κB, suggesting the involvement of another target. However, the mechanism of NF-κB inhibition was not investigated.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Hits of the Screening of 4-Aminophenylquinazoline Derivatives for Dual Inhibition of EGFR Kinase and the NF-κB Activation Pathway</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01774/20170407/images/medium/jm-2016-01774z_0009.gif" alt="" id="fx1" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup>Table a</sup><p class="last">Values are representative of at least two independent concentration–response experiments performed in triplicate per concentration, SD < 8%.</p></div><div class="footnote" id="t1fn2"><sup>Table b</sup><p class="last">Results shown are means of at least two independent experiments, SD < 14%.</p></div></div><div></div></div></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i6" class="anchor-spacer"></div><h3 class="article-section__title" id="_i6"> Screening of Hit Compound <b>VIa</b> against Kinases Directly Involved in TNFα Receptor Signaling</h3><div class="NLM_p">At this stage, it was straightforward to screen the most potent hit, <b>VIa</b>, against a panel of kinases specifically involved in NF-κB activation in U937 cells<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> in order to test whether selective inhibition of one of those kinases was responsible for the novel activity. Only one kinase in the panel shown in <a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>, RIPK-2, was weakly inhibited by <b>VIa</b>; however, with the estimated IC<sub>50</sub> above 10 μM at an ATP concentration of 5 μM in the assay, RIPK-2 was unlikely to be a target of this compound in cells. Thus, we could conclude that compound <b>VIa</b> did not affect a kinase which is directly involved in TNFα receptor signaling. The results also showed that <b>VIa</b> did not exhibit nonselective kinase inhibition, which encouraged us to carry out an optimization of the potency guided by the NF-κB reporter gene assay.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Selectivity Profiling of <b>VIa</b> against the Kinases Associated with the TNFα Receptor Complex in U937 Cells<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="left" /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">kinase</th><th class="colsep0 rowsep0" align="center" char=".">% activity at 10 μM<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">kinase</th><th class="colsep0 rowsep0" align="center" char=".">% activity at 10 μM<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">IKKα(h)</td><td class="colsep0 rowsep0" align="char" char=".">117</td><td class="colsep0 rowsep0" align="left">RIPK2(h)</td><td class="colsep0 rowsep0" align="char" char=".">54</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">IKKβ(h)</td><td class="colsep0 rowsep0" align="char" char=".">100</td><td class="colsep0 rowsep0" align="left">SAPK2a(h)</td><td class="colsep0 rowsep0" align="char" char=".">78</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PKCι(h)</td><td class="colsep0 rowsep0" align="char" char=".">106</td><td class="colsep0 rowsep0" align="left">TAK1(h)</td><td class="colsep0 rowsep0" align="char" char=".">106</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PKCζ(h)</td><td class="colsep0 rowsep0" align="char" char=".">92</td><td class="colsep0 rowsep0" align="left">TBK1(h)</td><td class="colsep0 rowsep0" align="char" char=".">92</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup>a</sup><p class="last">Values represent the mean of two experiments, SD < 5%. All kinases were tested using ATP concentrations at the respective <i>K</i><sub>M</sub> values.</p></div></div></div></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i8" class="anchor-spacer"></div><h3 class="article-section__title" id="_i8"> Chemistry</h3><div class="NLM_p">The identified hit compound <b>VIa</b> was subject to optimization by a targeted synthesis of analogues. Our modifications centered on the substituents at the 4-anilino ring, the side chain attached to the thiourea linker and the thiourea linker itself (<a class="ref internalNav" href="#sch1" aria-label="Schemes 1">Schemes 1</a> and <a class="ref internalNav" href="#sch2" aria-label="2">2</a>, <a class="ref internalNav" href="#cht2" aria-label="Chart 2">Chart 2</a>).</div><figure id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01774/20170407/images/medium/jm-2016-01774z_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01774/20170407/images/large/jm-2016-01774z_0006.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 1. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01774/20170407/images/large/jm-2016-01774z_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01774&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (i) TEOF, (Ac)<sub>2</sub>O, reflux, 16 h; (ii) R-NH<sub>2</sub>, CH<sub>3</sub>COOH, reflux, 1 h; (iii) SnCl<sub>2</sub>, MeOH, reflux, 30 min; (iv) PhCH<sub>2</sub>-NCS, DMF, rt, 5 h.</p></p></figure><figure id="sch2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01774/20170407/images/medium/jm-2016-01774z_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01774/20170407/images/large/jm-2016-01774z_0007.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 2. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01774/20170407/images/large/jm-2016-01774z_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01774&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (i) S═CCl<sub>2</sub>, HCl (ii) Ar-NH<sub>2</sub>, DMF, rt, 5 h; (iii) R-NH<sub>2</sub>, DMF, rt, 5 h; (iv) R-NCO, DMF, rt, 5 h.</p></p></figure><figure id="cht2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Chart 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01774/20170407/images/medium/jm-2016-01774z_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01774/20170407/images/large/jm-2016-01774z_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Chart 2. Overview on the Modifications of Hit Compound <b>VIa</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01774/20170407/images/large/jm-2016-01774z_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01774&amp;id=cht2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Synthesis of the quinazoline nucleus was done by refluxing of 5-nitro-2-aminobenzonitirile with triethyl orthoformate (TEOF) in the presence of drops of acetic anhydride to yield the formimidate derivative <b>1</b>. Cyclization to form the quinazoline nucleus took place by refluxing of <b>1</b> with different anilines in acetic acid to yield the nitroquinazoline derivatives <b>2a</b>–<b>q</b>. Reduction of the nitro intermediates <b>2a</b>–<b>q</b> to their amino derivatives <b>3a</b>–<b>q</b> was done by refluxing the nitro derivatives with stannous chloride in methanol under nitrogen atmosphere. The benzyl thiourea derivatives <b>4a</b>–<b>p</b> and <b>VIa</b> were obtained by stirring the aminoquinazoline derivatives <b>3a</b>–<b>q</b> with benzylisothiocyanate in DMF (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>).</div><div class="NLM_p">Reaction of compound <b>3q</b> with thiophosgene yielded the isothiocyanate derivative <b>5</b>, which upon stirring with different amines in DMF gave the thiourea derivatives <b>6a</b>–<b>q</b> and <b>7a</b>–<b>e</b> (<a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>). The <i>N</i><sup>4</sup>-(3-chlorophenyl) analogues of the later optimization campaign were synthesized in a similar manner (<a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>). The urea derivatives <b>8a</b>–<b>b</b> were obtained by stirring compound <b>3q</b> with different isocyanate derivatives in DMF (<a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>).</div><figure id="sch3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01774/20170407/images/medium/jm-2016-01774z_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01774/20170407/images/large/jm-2016-01774z_0008.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 3. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01774/20170407/images/large/jm-2016-01774z_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01774&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (i) S═CCl<sub>2</sub>, HCl; (ii) Ar-NH<sub>2</sub>, DMF, rt, 5 h [used for <b>9a</b>–<b>c</b>]; (iii) PhOCSCl, Ar-NH<sub>2</sub>, DMF, 1 h “used for <b>9d</b>–<b>g</b>”.</p></p></figure></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i10" class="anchor-spacer"></div><h3 class="article-section__title" id="_i10"> Optimization of Hit <b>VIa</b> As Dual Inhibitor of Both EGFR Kinase and NF-κB Activity</h3><div class="NLM_p">The optimization of the hit compound included three parts. The first part was concerned with the modifications of the substituents on the 4-anilino ring while keeping the benzylthiourea at position 6 of the quinazoline (<a class="ref internalNav" href="#cht2" aria-label="Chart 2">Chart 2</a>, <b>4a</b>–<b>p</b>). The second part focused on modifications in the side chain linked to the thiourea moiety while keeping the 3-bromoaniline at position 4 of the quinazoline (<a class="ref internalNav" href="#cht2" aria-label="Chart 2">Chart 2</a>, compound classes <b>6a</b>–<b>q</b> and <b>7a</b>–<b>e</b>). The last part was to confirm the importance of the thiourea group by replacing it with the urea moiety (<a class="ref internalNav" href="#cht2" aria-label="Chart 2">Chart 2</a>, <b>8a</b>–<b>b</b>).</div><div class="NLM_p">First, benzyl thiourea derivatives (<b>4a</b>–<b>p</b>) according to route A were explored (<a class="ref internalNav" href="#cht2" aria-label="Chart 2">Chart 2</a>). It was found that lipophilic substituents were highly preferred at the aniline ring, as the presence of polar groups impaired the activity. This was clearly seen with polar substituents such as the hydroxy (<b>4k</b> and <b>4l</b>), sulfonamide (<b>4m</b>), substituted sulfonamide (<b>4n</b> and <b>4o</b>), or even the bioisosteric pyridine (<b>4p</b>), which all exhibited markedly reduced NF-κB inhibitory activity (<a class="ref internalNav" href="#tbl3" aria-label="Table 3">Table 3</a>). It was unlikely that this was only due to decreased cell permeability. Rather, the uniform reduction of activity with the more polar moieties suggested that the 4-aminophenyl is not only important for the potency toward EGFR kinase (see SAR discussion below) but also seemed to interact with the unknown target(s) in the NF-κB pathway. With respect to the lipophilic <i>meta</i>-substituents on the aniline ring, it was found that the halogens were most favorable, with chlorine giving the highest NF-κB inhibitory activity (<b>4c</b>). This was followed by bromine (<b>VIa</b>), ethyl (<b>4f</b>), methyl (<b>4d</b>), and finally the 2,3-dimethyl (<b>4e</b>). Interestingly, the bromo substituent was tolerated in the <i>ortho</i>-, <i>meta</i>-, and <i>para</i>-position (<b>4a</b>, <b>VIa</b>, and <b>4b</b>, respectively), with a slight preference for the <i>para</i>-position. However, this was only true for the NF-κB suppression, whereas binding to EGFR strictly demanded the bromine to be in <i>meta</i> (<b>VIa</b>, <a class="ref internalNav" href="#tbl3" aria-label="Table 3">Table 3</a>, see discussion below). For the NF-κB inhibitory activity, the <i>para</i> position tolerated even more bulky groups, such as <i>t</i>-butyl (<b>4h</b>) and phenyl (<b>4i</b>), however, no further gain of activity could be achieved compared with the halogens.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Biological Evaluation of Hit Compound <b>VIa</b> Derivatives Modified at the 4-Anilino Ring</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01774/20170407/images/medium/jm-2016-01774z_0010.gif" alt="" id="fx2" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01774/20170407/images/medium/jm-2016-01774z_0011.gif" alt="" id="GRAPHIC-d46e911-autogenerated" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup>Table a</sup><p class="last">Values are representative of at least two independent concentration–response experiments performed in triplicate per concentration, SD < 8%.</p></div><div class="footnote" id="t3fn2"><sup>Table b</sup><p class="last">IC<sub>50</sub>s were determined for the compounds showing at least 50% inhibition at 150 nM.</p></div><div class="footnote" id="t3fn3"><sup>Table c</sup><p class="last">Results shown are means of at least two independent experiments, SD < 12%.</p></div></div><div></div></div><div class="NLM_p">The potency of EGFR inhibition was more critically dependent on the position of the substituents in the aniline ring. It was found that (i) the <i>meta</i> position was optimum for substitutions and (ii) that the substituents must be hydrophobic. Hence, fortunately, the SAR trend paralleled that of the NF-κB inhibition. Halogens provided the highest increase in potency, in particular chlorine (<b>4c</b>), which was slightly superior to bromine in the hit compound (<b>VIa</b>). Replacing the halogen by an alkyl group such as the methyl (<b>4d</b>) decreased the activity, which further dropped with the polar hydroxyl group (<b>4k</b>). The aminophenyl binding pocket in EGFR was completely filled by the <i>meta</i>-methylated derivative <b>4d</b>, whereas the more bulky ethyl group (<b>4f</b>) was less tolerated. Moreover, any substitutions in the <i>ortho</i>-position as in <b>4a</b> or <b>4e</b> resulted in a significantly decreased activity. Furthermore, all <i>para</i>-substitutions on the aniline also seemed to produce a steric clash with the binding pocket, irrespective to the nature of the substituent (cf. <b>4b</b>, <b>4g</b>–<b>j</b>, <b>4l</b>–<b>o</b>). On the basis of the sufficiently large overlap of the initial SAR, we concluded that optimization of the NF-κB inhibitory activity should be possible without loss of EGFR inhibition.</div><div class="NLM_p">Next we tested whether the methylene spacer between the thiourea linker and the aromatic ring was required. This was done by replacing the benzyl group as in <b>VIa</b> and <b>7c</b> by phenyl, leading to <b>6a</b> and <b>6d</b>, respectively (route B in <a class="ref internalNav" href="#cht2" aria-label="Chart 2">Chart 2</a>). As can be seen in <a class="ref internalNav" href="#tbl4" aria-label="Table 4">Table 4</a>, the nonsubstituted benzyl/phenyl pair <b>VIa</b>/<b>6a</b> showed comparable biological activities, whereas in the case of the <i>p</i>-chloro substituted matched pair <b>7c</b> and <b>6d</b>, the <i>p</i>-chorophenyl analogue <b>6d</b> was more potent than its benzyl homologue against both targets. This result suggested that the methylene group could be omitted without loss of activity and that the phenyl derivatives offered a higher potential for optimization.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Biological Evaluation of Hit Compound <b>VIa</b> Derivatives Modified at Position 6 of the Quinazoline</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01774/20170407/images/medium/jm-2016-01774z_0012.gif" alt="" id="fx3" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01774/20170407/images/medium/jm-2016-01774z_0013.gif" alt="" id="GRAPHIC-d46e1041-autogenerated" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup>Table a</sup><p class="last">Values are representative of at least two independent concentration–response experiments performed in triplicate per concentration, SD < 8%.</p></div><div class="footnote" id="t4fn2"><sup>Table b</sup><p class="last">IC<sub>50</sub>s were determined for the compounds showing at least 50% inhibition at 150 nM.</p></div><div class="footnote" id="t4fn3"><sup>Table c</sup><p class="last">Results shown are means of at least two independent experiments, SD < 12%.</p></div></div><div></div></div><div class="NLM_p">Furthermore, the importance of the thiourea group was explored by a direct comparison of the thiourea derivatives <b>VIa</b> and <b>6d</b> with their urea analogues <b>8a</b> and <b>8b</b> (route C, <a class="ref internalNav" href="#cht2" aria-label="Chart 2">Chart 2</a>). It became evident that the thiourea moiety was required for the activity toward the NF-κB pathway (<a class="ref internalNav" href="#tbl4" aria-label="Table 4">Table 4</a>) but not for EGFR inhibition. The urea motif gave more potent EGFR kinase inhibitors in the case of the benzyl substituent (cf. <b>8a</b> vs <b>VIa</b>), however, the urea and thiourea derivatives were equipotent in case of the phenyl substituent (cf. <b>8b</b> vs <b>6d</b>).</div><div class="NLM_p">Finally, we investigated if the aromatic ring linked to the thiourea moiety was essential for the activity. To this end, the aromatic ring was replaced by a methyl group (<b>7a</b>), a morpholino-4-carboxamide derivative (<b>7e</b>), and an ethyl morpholine (<b>7d</b>). Because the suppression of the reporter gene activity was much stronger with the benzyl (<b>VIa</b>) and phenyl (<b>6d</b>) analogues, it was concluded that the aromatic system significantly contributed to the NF-κB inhibitory activity (<a class="ref internalNav" href="#tbl4" aria-label="Table 4">Table 4</a>).</div><div class="NLM_p">Given that a <i>p</i>-chlorine substituent in <b>6d</b> was well tolerated, several substituents were added to the phenyl thiourea side chain in an attempt to further enhance the NF-κB inhibitory potency. First, we introduced several polar groups or heteroatoms in the phenyl ring (compounds <b>6e</b>, <b>6f</b>, <b>6g</b>, and <b>7b</b>), which all abolished the activity toward the NF-κB pathway in the U973 cells, except the hydroxyl group (<b>6e</b>) (<a class="ref internalNav" href="#tbl4" aria-label="Table 4">Table 4</a>); however, because phenolic compounds are known to affect NF-κB signaling by various, often nonspecific mechanisms,<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> this derivative was not further pursued. Hence we decided to switch to lipophilic substituents (compounds <b>6b</b>–<b>d</b>, <b>6h</b>–<b>q</b>, <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>); this modification resulted in sharp SAR, as indicated by highly variable activities depending on the size and the position of the substituents (compounds <b>6b</b>–<b>d</b>, <b>6h</b>–<b>q</b>, <a class="ref internalNav" href="#tbl4" aria-label="Table 4">Table 4</a>). Concerning the EGFR kinase inhibition, diverse substituents of either lipophilic or hydrophilic nature were tolerated, with the hydrophilic or heterocyclic moieties being the most potent (cf. <b>6e</b>, <b>6f</b>, <b>7b</b>, and <b>7d</b>). However, multiple and/or bulky lipophilic substituents on the phenyl ring (such as in <b>6i</b>, <b>6m</b>, <b>6o</b>–<b>q</b>) decreased or abolished the activity. The latter SAR were conflicting with the requirements for potent inhibition of NF-κB activation, thus it was not possible to optimize both biological activities in parallel to the same degree. Altogether, compounds <b>6c</b> and <b>6h</b> showed the best balance between EGFR inhibition and simultaneous suppression of the NF-κB activation in the reporter gene assay (<a class="ref internalNav" href="#tbl4" aria-label="Table 4">Table 4</a>).</div><div class="NLM_p last">The reference compound gefitinib, which is in clinical use for the treatment of NSCLC, was only moderately active against NF-κB in the reporter gene assay (<a class="ref internalNav" href="#tbl4" aria-label="Table 4">Table 4</a>), confirming that the inhibition of EGFR kinase was not responsible for the suppression of the NF-κB activity in the U937 cells. Moreover, several of the new compounds were considerably more potent in the inhibition of NF-κB, despite displaying lower EGFR kinase inhibition (cf. <b>6h</b>, <b>6j</b>, and <b>6l</b> in <a class="ref internalNav" href="#tbl4" aria-label="Table 4">Table 4</a>).</div></div><div id="sec2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i13" class="anchor-spacer"></div><h3 class="article-section__title" id="_i13"> Inhibition of MDA-MB-231 Breast Cancer Cell Growth</h3><div class="NLM_p">Next, we evaluated whether the dual inhibitory activity of the novel quinazoline derivatives boosts the efficacy as potential antitumor agents compared with EGFR inhibition alone. The breast cancer cell line MDA-MB-231 was chosen because it was frequently used as a model for studying the effects of EGFR inhibition in triple-negative breast cancer cells.<a onclick="showRef(event, 'ref9 ref11 ref34'); return false;" href="javascript:void(0);" class="ref ref9 ref11 ref34">(9, 11, 34)</a> Like many clinical triple-negative tumors, MDA-MB-231 cells are rather insensitive to the EGFR inhibitor gefitinib (reported GI<sub>50</sub> range for cell growth inhibition: 15–20 μM), in spite of the strong overexpression of EGFR kinase.<a onclick="showRef(event, 'ref9 ref35'); return false;" href="javascript:void(0);" class="ref ref9 ref35">(9, 35)</a> In addition, this cell line displays constitutive activation of NF-κB,<a onclick="showRef(event, 'ref11 ref12'); return false;" href="javascript:void(0);" class="ref ref11 ref12">(11, 12)</a> which is a frequent feature found in most breast cancer tumors.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a></div><div class="NLM_p last">Hence, any superior efficacy of our novel compounds should be easily detectable using this cell line. The results of the MTT assay are included in <a class="ref internalNav" href="#tbl3" aria-label="Tables 3">Tables 3</a> and <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a>; notably, two of the new compounds inhibited MDA-MB-231 cell growth more than 35 times stronger than the reference compound gefitinib (cf. <b>6h</b>, <b>6j</b>). Our data further indicated that, as a general trend, the potency to suppress MDA-MB-231 cell growth was determined by the NF-κB inhibitory activity rather than by the potency of EGFR kinase inhibition. This was obvious from the fact that, with the exception of <b>6n</b>, the most potent inhibitors of the NF-κB activation in U937 cells were also the strongest inhibitors of the MDA-MB-231 cell growth (cf. <b>6c</b>, <b>6h</b>, <b>6i</b>, <b>6j</b>, <b>6l</b>, and <b>6m</b> in <a class="ref internalNav" href="#tbl4" aria-label="Table 4">Table 4</a>), the more because among these, <b>6i</b>, <b>6j</b>, and <b>6m</b> showed only low potency against EGFR kinase. Vice versa, several congeners showing a high activity toward EGFR kinase (<b>VIa</b>, <b>6a</b>, <b>6b</b>, <b>6d</b>, <b>6e</b>, <b>6f</b>, <b>7a</b>, <b>7b</b>, <b>7d</b>, and <b>8a</b>), that were among the least potent inhibitors of NF-κB activation, inhibited the MDA-MB-231 cell growth with only moderate to poor GI<sub>50</sub>s between 8.2 and >30 μM, similarly to gefitinib. In conclusion, the suppression of the NF-κB activation was mainly responsible for the tumor cell growth inhibition.</div></div><div id="sec2_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i14" class="anchor-spacer"></div><h3 class="article-section__title" id="_i14"> Effects on A549 Lung Cancer Cells Vs Nontumor Cell Lines</h3><div class="NLM_p">The potency of the best compounds to inhibit the cell growth of the lung cancer cell line A549 was also tested. This assay was done to corroborate if the compounds with dual inhibitory activity still offer an advantage toward a cell line which is intermediately sensitive to potent EGFR inhibitors such as gefitinib. The results showed that the dual inhibitors are more potent than gefitinib in inhibiting the growth of A549 cancer cells (<a class="ref internalNav" href="#tbl5" aria-label="Table 5">Table 5</a>). Importantly, when the selected compounds were tested against nontumor cell lines (chinese hamster ovary (CHO)-K1 and human umbilical vein endothelial cells (HUVEC)), significantly weaker effects of <b>6c</b> and <b>6h</b> on the cell growth were noted, suggesting that the compounds exerted a rather tumor cell-selective cytotoxicity (<a class="ref internalNav" href="#tbl5" aria-label="Table 5">Table 5</a>). Of note, the efficacy/toxicity window was larger for <b>6c</b> and <b>6h</b> than for gefitinib with the cell lines tested.</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Tumor Cell-Selective Growth Inhibition by the Dual Inhibitors <b>6c</b> and <b>6h</b> vs Gefitinib</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="4" align="center" char=".">GI<sub>50</sub> (μM)<a class="ref internalNav" href="#t5fn1" aria-label="a">a</a></th><th class="rowsep1 colsep0" colspan="2" align="center" char=".">fold selectivity CHO vs tumor cell line</th><th class="rowsep1 colsep0" colspan="2" align="center" char=".">fold selectivity HUVEC vs tumor cell line</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center" char=".">A549</th><th class="colsep0 rowsep0" align="center" char=".">MDA</th><th class="colsep0 rowsep0" align="center" char=".">CHO</th><th class="colsep0 rowsep0" align="center" char=".">HUVEC</th><th class="colsep0 rowsep0" align="center" char=".">A549</th><th class="colsep0 rowsep0" align="center" char=".">MDA</th><th class="colsep0 rowsep0" align="center" char=".">A549</th><th class="colsep0 rowsep0" align="center" char=".">MDA</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6c</b></td><td class="colsep0 rowsep0" align="char" char=".">1.6</td><td class="colsep0 rowsep0" align="char" char=".">2.1</td><td class="colsep0 rowsep0" align="char" char=".">25.7</td><td class="colsep0 rowsep0" align="char" char=".">11.5</td><td class="colsep0 rowsep0" align="char" char=".">16.1</td><td class="colsep0 rowsep0" align="char" char=".">12.2</td><td class="colsep0 rowsep0" align="char" char=".">7.2</td><td class="colsep0 rowsep0" align="char" char=".">5.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6h</b></td><td class="colsep0 rowsep0" align="char" char=".">1.0</td><td class="colsep0 rowsep0" align="char" char=".">0.3</td><td class="colsep0 rowsep0" align="char" char=".">52.1</td><td class="colsep0 rowsep0" align="char" char=".">14.8</td><td class="colsep0 rowsep0" align="char" char=".">52.1</td><td class="colsep0 rowsep0" align="char" char=".">173.7</td><td class="colsep0 rowsep0" align="char" char=".">14.8</td><td class="colsep0 rowsep0" align="char" char=".">49.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">gefitinib</td><td class="colsep0 rowsep0" align="char" char=".">9.3</td><td class="colsep0 rowsep0" align="char" char=".">14.2</td><td class="colsep0 rowsep0" align="char" char=".">43.7</td><td class="colsep0 rowsep0" align="char" char=".">13.0</td><td class="colsep0 rowsep0" align="char" char=".">4.7</td><td class="colsep0 rowsep0" align="char" char=".">3.1</td><td class="colsep0 rowsep0" align="char" char=".">1.4</td><td class="colsep0 rowsep0" align="char" char=".">0.9</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup>a</sup><p class="last">Values are representative of three independent concentration–response experiments performed in triplicate per concentration; SD ≤ 12%</p></div></div></div></div><div id="sec2_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16"> Kinase Selectivity Profile of <b>6c</b></h3><div class="NLM_p">Because the novel dual inhibitors were developed based on a kinase inhibitor scaffold, it was straightforward to test the selectivity over other kinases and whether the suppression of the NF-κB activation was also due to inhibition of a kinase. To this end, an in vitro selectivity profiling was performed against a panel of 106 protein kinases, including both tyrosine and Ser/Thr kinases from each branch of the human kinome. For the profiling we selected <b>6c</b>, which had shown a slightly stronger EGFR kinase inhibition than <b>6h</b>. The screening results are summarized in <a class="ref internalNav" href="#notes-1" aria-label="Table S1">Table S1</a> (Supporting Information). It was found that compound <b>6c</b> exhibited an excellent selectivity for the EGFR kinase, with only a weak inhibition of two other kinases, namely Mnk2 and Pim-1. The IC<sub>50</sub>s for these two kinases were determined to be 2.7 and 1.2 μM, respectively. In the same assay campaign, the IC<sub>50</sub> for EGFR kinase was 41 nM (<a class="ref internalNav" href="#notes-1" aria-label="Table S2">Table S2</a>, Supporting Information). Interestingly, <b>6c</b> appeared to be more selective than gefitinib, as the latter had inhibited in a previously reported screening the kinases Mnk2, SIK2, Mnk1, LOK/STK10, ErbB2/HER2, RIPK2, EPHA6, and ErbB4/HER4 by 46–76% at 0.5 μM (Supporting Information, <a class="ref internalNav" href="#notes-1" aria-label="Table S3">Table S3</a> in ref <a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">37</a>). From these kinases, Mnk2, LOK, RIPK2, and ErbB4 were also present in the panel screened with <b>6c</b>, but only Mnk2 and ErbB4 were appreciably inhibited, by 78% and 54%, respectively, however at a 10 times higher concentration (5 μM). The cell-free potency of <b>6c</b> for Mnk2 inhibition appeared too low to explain the efficacy of <b>6c</b> in the cell-based NF-κB reporter gene assay (IC<sub>50</sub> = 1.9 μM). Moreover, gefitinib displayed a higher off-target inhibition of Mnk2<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> than <b>6c</b> but was less potent in our reporter gene assay. Thus, Mnk2 could be excluded as a potential target of the dual inhibitors in the NF-κB activation pathway. The inhibition of Pim-1 by <b>6c</b> was also rather weak, nevertheless, we decided to check the potential role of Pim-1 in the NF-κB activation pathway using the potent Pim-1 inhibitor SIM-4a (IC<sub>50</sub> for Pim-1: 17 nM at 100 μM ATP in the cell-free assay<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a>). Testing SIM-4a in the NF-κB reporter gene assay in concentrations from 1 to 5 μM, we could not detect any inhibition (<a class="ref internalNav" href="#notes-1" aria-label="Table S3">Table S3</a>, Supporting Information), ruling out Pim-1 as a target of <b>6c</b> in the NF-κB activation pathway.</div><div class="NLM_p last">In light of the remarkable selectivity of compound <b>6c</b>, it was rather unlikely that the new biological target was another protein kinase, although it could not be fully excluded because not the whole kinome was screened here. However, if it was a kinase, then it would be part of an unknown NF-κB activation pathway that is also induced by TNFα because all kinases identified as part of the TNFα receptor complex<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> had been included in the kinase screen, also all other kinases which had previously been mentioned in literature to play a role in NF-κB activation.</div></div><div id="sec2_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17"> Elucidation of the Mechanism of Action Responsible for NF-κB Suppression; <b>6c</b> and <b>6h</b> Do Not Inhibit the Cellular Proteasome</h3><div class="NLM_p">Having developed novel dual inhibitors, we aimed at investigating the cellular mechanism of action which was responsible for the observed suppression of NF-κB activation in the reporter gene assay, assuming that it was not the inhibition of another kinase. The most obvious biological activity to test was the potential inhibition of the cellular 26S proteasome, which is essential for the degradation of the inhibitory protein IκB.<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> The prototype of proteasome inhibitors, bortezomib, inhibits mainly two of the three distinct proteolytic activities, thus preventing the release of the NF-κB dimer.<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a></div><div class="NLM_p last">For each of the three proteolytic activities, the trypsin-like, the chymotrypsin-like, and the caspase-like, we used a specific fluorigenic peptide and total protein extract from MDA-MB-231 cells as a source of proteasomal activities, basically as described.<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> However, whereas bortezomib fully inhibited all three proteolytic activities at 1 μM, none of the test compounds showed any inhibitory activity even at 50 μM (data not shown). Thus, the three main proteolytic activities of the proteasome could be excluded as molecular targets.</div></div><div id="sec2_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> <b>6c</b> and <b>6h</b> Do Not Inhibit Translocation of NF-κB/p65 to the Nucleus</h3><div class="NLM_p last">It was theoretically possible that the compounds caused the cytoplasmic retention of the NF-κB dimer through an alternate mechanism; hence we analyzed whether the translocation of the RelA subunit (p65) of NF-κB was affected. To this end, we used a high-content screening system employing a CHO cell line stably expressing a GFP-p65 fusion protein. A cytoplasmic retention of this construct in the presence of the test compounds, as indicated by a diffuse cytoplasmic fluorescence, would signify an inhibition of the upstream NF-κB activation. The system automatically quantifies the ratio of cytoplasmic vs nuclear fluorescence and provides microphotographs of each well. The cells were first stimulated for 30 min by 25 ng/mL IL-1β, after which the translocation of the GFP-NFκB-p65 fusion protein from the cytoplasm to the nucleus was visualized. Bortezomib was used as a positive control, and gefitinib was also included for comparison. While bortezomib clearly prevented the migration of the NF-κB construct to the nucleus in a concentration-dependent manner, <b>6c</b>, <b>6h</b>, and gefitinib were completely inactive (<a class="ref internalNav" href="#notes-1" aria-label="Figure S1">Figure S1</a>, Supporting Information). To make sure that the lack of activity of the phenylthiourea derivatives was not due to solubility problems under the conditions used, Pluronic F-127 (indicated by “P”) was added in some experiments to increase the solubility at higher concentrations; however, this did not change the outcome (<a class="ref internalNav" href="#notes-1" aria-label="Figure S1">Figure S1</a>, Supporting Information).</div></div><div id="sec2_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> Compound <b>6c</b> Does Not Influence DNA Binding of NF-κB/p65</h3><div class="NLM_p last">Having ruled out that the dual inhibitors prevented the translocation of NF-κB/p65 to the nucleus, it was tempting to speculate that the DNA binding activity of the NF-κB complex was affected by the compounds. To investigate this possibility, the DNA binding capability of the NF-κB species in nuclear protein extracts isolated from MDA-MB 231 cells was analyzed using a commercial ELISA kit. This assay relied on measurement of the specific binding to the NF-κB response element oligonucleotide immobilized in a 96-well plate. The experiment was performed in two different ways: (i) MDA-MB 231 cells were incubated with <b>6c</b> for 12 h, followed by washing of the cells, isolation of the nuclear proteins, and DNA-binding analysis, and (ii) nuclear extracts were prepared from untreated cells and the DNA-binding quantified in the presence of <b>6c</b> vs DMSO. Method (i) would allow detecting any compound-induced, intrinsic down-regulation of the DNA-binding activity, whereas variant (ii) would identify a direct inhibition of DNA binding. The results of our experiments showed that <b>6c</b> did not impair the DNA-binding activity of the NF-κB complexes in the nuclear extract, neither directly nor via modulation of regulatory mechanisms (<a class="ref internalNav" href="#notes-1" aria-label="Figure S2">Figure S2</a>, Supporting Information).</div></div><div id="sec2_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20"> Compound <b>6c</b> Reduces the Amount of CREB-Binding Protein (CBP) in the NF-κB Transcription Factor Complex</h3><div class="NLM_p">One of the few remaining possibilities was that the new inhibitors interfere with the NF-κB activity at the level of transcriptional coactivators. It is known that, in order to become fully transcriptionally active in the nucleus, the NF-κB dimer recruits transcriptional coactivators such as the CREB-binding protein (CBP)/p300, which functions as a histone acetyl transferase.<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> Evidence from literature suggested that at least in some cell types, a CBP knockdown can cause a down-regulation of the NF-κB transcriptional activity without affecting nuclear translocation or DNA-binding affinity of NF-κB.<a onclick="showRef(event, 'ref43 ref44'); return false;" href="javascript:void(0);" class="ref ref43 ref44">(43, 44)</a> Hence, we decided to analyze the amount of CBP present in the DNA-binding NF-κB complex isolated from MDA-MB-231 cells that were treated with <b>6c</b>. Indeed, we found that compound <b>6c</b> but not gefitinib reduced the amount of CBP in the NF-κB transcription complex in a concentration-dependent manner (<a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>A). In the same samples, the amount of RelA/p65 bound to the immobilized NF-κB response element oligonucleotide was not changed by the compounds (<a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>B). Thus, we provide first evidence that our dual inhibitors down-regulate the transcriptional activity of NF-κB through depletion of the coactivator CBP from the transcription factor complex. However, further studies are needed to elucidate the underlying mechanism.</div><figure id="fig1" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01774/20170407/images/medium/jm-2016-01774z_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01774/20170407/images/large/jm-2016-01774z_0003.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Compound <b>6c</b> but not gefitinib reduces the amount of CREB-binding protein (CBP) in the NF-κB transcription complex. MDA-MB-231 cells were treated with compounds or DMSO for 12 h as indicated (in backets: concentration in μM). Then 5 μg of isolated nuclear proteins were analyzed for the specific binding to the NF-κB response element oligonucleotide on an ELISA plate. (A) CBP physically associated with bound RelA/p65 was detected using a specific primary antibody directed against CBP, followed by a HRP-coupled secondary antibody and colorimetric reaction. (B) The same nuclear extracts as in A were analyzed in parallel, however, anti-RelA/p65 was used as a primary antibody. OD450, optical density at 450 nm; Gft, gefitinib. The experiment was performed in triplicates; error bars indicate the SD values. One representative experiment out of three is shown, which essentially gave the same results.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01774/20170407/images/large/jm-2016-01774z_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01774&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Pharmacological disruption of the p65/CBP interaction might abolish the expression of several tumor-relevant genes. For instance, it was shown that the cooperation of p65/RelA and CBP was required for the expression of antiapoptotic genes such as cIAP2 and XIAP in rat fibroblasts<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> as well as the pro-inflammatory cytokines IL-1β and IL-6 and CSF2 in lung cells.<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a></div><div class="NLM_p">Thus, it seems possible that our novel dual inhibitors also suppress the NF-kB-mediated IL-6 expression in cancer cells. Of note, IL-6 was identified by Blakely et al. as the NF-κB target gene that was most significantly increased in the adaptive response to EGFR kinase inhibition by erlotinib, both at the mRNA and the protein level.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> This adaptive response mechanism was also confirmed in resected NSCLC.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> On the other hand, the interaction of RelA with CBP is only required for the expression of a subset of NF-κB-dependent genes,<a onclick="showRef(event, 'ref44 ref46'); return false;" href="javascript:void(0);" class="ref ref44 ref46">(44, 46)</a> which might result in lower toxicity than total inhibition of NF-κB activity, e.g., as mediated by IκB kinase inhibitors.<a onclick="showRef(event, 'ref47 ref48 ref49'); return false;" href="javascript:void(0);" class="ref ref47 ref48 ref49">(47-49)</a> Indeed, our in vitro and in vivo experiments suggested low toxicity against nontumor cells and tissues (see below). Also with respect to the therapeutic outcome, total suppression of NF-κB activity is not desirable because it will also affect the antitumor activity of T-lymphocytes in the tumor microenvironment.<a onclick="showRef(event, 'ref49 ref50'); return false;" href="javascript:void(0);" class="ref ref49 ref50">(49, 50)</a> Further studies are needed to investigate whether the thiourea quinazolines will inhibit the CBP-dependent NF-κB signaling in tumor cells sufficiently selectivity so that T cells of the M1 phenotype remain functional.</div><div class="NLM_p last">CBP is a coactivator in a multitude of transcription factor complexes; total depletion of CBP, in particular from the general transcription factors, would therefore lead to nonselective cytotoxicity, which was not observed with our dual inhibitors. This suggests a more selective modulation of CBP association by our compounds, which remains to be elucidated. Interestingly, CBP was already targeted previously by small molecules that inhibit the histone acetyltransferase activity of the protein for the therapy of leukemia.<a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(51)</a> These inhibitors also showed surprisingly little cytotoxicity, although besides histones, more than 100 proteins from a multitude of signaling pathways have been implicated as CBP acetylation substrates.<a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(52)</a></div></div><div id="sec2_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21"> Optimization of Pharmacokinetic (PK) Properties</h3><div class="NLM_p">To obtain candidates for metabolic stability and in vivo PK studies, we aimed at further optimizing the prototype dual inhibitors <b>6c</b> and <b>6h</b>. To this end, the most favorable compound features as identified in the initial phase were combined in order to increase the potency toward the NF-κB pathway. In addition, because this could result in predominantly lipophilic compounds, we aimed at enhancing the PK properties and druglikeness in parallel. As described above, a chlorine or bromine atom in the <i>meta</i> position of the 4-anilino ring was favorable for the NF-κB inhibitory activity (cf. <b>4c</b> and <b>VIa</b>, respectively, <a class="ref internalNav" href="#tbl3" aria-label="Table 3">Table 3</a>). Hence we decided to uniformly incorporate <i>m</i>-chloro due to the smaller size and more moderate impact on log <i>P</i> compared with bromine. It was furthermore favorable for the potency to include a lipophilic aromatic system on the thiourea group. Also considering metabolic stability issues, the chlorine as present in compounds <b>6c</b> and <b>6h</b> was replaced by fluorine (<b>9a</b> and <b>9b</b>). While the 3,4-difluorophenyl moiety led to reduced activities both in the NF-κB reporter gene and the EGFR kinase assay (<b>9a</b>), the 3,5-difluoro substitution (<b>9b</b>) favorably increased the potency to suppress the activation of NF-κB (IC<sub>50</sub> = 0.3 μM, <a class="ref internalNav" href="#tbl6" aria-label="Table 6">Table 6</a>) compared with <b>6c</b> and <b>6h</b> (IC<sub>50</sub>s: 1.9 and 1.0 μM, respectively). In addition, the inhibitory potency toward EGFR kinase was still in the nanomolar range (IC<sub>50</sub> = 60.1 nM). The last set of compounds aimed at the enhancement of water solubility through replacing the thiourea-linked phenyl by different <i>N</i>-heterocycles, comprising pyridine (<b>9c</b>), thiazole (<b>9d</b> and <b>9e</b>), and thiadiazole (<b>9f</b> and <b>9g</b>). To maintain a suitable balance between polarity and lipophilicity, all heterocyclic rings were decorated with a lipophilic substituent. The 3-chloropyridine (<b>9c</b>) and the electron-rich five-membered heterocycles had a distinct influence on the dual activity when compared with <b>6c</b>: while the pyridine ring slightly decreased both biological activities to a similar extent, the thiazole and thiadiazole rings reduced the potency against EGFR kinase by about 5–6-fold (<b>9d</b>–<b>g</b>, <a class="ref internalNav" href="#tbl6" aria-label="Table 6">Table 6</a>). On the other hand, the latter compounds showed preserved or even enhanced activity against the NF-κB pathway, with <b>9d</b> and <b>9e</b> exhibiting submicromolar IC<sub>50</sub>s. Altogether, aromatic heterocycles, in particular thiazole, were tolerated while enhancing the water solubility compared with the halogenated phenyl analogues (cf. <b>9d</b> vs <b>6c</b> and <b>9b</b>, <a class="ref internalNav" href="#notes-1" aria-label="Table S4">Table S4</a>, Supporting Information).</div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. Biological Evaluation of the Optimized Dual Inhibitors</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01774/20170407/images/medium/jm-2016-01774z_0014.gif" alt="" id="fx4" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01774/20170407/images/medium/jm-2016-01774z_0015.gif" alt="" id="GRAPHIC-d46e1842-autogenerated" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t6fn1"><div class="footnote" id="t6fn1"><sup>Table a</sup><p class="last">Results shown are means of three independent experiments, SD < 13%.</p></div><div class="footnote" id="t6fn2"><sup>Table b</sup><p class="last">Values are representative of at least two independent determinations based on triplicates per concentration, SD < 8%.</p></div></div><div></div></div><div class="NLM_p">The best compounds from this last optimization round, <b>9b</b>, <b>9d</b>, and <b>9e</b>, were then tested for growth inhibitory activity against MDA-MB-231 cells. While <b>9b</b> and <b>9d</b> exhibited comparable GI<sub>50</sub> values (1.1 and 0.9 μM, respectively), <b>9e</b> surprisingly lacked activity against this cell line even at 20 μM. The reason for this is unclear, but it could be possible that <b>9e</b> was unstable under the prolonged cell culture conditions.</div><div class="NLM_p">In summary, <b>9b</b> showed a balanced inhibitory profile and was the most potent compound in the NF-κB reporter gene assay (IC<sub>50</sub> = 0.3 μM). Because the substitution pattern of the phenyl was changed compared with <b>6c</b>, we eventually verified that this did not influence the kinase selectivity. It could be confirmed that the selectivity was retained or became even superior to <b>6c</b>, as indicated by the weaker inhibition of Pim-1 and ErbB4 compared with <b>6c</b> (<a class="ref internalNav" href="#notes-1" aria-label="Table S5">Table S5</a>).</div><div class="NLM_p last">The 4-(trifluoromethyl)thiazolyl analogue <b>9d</b> also exhibited a good NF-κB inhibitory activity (IC<sub>50</sub> = 0.6 μM) and efficiently inhibited MDA-MB-231 cell growth, although the activity toward purified EGFR kinase was decreased (IC<sub>50</sub> = 137 nM). However, because the potency to suppress MDA-MB-231 cell growth was mainly determined by the NF-κB inhibitory activity (cf. above), both <b>9b</b> and <b>9d</b> were selected as candidates for pharmacokinetic studies.</div></div><div id="sec2_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23"> Pharmacokinetic Evaluation in Vitro and in Vivo</h3><div class="NLM_p">First, the in vitro metabolic stability of lead compounds <b>9b</b> and <b>9d</b> was evaluated using rat liver microsomes. After incubation for defined periods, the remaining percentage of parent compound was determined by LC-MS/MS. Half-life and intrinsic clearance were calculated for the test compound and the two reference compounds diazepam and diphenhydramine (<a class="ref internalNav" href="#tbl7" aria-label="Table 7">Table 7</a>). Although <b>9d</b> was considerably less stable than <b>9b</b>, reaching only the half-life and predicted clearance of diphenhydramine, it was conceivable that this disadvantage might be compensated by the higher water solubility (<a class="ref internalNav" href="#notes-1" aria-label="Table S4">Table S4</a>, Supporting Information). In contrast, <b>9b</b> displayed higher stability in the microsomal assay than the reference drug diazepam, however, there was only a slight improvement of the water solubility compared with <b>6c</b> (<a class="ref internalNav" href="#notes-1" aria-label="Table S4">Table S4</a>, Supporting Information). Because of their complementary properties, <b>9d</b> and <b>9b</b> were both included in the in vivo PK study. As shown in <a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a> and <a class="ref internalNav" href="#tbl8" aria-label="Table 8">Table 8</a>, <b>9b</b> showed a good plasma half-life of about 7.8 h, and the compound was not completely eliminated after 24 h. Despite the lower water solubility, the AUC of <b>9b</b> was more than 5-times higher than that of <b>9d</b> (<a class="ref internalNav" href="#notes-1" aria-label="Table S4">Table S4</a>, Supporting Information). This was partially attributable to the more rapid liver metabolism of <b>9d</b>, however, the maximum plasma concentration (<i>C</i><sub>max</sub>) reached by <b>9d</b> was lower than expected with a subcutaneous injection, suggesting that further factors impaired the plasma availability. Finally, <b>9b</b> was evaluated further in a xenograft tumor model.</div><figure id="fig2" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01774/20170407/images/medium/jm-2016-01774z_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01774/20170407/images/large/jm-2016-01774z_0004.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Time-dependent plasma concentrations of <b>9b</b> and <b>9d</b> after subcutaneous administration to female NMRI nu/nu mice.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01774/20170407/images/large/jm-2016-01774z_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01774&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl7"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 7. Metabolic Stability of <b>9b</b>, <b>9d</b>, and Reference Compounds against Rat Liver Microsomes<a class="ref internalNav" href="#t7fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center" char=".">half-life [min]</th><th class="colsep0 rowsep0" align="center" char=".">Cl<sub>blood</sub><a class="ref internalNav" href="#t7fn2" aria-label="b">b</a> [mL/min/kg]</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>9b</b></td><td class="colsep0 rowsep0" align="char" char=".">139</td><td class="colsep0 rowsep0" align="char" char=".">19</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>9d</b></td><td class="colsep0 rowsep0" align="char" char=".">22</td><td class="colsep0 rowsep0" align="char" char=".">51</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">diphenhydramine</td><td class="colsep0 rowsep0" align="char" char=".">17</td><td class="colsep0 rowsep0" align="char" char=".">53</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">diazepam</td><td class="colsep0 rowsep0" align="char" char=".">88</td><td class="colsep0 rowsep0" align="char" char=".">27</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t7fn1"><div class="footnote" id="t7fn1"><sup>a</sup><p class="last">Protein 0.225 mg/mL, NADP<sup>+</sup>-regenerating system, [inhibitor]: 0.5 μM, incubation at 37 °C, samples taken at 0, 15, 30, 60, and 90 min, determination of parent compound by MS.</p></div><div class="footnote" id="t7fn2"><sup>b</sup><p class="last">Cl<sub>blood</sub>: estimated blood clearance in rats as calculated based on in vitro intrinsic clearance. The values are representative for two independent experiments that essentially gave the same results.</p></div></div></div><div class="NLM_table-wrap" id="tbl8"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 8. Pharmacokinetic Parameters for <b>9b</b> and <b>9d</b><a class="ref internalNav" href="#t8fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="center" /></col><col align="center" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"><b>9b</b></th><th class="colsep0 rowsep0" align="center"><b>9d</b></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>C</i><sub>max</sub> (ng/mL)</td><td class="colsep0 rowsep0" align="center">327</td><td class="colsep0 rowsep0" align="center">100.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>t</i><sub>max</sub> (h)<a class="ref internalNav" href="#t8fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="center">8.0</td><td class="colsep0 rowsep0" align="center">1.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">concentration after 24 h (ng/mL)</td><td class="colsep0 rowsep0" align="center">79.0</td><td class="colsep0 rowsep0" align="center">3.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>t</i><sub>1/2</sub> (h)</td><td class="colsep0 rowsep0" align="center">7.8<a class="ref internalNav" href="#t8fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="center">4.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">AUC<sub>0–24h</sub> (ng·h/mL)</td><td class="colsep0 rowsep0" align="center">5443</td><td class="colsep0 rowsep0" align="center">1042</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">AUC<sub>0–∞</sub> (ng·h/mL)</td><td class="colsep0 rowsep0" align="center">6334<a class="ref internalNav" href="#t8fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="center">1064</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CL/<i>f</i> (mL/(h·kg))<a class="ref internalNav" href="#t8fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="center">1578.8<a class="ref internalNav" href="#t8fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="center">9401.7</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t8fn1"><div class="footnote" id="t8fn1"><sup>a</sup><p class="last">Single dose sc injection (10 mg/kg) in PBS/propylene glycol (80:20).</p></div><div class="footnote" id="t8fn2"><sup>b</sup><p class="last">Time after drug administration needed to reach maximum plasma concentration.</p></div><div class="footnote" id="t8fn3"><sup>c</sup><p class="last">No complete elimination phase was characterized for <b>9b</b>; thus, the values were calculated based on an estimated elimination constant.</p></div><div class="footnote" id="t8fn4"><sup>d</sup><p class="last">Total body clearance not normalized to bioavailability.</p></div></div></div></div><div id="sec2_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i26" class="anchor-spacer"></div><h3 class="article-section__title" id="_i26"> Tumor Xenograft Study</h3><div class="NLM_p">MDA-MB-231 cells were injected under the skin of nude mice and the treatment by compounds or vehicle started after day 5 of the tumor cell inoculation. We decided to use a 10 mg/kg dose of <b>9b</b> to minimize solubility problems and 25 mg/kg of the reference drug gefitinib. The higher dose was chosen to make sure that gefitinib would show at least some measurable effect because the MDA-MB-231 cells were rather insensitive toward this drug (cf. <a class="ref internalNav" href="#tbl4" aria-label="Table 4">Table 4</a>).<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> In a previous study, sc application was demonstrated to be an efficient administration route for gefitinib in a tumor xenograft model in nude mice.<a onclick="showRef(event, 'ref53'); return false;" href="javascript:void(0);" class="ref ref53">(53)</a> In addition, gefitinib exhibits higher water solubility than our compounds (cf., <a class="ref internalNav" href="#notes-1" aria-label="Table S4">Table S4</a>) and was reported to achieve high and sustained blood levels in mice,<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(54)</a> suggesting an at least comparable bioavailability of gefitinib to the transplanted tumor cells in our model.</div><div class="NLM_p">It can be seen from <a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a> that the lower dose of <b>9b</b> inhibited the tumor growth to the same extent as gefitinib. During the study, tumor growth was unexpectedly slow, possibly impeding the observation of more pronounced effects of the drugs. Especially in the first 2 weeks of treatment, the delayed growth of some tumors caused high variations of the measured sizes. The tumors then started growing stronger in the vehicle, but not in the compound-treated group, so that significant differences were reached after day 21 (<a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>).</div><figure id="fig3" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01774/20170407/images/medium/jm-2016-01774z_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01774/20170407/images/large/jm-2016-01774z_0005.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. <b>9b</b> inhibits tumor growth in a xenograft model. MDA-MB-231 tumor cells were injected in female NMRI nu/nu mice, and the treatment with the test compounds or vehicle started 5 days after the inoculation (day 1) as described under <a class="ref internalNav" href="#sec4" aria-label="Experimental Section">Experimental Section</a>. Mean values of the measured tumor sizes are shown (error bars: ±SD). The asterisks denote statistical significance compared with the vehicle-treated group: *, <i>p</i> < 0.05; **, <i>p</i> < 0.01.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01774/20170407/images/large/jm-2016-01774z_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01774&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_15" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27"> Absence of Adverse Effects in Vivo</h3><div class="NLM_p last">In both the pharmacokinetic study (durance 24 h) and the xenograft study (treatment over 28 days), no adverse effects of <b>9d</b> and/or <b>9b</b> were observed. No anomalous behavior was seen, and the organs after killing of the animals appeared morphologically normal. The body weight was not affected by <b>9b</b> over the 28 days period. Thus, it can be concluded that the compounds were nontoxic to mice and well tolerated at the administered dose.</div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i28">Conclusion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_73148" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_73148" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Using a serendipity approach, thiourea quinazoline derivatives showing a dual inhibitory activity toward the EGFR and the NF-κB activity were discovered. Optimization of the hit compound <b>VIa</b> resulted in <b>9b</b> and <b>9d</b> as best compounds for NF-κB inhibition with cellular IC<sub>50</sub>s in the submicromolar range. We provided in vitro and in vivo evidence that tumor cells which are only weakly responsive toward EGFR inhibition can still be combatted by the novel NF-κB inhibitory activity. Compared to sole EGFR kinase inhibitors, our dual inhibitors might show higher efficacy in two scenarios: (i) The “in-built” NF-κB inhibitory activity might sensitize EGFR kinase-overexpressing, originally nonresponsive tumors to EGFR kinase inhibition, and (ii) it might suppress the occurrence of resistant tumor cells that were initially sensitive toward EGFR kinase inhibitors but amplify NF-κB signaling as an adaptive response.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a></div><div class="NLM_p">The modulation of the NF-κB transcriptional activity by the thiourea quinazoline derivatives involves depletion of the coactivator CBP, which is a novel mechanism requiring in-depth characterization in future studies. At any rate, the dual inhibitors exhibited a tumor cell-selective cytotoxicity.</div><div class="NLM_p last">On the basis of the encouraging results from our simplified in vivo model, more challenging and predictive tumor models can be envisaged in the future to test the efficacy of our dual inhibitors, such as patient-derived cancer tissue xenografts, which preserve the intratumoral heterogeneity of primary malignancies.<a onclick="showRef(event, 'ref55'); return false;" href="javascript:void(0);" class="ref ref55">(55)</a></div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i29">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_12515" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_12515" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i30" class="anchor-spacer"></div><h3 class="article-section__title" id="_i30"> Chemistry</h3><div class="NLM_p">Solvents and reagents were obtained from commercial suppliers and used as received. <sup>1</sup>H and <sup>13</sup>C NMR spectra were recorded on a Bruker DRX 500 spectrometer. Chemical shifts are referenced to the residual protonated solvent signals. The purities of all biologically tested compounds were determined by HPLC coupled with mass spectrometry and were higher than 95% in all cases. Mass spectrometric analysis (HPLC-ESI-MS) was performed on a TSQ quantum (Thermo Electron Corporation) instrument equipped with an ESI source and a triple quadrupole mass detector (Thermo Finnigan). The MS detection was carried out at a spray voltage of 4.2 kV, a nitrogen sheath gas pressure of 4.0 × 105 Pa, an auxiliary gas pressure of 1.0 × 105 Pa, a capillary temperature of 400 °C, a capillary voltage of 35 V, and a source CID of 10 V. All samples were injected by an autosampler (Surveyor, Thermo Finnigan) with an injection volume of 10 μL. An RP C18 NUCLEODUR 100–3 (125 mm × 3 mm) column (Macherey-Nagel) was used as the stationary phase. The solvent system consisted of water containing 0.1% TFA (A) and 0.1% TFA in acetonitrile (B). HPLC-method: flow rate 400 μL/min. The percentage of B started at an initial of 5%, was increased up to 100% during 16 min, kept at 100% for 2 min, and flushed back to 5% in 2 min. High resolution precise mass spectra were determined for compounds <b>6c</b>, <b>6h</b>, <b>9b</b>, and <b>9d</b> and were recorded on ThermoFisher Scientific (TF, Dreieich, Germany) Q Exactive Focus system equipped with heated electrospray ionization (HESI)-II source and Xcalibur (version 4.0.27.19) software. Mass calibration was done prior to analysis according to the manufacturer’s recommendations using external mass calibration. All samples were constituted in methanol and directly injected onto the Q Exactive Focus using the integrated syringe pump. All data acquisition was done in positive ion mode using voltage scans and the data collected in continuum mode. Melting points are uncorrected and were determined on Buchi melting point apparatus (B-540). The IR spectra were measured on Nicolet 380 FT-IR spectrometer.</div><div id="sec4_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i31" class="anchor-spacer"></div><h4 class="article-section__title" id="_i31"> 1-Benzyl-3-(4-((3-bromophenyl)amino)quinazolin-6-yl)thiourea (<b>VIa</b>)</h4><div class="NLM_p last">Yield 63%; mp 197–198 °C. <sup>1</sup>H NMR (500 MHz, DMSO) δ 9.91 (s, 1H), 9.83 (s, 1H), 8.64 (s, 1H), 8.47 (d, <i>J</i> = 1.3 Hz, 1H), 8.42 (s, 1H), 8.25 (t, <i>J</i> = 1.9 Hz, 1H), 7.93 (ddd, <i>J</i> = 8.2, 1.9, 0.9 Hz, 1H), 7.85 (dd, <i>J</i> = 8.9, 2.1 Hz, 1H), 7.78 (d, <i>J</i> = 8.9 Hz, 1H), 7.38–7.31 (m, 5H), 7.30 (ddd, <i>J</i> = 7.9, 1.9, 1.0 Hz, 1H), 7.25 (t, <i>J</i> = 7.1 Hz, 1H), 4.79 (d, <i>J</i> = 5.1 Hz, 2H). <sup>13</sup>C NMR (126 MHz, DMSO) δ 181.56, 157.11, 153.66, 147.51, 141.07, 139.00, 136.98, 131.83, 131.80, 130.41, 128.21, 127.41, 126.83, 125.86, 123.89, 121.21, 120.43, 117.77, 115.26, 47.51. MS (+ESI): <i>m</i>/<i>z</i> = 464.09 (M + H).</div></div><div id="sec4_2_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i32" class="anchor-spacer"></div><h4 class="article-section__title" id="_i32"> 1-(4-((3-Bromophenyl)amino)quinazolin-6-yl)-3-(3-chlorophenyl)thiourea (<b>6c</b>)</h4><div class="NLM_p last">Yield 60%; mp 180–182 °C. <sup>1</sup>H NMR (500 MHz, DMSO) δ 10.19 (s, 1H), 10.06 (s, 1H), 9.84 (s, 1H), 8.65 (s, 1H), 8.49 (d, <i>J</i> = 1.8 Hz, 1H), 8.23 (t, <i>J</i> = 1.8 Hz, 1H), 7.94–7.84 (m, 2H), 7.80 (d, <i>J</i> = 8.8 Hz, 1H), 7.70 (t, <i>J</i> = 2.0 Hz, 1H), 7.43 (d, <i>J</i> = 9.0 Hz, 1H), 7.36 (td, <i>J</i> = 8.0, 4.1 Hz, 2H), 7.30 (d, <i>J</i> = 8.7 Hz, 1H), 7.20 (ddd, <i>J</i> = 7.9, 2.0, 1.0 Hz, 1H). <sup>13</sup>C NMR (126 MHz, DMSO) δ 180.49, 157.15, 153.80, 147.66, 140.96, 140.89, 137.09, 132.49, 132.03, 130.40, 130.00, 128.10, 125.95, 124.34, 124.05, 123.52, 122.43, 121.18, 120.59, 118.36, 115.13. HRMS (+ESI) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>21</sub>H<sub>16</sub>BrClN<sub>5</sub>S 483.99983; found 483.99921.</div></div><div id="sec4_2_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i33" class="anchor-spacer"></div><h4 class="article-section__title" id="_i33"> 1-(4-((3-Bromophenyl)amino)quinazolin-6-yl)-3-(3-chloro-4-fluorophenyl)thiourea (<b>6h</b>)</h4><div class="NLM_p last">Yield 63%; mp 206–207 °C. <sup>1</sup>H NMR (500 MHz, DMSO) δ 10.19 (s, 1H), 9.98 (s, 1H), 9.84 (s, 1H), 8.65 (s, 1H), 8.49 (d, <i>J</i> = 2.1 Hz, 1H), 8.24 (t, <i>J</i> = 2.0 Hz, 1H), 7.91 (ddd, <i>J</i> = 8.1, 2.0, 1.0 Hz, 1H), 7.86 (dd, <i>J</i> = 8.9, 2.2 Hz, 1H), 7.80 (d, <i>J</i> = 8.9 Hz, 1H), 7.77 (dd, <i>J</i> = 6.8, 2.5 Hz, 1H), 7.44 (ddd, <i>J</i> = 8.9, 4.6, 2.5 Hz, 1H), 7.41 (d, <i>J</i> = 9.0 Hz, 1H), 7.36 (dd, <i>J</i> = 14.2, 6.1 Hz, 1H), 7.30 (ddd, <i>J</i> = 8.0, 1.9, 1.0 Hz, 1H). <sup>13</sup>C NMR (126 MHz, DMSO) δ 180.77, 157.17, 154.42 (d, <sup>1</sup><i>J</i><sub>C–F</sub> = 244.6 Hz), 153.87, 147.75, 140.98, 137.00, 136.59, 132.07, 130.41, 128.21, 126.43, 125.97, 125.20 (d, <sup>3</sup><i>J</i><sub>C–F</sub> = 7.2 Hz), 124.05, 121.21, 120.59, 118.71 (d, <sup>2</sup><i>J</i><sub>C–F</sub> = 18.6 Hz), 118.46, 116.47 (d, <sup>2</sup><i>J</i><sub>C–F</sub> = 21.8 Hz), 115.18. HRMS (+ESI) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>21</sub>H<sub>15</sub>BrClFN<sub>5</sub>S 501.99041; found 501.98968.</div></div><div id="sec4_2_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i34" class="anchor-spacer"></div><h4 class="article-section__title" id="_i34"> 1-(4-((3-Chlorophenyl)amino)quinazolin-6-yl)-3-(3,5-difluorophenyl)thiourea (<b>9b</b>)</h4><div class="NLM_p last">Yield 31%; mp 168.5–170.5 °C. <sup>1</sup>H NMR (500 MHz, DMSO) δ 10.36 (s, 1H), 10.25 (s, 1H), 9.87 (s, 1H), 8.65 (s, 1H), 8.50 (d, <i>J</i> = 2.0 Hz, 1H), 8.11 (t, <i>J</i> = 1.9 Hz, 1H), 7.87 (dd, <i>J</i> = 8.9, 2.1 Hz, 1H), 7.84 (dd, <i>J</i> = 8.3, 1.2 Hz, 1H), 7.81 (d, <i>J</i> = 8.8 Hz, 1H), 7.42 (t, <i>J</i> = 8.1 Hz, 1H), 7.36 (dd, <i>J</i> = 9.3, 2.2 Hz, 2H), 7.17 (ddd, <i>J</i> = 8.0, 2.1, 0.9 Hz, 1H), 6.99 (tt, <i>J</i> = 9.3, 2.3 Hz, 1H). <sup>13</sup>C NMR (126 MHz, DMSO) δ 180.40, 162.03 (dd, <i>J</i> = 243.3, 15.3 Hz), 157.22, 153.92, 147.80, 142.17 (t, <i>J</i> = 13.5 Hz), 140.84, 137.00, 132.77, 132.10, 130.13, 128.18, 123.12, 121.30, 120.24, 118.50, 115.18, 106.23 (dd, <i>J</i> = 27.9, 6.3 Hz), 99.49 (t, <i>J</i> = 26.0 Hz). HRMS (+ESI) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>21</sub>H<sub>15</sub>ClF<sub>2</sub>N<sub>5</sub>S 442.07048; found 442.06946.</div></div><div id="sec4_2_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i35" class="anchor-spacer"></div><h4 class="article-section__title" id="_i35"> 1-(4-((3-Chlorophenyl)amino)quinazolin-6-yl)-3-(4-(trifluoromethyl)thiazol-2-yl)thiourea (<b>9d</b>)</h4><div class="NLM_p last">Yield 25%; mp 226–228 °C. <sup>1</sup>H NMR (500 MHz, DMSO) δ 12.48 (s, 1H), 10.35 (s, 1H), 9.91 (s, 1H), 8.67 (s, 1H), 8.58 (d, <i>J</i> = 2.1 Hz, 1H), 8.10 (s, 1H), 7.95 (dd, <i>J</i> = 8.9, 2.2 Hz, 1H), 7.86 (d, <i>J</i> = 1.0 Hz, 1H), 7.84 (d, <i>J</i> = 8.9 Hz, 2H), 7.42 (t, <i>J</i> = 8.1 Hz, 1H), 7.18 (ddd, <i>J</i> = 8.0, 2.1, 0.9 Hz, 1H). <sup>13</sup>C NMR (126 MHz, DMSO) δ 177.95, 162.58 (q, <i>J</i> = 4.9, 2.7 Hz), 157.28, 154.12, 147.97, 140.74, 137.42 (q, <i>J</i> = 36.6 Hz), 136.24, 132.75, 131.85, 130.10, 128.25, 123.21, 121.41, 120.93 (q, <i>J</i> = 269.9 Hz), 120.34, 118.71, 115.55 (q, <i>J</i> = 3.3 Hz), 115.15. HRMS (+ESI) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>19</sub>H<sub>13</sub>ClF<sub>3</sub>N<sub>6</sub>S<sub>2</sub> 481.02837; found 481.02740.</div></div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i36" class="anchor-spacer"></div><h3 class="article-section__title" id="_i36"> Biology</h3><div id="sec4_3_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i37" class="anchor-spacer"></div><h4 class="article-section__title" id="_i37"> EGFR Kinase Phosphorylation Assay</h4><div class="NLM_p last">Phosphorylation assays were performed in a final volume of 20 μL containing 8 mM MOPS (pH 7.0), 0.2 mM EDTA, 10 mM MnCl<sub>2</sub>, 200 μM substrate peptide, 0.25 mM DTT, 0.1 mg/mL BSA, 10 ng of wild-type EGFR-kinase (catalogue no. 40187, BPS Bioscience), 10 mM magnesium acetate, 100 μM γ-[<sup>32</sup>P]ATP, and inhibitors or DMSO control (1.25% v/v). For IC<sub>50</sub> curves with the wild-type enzyme, the following concentrations of the compounds (in nM) were tested in triplicate: 150, 100, 50, 25, 15, 10, 7.5, 5, and 2.5. The assays were repeated at least once. Reactions were started by the addition of the magnesium acetate/ATP mixture. After 30 min incubation at 30 °C, 5 μL of each reaction was spotted on phosphocellulose P81 paper (Whatman). The P81 paper was then washed 5 times with 50 mM phosphoric acid for 15 min, dried, and exposed to a phosphorimager screen (Storm, GE Healthcare), which was scanned and densitometrically analyzed the next day. The sequence of the substrate peptide was derived from phospholipase C-γ1 and had the sequence “KHKKLAEGSAYEEV”, according to Fry et al.<a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(56)</a></div></div><div id="sec4_3_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i38" class="anchor-spacer"></div><h4 class="article-section__title" id="_i38"> Reporter Gene Assay</h4><div class="NLM_p last">The NF-κB reporter gene assay was performed in U937 cells exactly as previously described.<a onclick="showRef(event, 'ref57'); return false;" href="javascript:void(0);" class="ref ref57">(57)</a></div></div><div id="sec4_3_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i39" class="anchor-spacer"></div><h4 class="article-section__title" id="_i39"> MDA-MB-231 Cell Growth Inhibition Assay</h4><div class="NLM_p last">Cells were seeded in 96-well standard assay microplates at a density of 45000 cells per well, then allowed to adhere overnight before compound addition. After 24 h, cells were treated with different concentrations of the compounds. Cells were incubated for an additional 48 h at 37 °C, after which 20 μL of MTT reagent (prepared as 5 mg/mL PBS) were added and then incubated for additional 1 h. After that, 100 μL of SDS (prepared as 10% in 0.01 N HCl) were added and incubated for at least 2 h at 37 °C to allow for cell lysis. Absorbance was then measured at a wavelength of 570 nm in a plate reader (PolarStar, BMG Labtech, Freiburg, Germany).</div></div><div id="sec4_3_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i40" class="anchor-spacer"></div><h4 class="article-section__title" id="_i40"> Cultivation of HUVEC, CHO-K1, and A549 Cells for Cytotoxicity Assays</h4><div class="NLM_p">HUVEC cells purchased from the American Type Culture Collection (Manassas, VA) were maintained and seeded in F-12K nutrient mixture (Kaighn’s modification; Life Technologies) with 10% FBS, 100 μg/mL heparin (Sigma-Aldrich, St. Louis, MO), and 30 μg/mL endothelial cell growth supplement (Sigma-Aldrich). For the MTT assay, 6 × 10<sup>3</sup> cells per well of 96-well plates were used. CHO-K1 cells (ACC-110) were obtained from the German Collection of Microorganisms and Cell Cultures (Deutsche Sammlung für Mikroorganismen and Zellkulturen, DSMZ) and were cultured under conditions recommended by the depositor. Cells were seeded at 6 × 10<sup>3</sup> cells per well of 96-well plates in 180 μL of complete medium (F12K, 10% FBS). A549 cells obtained from the “Deutsche Sammlung für Mikroorganismen und Zellkulturen” (DSMZ) (ACC 107) were grown in Dulbecco’s Modified Eagle’s Medium (DMEM, Sigma) with 10% fetal calf serum (FCS, Sigma). Cells were also seeded at 6 × 10<sup>3</sup> cells per well of 96-well plates.</div><div class="NLM_p last">All cell media contained in addition penicillin G (final concentration 100 U/mL) and streptomycin sulfate (final concentration 100 mg/mL) and were maintained at 37 °C and 5% CO<sub>2</sub> in a humidified incubator. The cytotoxicity of the test compound was determined as described above, under “MDA-MB-231 Cell Growth Inhibition Assay”.</div></div><div id="sec4_3_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i41" class="anchor-spacer"></div><h4 class="article-section__title" id="_i41"> NF-κB (p65)-DNA Binding and p65/CREB-Binding Protein ELISA</h4><div class="NLM_p last">MDA-MB-231 breast cancer cells were grown in 6-well plates to 80% confluency in DMEM containing 10% FCS (low endotoxin quality, GIBCO, Thermo Fisher Scientific) and pen/strep mix. The cells were incubated with the test compounds or DMSO as solvent control for 12 h. In some experiments, TNFα was added at final concentration of 20 ng/mL (as indicated) and the incubation continued for 20 min at 37 °C. The plates were then put on ice, washed twice with ice-cold PBS, and harvested in 1 mL of PBS using a cell scraper (Sigma, catalogue no. CLS3010). The suspension was transferred to Eppendorf tubes on ice, and the cells were spun down at 500<i>g</i> in a cooled centrifuge (2 °C). Nuclear protein extracts were immediately prepared using the Pierce NE-PER nuclear and cytoplasmic extraction kit (Thermo Fisher Scientific, catalogue no. PI-78833) according to the manufacturer’s instructions. Protein concentrations were determined using Roti-Quant Bradford reagent (Carl Roth, catalogue no. K015.3) against a calibration curve generated with BSA as a standard. The absorbance values were measured at 595 nm in a BioPhotometer Plus (Eppendorf, Germany). Then 5 μg of each nuclear extract sample was analyzed using a NF-κB (p65) Transcription Factor Assay Kit (Cayman Chemicals, catalogue no. 10007889). In brief, samples were incubated with a specific double-stranded DNA oligonucleotide containing the NF-κB response element, which was immobilized on a 96-well plate. After washing, the NF-κB-containing complexes which bound to the immobilized DNA were detected using a specific primary antibody directed against NF-κB (p65). In some experiments, CREB-binding protein as a component of the NF-κB transcription factor complex was detected instead, using anti-CBP antibody (Santa Cruz Biotechnology, catalogue no. sc-583), at a 1:100 dilution. A secondary antibody conjugated to HRP was added to provide a colorimetric readout at 450 nm. The absorbance values were measured in a PolarStar plate reader (BMG Labtech, Germany). Specificity of the binding was verified by adding 10 μL of the NF-κB response element oligonucleotide solution (GGGACTTTCC, provided by the manufacturer), in a final volume of 100 μL, during the incubation with nuclear extracts.</div></div><div id="sec4_3_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i42" class="anchor-spacer"></div><h4 class="article-section__title" id="_i42"> Metabolic Stability Assay</h4><div class="NLM_p last">The assay was performed with liver microsomes from male Sprague–Dawley rats (BD Bioscience, catalogue no. 452501) exactly as described previously.<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a></div></div><div id="sec4_3_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i43" class="anchor-spacer"></div><h4 class="article-section__title" id="_i43"> In Vivo Pharmacokinetic Study</h4><div class="NLM_p last">Female NMRI nu/nu mice (weight 28–32 g, Janvier, France) were used. The animals were housed in a temperature-controlled room (20–24 °C) and maintained in a 12 h light/12 h dark cycle. Food and water were available ad libitum. For each test compound, nine animals were used. All experimental procedures were approved by and conducted in accordance with the regulations of the local Animal Welfare authorities. Compounds were formulated in PBS/propylene glycol (80:20, v/v) at a concentration of 1 mg/mL using ultrasonication. After subcutaneous application (10 mg/kg dose), blood samples (two per animal) were taken at 10 min, 30 min, 1, 3, 8, and 24 h. The blood was collected in heparinized tubes, stored on ice, and subsequently centrifuged at 3000<i>g</i> for 10 min at 4 °C. The plasma was prepared within 45 min after sampling and was kept at −20 °C until being assayed. A 20 μL aliquot of plasma sample was subjected to protein precipitation using 40 μL of acetonitrile containing 600 ng/mL of internal standard (griseofulvin). Samples were vigorously shaken and centrifuged for 10 min at 6000<i>g</i> and 20 °C. The particle free supernatant was diluted 1:1 with water. An aliquot was transferred to 200 μL sampler vials and subsequently subjected to LC-MS with an injection volume of 18 μL. The LC-MS system consisted of a Surveyor MS Plus HPLC system (Thermo Fisher Scientific) connected to a TSQ Quantum Discovery Max (Thermo Fisher Scientific) triple quad mass spectrometer; data handling and analysis was done using the standard software Xcalibur 2.0.7. The compound concentrations were quantified using a calibration curve based on calibration standards prepared in drug-free plasma.</div></div><div id="sec4_3_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i44" class="anchor-spacer"></div><h4 class="article-section__title" id="_i44"> In Vivo Tumor Xenograft Study</h4><div class="NLM_p last">MDA-MB-231 tumor cells suspended in Matrigel (2 × 10<sup>6</sup> cells per site in 100 μL) were injected in the left and right flank of female NMRI nu/nu mice (∼8 weeks of age). Five days after the inoculation, the treatment was started (= day 1, 6 mice per group). Compounds were formulated as described above for the pharmacokinetic study and injected sc. The animals were treated with compounds or vehicle for 14 days every week day. Then the treatment was paused for 6 days due to the occurrence of some precipitate under the skin. From day 21, the treatment was continued on every second day until the mice were sacrificed (day 28). Tumor size was analyzed by calipers (smallest and largest diameter) once a week, starting on the first day. Statistical significance between each compound-treated and the vehicle-treated group was calculated using the unpaired two-tailed Student’s <i>t</i> test.</div></div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i45"><a href="/doi/suppl/10.1021/acs.jmedchem.6b01774">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_33361" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_33361" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a href="/" class="ext-link">ACS Publications website</a> at DOI: <a href="/doi/abs/10.1021/acs.jmedchem.6b01774" class="ext-link">10.1021/acs.jmedchem.6b01774</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Complete set of screened compounds; kinase inhibition selectivity profile for compound <b>6c</b>, IC<sub>50</sub> for compound <b>6c</b> against EGFR, Mnk2, and Pim-1, percent inhibition in the NF-κB reporter gene assay by SIM-4a (Pim-1 inhibitor) and gefitinib at different concentrations, determination of water solubility, kinase inhibition selectivity profile for compound <b>9b</b>; NF-κB translocation assay, compound <b>6c</b> does not impair DNA binding of NF-κB/p65, LCMS data of compounds <b>6c</b>, <b>6h</b>, <b>9b</b>, and <b>9d</b>; experimental details. (<a href="/doi/suppl/10.1021/acs.jmedchem.6b01774/suppl_file/jm6b01774_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Molecular formula strings (<a href="/doi/suppl/10.1021/acs.jmedchem.6b01774/suppl_file/jm6b01774_si_002.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.6b01774/suppl_file/jm6b01774_si_001.pdf">jm6b01774_si_001.pdf (1.23 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.6b01774/suppl_file/jm6b01774_si_002.csv">jm6b01774_si_002.csv (3.7 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.6b01774" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_33124" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_33124" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Matthias Engel</span> - <span class="hlFld-Affiliation affiliation">Pharmaceutical
and Medicinal Chemistry, Saarland University, Campus C2.3, D-66123 Saarbrücken, Germany</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-5065-8634" title="Orcid link">http://orcid.org/0000-0001-5065-8634</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#d8b5b9f6bdb6bfbdb498b5a0f6adb6b1f5abb9b9aab4b9b6bcf6bcbd"><span class="__cf_email__" data-cfemail="f29f93dc979c95979eb29f8adc879c9bdf819393809e939c96dc9697">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mostafa M. Hamed</span> - <span class="hlFld-Affiliation affiliation">Pharmaceutical
and Medicinal Chemistry, Campus C2.3, and
Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), Saarland University, Campus E8.1, D-66123 Saarbrücken, Germany</span>; 
    <span class="hlFld-Affiliation affiliation">Department
of Pharmaceutical Chemistry, Faculty of Pharmacy and Biotechnology, German University in Cairo, Cairo 11835, Egypt</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sarah S. Darwish</span> - <span class="hlFld-Affiliation affiliation">Department
of Pharmaceutical Chemistry, Faculty of Pharmacy and Biotechnology, German University in Cairo, Cairo 11835, Egypt</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jennifer Herrmann</span> - <span class="hlFld-Affiliation affiliation">Helmholtz
Institute for Pharmaceutical Research Saarland (HIPS), Campus E8.1, D-66123 Saarbrücken, Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ashraf H. Abadi</span> - <span class="hlFld-Affiliation affiliation">Department
of Pharmaceutical Chemistry, Faculty of Pharmacy and Biotechnology, German University in Cairo, Cairo 11835, Egypt</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ACK-d46e2831-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i46">Acknowledgment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_05707" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_05707" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">We thank the Deutsche Forschungsgemeinschaft (DFG) for financial support to M.E. (grant no. EN 381/2-3). We are also grateful both to the Deutscher Akademischer Austauschdienst (DAAD) (grant no. 56607676) and the Science and Technology Development Fund (STDF), Egypt (grant no. 3579), for the support of M.M.H. and S.S.D. We thank Nadja Weber for her excellent work with the reporter gene and metabolic stability assays.</p></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i47" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i47"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i48" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i48"> Abbreviations Used</h2><tr><td class="NLM_term">CBP</td><td class="NLM_def"><p class="first last">CREB-binding protein</p></td></tr><tr><td class="NLM_term">RIPK-2</td><td class="NLM_def"><p class="first last">receptor-interacting serine/threonine–protein kinase 2</p></td></tr><tr><td class="NLM_term">CHO</td><td class="NLM_def"><p class="first last">Chinese hamster ovary cells</p></td></tr><tr><td class="NLM_term">HUVEC</td><td class="NLM_def"><p class="first last">human umbilical vein endothelial cells</p></td></tr><tr><td class="NLM_term">Pim-1</td><td class="NLM_def"><p class="first last">proto-oncogenic serine/threonine–protein kinase PIM1</p></td></tr><tr><td class="NLM_term">Mnk</td><td class="NLM_def"><p class="first last">MAP kinase-interacting serine/threonine–protein kinase</p></td></tr><tr><td class="NLM_term">SIK2</td><td class="NLM_def"><p class="first last">salt-inducible serine/threonine kinase 2</p></td></tr><tr><td class="NLM_term">LOK/STK10</td><td class="NLM_def"><p class="first last">lymphocyte-oriented kinase</p></td></tr><tr><td class="NLM_term">HER</td><td class="NLM_def"><p class="first last">human epidermal growth factor receptor</p></td></tr><tr><td class="NLM_term">EPHA6</td><td class="NLM_def"><p class="first last">ephrin type-A receptor 6</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i49">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_64314" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_64314" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 58 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">Sharma, S. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bell, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Settleman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haber, D. A.</span><span> </span><span class="NLM_article-title">Epidermal growth factor receptor mutations in lung cancer</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">169</span><span class="NLM_x">–</span> <span class="NLM_lpage">181</span><span class="refDoi"> DOI: 10.1038/nrc2088</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01774&amp;key=10.1038%2Fnrc2088" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01774&amp;key=17318210" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01774&amp;key=1%3ACAS%3A528%3ADC%252BD2sXitVGrsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2007&pages=169-181&author=S.+V.+Sharmaauthor=D.+W.+Bellauthor=J.+Settlemanauthor=D.+A.+Haber&title=Epidermal+growth+factor+receptor+mutations+in+lung+cancer&doi=10.1038%2Fnrc2088"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Epidermal growth factor receptor mutations in lung cancer</span></div><div class="casAuthors">Sharma, Sreenath V.; Bell, Daphne W.; Settleman, Jeffrey; Haber, Daniel A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">169-181</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The development and clin. application of inhibitors that target the epidermal growth factor receptor (EGFR) provide important insights for new lung cancer therapies, as well as for the broader field of targeted cancer therapies.  We review the results of genetic, biochem. and clin. studies focused on somatic mutations of EGFR that are assocd. with the phenomenon of oncogene addiction, describing 'oncogenic shock' as a mechanistic explanation for the apoptosis that follows the acute treatment of susceptible cells with kinase inhibitors.  Understanding the genetic heterogeneity of epithelial tumors and devising strategies to circumvent their rapid acquisition of resistance to targeted kinase inhibitors are essential to the successful use of targeted therapies in common epithelial cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMKw7Y4FUFM7Vg90H21EOLACvtfcHk0libGZoN3WG9qA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXitVGrsbo%253D&md5=46219ea3ae7b9f0977e4a4b7243fd875</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1038%2Fnrc2088&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2088%26sid%3Dliteratum%253Aachs%26aulast%3DSharma%26aufirst%3DS.%2BV.%26aulast%3DBell%26aufirst%3DD.%2BW.%26aulast%3DSettleman%26aufirst%3DJ.%26aulast%3DHaber%26aufirst%3DD.%2BA.%26atitle%3DEpidermal%2520growth%2520factor%2520receptor%2520mutations%2520in%2520lung%2520cancer%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2007%26volume%3D7%26spage%3D169%26epage%3D181%26doi%3D10.1038%2Fnrc2088" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">Sequist, L. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lynch, T. J.</span><span> </span><span class="NLM_article-title">EGFR tyrosine kinase inhibitors in lung cancer: an evolving story</span> <span class="citation_source-journal">Annu. Rev. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">59</span><span class="NLM_x">, </span> <span class="NLM_fpage">429</span><span class="NLM_x">–</span> <span class="NLM_lpage">442</span><span class="refDoi"> DOI: 10.1146/annurev.med.59.090506.202405</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01774&amp;key=10.1146%2Fannurev.med.59.090506.202405" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2008&pages=429-442&author=L.+V.+Sequistauthor=T.+J.+Lynch&title=EGFR+tyrosine+kinase+inhibitors+in+lung+cancer%3A+an+evolving+story&doi=10.1146%2Fannurev.med.59.090506.202405"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1146%2Fannurev.med.59.090506.202405&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev.med.59.090506.202405%26sid%3Dliteratum%253Aachs%26aulast%3DSequist%26aufirst%3DL.%2BV.%26aulast%3DLynch%26aufirst%3DT.%2BJ.%26atitle%3DEGFR%2520tyrosine%2520kinase%2520inhibitors%2520in%2520lung%2520cancer%253A%2520an%2520evolving%2520story%26jtitle%3DAnnu.%2520Rev.%2520Med.%26date%3D2008%26volume%3D59%26spage%3D429%26epage%3D442%26doi%3D10.1146%2Fannurev.med.59.090506.202405" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">da Cunha Santos, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shepherd, F. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsao, M. S.</span><span> </span><span class="NLM_article-title">EGFR mutations and lung cancer</span> <span class="citation_source-journal">Annu. Rev. Pathol.: Mech. Dis.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">49</span><span class="NLM_x">–</span> <span class="NLM_lpage">69</span><span class="refDoi"> DOI: 10.1146/annurev-pathol-011110-130206</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01774&amp;key=10.1146%2Fannurev-pathol-011110-130206" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01774&amp;key=20887192" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01774&amp;key=1%3ACAS%3A280%3ADC%252BC3M7jvVSitg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2011&pages=49-69&author=G.+da+Cunha+Santosauthor=F.+A.+Shepherdauthor=M.+S.+Tsao&title=EGFR+mutations+and+lung+cancer&doi=10.1146%2Fannurev-pathol-011110-130206"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">EGFR mutations and lung cancer</span></div><div class="casAuthors">da Cunha Santos Gilda; Shepherd Frances A; Tsao Ming Sound</div><div class="citationInfo"><span class="NLM_cas:title">Annual review of pathology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">49-69</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Epidermal growth factor receptor (EGFR) is a transmembrane protein with cytoplasmic kinase activity that transduces important growth factor signaling from the extracellular milieu to the cell.  Given that more than 60% of non-small cell lung carcinomas (NSCLCs) express EGFR, EGFR has become an important therapeutic target for the treatment of these tumors.  Inhibitors that target the kinase domain of EGFR have been developed and are clinically active.  More importantly, such tyrosine kinase inhibitors (TKIs) are especially effective in patients whose tumors harbor activating mutations in the tyrosine kinase domain of the EGFR gene.  More recent trials have suggested that for advanced NSCLC patients with EGFR mutant tumors, initial therapy with a TKI instead of chemotherapy may be the best choice of treatment.  Therefore, mutation testing is mandatory to identify these patients, given that selection based only on clinico-pathologic characteristics is inadequate.  We review the role of EGFR mutations in the diagnosis and management of NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSWZQp6wFX2j9yzdcP07UmufW6udTcc2eb8q_7I9F6SB7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3M7jvVSitg%253D%253D&md5=2ab255110cb58879af550a86e7155c35</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1146%2Fannurev-pathol-011110-130206&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev-pathol-011110-130206%26sid%3Dliteratum%253Aachs%26aulast%3Dda%2BCunha%2BSantos%26aufirst%3DG.%26aulast%3DShepherd%26aufirst%3DF.%2BA.%26aulast%3DTsao%26aufirst%3DM.%2BS.%26atitle%3DEGFR%2520mutations%2520and%2520lung%2520cancer%26jtitle%3DAnnu.%2520Rev.%2520Pathol.%253A%2520Mech.%2520Dis.%26date%3D2011%26volume%3D6%26spage%3D49%26epage%3D69%26doi%3D10.1146%2Fannurev-pathol-011110-130206" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">Godin-Heymann, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ulkus, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brannigan, B. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDermott, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lamb, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maheswaran, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Settleman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haber, D. A.</span><span> </span><span class="NLM_article-title">The T790M ″gatekeeper″ mutation in EGFR mediates resistance to low concentrations of an irreversible EGFR inhibitor</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">874</span><span class="NLM_x">–</span> <span class="NLM_lpage">879</span><span class="refDoi"> DOI: 10.1158/1535-7163.MCT-07-2387</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01774&amp;key=10.1158%2F1535-7163.MCT-07-2387" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01774&amp;key=18413800" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01774&amp;key=1%3ACAS%3A528%3ADC%252BD1cXks1GmsLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2008&pages=874-879&author=N.+Godin-Heymannauthor=L.+Ulkusauthor=B.+W.+Branniganauthor=U.+McDermottauthor=J.+Lambauthor=S.+Maheswaranauthor=J.+Settlemanauthor=D.+A.+Haber&title=The+T790M+%E2%80%B3gatekeeper%E2%80%B3+mutation+in+EGFR+mediates+resistance+to+low+concentrations+of+an+irreversible+EGFR+inhibitor&doi=10.1158%2F1535-7163.MCT-07-2387"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">The T790M "gatekeeper" mutation in EGFR mediates resistance to low concentrations of an irreversible EGFR inhibitor</span></div><div class="casAuthors">Godin-Heymann, Nadia; Ulkus, Lindsey; Brannigan, Brian W.; McDermott, Ultan; Lamb, Jennifer; Maheswaran, Shyamala; Settleman, Jeffrey; Haber, Daniel A.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">874-879</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Patients with non-small cell lung cancer (NSCLC) harboring activating mutations in the epidermal growth factor receptor (EGFR) kinase domain tend to respond well to the tyrosine kinase inhibitors, gefitinib and erlotinib.  However, following clin. response, these patients typically relapse within a year of treatment.  In many cases, resistance is caused by an acquired secondary EGFR kinase domain mutation, T790M.  In vitro studies have shown that a new class of EGFR-irreversible inhibitors could overcome the resistance conferred by T790M.  Clin. trials are under way to examine the efficacy of one of these inhibitors, HKI-272, in patients with NSCLC who initially responded to gefitinib/erlotinib and subsequently relapsed.  To anticipate the possibility that patients who respond to irreversible inhibitors will develop secondary resistance to such inhibitors, as has been seen in other similar settings, we modeled acquired resistance to the dual EGFR/HER2-irreversible tyrosine kinase inhibitor HKI-272 in a NSCLC cell culture model.  We found that HKI-272-resistant clones fall into two biochem. groups based on the retention of EGFR phosphorylation in the presence of the drug.  Cells that retain phosphorylated EGFR have acquired the secondary mutation T790M.  Moreover, HKI-272 can overcome T790M resistance only at suprapharmacol. concns.  We further model mutations at EGFR C797 as a mechanism of resistance to irreversible EGFR inhibitors and show that although these mutants are resistant to the irreversible inhibitor, they retain erlotinib sensitivity.  Our findings suggest that HKI-272 treatment at maximally tolerated dosing may lead to the emergence of T790M-mediated resistance, whereas treatment with a more potent irreversible inhibitor could yield a resistance mutation at EGFR C797.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGra5FtRNHnlNLVg90H21EOLACvtfcHk0ljBccV8Dji2Yw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXks1GmsLo%253D&md5=f71cd83bfabef2d7b2c5d8b6e5cfac6a</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-07-2387&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-07-2387%26sid%3Dliteratum%253Aachs%26aulast%3DGodin-Heymann%26aufirst%3DN.%26aulast%3DUlkus%26aufirst%3DL.%26aulast%3DBrannigan%26aufirst%3DB.%2BW.%26aulast%3DMcDermott%26aufirst%3DU.%26aulast%3DLamb%26aufirst%3DJ.%26aulast%3DMaheswaran%26aufirst%3DS.%26aulast%3DSettleman%26aufirst%3DJ.%26aulast%3DHaber%26aufirst%3DD.%2BA.%26atitle%3DThe%2520T790M%2520%25E2%2580%25B3gatekeeper%25E2%2580%25B3%2520mutation%2520in%2520EGFR%2520mediates%2520resistance%2520to%2520low%2520concentrations%2520of%2520an%2520irreversible%2520EGFR%2520inhibitor%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2008%26volume%3D7%26spage%3D874%26epage%3D879%26doi%3D10.1158%2F1535-7163.MCT-07-2387" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">Engelman, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zejnullahu, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mitsudomi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Song, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hyland, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, J. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lindeman, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gale, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kosaka, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holmes, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rogers, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cappuzzo, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mok, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cantley, L. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janne, P. A.</span><span> </span><span class="NLM_article-title">MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">316</span><span class="NLM_x">, </span> <span class="NLM_fpage">1039</span><span class="NLM_x">–</span> <span class="NLM_lpage">1043</span><span class="refDoi"> DOI: 10.1126/science.1141478</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01774&amp;key=10.1126%2Fscience.1141478" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01774&amp;key=17463250" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01774&amp;key=1%3ACAS%3A528%3ADC%252BD2sXltlOjt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=316&publication_year=2007&pages=1039-1043&author=J.+A.+Engelmanauthor=K.+Zejnullahuauthor=T.+Mitsudomiauthor=Y.+Songauthor=C.+Hylandauthor=J.+O.+Parkauthor=N.+Lindemanauthor=C.+M.+Galeauthor=X.+Zhaoauthor=J.+Christensenauthor=T.+Kosakaauthor=A.+J.+Holmesauthor=A.+M.+Rogersauthor=F.+Cappuzzoauthor=T.+Mokauthor=C.+Leeauthor=B.+E.+Johnsonauthor=L.+C.+Cantleyauthor=P.+A.+Janne&title=MET+amplification+leads+to+gefitinib+resistance+in+lung+cancer+by+activating+ERBB3+signaling&doi=10.1126%2Fscience.1141478"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling</span></div><div class="casAuthors">Engelman, Jeffrey A.; Zejnullahu, Kreshnik; Mitsudomi, Tetsuya; Song, Youngchul; Hyland, Courtney; Park, Joon Oh; Lindeman, Neal; Gale, Christopher-Michael; Zhao, Xiaojun; Christensen, James; Kosaka, Takayuki; Holmes, Alison J.; Rogers, Andrew M.; Cappuzzo, Federico; Mok, Tony; Lee, Charles; Johnson, Bruce E.; Cantley, Lewis C.; Jaenne, Pasi A.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">316</span>
        (<span class="NLM_cas:issue">5827</span>),
    <span class="NLM_cas:pages">1039-1043</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">The epidermal growth factor receptor (EGFR) kinase inhibitors gefitinib and erlotinib are effective treatments for lung cancers with EGFR activating mutations, but these tumors invariably develop drug resistance.  Here, we describe a gefitinib-sensitive lung cancer cell line that developed resistance to gefitinib as a result of focal amplification of the MET proto-oncogene. inhibition of MET signaling in these cells restored their sensitivity to gefitinib.  MET amplification was detected in 4 of 18 (22%) lung cancer specimens that had developed resistance to gefitinib or erlotinib.  We find that amplification of MET causes gefitinib resistance by driving ERBB3 (HER3)-dependent activation of PI3K, a pathway thought to be specific to EGFR/ERBB family receptors.  Thus, we propose that MET amplification may promote drug resistance in other ERBB-driven cancers as well.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr430gbvBeIoLVg90H21EOLACvtfcHk0ljBccV8Dji2Yw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXltlOjt7g%253D&md5=3da9383b4acb965f57529b095f8f4686</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1126%2Fscience.1141478&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1141478%26sid%3Dliteratum%253Aachs%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26aulast%3DZejnullahu%26aufirst%3DK.%26aulast%3DMitsudomi%26aufirst%3DT.%26aulast%3DSong%26aufirst%3DY.%26aulast%3DHyland%26aufirst%3DC.%26aulast%3DPark%26aufirst%3DJ.%2BO.%26aulast%3DLindeman%26aufirst%3DN.%26aulast%3DGale%26aufirst%3DC.%2BM.%26aulast%3DZhao%26aufirst%3DX.%26aulast%3DChristensen%26aufirst%3DJ.%26aulast%3DKosaka%26aufirst%3DT.%26aulast%3DHolmes%26aufirst%3DA.%2BJ.%26aulast%3DRogers%26aufirst%3DA.%2BM.%26aulast%3DCappuzzo%26aufirst%3DF.%26aulast%3DMok%26aufirst%3DT.%26aulast%3DLee%26aufirst%3DC.%26aulast%3DJohnson%26aufirst%3DB.%2BE.%26aulast%3DCantley%26aufirst%3DL.%2BC.%26aulast%3DJanne%26aufirst%3DP.%2BA.%26atitle%3DMET%2520amplification%2520leads%2520to%2520gefitinib%2520resistance%2520in%2520lung%2520cancer%2520by%2520activating%2520ERBB3%2520signaling%26jtitle%3DScience%26date%3D2007%26volume%3D316%26spage%3D1039%26epage%3D1043%26doi%3D10.1126%2Fscience.1141478" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group">Duffy, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGowan, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crown, J.</span><span> </span><span class="NLM_article-title">Targeted therapy for triple-negative breast cancer: where are we?</span> <span class="citation_source-journal">Int. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">131</span><span class="NLM_x">, </span> <span class="NLM_fpage">2471</span><span class="NLM_x">–</span> <span class="NLM_lpage">2477</span><span class="refDoi"> DOI: 10.1002/ijc.27632</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01774&amp;key=10.1002%2Fijc.27632" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01774&amp;key=22581656" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01774&amp;key=1%3ACAS%3A528%3ADC%252BC38XotFKmurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=131&publication_year=2012&pages=2471-2477&author=M.+J.+Duffyauthor=P.+M.+McGowanauthor=J.+Crown&title=Targeted+therapy+for+triple-negative+breast+cancer%3A+where+are+we%3F&doi=10.1002%2Fijc.27632"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Targeted therapy for triple-negative breast cancer: Where are we?</span></div><div class="casAuthors">Duffy, Michael J.; McGowan, Patricia M.; Crown, John</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Cancer</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">131</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2471-2477</span>CODEN:
                <span class="NLM_cas:coden">IJCNAW</span>;
        ISSN:<span class="NLM_cas:issn">0020-7136</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">A review.  Breast cancers that are neg. for estrogen receptor (ER), progesterone receptors (PR) and HER2, using std. clin. assays, have been dubbed triple-neg. (TN).  Unlike other mol. subtypes of invasive breast cancer, validated targeted therapies are currently unavailable for patients with TN breast cancer.  Preclin. studies however, have identified several potential targets such as epidermal growth factor receptor (EGFR), SRC, MET and poly ADP ribose polymerase 1/2 (PARP1/2).  Because of tumor heterogeneity, it is unlikely that any single targeted therapy will be efficacious in all patients with TN breast cancer.  The rational way forward for treating these patients is likely to be biomarker-driven, combination targeted therapies or combination of targeted therapy with cytotoxic chemotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqnmJkW7zwQsbVg90H21EOLACvtfcHk0lgsssQJykzhTw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XotFKmurg%253D&md5=3e09cb2672f68bc17b80bbc17253f039</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1002%2Fijc.27632&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fijc.27632%26sid%3Dliteratum%253Aachs%26aulast%3DDuffy%26aufirst%3DM.%2BJ.%26aulast%3DMcGowan%26aufirst%3DP.%2BM.%26aulast%3DCrown%26aufirst%3DJ.%26atitle%3DTargeted%2520therapy%2520for%2520triple-negative%2520breast%2520cancer%253A%2520where%2520are%2520we%253F%26jtitle%3DInt.%2520J.%2520Cancer%26date%3D2012%26volume%3D131%26spage%3D2471%26epage%3D2477%26doi%3D10.1002%2Fijc.27632" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">deFazio, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chiew, Y. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McEvoy, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watts, C. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sutherland, R. L.</span><span> </span><span class="NLM_article-title">Antisense estrogen receptor RNA expression increases epidermal growth factor receptor gene expression in breast cancer cells</span> <span class="citation_source-journal">Cell Growth Differ.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">903</span><span class="NLM_x">–</span> <span class="NLM_lpage">911</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01774&amp;key=9269899" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01774&amp;key=1%3ACAS%3A528%3ADyaK2sXlsVGgs7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=1997&pages=903-911&author=A.+deFazioauthor=Y.+E.+Chiewauthor=M.+McEvoyauthor=C.+K.+Wattsauthor=R.+L.+Sutherland&title=Antisense+estrogen+receptor+RNA+expression+increases+epidermal+growth+factor+receptor+gene+expression+in+breast+cancer+cells"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Antisense estrogen receptor RNA expression increases epidermal growth factor receptor gene expression in breast cancer cells</span></div><div class="casAuthors">Defazio, Anna; Chiew, Yoke-Eng; Mcevoy, Maryanne; Watts, Colin K. W.; Sutherland, Robert L.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Growth & Differentiation</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">903-911</span>CODEN:
                <span class="NLM_cas:coden">CGDIE7</span>;
        ISSN:<span class="NLM_cas:issn">1044-9523</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">In human breast cancer, progression to a more malignant phenotype is often accompanied by decreased expression of estrogen receptor (ER) and increased expression of epidermal growth factor receptor (EGFR).  Higher levels of this receptor tyrosine kinase are found in tumors lacking ER, and a quant., inverse relation exists between the level of ER and EGFR mRNA in human breast cell lines.  Antisense ER (ASER) RNA was used to evaluate the consequence of decreased ER expression in breast cancer cells, specifically to det. whether ER is involved in the regulation of EGFR gene expression.  ER-pos. MCF-7 human breast cancer cells were transfected with ASER, and clones constitutively expressing ASER RNA had decreased ER and up to a 3-fold increase in the expression of EGFR mRNA.  To confirm that this observation was a direct consequence of ASER expression, a metal-inducible ASER expression construct was transfected into MCF-7 cells, and transfected clones were isolated and characterized.  Northern anal. revealed an induction of ASER RNA within 1 h of the addn. of zinc, which was followed by a 4-fold increase in EGFR mRNA levels, maximal at 6-12 h.  The basal level of expression of the glucocorticoid receptor is also inversely related to that of ER among breast cancer cell lines but neither constitutive nor inducible expression of ASER affected the expression of glucocorticoid receptor.  These data support the hypothesis that the level of expression of ER specifically influences the expression of EGFR in human breast cancer cells and provides a potential link between loss of steroid sensitivity and the acquisition of autonomous growth.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrpLM5BDYb_0LVg90H21EOLACvtfcHk0lgsssQJykzhTw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXlsVGgs7c%253D&md5=a885da2b97b609942d5825f5a4900ed3</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DdeFazio%26aufirst%3DA.%26aulast%3DChiew%26aufirst%3DY.%2BE.%26aulast%3DMcEvoy%26aufirst%3DM.%26aulast%3DWatts%26aufirst%3DC.%2BK.%26aulast%3DSutherland%26aufirst%3DR.%2BL.%26atitle%3DAntisense%2520estrogen%2520receptor%2520RNA%2520expression%2520increases%2520epidermal%2520growth%2520factor%2520receptor%2520gene%2520expression%2520in%2520breast%2520cancer%2520cells%26jtitle%3DCell%2520Growth%2520Differ.%26date%3D1997%26volume%3D8%26spage%3D903%26epage%3D911" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">Nielsen, T. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hsu, F. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jensen, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheang, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karaca, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hernandez-Boussard, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Livasy, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cowan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dressler</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Akslen, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ragaz, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gown, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilks, C. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van de Rijn, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perou, C. M.</span><span> </span><span class="NLM_article-title">Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">5367</span><span class="NLM_x">–</span> <span class="NLM_lpage">5374</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-04-0220</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01774&amp;key=10.1158%2F1078-0432.CCR-04-0220" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01774&amp;key=15328174" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01774&amp;key=1%3ACAS%3A528%3ADC%252BD2cXmvFSlt7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2004&pages=5367-5374&author=T.+O.+Nielsenauthor=F.+D.+Hsuauthor=K.+Jensenauthor=M.+Cheangauthor=G.+Karacaauthor=Z.+Huauthor=T.+Hernandez-Boussardauthor=C.+Livasyauthor=D.+Cowanauthor=+Dresslerauthor=L.+A.+Akslenauthor=J.+Ragazauthor=A.+M.+Gownauthor=C.+B.+Gilksauthor=M.+van+de+Rijnauthor=C.+M.+Perou&title=Immunohistochemical+and+clinical+characterization+of+the+basal-like+subtype+of+invasive+breast+carcinoma&doi=10.1158%2F1078-0432.CCR-04-0220"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma</span></div><div class="casAuthors">Nielsen, Torsten O.; Hsu, Forrest D.; Jensen, Kristin; Cheang, Maggie; Karaca, Gamze; Hu, Zhiyuan; Hernandez-Boussard, Tina; Livasy, Chad; Cowan, Dave; Dressler, Lynn; Akslen, Lars A.; Ragaz, Joseph; Gown, Allen M.; Gilks, C. Blake; van de Rijn, Matt; Perou, Charles M.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">5367-5374</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Expression profiling studies classified breast carcinomas into estrogen receptor (ER)+/luminal, normal breast-like, HER2 overexpressing, and basal-like groups, with the latter two assocd. with poor outcomes.  Currently, there exist clin. assays that identify ER+/luminal and HER2-overexpressing tumors, and we sought to develop a clin. assay for breast basal-like tumors.  To identify an immunohistochem. profile for breast basal-like tumors, we collected a series of known basal-like tumors and tested them for protein patterns that are characteristic of this subtype.  Next, we examd. the significance of these protein patterns using tissue microarrays and evaluated the prognostic significance of these findings.  Using a panel of 21 basal-like tumors, which was detd. using gene expression profiles, we saw that this subtype was typically immunohistochem. neg. for estrogen receptor and HER2 but pos. for basal cytokeratins, HER1, and/or c-KIT.  Using breast carcinoma tissue microarrays representing 930 patients with 17.4-yr mean follow-up, basal cytokeratin expression was assocd. with low disease-specific survival.  HER1 expression was obsd. in 54% of cases pos. for basal cytokeratins (vs. 11% of neg. cases) and was assocd. with poor survival independent of nodal status and size. c-KIT expression was more common in basal-like tumors than in other breast cancers but did not influence prognosis.  A panel of four antibodies (ER, HER1, HER2, and cytokeratin 5/6) can accurately identify basal-like tumors using std. available clin. tools and shows high specificity.  These studies show that many basal-like tumors express HER1, which suggests candidate drugs for evaluation in these patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo71vxmorFG-LVg90H21EOLACvtfcHk0lgsssQJykzhTw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXmvFSlt7k%253D&md5=139e2accba56257f9557ea030b6270b7</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-04-0220&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-04-0220%26sid%3Dliteratum%253Aachs%26aulast%3DNielsen%26aufirst%3DT.%2BO.%26aulast%3DHsu%26aufirst%3DF.%2BD.%26aulast%3DJensen%26aufirst%3DK.%26aulast%3DCheang%26aufirst%3DM.%26aulast%3DKaraca%26aufirst%3DG.%26aulast%3DHu%26aufirst%3DZ.%26aulast%3DHernandez-Boussard%26aufirst%3DT.%26aulast%3DLivasy%26aufirst%3DC.%26aulast%3DCowan%26aufirst%3DD.%26aulast%3DDressler%26aulast%3DAkslen%26aufirst%3DL.%2BA.%26aulast%3DRagaz%26aufirst%3DJ.%26aulast%3DGown%26aufirst%3DA.%2BM.%26aulast%3DGilks%26aufirst%3DC.%2BB.%26aulast%3Dvan%2Bde%2BRijn%26aufirst%3DM.%26aulast%3DPerou%26aufirst%3DC.%2BM.%26atitle%3DImmunohistochemical%2520and%2520clinical%2520characterization%2520of%2520the%2520basal-like%2520subtype%2520of%2520invasive%2520breast%2520carcinoma%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2004%26volume%3D10%26spage%3D5367%26epage%3D5374%26doi%3D10.1158%2F1078-0432.CCR-04-0220" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group">Corkery, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crown, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clynes, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Donovan, N.</span><span> </span><span class="NLM_article-title">Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer</span> <span class="citation_source-journal">Ann. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">862</span><span class="NLM_x">–</span> <span class="NLM_lpage">867</span><span class="refDoi"> DOI: 10.1093/annonc/mdn710</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01774&amp;key=10.1093%2Fannonc%2Fmdn710" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01774&amp;key=19150933" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01774&amp;key=1%3ACAS%3A280%3ADC%252BD1MzgvVyitw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2009&pages=862-867&author=B.+Corkeryauthor=J.+Crownauthor=M.+Clynesauthor=N.+O%E2%80%99Donovan&title=Epidermal+growth+factor+receptor+as+a+potential+therapeutic+target+in+triple-negative+breast+cancer&doi=10.1093%2Fannonc%2Fmdn710"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer</span></div><div class="casAuthors">Corkery B; Crown J; Clynes M; O'Donovan N</div><div class="citationInfo"><span class="NLM_cas:title">Annals of oncology : official journal of the European Society for Medical Oncology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">862-7</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  No proven targeted therapy is currently available for the treatment of triple-negative breast cancer (TNBC).  Epidermal growth factor receptor (EGFR) is frequently overexpressed in TNBC.  We studied the activity of EGFR antagonists alone, and in combination with chemotherapy, in TNBC cell lines.  MATERIALS AND METHODS:  EGFR and phosphorylated EGFR were measured by enzyme-linked immunosorbent assay.  Sensitivity to EGFR inhibitors alone and in combination with chemotherapy was assessed.  Effects of gefitinib on EGFR signalling and cell cycle were also examined.  RESULTS:  EGFR was overexpressed in the TNBC compared with the human epidermal growth factor receptor 2 (HER-2)-positive cell lines.  Phosphorylation of EGFR was detected in the TNBC cells in response to epidermal growth factor stimulation and was blocked by gefitinib treatment.  However, the TNBC cell lines were less sensitive to EGFR inhibition than the HER-2-positive cell lines.  Response to gefitinib was associated with reduced phosphorylation of both mitogen activated protein kinase (MAPK) and Akt and induction of G(1) arrest.  Gefitinib enhanced response to both carboplatin and docetaxel in the TNBC cells, and the triple combination of gefitinib, carboplatin and docetaxel was synergistic.  CONCLUSIONS:  Although the TNBC cells are less sensitive to EGFR inhibition than the HER-2-positive cell lines, gefitinib enhanced response to chemotherapy.  Gefitinib combined with carboplatin and docetaxel warrants further investigation in TNBC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSwDYVxbcpKC_EeosoOnpOLfW6udTcc2eaW3kl0-KcqhLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1MzgvVyitw%253D%253D&md5=e5e1fc85f70552c7ffafca14fe9ed491</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1093%2Fannonc%2Fmdn710&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fannonc%252Fmdn710%26sid%3Dliteratum%253Aachs%26aulast%3DCorkery%26aufirst%3DB.%26aulast%3DCrown%26aufirst%3DJ.%26aulast%3DClynes%26aufirst%3DM.%26aulast%3DO%25E2%2580%2599Donovan%26aufirst%3DN.%26atitle%3DEpidermal%2520growth%2520factor%2520receptor%2520as%2520a%2520potential%2520therapeutic%2520target%2520in%2520triple-negative%2520breast%2520cancer%26jtitle%3DAnn.%2520Oncol.%26date%3D2009%26volume%3D20%26spage%3D862%26epage%3D867%26doi%3D10.1093%2Fannonc%2Fmdn710" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">Nakai, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hung, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamaguchi, H.</span><span> </span><span class="NLM_article-title">A perspective on anti-EGFR therapies targeting triple-negative breast cancer</span> <span class="citation_source-journal">Am. J. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">1609</span><span class="NLM_x">–</span> <span class="NLM_lpage">1623</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01774&amp;key=27648353" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01774&amp;key=1%3ACAS%3A528%3ADC%252BC1cXotFers7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2016&pages=1609-1623&author=K.+Nakaiauthor=M.+C.+Hungauthor=H.+Yamaguchi&title=A+perspective+on+anti-EGFR+therapies+targeting+triple-negative+breast+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">A perspective on anti-EGFR therapies targeting triple-negative breast cancer</span></div><div class="casAuthors">Nakai, Katsuya; Hung, Mien-Chie; Yamaguchi, Hirohito</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Cancer Research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1609-1623</span>CODEN:
                <span class="NLM_cas:coden">AJCRFT</span>;
        ISSN:<span class="NLM_cas:issn">2156-6976</span>.
    
            (<span class="NLM_cas:orgname">e-Century Publishing Corp.</span>)
        </div><div class="casAbstract">Triple-neg. breast cancer (TNBC), which lacks estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2), accounts for about 15-20% of breast cancers and is the most aggressive breast cancer subtype.  There are currently no effective therapies against metastatic TNBC.  Compared with other breast cancer subtypes, EGFR is frequently overexpressed in TNBC and a potential therapeutic target for this disease.  There are two types of EGFR inhibitors, small mol. tyrosine kinase inhibitor (TKI) and monoclonal antibody (mAb), for the treatment of cancers, such as non-small cell lung cancer and colorectal cancer.  For breast cancer, however, the clin. trials of EGFR inhibitors have failed due to low response rates.  Because a small portion of patients do demonstrate response to EGFR inhibitors, it may be necessary to stratify patients to enhance the efficacy of EGFR inhibitors in TNBC and to develop the effective combination therapy for this patient population.  In this review, we describe some of the mol. mechanisms underlying EGFR inhibitor sensitivity and further discuss the possible therapeutic strategies to increase the efficacy of EGFR inhibitors in TNBC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrGYTJlhdhPhLVg90H21EOLACvtfcHk0ljsE_uu0LVGRg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXotFers7g%253D&md5=e13cf20b285b00db54350e62423f5d80</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DNakai%26aufirst%3DK.%26aulast%3DHung%26aufirst%3DM.%2BC.%26aulast%3DYamaguchi%26aufirst%3DH.%26atitle%3DA%2520perspective%2520on%2520anti-EGFR%2520therapies%2520targeting%2520triple-negative%2520breast%2520cancer%26jtitle%3DAm.%2520J.%2520Cancer%2520Res.%26date%3D2016%26volume%3D6%26spage%3D1609%26epage%3D1623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">Biswas, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cruz, A. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gansberger, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pardee, A. B.</span><span> </span><span class="NLM_article-title">Epidermal growth factor-induced nuclear factor κB activation: a major pathway of cell-cycle progression in estrogen-receptor negative breast cancer cells</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">97</span><span class="NLM_x">, </span> <span class="NLM_fpage">8542</span><span class="NLM_x">–</span> <span class="NLM_lpage">8547</span><span class="refDoi"> DOI: 10.1073/pnas.97.15.8542</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01774&amp;key=10.1073%2Fpnas.97.15.8542" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=97&publication_year=2000&pages=8542-8547&author=D.+K.+Biswasauthor=A.+P.+Cruzauthor=E.+Gansbergerauthor=A.+B.+Pardee&title=Epidermal+growth+factor-induced+nuclear+factor+%CE%BAB+activation%3A+a+major+pathway+of+cell-cycle+progression+in+estrogen-receptor+negative+breast+cancer+cells&doi=10.1073%2Fpnas.97.15.8542"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1073%2Fpnas.97.15.8542&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.97.15.8542%26sid%3Dliteratum%253Aachs%26aulast%3DBiswas%26aufirst%3DD.%2BK.%26aulast%3DCruz%26aufirst%3DA.%2BP.%26aulast%3DGansberger%26aufirst%3DE.%26aulast%3DPardee%26aufirst%3DA.%2BB.%26atitle%3DEpidermal%2520growth%2520factor-induced%2520nuclear%2520factor%2520%25CE%25BAB%2520activation%253A%2520a%2520major%2520pathway%2520of%2520cell-cycle%2520progression%2520in%2520estrogen-receptor%2520negative%2520breast%2520cancer%2520cells%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2000%26volume%3D97%26spage%3D8542%26epage%3D8547%26doi%3D10.1073%2Fpnas.97.15.8542" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Nakshatri, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhat-Nakshatri, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goulet, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sledge, G. W. J.</span><span> </span><span class="NLM_article-title">Constitutive activation of NF-kB during progression of breast cancer to hormone-independent growth</span> <span class="citation_source-journal">Mol. Cell. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">3629</span><span class="NLM_x">–</span> <span class="NLM_lpage">3639</span><span class="refDoi"> DOI: 10.1128/MCB.17.7.3629</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01774&amp;key=10.1128%2FMCB.17.7.3629" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01774&amp;key=9199297" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01774&amp;key=1%3ACAS%3A528%3ADyaK2sXktFOhtLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=1997&pages=3629-3639&author=H.+Nakshatriauthor=P.+Bhat-Nakshatriauthor=D.+A.+Martinauthor=R.+J.+Gouletauthor=G.+W.+J.+Sledge&title=Constitutive+activation+of+NF-kB+during+progression+of+breast+cancer+to+hormone-independent+growth&doi=10.1128%2FMCB.17.7.3629"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Constitutive activation of NF-κB during progression of breast cancer to hormone-independent growth</span></div><div class="casAuthors">Nakshatri, Harikrishna; Bhat-Nakshatri, Poornima; Martin, Daniel A.; Goulet, Robert J., Jr.; Sledge, George W., Jr.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Biology</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">3629-3639</span>CODEN:
                <span class="NLM_cas:coden">MCEBD4</span>;
        ISSN:<span class="NLM_cas:issn">0270-7306</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Breast cancers often progress from a hormone-dependent, nonmetastatic, antiestrogen-sensitive phenotype to a hormone-independent, antiestrogen- and chemotherapy-resistant phenotype with highly invasive and metastatic growth properties.  This progression is usually accompanied by altered function of the estrogen receptor (ER) or outgrowth of ER-neg. cancer cells.  To understand the mol. mechanisms responsible for metastatic growth of ER-neg. breast cancers, the activities of the transcription factor NF-κB (which modulates the expression of genes involved in cell proliferation, differentiation, apoptosis, and metastasis) were compared in ER-pos. (MCF-7 and T47 D) and ER-neg. (MDA-MB-231 and MDA-MB-435) human breast cancer cell lines.  NF-κB, which is usually maintained in an inactive state by protein-protein interaction with inhibitor IκBs, was found to be constitutively active in ER-neg. breast cancer cell lines.  Constitutive DNA binding of NF-κB was also obsd. with exts. from ER-neg., poorly differentiated primary breast tumors.  Progression of the rat mammary carcinoma cell line RM22-F5 from an ER-pos., nonmalignant phenotype (E phenotype) to an ER-neg., malignant phenotype (F phenotype) was also accompanied by constitutive activation of NF-κB.  Anal. of individual subunits of NF-κB revealed that all ER-neg. cell lines, including RM22-F5 cells of F phenotype, contain a unique 37-kDa protein which is antigenically related to the RelA subunit.  Cell-type-specific differences in IκBα, -β, and -γ were also obsd.  In transient-transfection expts., constitutive activity of an NF-κB-dependent promoter was obsd. in MDA-MB-231 and RM22-F5 cells of F phenotype, and this activity was efficiently repressed by cotransfected ER.  Since ER inhibits the constitutive as well as inducible activation function of NFκB in a dose-dependent manner, the authors propose that breast cancers that lack functional ER overexpress NFκB-regulated genes.  Furthermore, since recent data indicate that NF-κB protects cells from tumor necrosis factor alpha-, ionizing radiation-, and chemotherapeutic agent daunorubicin-mediated apoptosis, the results provide an explanation for chemotherapeutic resistance in ER-neg. breast cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpnMGhiNR4C7bVg90H21EOLACvtfcHk0lgM6sxyOM3kkw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXktFOhtLY%253D&md5=dd1afb1617221b6e9d1da86f1a3c88b8</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1128%2FMCB.17.7.3629&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FMCB.17.7.3629%26sid%3Dliteratum%253Aachs%26aulast%3DNakshatri%26aufirst%3DH.%26aulast%3DBhat-Nakshatri%26aufirst%3DP.%26aulast%3DMartin%26aufirst%3DD.%2BA.%26aulast%3DGoulet%26aufirst%3DR.%2BJ.%26aulast%3DSledge%26aufirst%3DG.%2BW.%2BJ.%26atitle%3DConstitutive%2520activation%2520of%2520NF-kB%2520during%2520progression%2520of%2520breast%2520cancer%2520to%2520hormone-independent%2520growth%26jtitle%3DMol.%2520Cell.%2520Biol.%26date%3D1997%26volume%3D17%26spage%3D3629%26epage%3D3639%26doi%3D10.1128%2FMCB.17.7.3629" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">Shostak, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chariot, A.</span><span> </span><span class="NLM_article-title">Chariot, A. EGFR and NF-kappaB: partners in cancer</span> <span class="citation_source-journal">Trends Mol. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">385</span><span class="NLM_x">–</span> <span class="NLM_lpage">393</span><span class="refDoi"> DOI: 10.1016/j.molmed.2015.04.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01774&amp;key=10.1016%2Fj.molmed.2015.04.001" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2015&pages=385-393&author=K.+Shostakauthor=A.+Chariot&title=Chariot%2C+A.+EGFR+and+NF-kappaB%3A+partners+in+cancer&doi=10.1016%2Fj.molmed.2015.04.001"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1016%2Fj.molmed.2015.04.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molmed.2015.04.001%26sid%3Dliteratum%253Aachs%26aulast%3DShostak%26aufirst%3DK.%26aulast%3DChariot%26aufirst%3DA.%26atitle%3DChariot%252C%2520A.%2520EGFR%2520and%2520NF-kappaB%253A%2520partners%2520in%2520cancer%26jtitle%3DTrends%2520Mol.%2520Med.%26date%3D2015%26volume%3D21%26spage%3D385%26epage%3D393%26doi%3D10.1016%2Fj.molmed.2015.04.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Bivona, T. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hieronymus, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parker, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taron, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosell, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moonsamy, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dahlman, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, V. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Costa, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hannon, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sawyers, C. L.</span><span> </span><span class="NLM_article-title">FAS and NF-kappaB signalling modulate dependence of lung cancers on mutant EGFR</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">471</span><span class="NLM_x">, </span> <span class="NLM_fpage">523</span><span class="NLM_x">–</span> <span class="NLM_lpage">526</span><span class="refDoi"> DOI: 10.1038/nature09870</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01774&amp;key=10.1038%2Fnature09870" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=471&publication_year=2011&pages=523-526&author=T.+G.+Bivonaauthor=H.+Hieronymusauthor=J.+Parkerauthor=K.+Changauthor=M.+Taronauthor=R.+Rosellauthor=P.+Moonsamyauthor=K.+Dahlmanauthor=V.+A.+Millerauthor=C.+Costaauthor=G.+Hannonauthor=C.+L.+Sawyers&title=FAS+and+NF-kappaB+signalling+modulate+dependence+of+lung+cancers+on+mutant+EGFR&doi=10.1038%2Fnature09870"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1038%2Fnature09870&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature09870%26sid%3Dliteratum%253Aachs%26aulast%3DBivona%26aufirst%3DT.%2BG.%26aulast%3DHieronymus%26aufirst%3DH.%26aulast%3DParker%26aufirst%3DJ.%26aulast%3DChang%26aufirst%3DK.%26aulast%3DTaron%26aufirst%3DM.%26aulast%3DRosell%26aufirst%3DR.%26aulast%3DMoonsamy%26aufirst%3DP.%26aulast%3DDahlman%26aufirst%3DK.%26aulast%3DMiller%26aufirst%3DV.%2BA.%26aulast%3DCosta%26aufirst%3DC.%26aulast%3DHannon%26aufirst%3DG.%26aulast%3DSawyers%26aufirst%3DC.%2BL.%26atitle%3DFAS%2520and%2520NF-kappaB%2520signalling%2520modulate%2520dependence%2520of%2520lung%2520cancers%2520on%2520mutant%2520EGFR%26jtitle%3DNature%26date%3D2011%26volume%3D471%26spage%3D523%26epage%3D526%26doi%3D10.1038%2Fnature09870" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">Blakely, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pazarentzos, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olivas, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Asthana, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yan, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hrustanovic, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neel, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Newton, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bobb, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fouts, T. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meshulam, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gubens, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jablons, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bandyopadhyay, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krogan, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bivona, T. G.</span><span> </span><span class="NLM_article-title">NF-kappaB-activating complex engaged in response to EGFR oncogene inhibition drives tumor cell survival and residual disease in lung cancer</span> <span class="citation_source-journal">Cell Rep.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">98</span><span class="NLM_x">–</span> <span class="NLM_lpage">110</span><span class="refDoi"> DOI: 10.1016/j.celrep.2015.03.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01774&amp;key=10.1016%2Fj.celrep.2015.03.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01774&amp;key=25843712" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01774&amp;key=1%3ACAS%3A528%3ADC%252BC2MXlvVCisr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2015&pages=98-110&author=C.+M.+Blakelyauthor=E.+Pazarentzosauthor=V.+Olivasauthor=S.+Asthanaauthor=J.+J.+Yanauthor=I.+Tanauthor=G.+Hrustanovicauthor=E.+Chanauthor=L.+Linauthor=D.+S.+Neelauthor=W.+Newtonauthor=K.+L.+Bobbauthor=T.+R.+Foutsauthor=J.+Meshulamauthor=M.+A.+Gubensauthor=D.+M.+Jablonsauthor=J.+R.+Johnsonauthor=S.+Bandyopadhyayauthor=N.+J.+Kroganauthor=T.+G.+Bivona&title=NF-kappaB-activating+complex+engaged+in+response+to+EGFR+oncogene+inhibition+drives+tumor+cell+survival+and+residual+disease+in+lung+cancer&doi=10.1016%2Fj.celrep.2015.03.012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">NF-κB-Activating Complex Engaged in Response to EGFR Oncogene Inhibition Drives Tumor Cell Survival and Residual Disease in Lung Cancer</span></div><div class="casAuthors">Blakely, Collin M.; Pazarentzos, Evangelos; Olivas, Victor; Asthana, Saurabh; Yan, Jenny Jiacheng; Tan, Irena; Hrustanovic, Gorjan; Chan, Elton; Lin, Luping; Neel, Dana S.; Newton, William; Bobb, Kathryn L.; Fouts, Timothy R.; Meshulam, Jeffrey; Gubens, Matthew A.; Jablons, David M.; Johnson, Jeffrey R.; Bandyopadhyay, Sourav; Krogan, Nevan J.; Bivona, Trever G.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Reports</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">98-110</span>CODEN:
                <span class="NLM_cas:coden">CREED8</span>;
        ISSN:<span class="NLM_cas:issn">2211-1247</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Although oncogene-targeted therapy often elicits profound initial tumor responses in patients, responses are generally incomplete because some tumor cells survive initial therapy as residual disease that enables eventual acquired resistance.  The mechanisms underlying tumor cell adaptation and survival during initial therapy are incompletely understood.  Here, through the study of EGFR mutant lung adenocarcinoma, we show that NF-κB signaling is rapidly engaged upon initial EGFR inhibitor treatment to promote tumor cell survival and residual disease.  EGFR oncogene inhibition induced an EGFR-TRAF2-RIP1-IKK complex that stimulated an NF-κB-mediated transcriptional survival program.  The direct NF-κB inhibitor PBS-1086 suppressed this adaptive survival program and increased the magnitude and duration of initial EGFR inhibitor response in multiple NSCLC models, including a patient-derived xenograft.  These findings unveil NF-κB activation as a crit. adaptive survival mechanism engaged by EGFR oncogene inhibition and provide rationale for EGFR and NF-κB co-inhibition to eliminate residual disease and enhance patient responses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoC125gpHJNxLVg90H21EOLACvtfcHk0lgM6sxyOM3kkw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXlvVCisr0%253D&md5=819a5e83c2ad6549a1c88e68c6b75285</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1016%2Fj.celrep.2015.03.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.celrep.2015.03.012%26sid%3Dliteratum%253Aachs%26aulast%3DBlakely%26aufirst%3DC.%2BM.%26aulast%3DPazarentzos%26aufirst%3DE.%26aulast%3DOlivas%26aufirst%3DV.%26aulast%3DAsthana%26aufirst%3DS.%26aulast%3DYan%26aufirst%3DJ.%2BJ.%26aulast%3DTan%26aufirst%3DI.%26aulast%3DHrustanovic%26aufirst%3DG.%26aulast%3DChan%26aufirst%3DE.%26aulast%3DLin%26aufirst%3DL.%26aulast%3DNeel%26aufirst%3DD.%2BS.%26aulast%3DNewton%26aufirst%3DW.%26aulast%3DBobb%26aufirst%3DK.%2BL.%26aulast%3DFouts%26aufirst%3DT.%2BR.%26aulast%3DMeshulam%26aufirst%3DJ.%26aulast%3DGubens%26aufirst%3DM.%2BA.%26aulast%3DJablons%26aufirst%3DD.%2BM.%26aulast%3DJohnson%26aufirst%3DJ.%2BR.%26aulast%3DBandyopadhyay%26aufirst%3DS.%26aulast%3DKrogan%26aufirst%3DN.%2BJ.%26aulast%3DBivona%26aufirst%3DT.%2BG.%26atitle%3DNF-kappaB-activating%2520complex%2520engaged%2520in%2520response%2520to%2520EGFR%2520oncogene%2520inhibition%2520drives%2520tumor%2520cell%2520survival%2520and%2520residual%2520disease%2520in%2520lung%2520cancer%26jtitle%3DCell%2520Rep.%26date%3D2015%26volume%3D11%26spage%3D98%26epage%3D110%26doi%3D10.1016%2Fj.celrep.2015.03.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">Shimizu, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tolcher, A. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Papadopoulos, K. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beeram, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rasco, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, L. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gunn, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smetzer, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mays, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaiser, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wick, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alvarez, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cavazos, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mangold, G. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patnaik, A.</span><span> </span><span class="NLM_article-title">The clinical effect of the dual-targeting strategy involving PI3K/AKT/mTOR and RAS/MEK/ERK pathways in patients with advanced cancer</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">2316</span><span class="NLM_x">–</span> <span class="NLM_lpage">2325</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-11-2381</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01774&amp;key=10.1158%2F1078-0432.CCR-11-2381" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01774&amp;key=22261800" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01774&amp;key=1%3ACAS%3A528%3ADC%252BC38XmsFOnurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2012&pages=2316-2325&author=T.+Shimizuauthor=A.+W.+Tolcherauthor=K.+P.+Papadopoulosauthor=M.+Beeramauthor=D.+W.+Rascoauthor=L.+S.+Smithauthor=S.+Gunnauthor=L.+Smetzerauthor=T.+A.+Maysauthor=B.+Kaiserauthor=M.+J.+Wickauthor=C.+Alvarezauthor=A.+Cavazosauthor=G.+L.+Mangoldauthor=A.+Patnaik&title=The+clinical+effect+of+the+dual-targeting+strategy+involving+PI3K%2FAKT%2FmTOR+and+RAS%2FMEK%2FERK+pathways+in+patients+with+advanced+cancer&doi=10.1158%2F1078-0432.CCR-11-2381"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">The Clinical Effect of the Dual-Targeting Strategy Involving PI3K/AKT/mTOR and RAS/MEK/ERK Pathways in Patients with Advanced Cancer</span></div><div class="casAuthors">Shimizu, Toshio; Tolcher, Anthony W.; Papadopoulos, Kyriakos P.; Beeram, Muralidhar; Rasco, Drew W.; Smith, Lon S.; Gunn, Shelly; Smetzer, Leslie; Mays, Theresa A.; Kaiser, Brianne; Wick, Michael J.; Alvarez, Cathy; Cavazos, Aracely; Mangold, Gina L.; Patnaik, Amita</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2316-2325</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">PURPOSE: This study evaluated the clin. relevance of the dual-targeting strategy involving PI3K/AKT/mTOR and RAF/MEK/ERK pathways.  Exptl. Design: We investigated safety, efficacy, and correlations between tumor genetic alterations and clin. benefit in 236 patients with advanced cancers treated with phase I study drugs targeting phosphoinositide 3-kinase (PI3K) and/or mitogen-activated protein kinase (MAPK) pathways in our Phase I Clin. Trials Program.  RESULTS: Seventy-six (32.2%) patients received a PI3K pathway inhibitor in combination with a MAPK pathway inhibitor (D), whereas 124 (52.5%) and 36 (15.3%), resp., received an inhibitor of either the PI3K or MAPK pathways (S).  The rates of drug-related grade >III adverse events were 18.1% for (S) and 53.9% for (D; P < 0.001); the rates of dose-limiting toxicities were 9.4% for (S) and 18.4% for (D; P = 0.06).  The most frequent grade >III adverse events were transaminase elevations, skin rash, and mucositis.  In our comprehensive tumor genomic anal., of 9 patients who harbored coactivation of both pathways (colorectal cancer, n = 7; melanoma, n = 2), all 5 patients treated with (D) had tumor regression ranging from 2% to 64%.  CONCLUSIONS: These results suggest that dual inhibition of both pathways may potentially exhibit favorable efficacy compared with inhibition of either pathway, at the expense of greater toxicity.  Furthermore, this parallel pathway targeting strategy may be esp. important in patients with coexisting PI3K pathway genetic alterations and KRAS or BRAF mutations and suggests that mol. profiling and matching patients with combinations of these targeted drugs will need to be investigated in depth.  Clin Cancer Res; 18(8); 2316-25.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXSSzrpJOMr7Vg90H21EOLACvtfcHk0ljpzkEr_6WZVQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XmsFOnurk%253D&md5=553a4cfbbd2b3bb1c9a7c9afeb1c0f5e</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-11-2381&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-11-2381%26sid%3Dliteratum%253Aachs%26aulast%3DShimizu%26aufirst%3DT.%26aulast%3DTolcher%26aufirst%3DA.%2BW.%26aulast%3DPapadopoulos%26aufirst%3DK.%2BP.%26aulast%3DBeeram%26aufirst%3DM.%26aulast%3DRasco%26aufirst%3DD.%2BW.%26aulast%3DSmith%26aufirst%3DL.%2BS.%26aulast%3DGunn%26aufirst%3DS.%26aulast%3DSmetzer%26aufirst%3DL.%26aulast%3DMays%26aufirst%3DT.%2BA.%26aulast%3DKaiser%26aufirst%3DB.%26aulast%3DWick%26aufirst%3DM.%2BJ.%26aulast%3DAlvarez%26aufirst%3DC.%26aulast%3DCavazos%26aufirst%3DA.%26aulast%3DMangold%26aufirst%3DG.%2BL.%26aulast%3DPatnaik%26aufirst%3DA.%26atitle%3DThe%2520clinical%2520effect%2520of%2520the%2520dual-targeting%2520strategy%2520involving%2520PI3K%252FAKT%252FmTOR%2520and%2520RAS%252FMEK%252FERK%2520pathways%2520in%2520patients%2520with%2520advanced%2520cancer%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2012%26volume%3D18%26spage%3D2316%26epage%3D2325%26doi%3D10.1158%2F1078-0432.CCR-11-2381" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">Rewcastle, G. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Denny, W. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bridges, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cody, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McMichael, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fry, D. W.</span><span> </span><span class="NLM_article-title">Tyrosine kinase inhibitors. 5. Synthesis and structure-activity relationships for 4-[(phenylmethyl)amino]- and 4-(phenylamino)quinazolines as potent adenosine 5′-triphosphate binding site inhibitors of the tyrosine kinase domain of the epidermal growth factor receptor</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">38</span><span class="NLM_x">, </span> <span class="NLM_fpage">3482</span><span class="NLM_x">–</span> <span class="NLM_lpage">3487</span><span class="refDoi"> DOI: 10.1021/jm00018a008</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm00018a008" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=1995&pages=3482-3487&author=G.+W.+Rewcastleauthor=W.+A.+Dennyauthor=A.+J.+Bridgesauthor=H.+Zhouauthor=D.+R.+Codyauthor=A.+McMichaelauthor=D.+W.+Fry&title=Tyrosine+kinase+inhibitors.+5.+Synthesis+and+structure-activity+relationships+for+4-%5B%28phenylmethyl%29amino%5D-+and+4-%28phenylamino%29quinazolines+as+potent+adenosine+5%E2%80%B2-triphosphate+binding+site+inhibitors+of+the+tyrosine+kinase+domain+of+the+epidermal+growth+factor+receptor&doi=10.1021%2Fjm00018a008"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1021%2Fjm00018a008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00018a008%26sid%3Dliteratum%253Aachs%26aulast%3DRewcastle%26aufirst%3DG.%2BW.%26aulast%3DDenny%26aufirst%3DW.%2BA.%26aulast%3DBridges%26aufirst%3DA.%2BJ.%26aulast%3DZhou%26aufirst%3DH.%26aulast%3DCody%26aufirst%3DD.%2BR.%26aulast%3DMcMichael%26aufirst%3DA.%26aulast%3DFry%26aufirst%3DD.%2BW.%26atitle%3DTyrosine%2520kinase%2520inhibitors.%25205.%2520Synthesis%2520and%2520structure-activity%2520relationships%2520for%25204-%255B%2528phenylmethyl%2529amino%255D-%2520and%25204-%2528phenylamino%2529quinazolines%2520as%2520potent%2520adenosine%25205%25E2%2580%25B2-triphosphate%2520binding%2520site%2520inhibitors%2520of%2520the%2520tyrosine%2520kinase%2520domain%2520of%2520the%2520epidermal%2520growth%2520factor%2520receptor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1995%26volume%3D38%26spage%3D3482%26epage%3D3487%26doi%3D10.1021%2Fjm00018a008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">Smaill, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rewcastle, G. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loo, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greis, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, O. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reyner, E. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lipka, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Showalter, H. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vincent, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elliott, W. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Denny, W. A.</span><span> </span><span class="NLM_article-title">Tyrosine kinase inhibitors. 17. Irreversible inhibitors of the epidermal growth factor receptor: 4-(phenylamino)quinazoline- and 4-(phenylamino)pyrido[3,2-d]pyrimidine-6-acrylamides bearing additional solubilizing functions</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">43</span><span class="NLM_x">, </span> <span class="NLM_fpage">1380</span><span class="NLM_x">–</span> <span class="NLM_lpage">1397</span><span class="refDoi"> DOI: 10.1021/jm990482t</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm990482t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01774&amp;key=1%3ACAS%3A528%3ADC%252BD3cXhs1Crtr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2000&pages=1380-1397&author=J.+B.+Smaillauthor=G.+W.+Rewcastleauthor=J.+A.+Looauthor=K.+D.+Greisauthor=O.+H.+Chanauthor=E.+L.+Reynerauthor=E.+Lipkaauthor=H.+D.+Showalterauthor=P.+W.+Vincentauthor=W.+L.+Elliottauthor=W.+A.+Denny&title=Tyrosine+kinase+inhibitors.+17.+Irreversible+inhibitors+of+the+epidermal+growth+factor+receptor%3A+4-%28phenylamino%29quinazoline-+and+4-%28phenylamino%29pyrido%5B3%2C2-d%5Dpyrimidine-6-acrylamides+bearing+additional+solubilizing+functions&doi=10.1021%2Fjm990482t"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Tyrosine kinase inhibitors. 17. Irreversible inhibitors of the epidermal growth factor receptor: 4-(Phenylamino)quinazoline- and 4-(Phenylamino)pyrido[3,2-d]pyrimidine-6-acrylamides bearing additional solubilizing functions</span></div><div class="casAuthors">Smaill, Jeff B.; Rewcastle, Gordon W.; Loo, Joseph A.; Greis, Kenneth D.; Chan, O. Helen; Reyner, Eric L.; Lipka, Elke; Showalter, H. D. Hollis; Vincent, Patrick W.; Elliott, William L.; Denny, William A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1380-1397</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">4-Anilinoquinazoline- and 4-anilinopyrido[3,2-d]pyrimidine-6-acrylamides substituted with solubilizing 7-alkylamine or 7-alkoxyamine side chains were prepd. by reaction of the corresponding 6-amines with acrylic acid or acrylic acid anhydrides.  In the pyrido[3,2-d]pyrimidine series, the intermediate 6-amino-7-alkylamines were prepd. from 7-bromo-6-fluoropyrido[3,2-d]pyrimidine via Stille coupling with the appropriate stannane under palladium(0) catalysis.  This proved a versatile method for the introduction of cationic solubilizing side chains.  The compds. were evaluated for their inhibition of phosphorylation of the isolated EGFR enzyme and for inhibition of EGF-stimulated autophosphorylation of EGFR in A431 cells and of heregulin-stimulated autophosphorylation of erbB2 in MDA-MB 453 cells.  Quinazoline analogs with 7-alkoxyamine solubilizing groups were potent irreversible inhibitors of the isolated EGFR enzyme, with IC50[app] values from 2 to 4 nM, and potently inhibited both EGFR and erbB2 autophosphorylation in cells. 7-Alkylamino- and 7-alkoxyaminopyrido[3,2-d]pyrimidines were also irreversible inhibitors with equal or superior potency against the isolated enzyme but were less effective in the cellular autophosphorylation assays.  Both quinazoline- and pyrido[3,2-d]pyrimidine-6-acrylamides bound at the ATP site alkylating cysteine 773, as shown by electrospray ionization mass spectrometry, and had similar rates of absorptive and secretory transport in Caco-2 cells.  A comparison of two 7-propoxymorpholide analogs showed that the pyrido[3,2-d]pyrimidine-6-acrylamide had greater amide instability and higher acrylamide reactivity, being converted to glutathione adducts in cells more rapidly than the corresponding quinazoline.  This difference may contribute to the obsd. lower cellular potency of the pyrido[3,2-d]pyrimidine-6-acrylamides.  Selected compds. showed high in vivo activity against A431 xenografts on oral dosing, with the quinazolines being superior to the pyrido[3,2-d]pyrimidines. Overall, the quinazolines proved superior to previous analogs in terms of aq. soly., potency, and in vivo antitumor activity, and one example (CI 1033) has been selected for clin. evaluation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpF5L1nBGlu6rVg90H21EOLACvtfcHk0lhlnWET49OCNA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXhs1Crtr0%253D&md5=6c569a822c398df08559abde31a1d4ac</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1021%2Fjm990482t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm990482t%26sid%3Dliteratum%253Aachs%26aulast%3DSmaill%26aufirst%3DJ.%2BB.%26aulast%3DRewcastle%26aufirst%3DG.%2BW.%26aulast%3DLoo%26aufirst%3DJ.%2BA.%26aulast%3DGreis%26aufirst%3DK.%2BD.%26aulast%3DChan%26aufirst%3DO.%2BH.%26aulast%3DReyner%26aufirst%3DE.%2BL.%26aulast%3DLipka%26aufirst%3DE.%26aulast%3DShowalter%26aufirst%3DH.%2BD.%26aulast%3DVincent%26aufirst%3DP.%2BW.%26aulast%3DElliott%26aufirst%3DW.%2BL.%26aulast%3DDenny%26aufirst%3DW.%2BA.%26atitle%3DTyrosine%2520kinase%2520inhibitors.%252017.%2520Irreversible%2520inhibitors%2520of%2520the%2520epidermal%2520growth%2520factor%2520receptor%253A%25204-%2528phenylamino%2529quinazoline-%2520and%25204-%2528phenylamino%2529pyrido%255B3%252C2-d%255Dpyrimidine-6-acrylamides%2520bearing%2520additional%2520solubilizing%2520functions%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2000%26volume%3D43%26spage%3D1380%26epage%3D1397%26doi%3D10.1021%2Fjm990482t" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">Sajan, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nimal, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mastorides, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Acevedo-Duncan, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kahn, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fields, A. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Braun, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leitges, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Farese, R. V.</span><span> </span><span class="NLM_article-title">Correction of metabolic abnormalities in a rodent model of obesity, metabolic syndrome, and type 2 diabetes mellitus by inhibitors of hepatic protein kinase C-iota</span> <span class="citation_source-journal">Metab., Clin. Exp.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">61</span><span class="NLM_x">, </span> <span class="NLM_fpage">459</span><span class="NLM_x">–</span> <span class="NLM_lpage">469</span><span class="refDoi"> DOI: 10.1016/j.metabol.2011.12.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01774&amp;key=10.1016%2Fj.metabol.2011.12.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01774&amp;key=22225955" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01774&amp;key=1%3ACAS%3A528%3ADC%252BC38XjvFKrtrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2012&pages=459-469&author=M.+P.+Sajanauthor=S.+Nimalauthor=S.+Mastoridesauthor=M.+Acevedo-Duncanauthor=C.+R.+Kahnauthor=A.+P.+Fieldsauthor=U.+Braunauthor=M.+Leitgesauthor=R.+V.+Farese&title=Correction+of+metabolic+abnormalities+in+a+rodent+model+of+obesity%2C+metabolic+syndrome%2C+and+type+2+diabetes+mellitus+by+inhibitors+of+hepatic+protein+kinase+C-iota&doi=10.1016%2Fj.metabol.2011.12.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Correction of metabolic abnormalities in a rodent model of obesity, metabolic syndrome, and type 2 diabetes mellitus by inhibitors of hepatic protein kinase C-ι</span></div><div class="casAuthors">Sajan, Mini P.; Nimal, Sonali; Mastorides, Stephen; Acevedo-Duncan, Mildred; Kahn, C. Ronald; Fields, Alan P.; Braun, Ursula; Leitges, Michael; Farese, Robert V.</div><div class="citationInfo"><span class="NLM_cas:title">Metabolism, Clinical and Experimental</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">459-469</span>CODEN:
                <span class="NLM_cas:coden">METAAJ</span>;
        ISSN:<span class="NLM_cas:issn">0026-0495</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Excessive activity of hepatic atypical protein kinase (aPKC) is proposed to play a crit. role in mediating lipid and carbohydrate abnormalities in obesity, the metabolic syndrome, and type 2 diabetes mellitus.  In previous studies of rodent models of obesity and type 2 diabetes mellitus, adenoviral-mediated expression of kinase-inactive aPKC rapidly reversed or markedly improved most if not all metabolic abnormalities.  Here, we examd. effects of 2 newly developed small-mol. PKC-ι/λ inhibitors.  We used the mouse model of heterozygous muscle-specific knockout of PKC-λ, in which partial deficiency of muscle PKC-λ impairs glucose transport in muscle and thereby causes glucose intolerance and hyperinsulinemia, which, via hepatic aPKC activation, leads to abdominal obesity, hepatosteatosis, hypertriglyceridemia, and hypercholesterolemia.  One inhibitor, 1H-imidazole-4-carboxamide, 5-amino-1-[2,3-dihydroxy-4-[(phosphonooxy)methyl]cyclopentyl-[1R-(1a,2b,3b,4a)]], binds to the substrate-binding site of PKC-λ/ι, but not other PKCs.  The other inhibitor, aurothiomalate, binds to cysteine residues in the PB1-binding domains of aPKC-λ/ι/ζ and inhibits scaffolding.  Treatment with either inhibitor for 7 days inhibited aPKC, but not Akt, in liver and concomitantly improved insulin signaling to Akt and aPKC in muscle and adipocytes.  Moreover, both inhibitors diminished excessive expression of hepatic, aPKC-dependent lipogenic, proinflammatory, and gluconeogenic factors; and this was accompanied by reversal or marked improvements in hyperglycemia, hyperinsulinemia, abdominal obesity, hepatosteatosis, hypertriglyceridemia, and hypercholesterolemia.  Our findings highlight the pathogenetic importance of insulin signaling to hepatic PKC-ι in obesity, the metabolic syndrome, and type 2 diabetes mellitus and suggest that 1H-imidazole-4-carboxamide, 5-amino-1-[2,3-dihydroxy-4-[(phosphonooxy)methyl]cyclopentyl-[1R-(1a,2b,3b,4a)]] and aurothiomalate or similar agents that selectively inhibit hepatic aPKC may be useful treatments.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo6O8rXWz2X57Vg90H21EOLACvtfcHk0lhlnWET49OCNA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XjvFKrtrY%253D&md5=7c783772ef69767ed31689a28cad2916</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1016%2Fj.metabol.2011.12.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.metabol.2011.12.008%26sid%3Dliteratum%253Aachs%26aulast%3DSajan%26aufirst%3DM.%2BP.%26aulast%3DNimal%26aufirst%3DS.%26aulast%3DMastorides%26aufirst%3DS.%26aulast%3DAcevedo-Duncan%26aufirst%3DM.%26aulast%3DKahn%26aufirst%3DC.%2BR.%26aulast%3DFields%26aufirst%3DA.%2BP.%26aulast%3DBraun%26aufirst%3DU.%26aulast%3DLeitges%26aufirst%3DM.%26aulast%3DFarese%26aufirst%3DR.%2BV.%26atitle%3DCorrection%2520of%2520metabolic%2520abnormalities%2520in%2520a%2520rodent%2520model%2520of%2520obesity%252C%2520metabolic%2520syndrome%252C%2520and%2520type%25202%2520diabetes%2520mellitus%2520by%2520inhibitors%2520of%2520hepatic%2520protein%2520kinase%2520C-iota%26jtitle%3DMetab.%252C%2520Clin.%2520Exp.%26date%3D2012%26volume%3D61%26spage%3D459%26epage%3D469%26doi%3D10.1016%2Fj.metabol.2011.12.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group">Jones, T. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thornton, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flinn, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jackman, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Newell, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Calvert, A. H.</span><span> </span><span class="NLM_article-title">Quinazoline antifolates inhibiting thymidylate synthase: 2-desamino derivatives with enhanced solubility and potency</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1989</span><span class="NLM_x">, </span> <span class="NLM_volume">32</span><span class="NLM_x">, </span> <span class="NLM_fpage">847</span><span class="NLM_x">–</span> <span class="NLM_lpage">852</span><span class="refDoi"> DOI: 10.1021/jm00124a018</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm00124a018" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=1989&pages=847-852&author=T.+R.+Jonesauthor=T.+J.+Thorntonauthor=A.+Flinnauthor=A.+L.+Jackmanauthor=D.+R.+Newellauthor=A.+H.+Calvert&title=Quinazoline+antifolates+inhibiting+thymidylate+synthase%3A+2-desamino+derivatives+with+enhanced+solubility+and+potency&doi=10.1021%2Fjm00124a018"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1021%2Fjm00124a018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00124a018%26sid%3Dliteratum%253Aachs%26aulast%3DJones%26aufirst%3DT.%2BR.%26aulast%3DThornton%26aufirst%3DT.%2BJ.%26aulast%3DFlinn%26aufirst%3DA.%26aulast%3DJackman%26aufirst%3DA.%2BL.%26aulast%3DNewell%26aufirst%3DD.%2BR.%26aulast%3DCalvert%26aufirst%3DA.%2BH.%26atitle%3DQuinazoline%2520antifolates%2520inhibiting%2520thymidylate%2520synthase%253A%25202-desamino%2520derivatives%2520with%2520enhanced%2520solubility%2520and%2520potency%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1989%26volume%3D32%26spage%3D847%26epage%3D852%26doi%3D10.1021%2Fjm00124a018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group">Cavalli, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lizzi, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bongarzone, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brun, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luise Krauth-Siegel, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bolognesi, M. L.</span><span> </span><span class="NLM_article-title">Privileged structure-guided synthesis of quinazoline derivatives as inhibitors of trypanothione reductase</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">3031</span><span class="NLM_x">–</span> <span class="NLM_lpage">3035</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2009.04.060</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01774&amp;key=10.1016%2Fj.bmcl.2009.04.060" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=3031-3035&author=A.+Cavalliauthor=F.+Lizziauthor=S.+Bongarzoneauthor=R.+Brunauthor=R.+Luise+Krauth-Siegelauthor=M.+L.+Bolognesi&title=Privileged+structure-guided+synthesis+of+quinazoline+derivatives+as+inhibitors+of+trypanothione+reductase&doi=10.1016%2Fj.bmcl.2009.04.060"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2009.04.060&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2009.04.060%26sid%3Dliteratum%253Aachs%26aulast%3DCavalli%26aufirst%3DA.%26aulast%3DLizzi%26aufirst%3DF.%26aulast%3DBongarzone%26aufirst%3DS.%26aulast%3DBrun%26aufirst%3DR.%26aulast%3DLuise%2BKrauth-Siegel%26aufirst%3DR.%26aulast%3DBolognesi%26aufirst%3DM.%2BL.%26atitle%3DPrivileged%2520structure-guided%2520synthesis%2520of%2520quinazoline%2520derivatives%2520as%2520inhibitors%2520of%2520trypanothione%2520reductase%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26spage%3D3031%26epage%3D3035%26doi%3D10.1016%2Fj.bmcl.2009.04.060" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">Takase, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saeki, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watanabe, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adachi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Souda, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saito, I.</span><span> </span><span class="NLM_article-title">Cyclic GMP phosphodiesterase inhibitors. 2. Requirement of 6-substitution of quinazoline derivatives for potent and selective inhibitory activity</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_volume">37</span><span class="NLM_x">, </span> <span class="NLM_fpage">2106</span><span class="NLM_x">–</span> <span class="NLM_lpage">2111</span><span class="refDoi"> DOI: 10.1021/jm00039a024</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm00039a024" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=1994&pages=2106-2111&author=Y.+Takaseauthor=T.+Saekiauthor=N.+Watanabeauthor=H.+Adachiauthor=S.+Soudaauthor=I.+Saito&title=Cyclic+GMP+phosphodiesterase+inhibitors.+2.+Requirement+of+6-substitution+of+quinazoline+derivatives+for+potent+and+selective+inhibitory+activity&doi=10.1021%2Fjm00039a024"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1021%2Fjm00039a024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00039a024%26sid%3Dliteratum%253Aachs%26aulast%3DTakase%26aufirst%3DY.%26aulast%3DSaeki%26aufirst%3DT.%26aulast%3DWatanabe%26aufirst%3DN.%26aulast%3DAdachi%26aufirst%3DH.%26aulast%3DSouda%26aufirst%3DS.%26aulast%3DSaito%26aufirst%3DI.%26atitle%3DCyclic%2520GMP%2520phosphodiesterase%2520inhibitors.%25202.%2520Requirement%2520of%25206-substitution%2520of%2520quinazoline%2520derivatives%2520for%2520potent%2520and%2520selective%2520inhibitory%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1994%26volume%3D37%26spage%3D2106%26epage%3D2111%26doi%3D10.1021%2Fjm00039a024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group">Berra, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Diaz-Meco, M. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lozano, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frutos, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Municio, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sanchez, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sanz, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moscat, J.</span><span> </span><span class="NLM_article-title">Evidence for a role of MEK and MAPK during signal transduction by protein kinase C zeta</span> <span class="citation_source-journal">EMBO. J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">6157</span><span class="NLM_x">–</span> <span class="NLM_lpage">6163</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=1995&pages=6157-6163&author=E.+Berraauthor=M.+T.+Diaz-Mecoauthor=J.+Lozanoauthor=S.+Frutosauthor=M.+M.+Municioauthor=P.+Sanchezauthor=L.+Sanzauthor=J.+Moscat&title=Evidence+for+a+role+of+MEK+and+MAPK+during+signal+transduction+by+protein+kinase+C+zeta"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBerra%26aufirst%3DE.%26aulast%3DDiaz-Meco%26aufirst%3DM.%2BT.%26aulast%3DLozano%26aufirst%3DJ.%26aulast%3DFrutos%26aufirst%3DS.%26aulast%3DMunicio%26aufirst%3DM.%2BM.%26aulast%3DSanchez%26aufirst%3DP.%26aulast%3DSanz%26aufirst%3DL.%26aulast%3DMoscat%26aufirst%3DJ.%26atitle%3DEvidence%2520for%2520a%2520role%2520of%2520MEK%2520and%2520MAPK%2520during%2520signal%2520transduction%2520by%2520protein%2520kinase%2520C%2520zeta%26jtitle%3DEMBO.%2520J.%26date%3D1995%26volume%3D14%26spage%3D6157%26epage%3D6163" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group">Marugan, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zheng, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Motabar, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Southall, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldin, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Westbroek, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stubblefield, B. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sidransky, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aungst, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lea, W. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simeonov, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leister, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Austin, C. P.</span><span> </span><span class="NLM_article-title">Evaluation of quinazoline analogues as glucocerebrosidase inhibitors with chaperone activity</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">1033</span><span class="NLM_x">–</span> <span class="NLM_lpage">1058</span><span class="refDoi"> DOI: 10.1021/jm1008902</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm1008902" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=1033-1058&author=J.+J.+Maruganauthor=W.+Zhengauthor=O.+Motabarauthor=N.+Southallauthor=E.+Goldinauthor=W.+Westbroekauthor=B.+K.+Stubblefieldauthor=E.+Sidranskyauthor=R.+A.+Aungstauthor=W.+A.+Leaauthor=A.+Simeonovauthor=W.+Leisterauthor=C.+P.+Austin&title=Evaluation+of+quinazoline+analogues+as+glucocerebrosidase+inhibitors+with+chaperone+activity&doi=10.1021%2Fjm1008902"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1021%2Fjm1008902&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm1008902%26sid%3Dliteratum%253Aachs%26aulast%3DMarugan%26aufirst%3DJ.%2BJ.%26aulast%3DZheng%26aufirst%3DW.%26aulast%3DMotabar%26aufirst%3DO.%26aulast%3DSouthall%26aufirst%3DN.%26aulast%3DGoldin%26aufirst%3DE.%26aulast%3DWestbroek%26aufirst%3DW.%26aulast%3DStubblefield%26aufirst%3DB.%2BK.%26aulast%3DSidransky%26aufirst%3DE.%26aulast%3DAungst%26aufirst%3DR.%2BA.%26aulast%3DLea%26aufirst%3DW.%2BA.%26aulast%3DSimeonov%26aufirst%3DA.%26aulast%3DLeister%26aufirst%3DW.%26aulast%3DAustin%26aufirst%3DC.%2BP.%26atitle%3DEvaluation%2520of%2520quinazoline%2520analogues%2520as%2520glucocerebrosidase%2520inhibitors%2520with%2520chaperone%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D1033%26epage%3D1058%26doi%3D10.1021%2Fjm1008902" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group">Levy, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuo, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schaefer, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kitson, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheung, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Espejo, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zee, B. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tangsombatvisit, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tennen, R. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuo, A. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tanjing, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheung, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chua, K. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Utz, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prinjha, R. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garcia, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bedford, M. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tarakhovsky, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, O.</span><span> </span><span class="NLM_article-title">Bedford, M. T.; Tarakhovsky, A.; Cheng, X.; Gozani, O. Lysine methylation of the NF-kappaB subunit RelA by SETD6 couples activity of the histone methyltransferase GLP at chromatin to tonic repression of NF-kappaB signaling</span> <span class="citation_source-journal">Nat. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">29</span><span class="NLM_x">–</span> <span class="NLM_lpage">36</span><span class="refDoi"> DOI: 10.1038/ni.1968</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01774&amp;key=10.1038%2Fni.1968" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01774&amp;key=21131967" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01774&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsFajur%252FO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2011&pages=29-36&author=D.+Levyauthor=A.+J.+Kuoauthor=Y.+Changauthor=U.+Schaeferauthor=C.+Kitsonauthor=P.+Cheungauthor=A.+Espejoauthor=B.+M.+Zeeauthor=C.+L.+Liuauthor=S.+Tangsombatvisitauthor=R.+I.+Tennenauthor=A.+Y.+Kuoauthor=S.+Tanjingauthor=R.+Cheungauthor=K.+F.+Chuaauthor=P.+J.+Utzauthor=X.+Shiauthor=R.+K.+Prinjhaauthor=K.+Leeauthor=B.+A.+Garciaauthor=M.+T.+Bedfordauthor=A.+Tarakhovskyauthor=X.+Chengauthor=O.+Cheng&title=Bedford%2C+M.+T.%3B+Tarakhovsky%2C+A.%3B+Cheng%2C+X.%3B+Gozani%2C+O.+Lysine+methylation+of+the+NF-kappaB+subunit+RelA+by+SETD6+couples+activity+of+the+histone+methyltransferase+GLP+at+chromatin+to+tonic+repression+of+NF-kappaB+signaling&doi=10.1038%2Fni.1968"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Lysine methylation of the NF-κB subunit RelA by SETD6 couples activity of the histone methyltransferase GLP at chromatin to tonic repression of NF-κB signaling</span></div><div class="casAuthors">Levy, Dan; Kuo, Alex J.; Chang, Yanqi; Schaefer, Uwe; Kitson, Christopher; Cheung, Peggie; Espejo, Alexsandra; Zee, Barry M.; Liu, Chih Long; Tangsombatvisit, Stephanie; Tennen, Ruth I.; Kuo, Andrew Y.; Tanjing, Song; Cheung, Regina; Chua, Katrin F.; Utz, Paul J.; Shi, Xiaobing; Prinjha, Rab K.; Lee, Kevin; Garcia, Benjamin A.; Bedford, Mark T.; Tarakhovsky, Alexander; Cheng, Xiaodong; Gozani, Or</div><div class="citationInfo"><span class="NLM_cas:title">Nature Immunology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">29-36</span>CODEN:
                <span class="NLM_cas:coden">NIAMCZ</span>;
        ISSN:<span class="NLM_cas:issn">1529-2908</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Signaling via the methylation of lysine residues in proteins has been linked to diverse biol. and disease processes, yet the catalytic activity and substrate specificity of many human protein lysine methyltransferases (PKMTs) are unknown.  We screened over 40 candidate PKMTs and identified SETD6 as a methyltransferase that monomethylated chromatin-assocd. transcription factor NF-κB subunit RelA at Lys310 (RelAK310me1).  SETD6-mediated methylation rendered RelA inert and attenuated RelA-driven transcriptional programs, including inflammatory responses in primary immune cells.  RelAK310me1 was recognized by the ankryin repeat of the histone methyltransferase GLP, which under basal conditions promoted a repressed chromatin state at RelA target genes through GLP-mediated methylation of histone H3 Lys9 (H3K9).  NF-κB-activation-linked phosphorylation of RelA at Ser311 by protein kinase C-ζ (PKC-ζ) blocked the binding of GLP to RelAK310me1 and relieved repression of the target gene.  Our findings establish a previously uncharacterized mechanism by which chromatin signaling regulates inflammation programs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrG8M_FlbB1DbVg90H21EOLACvtfcHk0liyg_w69yzuWA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsFajur%252FO&md5=e35e84351e9cb605a3423b3b2c98064b</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1038%2Fni.1968&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fni.1968%26sid%3Dliteratum%253Aachs%26aulast%3DLevy%26aufirst%3DD.%26aulast%3DKuo%26aufirst%3DA.%2BJ.%26aulast%3DChang%26aufirst%3DY.%26aulast%3DSchaefer%26aufirst%3DU.%26aulast%3DKitson%26aufirst%3DC.%26aulast%3DCheung%26aufirst%3DP.%26aulast%3DEspejo%26aufirst%3DA.%26aulast%3DZee%26aufirst%3DB.%2BM.%26aulast%3DLiu%26aufirst%3DC.%2BL.%26aulast%3DTangsombatvisit%26aufirst%3DS.%26aulast%3DTennen%26aufirst%3DR.%2BI.%26aulast%3DKuo%26aufirst%3DA.%2BY.%26aulast%3DTanjing%26aufirst%3DS.%26aulast%3DCheung%26aufirst%3DR.%26aulast%3DChua%26aufirst%3DK.%2BF.%26aulast%3DUtz%26aufirst%3DP.%2BJ.%26aulast%3DShi%26aufirst%3DX.%26aulast%3DPrinjha%26aufirst%3DR.%2BK.%26aulast%3DLee%26aufirst%3DK.%26aulast%3DGarcia%26aufirst%3DB.%2BA.%26aulast%3DBedford%26aufirst%3DM.%2BT.%26aulast%3DTarakhovsky%26aufirst%3DA.%26aulast%3DCheng%26aufirst%3DX.%26aulast%3DCheng%26aufirst%3DO.%26atitle%3DBedford%252C%2520M.%2520T.%253B%2520Tarakhovsky%252C%2520A.%253B%2520Cheng%252C%2520X.%253B%2520Gozani%252C%2520O.%2520Lysine%2520methylation%2520of%2520the%2520NF-kappaB%2520subunit%2520RelA%2520by%2520SETD6%2520couples%2520activity%2520of%2520the%2520histone%2520methyltransferase%2520GLP%2520at%2520chromatin%2520to%2520tonic%2520repression%2520of%2520NF-kappaB%2520signaling%26jtitle%3DNat.%2520Immunol.%26date%3D2011%26volume%3D12%26spage%3D29%26epage%3D36%26doi%3D10.1038%2Fni.1968" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group">Evans, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rittle, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bock, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DiPardo, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Freidinger, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whitter, W. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lundell, G. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Veber, D. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderson, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lotti, V. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cerino, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, T. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kling, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kunkel, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Springer, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirshfield, J.</span><span> </span><span class="NLM_article-title">Methods for drug discovery: development of potent, selective, orally effective cholecystokinin antagonists</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1988</span><span class="NLM_x">, </span> <span class="NLM_volume">31</span><span class="NLM_x">, </span> <span class="NLM_fpage">2235</span><span class="NLM_x">–</span> <span class="NLM_lpage">2246</span><span class="refDoi"> DOI: 10.1021/jm00120a002</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm00120a002" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01774&amp;key=1%3ACAS%3A528%3ADyaL1cXmtVCgurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=1988&pages=2235-2246&author=B.+E.+Evansauthor=K.+E.+Rittleauthor=M.+G.+Bockauthor=R.+M.+DiPardoauthor=R.+M.+Freidingerauthor=W.+L.+Whitterauthor=G.+F.+Lundellauthor=D.+F.+Veberauthor=P.+S.+Andersonauthor=R.+S.+Changauthor=V.+J.+Lottiauthor=D.+J.+Cerinoauthor=T.+B.+Chenauthor=P.+J.+Klingauthor=K.+A.+Kunkelauthor=J.+P.+Springerauthor=J.+Hirshfield&title=Methods+for+drug+discovery%3A+development+of+potent%2C+selective%2C+orally+effective+cholecystokinin+antagonists&doi=10.1021%2Fjm00120a002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Methods for drug discovery:  development of potent, selective, orally effective cholecystokinin antagonists</span></div><div class="casAuthors">Evans, B. E.; Rittle, K. E.; Bock, M. G.; DiPardo, R. M.; Freidinger, R. M.; Whitter, W. L.; Lundell, G. F.; Veber, D. F.; Anderson, P. S.; et al.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1988</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2235-46</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    </div><div class="casAbstract">3-(Acylamino)-5-phenyl-2H-1,4-benzodiazepines) (I, X = H or F; R1 = H, Me, CH2CO2Et, CH2CO2H; R2 = acylamino, indolylalkyl, heterocyclic contg. groups, substituted benzoyl, etc.), antagonists of the peptide hormone cholecystokinin (CCK), are described.  Developed by reasoned modification of the known anxiolytic benzodiazepines, these compds. provide highly potent, orally effective ligands selective for peripheral (CCK-A) receptors, with binding affinities approaching or equaling that of the natural ligand CCK-8.  The distinction between CCK-A receptors on the one hand and CNS (CCK-B), gastrin, and central benzodiazepine receptors on the other is demonstrated by using the structure-activity profiles of the new compds.  Details of the binding of these agents to CCK-A receptors are examd., and the method of development of these compds. is discussed in terms of its relevance to the general problem of drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrF3uSMSNckhrVg90H21EOLACvtfcHk0ljZb8Ie7v7dUg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL1cXmtVCgurs%253D&md5=783be926d2512ab8f67c8786afcf0276</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1021%2Fjm00120a002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00120a002%26sid%3Dliteratum%253Aachs%26aulast%3DEvans%26aufirst%3DB.%2BE.%26aulast%3DRittle%26aufirst%3DK.%2BE.%26aulast%3DBock%26aufirst%3DM.%2BG.%26aulast%3DDiPardo%26aufirst%3DR.%2BM.%26aulast%3DFreidinger%26aufirst%3DR.%2BM.%26aulast%3DWhitter%26aufirst%3DW.%2BL.%26aulast%3DLundell%26aufirst%3DG.%2BF.%26aulast%3DVeber%26aufirst%3DD.%2BF.%26aulast%3DAnderson%26aufirst%3DP.%2BS.%26aulast%3DChang%26aufirst%3DR.%2BS.%26aulast%3DLotti%26aufirst%3DV.%2BJ.%26aulast%3DCerino%26aufirst%3DD.%2BJ.%26aulast%3DChen%26aufirst%3DT.%2BB.%26aulast%3DKling%26aufirst%3DP.%2BJ.%26aulast%3DKunkel%26aufirst%3DK.%2BA.%26aulast%3DSpringer%26aufirst%3DJ.%2BP.%26aulast%3DHirshfield%26aufirst%3DJ.%26atitle%3DMethods%2520for%2520drug%2520discovery%253A%2520development%2520of%2520potent%252C%2520selective%252C%2520orally%2520effective%2520cholecystokinin%2520antagonists%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1988%26volume%3D31%26spage%3D2235%26epage%3D2246%26doi%3D10.1021%2Fjm00120a002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group">Hamed, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abou El Ella, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keeton, A. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Piazza, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engel, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hartmann, R. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abadi, A. H.</span><span> </span><span class="NLM_article-title">Quinazoline and tetrahydropyridothieno[2,3-d]pyrimidine derivatives as irreversible EGFR tyrosine kinase inhibitors: influence of the position 4 substituent</span> <span class="citation_source-journal">MedChemComm</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">1202</span><span class="NLM_x">–</span> <span class="NLM_lpage">1207</span><span class="refDoi"> DOI: 10.1039/c3md00118k</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01774&amp;key=10.1039%2Fc3md00118k" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2013&pages=1202-1207&author=M.+M.+Hamedauthor=D.+A.+Abou+El+Ellaauthor=A.+B.+Keetonauthor=G.+A.+Piazzaauthor=M.+Engelauthor=R.+W.+Hartmannauthor=A.+H.+Abadi&title=Quinazoline+and+tetrahydropyridothieno%5B2%2C3-d%5Dpyrimidine+derivatives+as+irreversible+EGFR+tyrosine+kinase+inhibitors%3A+influence+of+the+position+4+substituent&doi=10.1039%2Fc3md00118k"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1039%2Fc3md00118k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fc3md00118k%26sid%3Dliteratum%253Aachs%26aulast%3DHamed%26aufirst%3DM.%2BM.%26aulast%3DAbou%2BEl%2BElla%26aufirst%3DD.%2BA.%26aulast%3DKeeton%26aufirst%3DA.%2BB.%26aulast%3DPiazza%26aufirst%3DG.%2BA.%26aulast%3DEngel%26aufirst%3DM.%26aulast%3DHartmann%26aufirst%3DR.%2BW.%26aulast%3DAbadi%26aufirst%3DA.%2BH.%26atitle%3DQuinazoline%2520and%2520tetrahydropyridothieno%255B2%252C3-d%255Dpyrimidine%2520derivatives%2520as%2520irreversible%2520EGFR%2520tyrosine%2520kinase%2520inhibitors%253A%2520influence%2520of%2520the%2520position%25204%2520substituent%26jtitle%3DMedChemComm%26date%3D2013%26volume%3D4%26spage%3D1202%26epage%3D1207%26doi%3D10.1039%2Fc3md00118k" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group">Hamed, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abou El Ella, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keeton, A. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Piazza, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abadi, A. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hartmann, R. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engel, M.</span><span> </span><span class="NLM_article-title">6-Aryl and heterocycle quinazoline derivatives as potent EGFR inhibitors with improved activity toward gefitinib-sensitive and -resistant tumor cell lines</span> <span class="citation_source-journal">ChemMedChem</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">1495</span><span class="NLM_x">–</span> <span class="NLM_lpage">504</span><span class="refDoi"> DOI: 10.1002/cmdc.201300147</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01774&amp;key=10.1002%2Fcmdc.201300147" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01774&amp;key=23847159" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01774&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtVykurzF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2013&pages=1495-504&author=M.+M.+Hamedauthor=D.+A.+Abou+El+Ellaauthor=A.+B.+Keetonauthor=G.+A.+Piazzaauthor=A.+H.+Abadiauthor=R.+W.+Hartmannauthor=M.+Engel&title=6-Aryl+and+heterocycle+quinazoline+derivatives+as+potent+EGFR+inhibitors+with+improved+activity+toward+gefitinib-sensitive+and+-resistant+tumor+cell+lines&doi=10.1002%2Fcmdc.201300147"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">6-Aryl and Heterocycle Quinazoline Derivatives as Potent EGFR Inhibitors with Improved Activity toward Gefitinib-Sensitive and -Resistant Tumor Cell Lines</span></div><div class="casAuthors">Hamed, Mostafa M.; Abou El Ella, Dalal A.; Keeton, Adam B.; Piazza, Gary A.; Abadi, Ashraf H.; Hartmann, Rolf W.; Engel, Matthias</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1495-1504</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Anilinoquinazolinyl benzaldimines I [R = R1CH:N; R1 = 4-HOC6H4, 2,4-(HO)2C6H3, 3-O2NC6H4, 4-O2NC6H4, 2-MeOC6H4], thioureas I [R = R1NHC(:S)NH; R1 = PhCH2, 2-(4-morpholinyl)ethyl], aminoacetamides and aminopropanamides II [R = R1NHCH2CONH, R1NHCH2CH2CONH; R1 = PhCH2, 4-(2-thiazolylaminosulfonyl)phenyl], and amides [R = R1CONH; R1 = 4-H2NC6H4, 4-NCC6H4, 4-MeCONHC6H4, 4-O2NC6H4, 3,5-(O2N)2C6H3, 4-MeOC6H4, 3,4-(MeO)2C6H3, 4-morpholinyl, 2-furyl, 3-pyridinyl, 4-pyridinyl] were prepd. as inhibitors of wild-type and mutant epidermal growth factor receptor (EGFR) for potential use as antitumor agents.  Most of the compds. inhibited wild-type EGFR with IC50 values of 4-62 nM; I [R = BnNHC(:S)NH, 4-morpholinylethylaminothiocarbonylamino, R1NHCH2CH2CONH; R1 = 4-(2-thiazolylaminosulfonyl)phenyl] also retained significant activity toward the gefitinib-insensitive EGFRT790M/L858R mutant, displaying up to 24-fold greater potency than gefitinib.  The inhibition of the growth of cancer cells with wild-type and mutant EGFR was detd.; I [R = BnNHC(:S)NH, R1NHCH2CH2CONH; R1 = 4-(2-thiazolylaminosulfonyl)phenyl] inhibited cancer cell growth more effectively than the std. gefitinib.  Mol. docking calcns. of I [R = BnNHC(:S)NH, 4-morpholinylethylaminothiocarbonylamino, R1NHCH2CH2CONH; R1 = 4-(2-thiazolylaminosulfonyl)phenyl] in double mutant EGFR and of I (R = PhCH2NHCH2CONH, 2-furylcarbonylamino) in wild-type EGFR were performed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp9J8DhyAlHb7Vg90H21EOLACvtfcHk0liT4-Q2OFcxgw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtVykurzF&md5=c951d913a38a5062783da74c4cf6afef</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201300147&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201300147%26sid%3Dliteratum%253Aachs%26aulast%3DHamed%26aufirst%3DM.%2BM.%26aulast%3DAbou%2BEl%2BElla%26aufirst%3DD.%2BA.%26aulast%3DKeeton%26aufirst%3DA.%2BB.%26aulast%3DPiazza%26aufirst%3DG.%2BA.%26aulast%3DAbadi%26aufirst%3DA.%2BH.%26aulast%3DHartmann%26aufirst%3DR.%2BW.%26aulast%3DEngel%26aufirst%3DM.%26atitle%3D6-Aryl%2520and%2520heterocycle%2520quinazoline%2520derivatives%2520as%2520potent%2520EGFR%2520inhibitors%2520with%2520improved%2520activity%2520toward%2520gefitinib-sensitive%2520and%2520-resistant%2520tumor%2520cell%2520lines%26jtitle%3DChemMedChem%26date%3D2013%26volume%3D8%26spage%3D1495%26epage%3D504%26doi%3D10.1002%2Fcmdc.201300147" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group">Passmore, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lukey, P. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ress, S. R.</span><span> </span><span class="NLM_article-title">The human macrophage cell line U937 as an in vitro model for selective evaluation of mycobacterial antigen-specific cytotoxic T-cell function</span> <span class="citation_source-journal">Immunology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">102</span><span class="NLM_x">, </span> <span class="NLM_fpage">146</span><span class="NLM_x">–</span> <span class="NLM_lpage">156</span><span class="refDoi"> DOI: 10.1046/j.1365-2567.2001.01164.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01774&amp;key=10.1046%2Fj.1365-2567.2001.01164.x" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=2001&pages=146-156&author=J.+S.+Passmoreauthor=P.+T.+Lukeyauthor=S.+R.+Ress&title=The+human+macrophage+cell+line+U937+as+an+in+vitro+model+for+selective+evaluation+of+mycobacterial+antigen-specific+cytotoxic+T-cell+function&doi=10.1046%2Fj.1365-2567.2001.01164.x"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1046%2Fj.1365-2567.2001.01164.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1046%252Fj.1365-2567.2001.01164.x%26sid%3Dliteratum%253Aachs%26aulast%3DPassmore%26aufirst%3DJ.%2BS.%26aulast%3DLukey%26aufirst%3DP.%2BT.%26aulast%3DRess%26aufirst%3DS.%2BR.%26atitle%3DThe%2520human%2520macrophage%2520cell%2520line%2520U937%2520as%2520an%2520in%2520vitro%2520model%2520for%2520selective%2520evaluation%2520of%2520mycobacterial%2520antigen-specific%2520cytotoxic%2520T-cell%2520function%26jtitle%3DImmunology%26date%3D2001%26volume%3D102%26spage%3D146%26epage%3D156%26doi%3D10.1046%2Fj.1365-2567.2001.01164.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group">Tobe, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Isobe, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tomizawa, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nagasaki, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takahashi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fukazawa, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hayashi, H.</span><span> </span><span class="NLM_article-title">Discovery of quinazolines as a novel structural class of potent inhibitors of NF-kappa B activation</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">383</span><span class="NLM_x">–</span> <span class="NLM_lpage">391</span><span class="refDoi"> DOI: 10.1016/S0968-0896(02)00440-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01774&amp;key=10.1016%2FS0968-0896%2802%2900440-6" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2003&pages=383-391&author=M.+Tobeauthor=Y.+Isobeauthor=H.+Tomizawaauthor=T.+Nagasakiauthor=H.+Takahashiauthor=T.+Fukazawaauthor=H.+Hayashi&title=Discovery+of+quinazolines+as+a+novel+structural+class+of+potent+inhibitors+of+NF-kappa+B+activation&doi=10.1016%2FS0968-0896%2802%2900440-6"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1016%2FS0968-0896%2802%2900440-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0968-0896%252802%252900440-6%26sid%3Dliteratum%253Aachs%26aulast%3DTobe%26aufirst%3DM.%26aulast%3DIsobe%26aufirst%3DY.%26aulast%3DTomizawa%26aufirst%3DH.%26aulast%3DNagasaki%26aufirst%3DT.%26aulast%3DTakahashi%26aufirst%3DH.%26aulast%3DFukazawa%26aufirst%3DT.%26aulast%3DHayashi%26aufirst%3DH.%26atitle%3DDiscovery%2520of%2520quinazolines%2520as%2520a%2520novel%2520structural%2520class%2520of%2520potent%2520inhibitors%2520of%2520NF-kappa%2520B%2520activation%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2003%26volume%3D11%26spage%3D383%26epage%3D391%26doi%3D10.1016%2FS0968-0896%2802%2900440-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group">Tobe, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Isobe, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tomizawa, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nagasaki, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takahashi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hayashi, H.</span><span> </span><span class="NLM_article-title">A novel structural class of potent inhibitors of NF-kappa B activation: structure-activity relationships and biological effects of 6-aminoquinazoline derivatives</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">3869</span><span class="NLM_x">–</span> <span class="NLM_lpage">3878</span><span class="refDoi"> DOI: 10.1016/S0968-0896(03)00438-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01774&amp;key=10.1016%2FS0968-0896%2803%2900438-3" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2003&pages=3869-3878&author=M.+Tobeauthor=Y.+Isobeauthor=H.+Tomizawaauthor=T.+Nagasakiauthor=H.+Takahashiauthor=H.+Hayashi&title=A+novel+structural+class+of+potent+inhibitors+of+NF-kappa+B+activation%3A+structure-activity+relationships+and+biological+effects+of+6-aminoquinazoline+derivatives&doi=10.1016%2FS0968-0896%2803%2900438-3"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1016%2FS0968-0896%2803%2900438-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0968-0896%252803%252900438-3%26sid%3Dliteratum%253Aachs%26aulast%3DTobe%26aufirst%3DM.%26aulast%3DIsobe%26aufirst%3DY.%26aulast%3DTomizawa%26aufirst%3DH.%26aulast%3DNagasaki%26aufirst%3DT.%26aulast%3DTakahashi%26aufirst%3DH.%26aulast%3DHayashi%26aufirst%3DH.%26atitle%3DA%2520novel%2520structural%2520class%2520of%2520potent%2520inhibitors%2520of%2520NF-kappa%2520B%2520activation%253A%2520structure-activity%2520relationships%2520and%2520biological%2520effects%2520of%25206-aminoquinazoline%2520derivatives%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2003%26volume%3D11%26spage%3D3869%26epage%3D3878%26doi%3D10.1016%2FS0968-0896%2803%2900438-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group">Haas, T. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Emmerich, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gerlach, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmukle, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cordier, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rieser, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feltham, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vince, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warnken, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wenger, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koschny, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Komander, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Silke, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walczak, H.</span><span> </span><span class="NLM_article-title">Recruitment of the linear ubiquitin chain assembly complex stabilizes the TNF-R1 signaling complex and is required for TNF-mediated gene induction</span> <span class="citation_source-journal">Mol. Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">36</span><span class="NLM_x">, </span> <span class="NLM_fpage">831</span><span class="NLM_x">–</span> <span class="NLM_lpage">844</span><span class="refDoi"> DOI: 10.1016/j.molcel.2009.10.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01774&amp;key=10.1016%2Fj.molcel.2009.10.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01774&amp;key=20005846" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01774&amp;key=1%3ACAS%3A528%3ADC%252BC3cXht1Cjsr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2009&pages=831-844&author=T.+L.+Haasauthor=C.+H.+Emmerichauthor=B.+Gerlachauthor=A.+C.+Schmukleauthor=S.+M.+Cordierauthor=E.+Rieserauthor=R.+Felthamauthor=J.+Vinceauthor=U.+Warnkenauthor=T.+Wengerauthor=R.+Koschnyauthor=D.+Komanderauthor=J.+Silkeauthor=H.+Walczak&title=Recruitment+of+the+linear+ubiquitin+chain+assembly+complex+stabilizes+the+TNF-R1+signaling+complex+and+is+required+for+TNF-mediated+gene+induction&doi=10.1016%2Fj.molcel.2009.10.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Recruitment of the linear ubiquitin chain assembly complex stabilizes the TNF-R1 signaling complex and is required for TNF-mediated gene induction</span></div><div class="casAuthors">Haas, Tobias L.; Emmerich, Christoph H.; Gerlach, Bjoern; Schmukle, Anna C.; Cordier, Stefanie M.; Rieser, Eva; Feltham, Rebecca; Vince, James; Warnken, Uwe; Wenger, Till; Koschny, Ronald; Komander, David; Silke, John; Walczak, Henning</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cell</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">831-844</span>CODEN:
                <span class="NLM_cas:coden">MOCEFL</span>;
        ISSN:<span class="NLM_cas:issn">1097-2765</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">TNF is a key inflammatory cytokine.  Using a modified tandem affinity purifn. approach, the authors identified HOIL-1 and HOIP as functional components of the native TNF-R1 signaling complex (TNF-RSC).  Together, they were shown to form a linear ubiquitin chain assembly complex (LUBAC) and to ubiquitylate NEMO.  The authors show that LUBAC binds to ubiquitin chains of different linkage types and that its recruitment to the TNF-RSC is impaired in TRADD-, TRAF2-, and cIAP1/2- but not in RIP1- or NEMO-deficient MEFs.  Furthermore, the E3 ligase activity of cIAPs, but not TRAF2, is required for HOIL-1 recruitment to the TNF-RSC.  LUBAC enhances NEMO interaction with the TNF-RSC, stabilizes this protein complex, and is required for efficient TNF-induced activation of NF-κB and JNK, resulting in apoptosis inhibition.  Finally, the authors demonstrate that sustained stability of the TNF-RSC requires LUBAC's enzymic activity, thereby adding a third form of ubiquitin linkage to the triggering of TNF signaling by the TNF-RSC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpouDjeBY7XcbVg90H21EOLACvtfcHk0liTHd8FfJwA-A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXht1Cjsr4%253D&md5=a4dc338f1a4185a09c8ce8533ea87084</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1016%2Fj.molcel.2009.10.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molcel.2009.10.013%26sid%3Dliteratum%253Aachs%26aulast%3DHaas%26aufirst%3DT.%2BL.%26aulast%3DEmmerich%26aufirst%3DC.%2BH.%26aulast%3DGerlach%26aufirst%3DB.%26aulast%3DSchmukle%26aufirst%3DA.%2BC.%26aulast%3DCordier%26aufirst%3DS.%2BM.%26aulast%3DRieser%26aufirst%3DE.%26aulast%3DFeltham%26aufirst%3DR.%26aulast%3DVince%26aufirst%3DJ.%26aulast%3DWarnken%26aufirst%3DU.%26aulast%3DWenger%26aufirst%3DT.%26aulast%3DKoschny%26aufirst%3DR.%26aulast%3DKomander%26aufirst%3DD.%26aulast%3DSilke%26aufirst%3DJ.%26aulast%3DWalczak%26aufirst%3DH.%26atitle%3DRecruitment%2520of%2520the%2520linear%2520ubiquitin%2520chain%2520assembly%2520complex%2520stabilizes%2520the%2520TNF-R1%2520signaling%2520complex%2520and%2520is%2520required%2520for%2520TNF-mediated%2520gene%2520induction%26jtitle%3DMol.%2520Cell%26date%3D2009%26volume%3D36%26spage%3D831%26epage%3D844%26doi%3D10.1016%2Fj.molcel.2009.10.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group">Golan-Goldhirsh, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gopas, J.</span><span> </span><span class="NLM_article-title">Plant derived inhibitors of NF-κB</span> <span class="citation_source-journal">Phytochem. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">107</span><span class="NLM_x">–</span> <span class="NLM_lpage">121</span><span class="refDoi"> DOI: 10.1007/s11101-013-9293-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01774&amp;key=10.1007%2Fs11101-013-9293-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01774&amp;key=1%3ACAS%3A528%3ADC%252BC2cXislChu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=107-121&author=A.+Golan-Goldhirshauthor=J.+Gopas&title=Plant+derived+inhibitors+of+NF-%CE%BAB&doi=10.1007%2Fs11101-013-9293-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Plant derived inhibitors of NF-κB</span></div><div class="casAuthors">Golan-Goldhirsh, Avi; Gopas, Jacob</div><div class="citationInfo"><span class="NLM_cas:title">Phytochemistry Reviews</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">107-121</span>CODEN:
                <span class="NLM_cas:coden">PRHEBS</span>;
        ISSN:<span class="NLM_cas:issn">1568-7767</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  Plant secondary metabolites (natural products) have been a source for many of our medicines.  Their functions in plants remain often unknown, but in recent years there are more and more new compds. isolated and identified and their medicinal potential investigated.  The major classes of plant natural products and various derivs. thereof are: phenolics, terpenoids, alkaloids and lignans.  The major transcription factor, nuclear factor-κB (NF-κB) is a central downstream regulator of inflammation, cell proliferation and apoptosis that controls the expression of more than 500 genes.  It plays an essential role in several aspects of human health including the development of innate and adaptive immunity.  The deregulation of NF-κB is assocd. with many ailments including cancer and chronic inflammatory diseases.  In spite of a vast literature describing NF-κB inhibitors from many natural or synthetic sources, such modulators have not been fully tapped for therapeutic purposes and the search for effective and specific inhibitors for therapeutic use and minimal side effects is still relevant and ongoing.  Plant-derived phytochems. are promising lead compds. to develop potent and safe inhibitors for cancer and inflammatory disorders driven by NF-κB.  We briefly review the recent knowledge on plant derived phytochems. and their major NF-κB mol. targets.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpO4RD0fDWWE7Vg90H21EOLACvtfcHk0liTHd8FfJwA-A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXislChu7s%253D&md5=387be35abe847685ee286394a8447bc4</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1007%2Fs11101-013-9293-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11101-013-9293-5%26sid%3Dliteratum%253Aachs%26aulast%3DGolan-Goldhirsh%26aufirst%3DA.%26aulast%3DGopas%26aufirst%3DJ.%26atitle%3DPlant%2520derived%2520inhibitors%2520of%2520NF-%25CE%25BAB%26jtitle%3DPhytochem.%2520Rev.%26date%3D2014%26volume%3D13%26spage%3D107%26epage%3D121%26doi%3D10.1007%2Fs11101-013-9293-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group">Fan, W. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, Y. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deng, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ge, X. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, P. H.</span><span> </span><span class="NLM_article-title">EGFR antisense RNA blocks expression of the epidermal growth factor receptor and partially reverse the malignant phenotype of human breast cancer MDA-MB-231 cells</span> <span class="citation_source-journal">Cell Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">63</span><span class="NLM_x">–</span> <span class="NLM_lpage">71</span><span class="refDoi"> DOI: 10.1038/cr.1998.7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01774&amp;key=10.1038%2Fcr.1998.7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01774&amp;key=9570018" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01774&amp;key=1%3ACAS%3A280%3ADyaK1c3jtFGgtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=1998&pages=63-71&author=W.+H.+Fanauthor=Y.+L.+Luauthor=F.+Dengauthor=X.+M.+Geauthor=S.+Liuauthor=P.+H.+Tang&title=EGFR+antisense+RNA+blocks+expression+of+the+epidermal+growth+factor+receptor+and+partially+reverse+the+malignant+phenotype+of+human+breast+cancer+MDA-MB-231+cells&doi=10.1038%2Fcr.1998.7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">EGFR antisense RNA blocks expression of the epidermal growth factor receptor and partially reverse the malignant phenotype of human breast cancer MDA-MB-231 cells</span></div><div class="casAuthors">Fan W H; Lu Y L; Deng F; Ge X M; Liu S; Tang P H</div><div class="citationInfo"><span class="NLM_cas:title">Cell research</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">63-71</span>
        ISSN:<span class="NLM_cas:issn">1001-0602</span>.
    </div><div class="casAbstract">The effects of human EGFR to the malignant phenotype of human breast cancer cell line MDA-MB-231 were investigated experimentally.  A retroviral vector containing a 5'1350bp fragment of the human EGFR cDNA in the antisense orientation was transfected into targeted cells by lipofectamine.  The effects on cell proliferation, cell cycle and adherent ability to extracellular matrix (ECM) components were studied after the expression of antisense transcripts to EGFR 5'1350bp fragment in target cells.  In vitro studies showed that the growth ability of the transfected cells was partially inhibited in comparison to parental cells and to cells transfected with the plasmid containing the neomycin resistance gene only.  It was found that EGF (10 ng/ml) had an argumenation effect on the growth of transfected MDA-AS10 cells but not MDA-MB-231 cells.  Flow cytometric analysis showed that the cell cycle of the transfected cells was abnormal with a decrease of cells in G2/M and S phases and an increase of cells in G1 phase, indicating a blockage in phase G1.  Immunofluorescence of EGFR expression in transfectants stained with an anti-EGFR antibody was decreased and their growth in soft agarose was also severely impaired.  The transfected cells showed less adherence to laminin (LN) and fibronectin (FN).  In short, EGFR antisense RNA decreases the expression of EGFR on MDA-MB-231 cells and partially reverses their malignant phenotype as well.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQPXKIOPAgUKs-crCu0nI_sfW6udTcc2eag8Br-AGd2Z7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK1c3jtFGgtQ%253D%253D&md5=6d62c7311813bfacbbd54a8774cfd467</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1038%2Fcr.1998.7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fcr.1998.7%26sid%3Dliteratum%253Aachs%26aulast%3DFan%26aufirst%3DW.%2BH.%26aulast%3DLu%26aufirst%3DY.%2BL.%26aulast%3DDeng%26aufirst%3DF.%26aulast%3DGe%26aufirst%3DX.%2BM.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DTang%26aufirst%3DP.%2BH.%26atitle%3DEGFR%2520antisense%2520RNA%2520blocks%2520expression%2520of%2520the%2520epidermal%2520growth%2520factor%2520receptor%2520and%2520partially%2520reverse%2520the%2520malignant%2520phenotype%2520of%2520human%2520breast%2520cancer%2520MDA-MB-231%2520cells%26jtitle%3DCell%2520Res.%26date%3D1998%26volume%3D8%26spage%3D63%26epage%3D71%26doi%3D10.1038%2Fcr.1998.7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group">Ferrer-Soler, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vazquez-Martin, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brunet, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Menendez, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Llorens, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colomer, R.</span><span> </span><span class="NLM_article-title">An update of the mechanisms of resistance to EGFR-tyrosine kinase inhibitors in breast cancer: gefitinib (Iressa) -induced changes in the expression and nucleo-cytoplasmic trafficking of HER-ligands (Review)</span> <span class="citation_source-journal">Int. J. Mol. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">3</span><span class="NLM_x">–</span> <span class="NLM_lpage">10</span><span class="refDoi"> DOI: 10.3892/ijmm.20.1.3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01774&amp;key=10.3892%2Fijmm.20.1.3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01774&amp;key=17549382" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01774&amp;key=1%3ACAS%3A528%3ADC%252BD2sXot1Kqt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2007&pages=3-10&author=L.+Ferrer-Solerauthor=A.+Vazquez-Martinauthor=J.+Brunetauthor=J.+A.+Menendezauthor=R.+De+Llorensauthor=R.+Colomer&title=An+update+of+the+mechanisms+of+resistance+to+EGFR-tyrosine+kinase+inhibitors+in+breast+cancer%3A+gefitinib+%28Iressa%29+-induced+changes+in+the+expression+and+nucleo-cytoplasmic+trafficking+of+HER-ligands+%28Review%29&doi=10.3892%2Fijmm.20.1.3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">An update of the mechanisms of resistance to EGFR-tyrosine kinase inhibitors in breast cancer: gefitinib (Iressa)-induced changes in the expression and nucleo-cytoplasmic trafficking of HER-ligands (Review)</span></div><div class="casAuthors">Ferrer-Soler, Laura; Vazquez-Martin, Alejandro; Brunet, Joan; Menendez, Javier A.; De Llorens, Rafael; Colomer, Ramon</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Molecular Medicine</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">3-10</span>CODEN:
                <span class="NLM_cas:coden">IJMMFG</span>;
        ISSN:<span class="NLM_cas:issn">1107-3756</span>.
    
            (<span class="NLM_cas:orgname">International Journal of Molecular Medicine</span>)
        </div><div class="casAbstract">A review.  Intrinsic resistance to the epidermal growth factor receptor (EGFR; HER1) tyrosine kinase inhibitor (TKI) gefitinib, and more generally to EGFR TKIs, is a common phenomenon in breast cancer.  The availability of mol. criteria for predicting sensitivity to EGFR-TKIs is, therefore, the most relevant issue for their correct use and for planning future research.  Though it appears that in non-small-cell lung cancer (NSCLC) response to gefitinib is directly related to the occurrence of specific mutations in the EGFR TK domain, breast cancer patients cannot be selected for treatment with gefitinib on the same basis as such EGFR mutations have been reported neither in primary breast carcinomas nor in several breast cancer cell lines.  Alternatively, there is a general agreement on the hypothesis that the occurrence of mol. alterations that activate transduction pathways downstream of EGFR (i.e., MEK1/MEK2 → ERK1/2 MAPK and PI-3'K → AKT growth/survival signaling cascades) significantly affect the response to EGFR TKIs in breast carcinomas.  However, there are no studies so far addressing a role of EGF-related ligands as intrinsic breast cancer cell modulators of EGFR TKI efficacy.  We recently monitored gene expression profiles and sub-cellular localization of HER-1/-2/-3/-4 related ligands (i.e., EGF, amphiregulin, transforming growth factor-α, β-cellulin, epiregulin and neuregulins) prior to and after gefitinib treatment in a panel of human breast cancer cell lines.  First, gefitinib-induced changes in the endogenous levels of EGF-related ligands correlated with the natural degree of breast cancer cell sensitivity to gefitinib.  While breast cancer cells intrinsically resistant to gefitinib (IC50 ≥15 μM) markedly up-regulated (up to 600 times) the expression of genes codifying for HER-specific ligands, a significant down-regulation (up to 106 times) of HER ligand gene transcription was found in breast cancer cells intrinsically sensitive to gefitinib (IC50 ≤1 μM).  Second, loss of HER1 function differentially regulated the nuclear trafficking of HER-related ligands.  While gefitinib treatment induced an active import and nuclear accumulation of the HER ligand NRG in intrinsically gefitinib-resistant breast cancer cells, an active export and nuclear loss of NRG was obsd. in intrinsically gefitinib-sensitive breast cancer cells.  In summary, through in vitro and pharmacodynamic studies we have learned that, besides mutations in the HER1 gene, oncogenic changes downstream of HER1 are the key players regulating gefitinib efficacy in breast cancer cells.  It now appears that pharmacol. inhibition of HER1 function also leads to striking changes in both the gene expression and the nucleo-cytoplasmic trafficking of HER-specific ligands, and that this response correlates with the intrinsic degree of breast cancer sensitivity to the EGFR TKI gefitinib.  The relevance of this previously unrecognized intracrine feedback to gefitinib warrants further studies as cancer cells could bypass the antiproliferative effects of HER1-targeted therapeutics without a need for the overexpression and/or activation of other HER family members and/or the activation of HER-driven downstream signaling cascades.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqwSC5Rsb6FG7Vg90H21EOLACvtfcHk0lhh7fjoGMLTxg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXot1Kqt74%253D&md5=6ef1ec64a3e1aea5a13b2e7d088947e5</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.3892%2Fijmm.20.1.3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3892%252Fijmm.20.1.3%26sid%3Dliteratum%253Aachs%26aulast%3DFerrer-Soler%26aufirst%3DL.%26aulast%3DVazquez-Martin%26aufirst%3DA.%26aulast%3DBrunet%26aufirst%3DJ.%26aulast%3DMenendez%26aufirst%3DJ.%2BA.%26aulast%3DDe%2BLlorens%26aufirst%3DR.%26aulast%3DColomer%26aufirst%3DR.%26atitle%3DAn%2520update%2520of%2520the%2520mechanisms%2520of%2520resistance%2520to%2520EGFR-tyrosine%2520kinase%2520inhibitors%2520in%2520breast%2520cancer%253A%2520gefitinib%2520%2528Iressa%2529%2520-induced%2520changes%2520in%2520the%2520expression%2520and%2520nucleo-cytoplasmic%2520trafficking%2520of%2520HER-ligands%2520%2528Review%2529%26jtitle%3DInt.%2520J.%2520Mol.%2520Med.%26date%3D2007%26volume%3D20%26spage%3D3%26epage%3D10%26doi%3D10.3892%2Fijmm.20.1.3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group">Sovak, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bellas, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zanieski, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rogers, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Traish, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sonenshein, G. E.</span><span> </span><span class="NLM_article-title">Aberrant nuclear factor-kappaB/Rel expression and the pathogenesis of breast cancer</span> <span class="citation_source-journal">J. Clin. Invest.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">100</span><span class="NLM_x">, </span> <span class="NLM_fpage">2952</span><span class="NLM_x">–</span> <span class="NLM_lpage">2960</span><span class="refDoi"> DOI: 10.1172/JCI119848</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01774&amp;key=10.1172%2FJCI119848" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=100&publication_year=1997&pages=2952-2960&author=M.+A.+Sovakauthor=R.+E.+Bellasauthor=D.+W.+Kimauthor=G.+J.+Zanieskiauthor=A.+E.+Rogersauthor=A.+M.+Traishauthor=G.+E.+Sonenshein&title=Aberrant+nuclear+factor-kappaB%2FRel+expression+and+the+pathogenesis+of+breast+cancer&doi=10.1172%2FJCI119848"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1172%2FJCI119848&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI119848%26sid%3Dliteratum%253Aachs%26aulast%3DSovak%26aufirst%3DM.%2BA.%26aulast%3DBellas%26aufirst%3DR.%2BE.%26aulast%3DKim%26aufirst%3DD.%2BW.%26aulast%3DZanieski%26aufirst%3DG.%2BJ.%26aulast%3DRogers%26aufirst%3DA.%2BE.%26aulast%3DTraish%26aufirst%3DA.%2BM.%26aulast%3DSonenshein%26aufirst%3DG.%2BE.%26atitle%3DAberrant%2520nuclear%2520factor-kappaB%252FRel%2520expression%2520and%2520the%2520pathogenesis%2520of%2520breast%2520cancer%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D1997%26volume%3D100%26spage%3D2952%26epage%3D2960%26doi%3D10.1172%2FJCI119848" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group">Anastassiadis, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deacon, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Devarajan, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peterson, J. R.</span><span> </span><span class="NLM_article-title">Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity</span> <span class="citation_source-journal">Nat. Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">1039</span><span class="NLM_x">–</span> <span class="NLM_lpage">1045</span><span class="refDoi"> DOI: 10.1038/nbt.2017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01774&amp;key=10.1038%2Fnbt.2017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01774&amp;key=22037377" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01774&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtlyisL7E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2011&pages=1039-1045&author=T.+Anastassiadisauthor=S.+W.+Deaconauthor=K.+Devarajanauthor=H.+Maauthor=J.+R.+Peterson&title=Comprehensive+assay+of+kinase+catalytic+activity+reveals+features+of+kinase+inhibitor+selectivity&doi=10.1038%2Fnbt.2017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity</span></div><div class="casAuthors">Anastassiadis, Theonie; Deacon, Sean W.; Devarajan, Karthik; Ma, Haiching; Peterson, Jeffrey R.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1039-1045</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Small-mol. protein kinase inhibitors are widely used to elucidate cellular signaling pathways and are promising therapeutic agents.  Owing to evolutionary conservation of the ATP-binding site, most kinase inhibitors that target this site promiscuously inhibit multiple kinases.  Interpretation of expts. that use these compds. is confounded by a lack of data on the comprehensive kinase selectivity of most inhibitors.  Here we used functional assays to profile the activity of 178 com. available kinase inhibitors against a panel of 300 recombinant protein kinases.  Quant. anal. revealed complex and often unexpected interactions between protein kinases and kinase inhibitors, with a wide spectrum of promiscuity.  Many off-target interactions occur with seemingly unrelated kinases, revealing how large-scale profiling can identify multitargeted inhibitors of specific, diverse kinases.  The results have implications for drug development and provide a resource for selecting compds. to elucidate kinase function and for interpreting the results of expts. involving kinase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpUljWIhZGPkrVg90H21EOLACvtfcHk0lhgRLXANbG3uQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtlyisL7E&md5=b2f705509b0e09afa46b01d4669f0515</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1038%2Fnbt.2017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt.2017%26sid%3Dliteratum%253Aachs%26aulast%3DAnastassiadis%26aufirst%3DT.%26aulast%3DDeacon%26aufirst%3DS.%2BW.%26aulast%3DDevarajan%26aufirst%3DK.%26aulast%3DMa%26aufirst%3DH.%26aulast%3DPeterson%26aufirst%3DJ.%2BR.%26atitle%3DComprehensive%2520assay%2520of%2520kinase%2520catalytic%2520activity%2520reveals%2520features%2520of%2520kinase%2520inhibitor%2520selectivity%26jtitle%3DNat.%2520Biotechnol.%26date%3D2011%26volume%3D29%26spage%3D1039%26epage%3D1045%26doi%3D10.1038%2Fnbt.2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group">Beharry, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zemskova, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mahajan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xia, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lilly, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kraft, A. S.</span><span> </span><span class="NLM_article-title">Novel benzylidene-thiazolidine-2,4-diones inhibit Pim protein kinase activity and induce cell cycle arrest in leukemia and prostate cancer cells</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">1473</span><span class="NLM_x">–</span> <span class="NLM_lpage">1483</span><span class="refDoi"> DOI: 10.1158/1535-7163.MCT-08-1037</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01774&amp;key=10.1158%2F1535-7163.MCT-08-1037" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01774&amp;key=19509254" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01774&amp;key=1%3ACAS%3A528%3ADC%252BD1MXntVKgsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2009&pages=1473-1483&author=Z.+Beharryauthor=M.+Zemskovaauthor=S.+Mahajanauthor=F.+Zhangauthor=J.+Maauthor=Z.+Xiaauthor=M.+Lillyauthor=C.+D.+Smithauthor=A.+S.+Kraft&title=Novel+benzylidene-thiazolidine-2%2C4-diones+inhibit+Pim+protein+kinase+activity+and+induce+cell+cycle+arrest+in+leukemia+and+prostate+cancer+cells&doi=10.1158%2F1535-7163.MCT-08-1037"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Novel benzylidene-thiazolidine-2,4-diones inhibit Pim protein kinase activity and induce cell cycle arrest in leukemia and prostate cancer cells</span></div><div class="casAuthors">Beharry, Zanna; Zemskova, Marina; Mahajan, Sandeep; Zhang, Fengxue; Ma, Jian; Xia, Zuping; Lilly, Michael; Smith, Charles D.; Kraft, Andrew S.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1473-1483</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The Pim protein kinases play important roles in cancer development and progression, including prostate tumors and hematol. malignancies.  To investigate the potential role of these enzymes as anticancer drug targets, we have synthesized novel benzylidene-thiazolidine-2,4-diones that function as potent Pim protein kinase inhibitors.  With IC50 values in the nanomolar range, these compds. block the ability of Pim to phosphorylate peptides and proteins in vitro and, when added to DU145 prostate cancer cells overexpressing Pim, inhibit the ability of this enzyme to phosphorylate a known substrate, the BH3 protein BAD.  When added to prostate cancer cell lines, including PC3, DU145, and CWR22Rv1, and human leukemic cells, MV4;11, K562, and U937 cells, these compds. induce G1-S cell cycle arrest and block the antiapoptotic effect of the Pim protein kinase.  The cell cycle arrest induced by these compds. is assocd. with an inhibition of cyclin-dependent kinase 2 and activity and translocation of the Pim-1 substrate p27Kip1, a cyclin-dependent kinase 2 inhibitory protein, to the nucleus.  Furthermore, when added to leukemic cells, these compds. synergize with the mammalian target of rapamycin inhibitor rapamycin to decrease the phosphorylation level of the translational repressor 4E-BP1 at sites phosphorylated by mammalian target of rapamycin.  Combinations of rapamycin and the benzylidene-thiazolidine-2,4-diones synergistically block the growth of leukemic cells.  Thus, these agents represent novel Pim inhibitors and point to an important role for the Pim protein kinases in cell cycle control in multiple types of cancer cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrLAvby3We1JbVg90H21EOLACvtfcHk0lhgRLXANbG3uQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXntVKgsb8%253D&md5=7a66bb477cc0e5372d620fb0921c3262</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-08-1037&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-08-1037%26sid%3Dliteratum%253Aachs%26aulast%3DBeharry%26aufirst%3DZ.%26aulast%3DZemskova%26aufirst%3DM.%26aulast%3DMahajan%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DF.%26aulast%3DMa%26aufirst%3DJ.%26aulast%3DXia%26aufirst%3DZ.%26aulast%3DLilly%26aufirst%3DM.%26aulast%3DSmith%26aufirst%3DC.%2BD.%26aulast%3DKraft%26aufirst%3DA.%2BS.%26atitle%3DNovel%2520benzylidene-thiazolidine-2%252C4-diones%2520inhibit%2520Pim%2520protein%2520kinase%2520activity%2520and%2520induce%2520cell%2520cycle%2520arrest%2520in%2520leukemia%2520and%2520prostate%2520cancer%2520cells%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2009%26volume%3D8%26spage%3D1473%26epage%3D1483%26doi%3D10.1158%2F1535-7163.MCT-08-1037" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group">Palombella, V. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rando, O. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldberg, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maniatis, T.</span><span> </span><span class="NLM_article-title">The ubiquitin-proteasome pathway is required for processing the NF-kB1 precursor protein and the activation of NF-kB</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_volume">78</span><span class="NLM_x">, </span> <span class="NLM_fpage">773</span><span class="NLM_x">–</span> <span class="NLM_lpage">785</span><span class="refDoi"> DOI: 10.1016/S0092-8674(94)90482-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01774&amp;key=10.1016%2FS0092-8674%2894%2990482-0" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=1994&pages=773-785&author=V.+J.+Palombellaauthor=O.+J.+Randoauthor=A.+L.+Goldbergauthor=T.+Maniatis&title=The+ubiquitin-proteasome+pathway+is+required+for+processing+the+NF-kB1+precursor+protein+and+the+activation+of+NF-kB&doi=10.1016%2FS0092-8674%2894%2990482-0"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1016%2FS0092-8674%2894%2990482-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0092-8674%252894%252990482-0%26sid%3Dliteratum%253Aachs%26aulast%3DPalombella%26aufirst%3DV.%2BJ.%26aulast%3DRando%26aufirst%3DO.%2BJ.%26aulast%3DGoldberg%26aufirst%3DA.%2BL.%26aulast%3DManiatis%26aufirst%3DT.%26atitle%3DThe%2520ubiquitin-proteasome%2520pathway%2520is%2520required%2520for%2520processing%2520the%2520NF-kB1%2520precursor%2520protein%2520and%2520the%2520activation%2520of%2520NF-kB%26jtitle%3DCell%26date%3D1994%26volume%3D78%26spage%3D773%26epage%3D785%26doi%3D10.1016%2FS0092-8674%2894%2990482-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group">Montagut, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rovira, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gascon, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ross, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Albanell, J.</span><span> </span><span class="NLM_article-title">Preclinical and clinical development of the proteasome inhibitor bortezomib in cancer treatment</span> <span class="citation_source-journal">Drugs Today</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">41</span><span class="NLM_x">, </span> <span class="NLM_fpage">299</span><span class="NLM_x">–</span> <span class="NLM_lpage">315</span><span class="refDoi"> DOI: 10.1358/dot.2005.41.5.893706</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01774&amp;key=10.1358%2Fdot.2005.41.5.893706" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01774&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtV2itr7J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2005&pages=299-315&author=C.+Montagutauthor=A.+Roviraauthor=P.+Gasconauthor=J.+S.+Rossauthor=J.+Albanell&title=Preclinical+and+clinical+development+of+the+proteasome+inhibitor+bortezomib+in+cancer+treatment&doi=10.1358%2Fdot.2005.41.5.893706"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical and clinical development of the proteasome inhibitor bortezomib in cancer treatment</span></div><div class="casAuthors">Montagut, C.; Rovira, A.; Mellado, B.; Gascon, P.; Ross, J. S.; Albanell, J.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs of Today</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">299-315</span>CODEN:
                <span class="NLM_cas:coden">MDACAP</span>;
        ISSN:<span class="NLM_cas:issn">0025-7656</span>.
    
            (<span class="NLM_cas:orgname">Prous Science</span>)
        </div><div class="casAbstract">A review.  The proteasome is a ubiquitous enzyme complex that plays a crit. role in the degrdn. of many proteins involved in cell cycle regulation, apoptosis and angiogenesis.  Since these pathways are fundamental for cell survival and proliferation, particularly in cancer cells, the inhibition of proteasome is an attractive potential anticancer therapy.  The present review will focus on the proteasome inhibitor bortezomib (Velcade, formerly PS-341; Millennium Pharmaceuticals, Inc., Cambridge, MA, USA).  Bortezomib is an extremely potent and selective proteasome inhibitor that shows strong activity in in vitro and in vivo lab. studies against many solid and hematol. tumor types.  Moreover, bortezomib, mainly by inhibition of the NF-κB pathway, has a chemosensitizing effect when administered together with other antitumoral drugs.  Based on these results, bortezomib entered clin. phase I trials, alone or in combination with chemotherapy, that showed good tolerance at doses that achieved a desired degree of proteasome inhibition.  Phase II studies showed high response rates in refractory multiple myeloma patients, which led to the accelerated approval of bortezomib by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMEA) for this indication.  A phase III trial comparing bortezomib with dexamethasone in refractory/relapsed multiple myeloma patients had to be halted due to a survival advantage in the bortezomib arm.  Addnl. studies are focusing on the potential benefit of bortezomib in newly diagnosed multiple myeloma patients.  In other solid and hematol. malignancies, phase II studies with bortezomib alone or in combination with other agents are ongoing.  Encouraging results, particularly in lung cancer and lymphoma, have been obsd.  The crit. mols. or genes responsible for tumor sensitivity to bortezomib continue to be evaluated using novel technologies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq1vSaOr12debVg90H21EOLACvtfcHk0li7XQsrTSRH4A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtV2itr7J&md5=9f863821579e7dac2fa1d831a522b376</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1358%2Fdot.2005.41.5.893706&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1358%252Fdot.2005.41.5.893706%26sid%3Dliteratum%253Aachs%26aulast%3DMontagut%26aufirst%3DC.%26aulast%3DRovira%26aufirst%3DA.%26aulast%3DGascon%26aufirst%3DP.%26aulast%3DRoss%26aufirst%3DJ.%2BS.%26aulast%3DAlbanell%26aufirst%3DJ.%26atitle%3DPreclinical%2520and%2520clinical%2520development%2520of%2520the%2520proteasome%2520inhibitor%2520bortezomib%2520in%2520cancer%2520treatment%26jtitle%3DDrugs%2520Today%26date%3D2005%26volume%3D41%26spage%3D299%26epage%3D315%26doi%3D10.1358%2Fdot.2005.41.5.893706" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group">Berkers, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verdoes, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lichtman, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fiebiger, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kessler, B. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderson, K. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ploegh, H. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ovaa, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galardy, P. J.</span><span> </span><span class="NLM_article-title">Activity probe for in vivo profiling of the specificity of proteasome inhibitor bortezomib</span> <span class="citation_source-journal">Nat. Methods</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">357</span><span class="NLM_x">–</span> <span class="NLM_lpage">362</span><span class="refDoi"> DOI: 10.1038/nmeth759</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01774&amp;key=10.1038%2Fnmeth759" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01774&amp;key=15846363" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01774&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjsVyls70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2005&pages=357-362&author=C.+R.+Berkersauthor=M.+Verdoesauthor=E.+Lichtmanauthor=E.+Fiebigerauthor=B.+M.+Kesslerauthor=K.+C.+Andersonauthor=H.+L.+Ploeghauthor=H.+Ovaaauthor=P.+J.+Galardy&title=Activity+probe+for+in+vivo+profiling+of+the+specificity+of+proteasome+inhibitor+bortezomib&doi=10.1038%2Fnmeth759"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Activity probe for in vivo profiling of the specificity of proteasome inhibitor bortezomib</span></div><div class="casAuthors">Berkers, Celia R.; Verdoes, Martijn; Lichtman, Eben; Fiebiger, Edda; Kessler, Benedikt M.; Anderson, Kenneth C.; Ploegh, Hidde L.; Ovaa, Huib; Galardy, Paul J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Methods</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">357-362</span>CODEN:
                <span class="NLM_cas:coden">NMAEA3</span>;
        ISSN:<span class="NLM_cas:issn">1548-7091</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Proteasome inhibitors, such as the dipeptide boronic acid bortezomib, are emerging as important tools in the treatment of the fatal hematol. malignancy multiple myeloma.  Despite the recent US Food and Drug Administration approval of bortezomib (PS341, Velcade) for the treatment of refractory multiple myeloma, many of the basic pharmacol. parameters of bortezomib and its mode of action on myeloma cells remain to be detd.  We describe the synthesis and use of a cell-permeant active site-directed probe, which allows profiling of proteasomal activities in living cells.  When we compared proteasome activity patterns in cultured cells and crude cell exts. with this probe, we obsd. substantial differences, stressing the importance for bioassays compatible with live cells to ensure accuracy of such measurements.  Using this probe, we investigated the in vivo subunit specificities of bortezomib and another inhibitor, MG132.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGomPqiElUEWtLVg90H21EOLACvtfcHk0li7XQsrTSRH4A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjsVyls70%253D&md5=5055e0a80ecfd5ea8272e6b38f0c73bc</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1038%2Fnmeth759&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnmeth759%26sid%3Dliteratum%253Aachs%26aulast%3DBerkers%26aufirst%3DC.%2BR.%26aulast%3DVerdoes%26aufirst%3DM.%26aulast%3DLichtman%26aufirst%3DE.%26aulast%3DFiebiger%26aufirst%3DE.%26aulast%3DKessler%26aufirst%3DB.%2BM.%26aulast%3DAnderson%26aufirst%3DK.%2BC.%26aulast%3DPloegh%26aufirst%3DH.%2BL.%26aulast%3DOvaa%26aufirst%3DH.%26aulast%3DGalardy%26aufirst%3DP.%2BJ.%26atitle%3DActivity%2520probe%2520for%2520in%2520vivo%2520profiling%2520of%2520the%2520specificity%2520of%2520proteasome%2520inhibitor%2520bortezomib%26jtitle%3DNat.%2520Methods%26date%3D2005%26volume%3D2%26spage%3D357%26epage%3D362%26doi%3D10.1038%2Fnmeth759" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group">Hayden, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghosh, S.</span><span> </span><span class="NLM_article-title">Signaling to NF-kappaB</span> <span class="citation_source-journal">Genes Dev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">2195</span><span class="NLM_x">–</span> <span class="NLM_lpage">2224</span><span class="refDoi"> DOI: 10.1101/gad.1228704</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01774&amp;key=10.1101%2Fgad.1228704" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01774&amp;key=15371334" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01774&amp;key=1%3ACAS%3A528%3ADC%252BD2cXnslCntbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2004&pages=2195-2224&author=M.+S.+Haydenauthor=S.+Ghosh&title=Signaling+to+NF-kappaB&doi=10.1101%2Fgad.1228704"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Signaling to NF-κB</span></div><div class="casAuthors">Hayden, Matthew S.; Ghosh, Sankar</div><div class="citationInfo"><span class="NLM_cas:title">Genes & Development</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">2195-2224</span>CODEN:
                <span class="NLM_cas:coden">GEDEEP</span>;
        ISSN:<span class="NLM_cas:issn">0890-9369</span>.
    
            (<span class="NLM_cas:orgname">Cold Spring Harbor Laboratory Press</span>)
        </div><div class="casAbstract">A review.  The transcription factor NF-κB has been the focus of intense investigation for nearly two decades.  Over this period, considerable progress has been made in detg. the function and regulation of NF-κB, although there are nuances in this important signaling pathway that still remain to be understood.  The challenge now is to reconcile the regulatory complexity in this pathway with the complexity of responses in which NF-κB family members play important roles.  In this review, authors provide an overview of established NF-κB signaling pathways with focus on the current state of research into the mechanisms that regulate IKK activation and NF-κB transcriptional activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqGn6Te9a4IB7Vg90H21EOLACvtfcHk0lgYPaYurHneYA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXnslCntbY%253D&md5=59ac1691d86e059c8f4b62d8629729dd</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1101%2Fgad.1228704&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1101%252Fgad.1228704%26sid%3Dliteratum%253Aachs%26aulast%3DHayden%26aufirst%3DM.%2BS.%26aulast%3DGhosh%26aufirst%3DS.%26atitle%3DSignaling%2520to%2520NF-kappaB%26jtitle%3DGenes%2520Dev.%26date%3D2004%26volume%3D18%26spage%3D2195%26epage%3D2224%26doi%3D10.1101%2Fgad.1228704" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group">Yang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, W. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, J. C.</span><span> </span><span class="NLM_article-title">CBP knockdown inhibits angiotensin II-induced vascular smooth muscle cells proliferation through downregulating NF-kB transcriptional activity</span> <span class="citation_source-journal">Mol. Cell. Biochem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">340</span><span class="NLM_x">, </span> <span class="NLM_fpage">55</span><span class="NLM_x">–</span> <span class="NLM_lpage">62</span><span class="refDoi"> DOI: 10.1007/s11010-010-0400-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01774&amp;key=10.1007%2Fs11010-010-0400-2" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=340&publication_year=2010&pages=55-62&author=J.+Yangauthor=H.+Jiangauthor=S.+S.+Chenauthor=J.+Chenauthor=S.+K.+Xuauthor=W.+Q.+Liauthor=J.+C.+Wang&title=CBP+knockdown+inhibits+angiotensin+II-induced+vascular+smooth+muscle+cells+proliferation+through+downregulating+NF-kB+transcriptional+activity&doi=10.1007%2Fs11010-010-0400-2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1007%2Fs11010-010-0400-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11010-010-0400-2%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DJiang%26aufirst%3DH.%26aulast%3DChen%26aufirst%3DS.%2BS.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DXu%26aufirst%3DS.%2BK.%26aulast%3DLi%26aufirst%3DW.%2BQ.%26aulast%3DWang%26aufirst%3DJ.%2BC.%26atitle%3DCBP%2520knockdown%2520inhibits%2520angiotensin%2520II-induced%2520vascular%2520smooth%2520muscle%2520cells%2520proliferation%2520through%2520downregulating%2520NF-kB%2520transcriptional%2520activity%26jtitle%3DMol.%2520Cell.%2520Biochem.%26date%3D2010%26volume%3D340%26spage%3D55%26epage%3D62%26doi%3D10.1007%2Fs11010-010-0400-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group">Ma, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fey, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hottiger, M. O.</span><span> </span><span class="NLM_article-title">WNT/beta-catenin signaling inhibits CBP-mediated RelA acetylation and expression of proinflammatory NF-kappaB target genes</span> <span class="citation_source-journal">J. Cell Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">128</span><span class="NLM_x">, </span> <span class="NLM_fpage">2430</span><span class="NLM_x">–</span> <span class="NLM_lpage">2436</span><span class="refDoi"> DOI: 10.1242/jcs.168542</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01774&amp;key=10.1242%2Fjcs.168542" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01774&amp;key=26021349" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01774&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsVamsLfN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=128&publication_year=2015&pages=2430-2436&author=B.+Maauthor=M.+Feyauthor=M.+O.+Hottiger&title=WNT%2Fbeta-catenin+signaling+inhibits+CBP-mediated+RelA+acetylation+and+expression+of+proinflammatory+NF-kappaB+target+genes&doi=10.1242%2Fjcs.168542"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">WNT/β-catenin signaling inhibits CBP-mediated RelA acetylation and expression of proinflammatory NF-κB target genes</span></div><div class="casAuthors">Ma, Bin; Fey, Monika; Hottiger, Michael O.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cell Science</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">128</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">2430-2436</span>CODEN:
                <span class="NLM_cas:coden">JNCSAI</span>;
        ISSN:<span class="NLM_cas:issn">0021-9533</span>.
    
            (<span class="NLM_cas:orgname">Company of Biologists Ltd.</span>)
        </div><div class="casAbstract">The discovery of functional crosstalk between WNT and nuclear factor κB (NF-κB) signaling has established a more complex role for these two pathways in inflammation and cancer.  However, the mol. mechanisms of the crosstalk and its biol. consequences are largely unknown.  Here, we show that WNT/β-catenin signaling selectively inhibits the expression of a proinflammatory subset of IL-1β-induced NF-κB target genes.  WNT/β-catenin signaling does not affect nuclear translocation of the RelA subunit of NF-κB or its assocn. with CBP (also known as CREBBP), but reduces CBP-mediated acetylation and chromatin recruitment of RelA.  Thus, β-catenin selectively regulates NF-κB gene expression through its neg. effects on RelA acetylation.  This anti-inflammatory effect may be relevant for cancer treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpvPgHrhvl7Z7Vg90H21EOLACvtfcHk0lgYPaYurHneYA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsVamsLfN&md5=9994710454a8600497fd4fd6ac4594e9</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1242%2Fjcs.168542&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1242%252Fjcs.168542%26sid%3Dliteratum%253Aachs%26aulast%3DMa%26aufirst%3DB.%26aulast%3DFey%26aufirst%3DM.%26aulast%3DHottiger%26aufirst%3DM.%2BO.%26atitle%3DWNT%252Fbeta-catenin%2520signaling%2520inhibits%2520CBP-mediated%2520RelA%2520acetylation%2520and%2520expression%2520of%2520proinflammatory%2520NF-kappaB%2520target%2520genes%26jtitle%3DJ.%2520Cell%2520Sci.%26date%3D2015%26volume%3D128%26spage%3D2430%26epage%3D2436%26doi%3D10.1242%2Fjcs.168542" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group">Hua, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tamamori-Adachi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luo, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tamura, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morioka, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fukuda, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tanaka, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kitajima, S.</span><span> </span><span class="NLM_article-title">A splice variant of stress response gene ATF3 counteracts NF-kappaB-dependent anti-apoptosis through inhibiting recruitment of CREB-binding protein/p300 coactivator</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">281</span><span class="NLM_x">, </span> <span class="NLM_fpage">1620</span><span class="NLM_x">–</span> <span class="NLM_lpage">1629</span><span class="refDoi"> DOI: 10.1074/jbc.M508471200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01774&amp;key=10.1074%2Fjbc.M508471200" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=281&publication_year=2006&pages=1620-1629&author=B.+Huaauthor=M.+Tamamori-Adachiauthor=Y.+Luoauthor=K.+Tamuraauthor=M.+Moriokaauthor=M.+Fukudaauthor=Y.+Tanakaauthor=S.+Kitajima&title=A+splice+variant+of+stress+response+gene+ATF3+counteracts+NF-kappaB-dependent+anti-apoptosis+through+inhibiting+recruitment+of+CREB-binding+protein%2Fp300+coactivator&doi=10.1074%2Fjbc.M508471200"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M508471200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M508471200%26sid%3Dliteratum%253Aachs%26aulast%3DHua%26aufirst%3DB.%26aulast%3DTamamori-Adachi%26aufirst%3DM.%26aulast%3DLuo%26aufirst%3DY.%26aulast%3DTamura%26aufirst%3DK.%26aulast%3DMorioka%26aufirst%3DM.%26aulast%3DFukuda%26aufirst%3DM.%26aulast%3DTanaka%26aufirst%3DY.%26aulast%3DKitajima%26aufirst%3DS.%26atitle%3DA%2520splice%2520variant%2520of%2520stress%2520response%2520gene%2520ATF3%2520counteracts%2520NF-kappaB-dependent%2520anti-apoptosis%2520through%2520inhibiting%2520recruitment%2520of%2520CREB-binding%2520protein%252Fp300%2520coactivator%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2006%26volume%3D281%26spage%3D1620%26epage%3D1629%26doi%3D10.1074%2Fjbc.M508471200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group">Mukherjee, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Behar, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Birnbaum, H. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoffmann, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wright, P. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghosh, G.</span><span> </span><span class="NLM_article-title">Analysis of the RelA:CBP/p300 interaction reveals its involvement in NF-kappaB-driven transcription</span> <span class="citation_source-journal">PLoS Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">e1001647</span><span class="refDoi"> DOI: 10.1371/journal.pbio.1001647</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01774&amp;key=10.1371%2Fjournal.pbio.1001647" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2013&pages=e1001647&author=S.+P.+Mukherjeeauthor=M.+Beharauthor=H.+A.+Birnbaumauthor=A.+Hoffmannauthor=P.+E.+Wrightauthor=G.+Ghosh&title=Analysis+of+the+RelA%3ACBP%2Fp300+interaction+reveals+its+involvement+in+NF-kappaB-driven+transcription&doi=10.1371%2Fjournal.pbio.1001647"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pbio.1001647&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pbio.1001647%26sid%3Dliteratum%253Aachs%26aulast%3DMukherjee%26aufirst%3DS.%2BP.%26aulast%3DBehar%26aufirst%3DM.%26aulast%3DBirnbaum%26aufirst%3DH.%2BA.%26aulast%3DHoffmann%26aufirst%3DA.%26aulast%3DWright%26aufirst%3DP.%2BE.%26aulast%3DGhosh%26aufirst%3DG.%26atitle%3DAnalysis%2520of%2520the%2520RelA%253ACBP%252Fp300%2520interaction%2520reveals%2520its%2520involvement%2520in%2520NF-kappaB-driven%2520transcription%26jtitle%3DPLoS%2520Biol.%26date%3D2013%26volume%3D11%26spage%3De1001647%26doi%3D10.1371%2Fjournal.pbio.1001647" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group">Tilstra, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gaddy, D. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dave, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niedernhofer, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Plevy, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robbins, P. D.</span><span> </span><span class="NLM_article-title">Pharmacologic IKK/NF-kappaB inhibition causes antigen presenting cells to undergo TNFalpha dependent ROS-mediated programmed cell death</span> <span class="citation_source-journal">Sci. Rep.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">3631</span><span class="refDoi"> DOI: 10.1038/srep03631</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01774&amp;key=10.1038%2Fsrep03631" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01774&amp;key=24406986" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01774&amp;key=1%3ACAS%3A528%3ADC%252BC2cXjslCjurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2014&pages=3631&author=J.+S.+Tilstraauthor=D.+F.+Gaddyauthor=J.+Zhaoauthor=S.+H.+Daveauthor=L.+J.+Niedernhoferauthor=S.+E.+Plevyauthor=P.+D.+Robbins&title=Pharmacologic+IKK%2FNF-kappaB+inhibition+causes+antigen+presenting+cells+to+undergo+TNFalpha+dependent+ROS-mediated+programmed+cell+death&doi=10.1038%2Fsrep03631"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacologic IKK/NF-κB inhibition causes antigen presenting cells to undergo TNFα dependent ROS-mediated programmed cell death</span></div><div class="casAuthors">Tilstra, Jeremy S.; Gaddy, Daniel F.; Zhao, Jing; Dave, Shaival H.; Niedernhofer, Laura J.; Plevy, Scott E.; Robbins, Paul D.</div><div class="citationInfo"><span class="NLM_cas:title">Scientific Reports</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">3631/1-3631/11</span>CODEN:
                <span class="NLM_cas:coden">SRCEC3</span>;
        ISSN:<span class="NLM_cas:issn">2045-2322</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Monocyte-derived antigen presenting cells (APC) are central mediators of the innate and adaptive immune response in inflammatory diseases.  As such, APC are appropriate targets for therapeutic intervention to ameliorate certain diseases.  APC differentiation, activation and functions are regulated by the NF-κB family of transcription factors.  Herein, the authors examd. the effect of NF-κB inhibition, via suppression of the IκB Kinase (IKK) complex, on APC function.  Murine bone marrow-derived macrophages and dendritic cells (DC), as well as macrophage and DC lines, underwent rapid programmed cell death (PCD) after treatment with several IKK/NF-κB inhibitors through a TNFα-dependent mechanism.  PCD was induced proximally by reactive oxygen species (ROS) formation, which causes a loss of mitochondrial membrane potential and activation of a caspase signaling cascade.  NF-κB-inhibition-induced PCD of APC may be a key mechanism through which therapeutic targeting of NF-κB reduces inflammatory pathologies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrGEhCbne7HD7Vg90H21EOLACvtfcHk0ljhUamJ_wIw8g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXjslCjurY%253D&md5=f40f14d2c4db3e170a8f50e42c82c540</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1038%2Fsrep03631&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsrep03631%26sid%3Dliteratum%253Aachs%26aulast%3DTilstra%26aufirst%3DJ.%2BS.%26aulast%3DGaddy%26aufirst%3DD.%2BF.%26aulast%3DZhao%26aufirst%3DJ.%26aulast%3DDave%26aufirst%3DS.%2BH.%26aulast%3DNiedernhofer%26aufirst%3DL.%2BJ.%26aulast%3DPlevy%26aufirst%3DS.%2BE.%26aulast%3DRobbins%26aufirst%3DP.%2BD.%26atitle%3DPharmacologic%2520IKK%252FNF-kappaB%2520inhibition%2520causes%2520antigen%2520presenting%2520cells%2520to%2520undergo%2520TNFalpha%2520dependent%2520ROS-mediated%2520programmed%2520cell%2520death%26jtitle%3DSci.%2520Rep.%26date%3D2014%26volume%3D4%26spage%3D3631%26doi%3D10.1038%2Fsrep03631" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group">Verstrepen, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beyaert, R.</span><span> </span><span class="NLM_article-title">Receptor proximal kinases in NF-kappaB signaling as potential therapeutic targets in cancer and inflammation</span> <span class="citation_source-journal">Biochem. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">92</span><span class="NLM_x">, </span> <span class="NLM_fpage">519</span><span class="NLM_x">–</span> <span class="NLM_lpage">29</span><span class="refDoi"> DOI: 10.1016/j.bcp.2014.10.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01774&amp;key=10.1016%2Fj.bcp.2014.10.017" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=92&publication_year=2014&pages=519-29&author=L.+Verstrepenauthor=R.+Beyaert&title=Receptor+proximal+kinases+in+NF-kappaB+signaling+as+potential+therapeutic+targets+in+cancer+and+inflammation&doi=10.1016%2Fj.bcp.2014.10.017"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1016%2Fj.bcp.2014.10.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bcp.2014.10.017%26sid%3Dliteratum%253Aachs%26aulast%3DVerstrepen%26aufirst%3DL.%26aulast%3DBeyaert%26aufirst%3DR.%26atitle%3DReceptor%2520proximal%2520kinases%2520in%2520NF-kappaB%2520signaling%2520as%2520potential%2520therapeutic%2520targets%2520in%2520cancer%2520and%2520inflammation%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2014%26volume%3D92%26spage%3D519%26epage%3D29%26doi%3D10.1016%2Fj.bcp.2014.10.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group">Enzler, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sano, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choo, M. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cottam, H. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karin, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsao, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, J. M.</span><span> </span><span class="NLM_article-title">Cell-selective inhibition of NF-kappaB signaling improves therapeutic index in a melanoma chemotherapy model</span> <span class="citation_source-journal">Cancer Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">496</span><span class="NLM_x">–</span> <span class="NLM_lpage">507</span><span class="refDoi"> DOI: 10.1158/2159-8290.CD-11-0143</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01774&amp;key=10.1158%2F2159-8290.CD-11-0143" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2011&pages=496-507&author=T.+Enzlerauthor=Y.+Sanoauthor=M.+K.+Chooauthor=H.+B.+Cottamauthor=M.+Karinauthor=H.+Tsaoauthor=J.+M.+Park&title=Cell-selective+inhibition+of+NF-kappaB+signaling+improves+therapeutic+index+in+a+melanoma+chemotherapy+model&doi=10.1158%2F2159-8290.CD-11-0143"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-11-0143&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-11-0143%26sid%3Dliteratum%253Aachs%26aulast%3DEnzler%26aufirst%3DT.%26aulast%3DSano%26aufirst%3DY.%26aulast%3DChoo%26aufirst%3DM.%2BK.%26aulast%3DCottam%26aufirst%3DH.%2BB.%26aulast%3DKarin%26aufirst%3DM.%26aulast%3DTsao%26aufirst%3DH.%26aulast%3DPark%26aufirst%3DJ.%2BM.%26atitle%3DCell-selective%2520inhibition%2520of%2520NF-kappaB%2520signaling%2520improves%2520therapeutic%2520index%2520in%2520a%2520melanoma%2520chemotherapy%2520model%26jtitle%3DCancer%2520Discovery%26date%3D2011%26volume%3D1%26spage%3D496%26epage%3D507%26doi%3D10.1158%2F2159-8290.CD-11-0143" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group">Aggarwal, B. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sung, B.</span><span> </span><span class="NLM_article-title">NF-kappaB in cancer: a matter of life and death</span> <span class="citation_source-journal">Cancer Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">469</span><span class="NLM_x">–</span> <span class="NLM_lpage">471</span><span class="refDoi"> DOI: 10.1158/2159-8290.CD-11-0260</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01774&amp;key=10.1158%2F2159-8290.CD-11-0260" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2011&pages=469-471&author=B.+B.+Aggarwalauthor=B.+Sung&title=NF-kappaB+in+cancer%3A+a+matter+of+life+and+death&doi=10.1158%2F2159-8290.CD-11-0260"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-11-0260&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-11-0260%26sid%3Dliteratum%253Aachs%26aulast%3DAggarwal%26aufirst%3DB.%2BB.%26aulast%3DSung%26aufirst%3DB.%26atitle%3DNF-kappaB%2520in%2520cancer%253A%2520a%2520matter%2520of%2520life%2520and%2520death%26jtitle%3DCancer%2520Discovery%26date%3D2011%26volume%3D1%26spage%3D469%26epage%3D471%26doi%3D10.1158%2F2159-8290.CD-11-0260" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group">Picaud, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fedorov, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thanasopoulou, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leonards, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meier, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olzscha, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Monteiro, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Philpott, M.-.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tumber, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Filippakopoulos, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yapp, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wells, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Che, K. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bannister, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robson, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kumar, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parr, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lugo, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jeffrey, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vecellio, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bountra, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brennan, P.-.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Mahony, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Velichko, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Müller, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hay, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Daniels, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Urh, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">La Thangue, N. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kouzarides, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prinjha, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwaller, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knapp, S.</span><span> </span><span class="NLM_article-title">Generation of a selective small molecule inhibitor of the CBP/p300 bromodomain for leukemia therapy</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">75</span><span class="NLM_x">, </span> <span class="NLM_fpage">5106</span><span class="NLM_x">–</span> <span class="NLM_lpage">5119</span><span class="refDoi"> DOI: 10.1158/0008-5472.CAN-15-0236</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01774&amp;key=10.1158%2F0008-5472.CAN-15-0236" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01774&amp;key=26552700" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01774&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvFensrzN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2015&pages=5106-5119&author=S.+Picaudauthor=O.+Fedorovauthor=A.+Thanasopoulouauthor=K.+Leonardsauthor=K.+Jonesauthor=J.+Meierauthor=H.+Olzschaauthor=O.+Monteiroauthor=S.+Martinauthor=M.-.+Philpottauthor=A.+Tumberauthor=P.+Filippakopoulosauthor=C.+Yappauthor=C.+Wellsauthor=K.+H.+Cheauthor=A.+Bannisterauthor=S.+Robsonauthor=U.+Kumarauthor=N.+Parrauthor=K.+Leeauthor=D.+Lugoauthor=P.+Jeffreyauthor=S.+Taylorauthor=L.+M.+Vecellioauthor=C.+Bountraauthor=P.-.+Brennanauthor=A.+O%E2%80%99Mahonyauthor=S.+Velichkoauthor=S.+M%C3%BCllerauthor=D.+Hayauthor=D.+L.+Danielsauthor=M.+Urhauthor=N.+B.+La+Thangueauthor=T.+Kouzaridesauthor=R.+Prinjhaauthor=J.+Schwallerauthor=S.+Knapp&title=Generation+of+a+selective+small+molecule+inhibitor+of+the+CBP%2Fp300+bromodomain+for+leukemia+therapy&doi=10.1158%2F0008-5472.CAN-15-0236"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Generation of a Selective Small Molecule Inhibitor of the CBP/p300 Bromodomain for Leukemia Therapy</span></div><div class="casAuthors">Picaud, Sarah; Fedorov, Oleg; Thanasopoulou, Angeliki; Leonards, Katharina; Jones, Katherine; Meier, Julia; Olzscha, Heidi; Monteiro, Octovia; Martin, Sarah; Philpott, Martin; Tumber, Anthony; Filippakopoulos, Panagis; Yapp, Clarence; Wells, Christopher; Che, Ka Hing; Bannister, Andrew; Robson, Samuel; Kumar, Umesh; Parr, Nigel; Lee, Kevin; Lugo, Dave; Jeffrey, Philip; Taylor, Simon; Vecellio, Matteo L.; Bountra, Chas; Brennan, Paul E.; O'Mahony, Alison; Velichko, Sharlene; Mueller, Susanne; Hay, Duncan; Daniels, Danette L.; Urh, Marjeta; La Thangue, Nicholas B.; Kouzarides, Tony; Prinjha, Rab; Schwaller, Juerg; Knapp, Stefan</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">75</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">5106-5119</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The histone acetyltransferases CBP/p300 are involved in recurrent leukemia-assocd. chromosomal translocations and are key regulators of cell growth.  Therefore, efforts to generate inhibitors of CBP/p300 are of clin. value.  We developed a specific and potent acetyl-lysine competitive protein-protein interaction inhibitor, I-CBP112, that targets the CBP/p300 bromodomains.  Exposure of human and mouse leukemic cell lines to I-CBP112 resulted in substantially impaired colony formation and induced cellular differentiation without significant cytotoxicity.  I-CBP112 significantly reduced the leukemia-initiating potential of MLL-AF9+ acute myeloid leukemia cells in a dose-dependent manner in vitro and in vivo.  Interestingly, I-CBP112 increased the cytotoxic activity of BET bromodomain inhibitor JQ1 as well as doxorubicin.  Collectively, we report the development and preclin. evaluation of a novel, potent inhibitor targeting CBP/p300 bromodomains that impairs aberrant self-renewal of leukemic cells.  The synergistic effects of I-CBP112 and current std. therapy (doxorubicin) as well as emerging treatment strategies (BET inhibition) provide new opportunities for combinatorial treatment of leukemia and potentially other cancers.  Cancer Res; 75(23); 5106-19. ©2015 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWk5dMbmC6K7Vg90H21EOLACvtfcHk0lhZcDCPBEptng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvFensrzN&md5=da936fa34139ba27abc748db5f78c95e</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-15-0236&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-15-0236%26sid%3Dliteratum%253Aachs%26aulast%3DPicaud%26aufirst%3DS.%26aulast%3DFedorov%26aufirst%3DO.%26aulast%3DThanasopoulou%26aufirst%3DA.%26aulast%3DLeonards%26aufirst%3DK.%26aulast%3DJones%26aufirst%3DK.%26aulast%3DMeier%26aufirst%3DJ.%26aulast%3DOlzscha%26aufirst%3DH.%26aulast%3DMonteiro%26aufirst%3DO.%26aulast%3DMartin%26aufirst%3DS.%26aulast%3DPhilpott%26aufirst%3DM.-.%26aulast%3DTumber%26aufirst%3DA.%26aulast%3DFilippakopoulos%26aufirst%3DP.%26aulast%3DYapp%26aufirst%3DC.%26aulast%3DWells%26aufirst%3DC.%26aulast%3DChe%26aufirst%3DK.%2BH.%26aulast%3DBannister%26aufirst%3DA.%26aulast%3DRobson%26aufirst%3DS.%26aulast%3DKumar%26aufirst%3DU.%26aulast%3DParr%26aufirst%3DN.%26aulast%3DLee%26aufirst%3DK.%26aulast%3DLugo%26aufirst%3DD.%26aulast%3DJeffrey%26aufirst%3DP.%26aulast%3DTaylor%26aufirst%3DS.%26aulast%3DVecellio%26aufirst%3DL.%2BM.%26aulast%3DBountra%26aufirst%3DC.%26aulast%3DBrennan%26aufirst%3DP.-.%26aulast%3DO%25E2%2580%2599Mahony%26aufirst%3DA.%26aulast%3DVelichko%26aufirst%3DS.%26aulast%3DM%25C3%25BCller%26aufirst%3DS.%26aulast%3DHay%26aufirst%3DD.%26aulast%3DDaniels%26aufirst%3DD.%2BL.%26aulast%3DUrh%26aufirst%3DM.%26aulast%3DLa%2BThangue%26aufirst%3DN.%2BB.%26aulast%3DKouzarides%26aufirst%3DT.%26aulast%3DPrinjha%26aufirst%3DR.%26aulast%3DSchwaller%26aufirst%3DJ.%26aulast%3DKnapp%26aufirst%3DS.%26atitle%3DGeneration%2520of%2520a%2520selective%2520small%2520molecule%2520inhibitor%2520of%2520the%2520CBP%252Fp300%2520bromodomain%2520for%2520leukemia%2520therapy%26jtitle%3DCancer%2520Res.%26date%3D2015%26volume%3D75%26spage%3D5106%26epage%3D5119%26doi%3D10.1158%2F0008-5472.CAN-15-0236" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group">Dancy, B. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cole, P. A.</span><span> </span><span class="NLM_article-title">Protein lysine acetylation by p300/CBP</span> <span class="citation_source-journal">Chem. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">115</span><span class="NLM_x">, </span> <span class="NLM_fpage">2419</span><span class="NLM_x">–</span> <span class="NLM_lpage">2452</span><span class="refDoi"> DOI: 10.1021/cr500452k</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cr500452k" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01774&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtVCiu7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=115&publication_year=2015&pages=2419-2452&author=B.+M.+Dancyauthor=P.+A.+Cole&title=Protein+lysine+acetylation+by+p300%2FCBP&doi=10.1021%2Fcr500452k"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Protein Lysine Acetylation by p300/CBP</span></div><div class="casAuthors">Dancy, Beverley M.; Cole, Philip A.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Reviews (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">115</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2419-2452</span>CODEN:
                <span class="NLM_cas:coden">CHREAY</span>;
        ISSN:<span class="NLM_cas:issn">0009-2665</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The human protein lysine acetyltransferase encoded by the paralogous p300 and CBP genes is involved in regulating the expression of genes.  In this capacity, p300/CBP controls several basic cellular processes such as proliferation and homeostasis, and plays a role in a variety of human diseases, particularly solid tumors.  This review summarizes information related to the current understanding of p300/CBP, including the novel technologies that have co-evolved with p300/CBP research.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpYgTImMiuo7rVg90H21EOLACvtfcHk0lhZcDCPBEptng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtVCiu7Y%253D&md5=40a46cf68990f4a7d11a338c54081628</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1021%2Fcr500452k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcr500452k%26sid%3Dliteratum%253Aachs%26aulast%3DDancy%26aufirst%3DB.%2BM.%26aulast%3DCole%26aufirst%3DP.%2BA.%26atitle%3DProtein%2520lysine%2520acetylation%2520by%2520p300%252FCBP%26jtitle%3DChem.%2520Rev.%26date%3D2015%26volume%3D115%26spage%3D2419%26epage%3D2452%26doi%3D10.1021%2Fcr500452k" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group">Naruse, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohmori, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fukumoto, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuroki, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mori, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saijo, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nishio, K.</span><span> </span><span class="NLM_article-title">Antitumor activity of the selective epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) Iressa® (ZD1839) in an EGFR-expressing multidrug-resistant cell line in vitro and in vivo</span> <span class="citation_source-journal">Int. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">98</span><span class="NLM_x">, </span> <span class="NLM_fpage">310</span><span class="NLM_x">–</span> <span class="NLM_lpage">315</span><span class="refDoi"> DOI: 10.1002/ijc.10173</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01774&amp;key=10.1002%2Fijc.10173" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01774&amp;key=11857424" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01774&amp;key=1%3ACAS%3A528%3ADC%252BD38XhsVSku7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=98&publication_year=2002&pages=310-315&author=I.+Naruseauthor=T.+Ohmoriauthor=Y.+Aoauthor=H.+Fukumotoauthor=T.+Kurokiauthor=M.+Moriauthor=N.+Saijoauthor=K.+Nishio&title=Antitumor+activity+of+the+selective+epidermal+growth+factor+receptor-tyrosine+kinase+inhibitor+%28EGFR-TKI%29+Iressa%C2%AE+%28ZD1839%29+in+an+EGFR-expressing+multidrug-resistant+cell+line+in+vitro+and+in+vivo&doi=10.1002%2Fijc.10173"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Antitumor activity of the selective epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) Iressa (ZD1839) in an EGFR-expressing multidrug-resistant cell line in vitro and in vivo</span></div><div class="casAuthors">Naruse, Ichiro; Ohmori, Tohru; Ao, Yoko; Fukumoto, Hisao; Kuroki, Toshio; Mori, Masatomo; Saijo, Nagahiro; Nishio, Kazuto</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Cancer</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">98</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">310-315</span>CODEN:
                <span class="NLM_cas:coden">IJCNAW</span>;
        ISSN:<span class="NLM_cas:issn">0020-7136</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">Selective tyrosine kinase inhibitors are regarded as promising antitumor agents for cancer treatment.  Iressa (ZD1839) is an orally active, selective EGFR-TKI (epidermal growth factor receptor-tyrosine kinase inhibitor) that blocks signal transduction pathways implicated in cancer cell proliferation, survival and other host-dependent processes promoting cancer growth.  The cellular mechanisms of ZD1839 action against human malignant cells and drug-resistant cells were evaluated in vitro.  Among the cell lines tested, ZD1839 showed a strong growth-inhibitory effect in vitro on human leukemic cells resistant to phorbol ester.  This cell line, K562/TPA, shows a non-P-glycoprotein-mediated multidrug-resistant phenotype.  The IC50 value of ZD1839 on K562/TPA was approx. 400-fold lower than that on the parental K562 cell (K562 = 12 ± 2 μM; K562/TPA = 0.025 ± 0.002 μM) in vitro as detd. by a dye formation assay.  The expression of EGFR and EGFR mRNA was clearly present in K562/TPA but not in parental K562 cells as detd. by Western blotting and RT-PCR.  EGFR was autophosphorylated in K562/TPA detected by the antiphosphotyrosine antibody.  The in vivo antitumor effects of ZD1839 on K562 and K562/TPA cells were also investigated in BALB/c nude mice.  K562/TPA cells transplanted s.c. into mice disappeared completely with ZD1839 treatment (20 mg/kg/day, days 3-9).  This was not the case in K562 cells.  These results suggest that ZD1839 is highly active against tumor cells with non-P-glycoprotein-mediated multidrug resistance that express EGFR.  Iressa is a trademark of AstraZeneca (Cheshire, UK).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqWYzrtWh_34rVg90H21EOLACvtfcHk0lhZcDCPBEptng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XhsVSku7w%253D&md5=665a402587212a4b02b794a69a1755c7</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1002%2Fijc.10173&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fijc.10173%26sid%3Dliteratum%253Aachs%26aulast%3DNaruse%26aufirst%3DI.%26aulast%3DOhmori%26aufirst%3DT.%26aulast%3DAo%26aufirst%3DY.%26aulast%3DFukumoto%26aufirst%3DH.%26aulast%3DKuroki%26aufirst%3DT.%26aulast%3DMori%26aufirst%3DM.%26aulast%3DSaijo%26aufirst%3DN.%26aulast%3DNishio%26aufirst%3DK.%26atitle%3DAntitumor%2520activity%2520of%2520the%2520selective%2520epidermal%2520growth%2520factor%2520receptor-tyrosine%2520kinase%2520inhibitor%2520%2528EGFR-TKI%2529%2520Iressa%25C2%25AE%2520%2528ZD1839%2529%2520in%2520an%2520EGFR-expressing%2520multidrug-resistant%2520cell%2520line%2520in%2520vitro%2520and%2520in%2520vivo%26jtitle%3DInt.%2520J.%2520Cancer%26date%3D2002%26volume%3D98%26spage%3D310%26epage%3D315%26doi%3D10.1002%2Fijc.10173" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group">Barker, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gibson, K. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grundy, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Godfrey, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barlow, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Healy, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woodburn, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ashton, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curry, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scarlett, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Henthorn, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richards, L.</span><span> </span><span class="NLM_article-title">Studies leading to the identification of ZD1839 (IressaTM): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">1911</span><span class="NLM_x">–</span> <span class="NLM_lpage">1914</span><span class="refDoi"> DOI: 10.1016/S0960-894X(01)00344-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01774&amp;key=10.1016%2FS0960-894X%2801%2900344-4" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2001&pages=1911-1914&author=A.+J.+Barkerauthor=K.+H.+Gibsonauthor=W.+Grundyauthor=A.+A.+Godfreyauthor=J.+J.+Barlowauthor=M.+P.+Healyauthor=J.+R.+Woodburnauthor=S.+E.+Ashtonauthor=B.+J.+Curryauthor=L.+Scarlettauthor=L.+Henthornauthor=L.+Richards&title=Studies+leading+to+the+identification+of+ZD1839+%28IressaTM%29%3A+an+orally+active%2C+selective+epidermal+growth+factor+receptor+tyrosine+kinase+inhibitor+targeted+to+the+treatment+of+cancer&doi=10.1016%2FS0960-894X%2801%2900344-4"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1016%2FS0960-894X%2801%2900344-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0960-894X%252801%252900344-4%26sid%3Dliteratum%253Aachs%26aulast%3DBarker%26aufirst%3DA.%2BJ.%26aulast%3DGibson%26aufirst%3DK.%2BH.%26aulast%3DGrundy%26aufirst%3DW.%26aulast%3DGodfrey%26aufirst%3DA.%2BA.%26aulast%3DBarlow%26aufirst%3DJ.%2BJ.%26aulast%3DHealy%26aufirst%3DM.%2BP.%26aulast%3DWoodburn%26aufirst%3DJ.%2BR.%26aulast%3DAshton%26aufirst%3DS.%2BE.%26aulast%3DCurry%26aufirst%3DB.%2BJ.%26aulast%3DScarlett%26aufirst%3DL.%26aulast%3DHenthorn%26aufirst%3DL.%26aulast%3DRichards%26aufirst%3DL.%26atitle%3DStudies%2520leading%2520to%2520the%2520identification%2520of%2520ZD1839%2520%2528IressaTM%2529%253A%2520an%2520orally%2520active%252C%2520selective%2520epidermal%2520growth%2520factor%2520receptor%2520tyrosine%2520kinase%2520inhibitor%2520targeted%2520to%2520the%2520treatment%2520of%2520cancer%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2001%26volume%3D11%26spage%3D1911%26epage%3D1914%26doi%3D10.1016%2FS0960-894X%2801%2900344-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group">Choi, S. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gout, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Collins, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span> </span><span class="NLM_article-title">Lessons from patient-derived xenografts for better in vitro modeling of human cancer</span> <span class="citation_source-journal">Adv. Drug Delivery Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">79–80</span><span class="NLM_x">, </span> <span class="NLM_fpage">222</span><span class="NLM_x">–</span> <span class="NLM_lpage">237</span><span class="refDoi"> DOI: 10.1016/j.addr.2014.09.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01774&amp;key=10.1016%2Fj.addr.2014.09.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01774&amp;key=25305336" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01774&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhslGnsb7F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79%E2%80%9380&publication_year=2014&pages=222-237&author=S.+Y.+Choiauthor=D.+Linauthor=P.+W.+Goutauthor=C.+C.+Collinsauthor=Y.+Xuauthor=Y.+Wang&title=Lessons+from+patient-derived+xenografts+for+better+in+vitro+modeling+of+human+cancer&doi=10.1016%2Fj.addr.2014.09.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Lessons from patient-derived xenografts for better in vitro modeling of human cancer</span></div><div class="casAuthors">Choi, Stephen Yiu Chuen; Lin, Dong; Gout, Peter W.; Collins, Colin C.; Xu, Yong; Wang, Yuzhuo</div><div class="citationInfo"><span class="NLM_cas:title">Advanced Drug Delivery Reviews</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">79-80</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">222-237</span>CODEN:
                <span class="NLM_cas:coden">ADDREP</span>;
        ISSN:<span class="NLM_cas:issn">0169-409X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The development of novel cancer therapeutics is often plagued by discrepancies between drug efficacies obtained in preclin. studies and outcomes of clin. trials.  The inconsistencies can be attributed to a lack of clin. relevance of the cancer models used for drug testing.  While commonly used in vitro culture systems are advantageous for addressing specific exptl. questions, they are often gross, fidelity-lacking simplifications that largely ignore the heterogeneity of cancers as well as the complexity of the tumor microenvironment.  Factors such as tumor architecture, interactions among cancer cells and between cancer and stromal cells, and an acidic tumor microenvironment are crit. characteristics obsd. in patient-derived cancer xenograft models and in the clinic.  By mimicking these crucial in vivo characteristics through use of 3D cultures, co-culture systems and acidic culture conditions, an in vitro cancer model/microenvironment that is more physiol. relevant may be engineered to produce results more readily applicable to the clinic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXoTBcCs2UHbVg90H21EOLACvtfcHk0lg9n5Kcel9vBw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhslGnsb7F&md5=9b1d3ad6233457db04bab2dd6c88e891</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1016%2Fj.addr.2014.09.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.addr.2014.09.009%26sid%3Dliteratum%253Aachs%26aulast%3DChoi%26aufirst%3DS.%2BY.%26aulast%3DLin%26aufirst%3DD.%26aulast%3DGout%26aufirst%3DP.%2BW.%26aulast%3DCollins%26aufirst%3DC.%2BC.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DY.%26atitle%3DLessons%2520from%2520patient-derived%2520xenografts%2520for%2520better%2520in%2520vitro%2520modeling%2520of%2520human%2520cancer%26jtitle%3DAdv.%2520Drug%2520Delivery%2520Rev.%26date%3D2014%26volume%3D79%25E2%2580%259380%26spage%3D222%26epage%3D237%26doi%3D10.1016%2Fj.addr.2014.09.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group">Fry, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kraker, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McMichael, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ambroso, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nelson, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leopold, W. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Connors, R. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bridges, A. J.</span><span> </span><span class="NLM_article-title">A specific inhibitor of the epidermal growth factor receptor tyrosine kinase</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_volume">265</span><span class="NLM_x">, </span> <span class="NLM_fpage">1093</span><span class="NLM_x">–</span> <span class="NLM_lpage">1095</span><span class="refDoi"> DOI: 10.1126/science.8066447</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01774&amp;key=10.1126%2Fscience.8066447" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01774&amp;key=8066447" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01774&amp;key=1%3ACAS%3A528%3ADyaK1cXjvFyisA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=265&publication_year=1994&pages=1093-1095&author=D.+W.+Fryauthor=A.+J.+Krakerauthor=A.+McMichaelauthor=L.+A.+Ambrosoauthor=J.+M.+Nelsonauthor=W.+R.+Leopoldauthor=R.+W.+Connorsauthor=A.+J.+Bridges&title=A+specific+inhibitor+of+the+epidermal+growth+factor+receptor+tyrosine+kinase&doi=10.1126%2Fscience.8066447"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">A specific inhibitor of the epidermal growth factor receptor tyrosine kinase</span></div><div class="casAuthors">Fry, David W.; Kraker, Alan J.; McMichael, Amy; Ambroso, Linda A.; Nelson, James M.; Leopold, Wilbur R.; Connors, Richard W.; Bridges, Alexander J.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, D. C.)</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">265</span>
        (<span class="NLM_cas:issue">5175</span>),
    <span class="NLM_cas:pages">1093-1095</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">A small mol. called PD 153035 inhibited the epidermal growth factor (EGF) receptor tyrosine kinase with a 5-pM inhibition const.  The inhibitor was specific for the EGF receptor tyrosine kinase and inhibited other purified tyrosine kinases only at micromolar or higher concns.  PD 153035 rapidly suppressed autophosphorylation of the EGF receptor at low nanomolar concns. in fibroblasts or in human epidermoid carcinoma cells and selectively blocked EGF-mediated cellular processes including mitogenesis, early gene expression, and oncogenic transformation.  PD 153035 demonstrates an increase in potency over that of other tyrosine kinase inhibitors of four to five orders of magnitude for inhibition of isolated EGF receptor tyrosine kinase and three to four orders of magnitude for inhibition of cellular phosphorylation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpsdxz-fMjijrVg90H21EOLACvtfcHk0lg9n5Kcel9vBw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXjvFyisA%253D%253D&md5=5c0599c2e75f0f086313ce2cef8eacef</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1126%2Fscience.8066447&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.8066447%26sid%3Dliteratum%253Aachs%26aulast%3DFry%26aufirst%3DD.%2BW.%26aulast%3DKraker%26aufirst%3DA.%2BJ.%26aulast%3DMcMichael%26aufirst%3DA.%26aulast%3DAmbroso%26aufirst%3DL.%2BA.%26aulast%3DNelson%26aufirst%3DJ.%2BM.%26aulast%3DLeopold%26aufirst%3DW.%2BR.%26aulast%3DConnors%26aufirst%3DR.%2BW.%26aulast%3DBridges%26aufirst%3DA.%2BJ.%26atitle%3DA%2520specific%2520inhibitor%2520of%2520the%2520epidermal%2520growth%2520factor%2520receptor%2520tyrosine%2520kinase%26jtitle%3DScience%26date%3D1994%26volume%3D265%26spage%3D1093%26epage%3D1095%26doi%3D10.1126%2Fscience.8066447" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group">Frohner, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lopez-Garcia, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neimanis, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weber, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Navratil, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maurer, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stroba, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Biondi, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engel, M.</span><span> </span><span class="NLM_article-title">4-Benzimidazolyl-3-phenylbutanoic acids as novel PIF-pocket-targeting allosteric inhibitors of protein kinase PKCzeta</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">6714</span><span class="NLM_x">–</span> <span class="NLM_lpage">6723</span><span class="refDoi"> DOI: 10.1021/jm2005892</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm2005892" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=6714-6723&author=W.+Frohnerauthor=L.+A.+Lopez-Garciaauthor=S.+Neimanisauthor=N.+Weberauthor=J.+Navratilauthor=F.+Maurerauthor=A.+Strobaauthor=H.+Zhangauthor=R.+M.+Biondiauthor=M.+Engel&title=4-Benzimidazolyl-3-phenylbutanoic+acids+as+novel+PIF-pocket-targeting+allosteric+inhibitors+of+protein+kinase+PKCzeta&doi=10.1021%2Fjm2005892"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1021%2Fjm2005892&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm2005892%26sid%3Dliteratum%253Aachs%26aulast%3DFrohner%26aufirst%3DW.%26aulast%3DLopez-Garcia%26aufirst%3DL.%2BA.%26aulast%3DNeimanis%26aufirst%3DS.%26aulast%3DWeber%26aufirst%3DN.%26aulast%3DNavratil%26aufirst%3DJ.%26aulast%3DMaurer%26aufirst%3DF.%26aulast%3DStroba%26aufirst%3DA.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DBiondi%26aufirst%3DR.%2BM.%26aulast%3DEngel%26aufirst%3DM.%26atitle%3D4-Benzimidazolyl-3-phenylbutanoic%2520acids%2520as%2520novel%2520PIF-pocket-targeting%2520allosteric%2520inhibitors%2520of%2520protein%2520kinase%2520PKCzeta%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D6714%26epage%3D6723%26doi%3D10.1021%2Fjm2005892" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit58"><span><span class="NLM_contrib-group">Schmitt, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kail, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mariano, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Empting, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weber, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paul, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hartmann, R. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engel, M.</span><span> </span><span class="NLM_article-title">Design and synthesis of a library of lead-like 2,4-bisheterocyclic substituted thiophenes as selective Dyrk/Clk inhibitors</span> <span class="citation_source-journal">PLoS One</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">e87851</span><span class="refDoi"> DOI: 10.1371/journal.pone.0087851</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01774&amp;key=10.1371%2Fjournal.pone.0087851" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&pages=e87851&author=C.+Schmittauthor=D.+Kailauthor=M.+Marianoauthor=M.+Emptingauthor=N.+Weberauthor=T.+Paulauthor=R.+W.+Hartmannauthor=M.+Engel&title=Design+and+synthesis+of+a+library+of+lead-like+2%2C4-bisheterocyclic+substituted+thiophenes+as+selective+Dyrk%2FClk+inhibitors&doi=10.1371%2Fjournal.pone.0087851"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0087851&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0087851%26sid%3Dliteratum%253Aachs%26aulast%3DSchmitt%26aufirst%3DC.%26aulast%3DKail%26aufirst%3DD.%26aulast%3DMariano%26aufirst%3DM.%26aulast%3DEmpting%26aufirst%3DM.%26aulast%3DWeber%26aufirst%3DN.%26aulast%3DPaul%26aufirst%3DT.%26aulast%3DHartmann%26aufirst%3DR.%2BW.%26aulast%3DEngel%26aufirst%3DM.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520a%2520library%2520of%2520lead-like%25202%252C4-bisheterocyclic%2520substituted%2520thiophenes%2520as%2520selective%2520Dyrk%252FClk%2520inhibitors%26jtitle%3DPLoS%2520One%26date%3D2014%26volume%3D9%26spage%3De87851%26doi%3D10.1371%2Fjournal.pone.0087851" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57'],'ref58':['cit58']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 14 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ashwaq  Bahkali</span>, <span class="hlFld-ContribAuthor ">Jacob Xin  Wei</span>, <span class="hlFld-ContribAuthor ">Yuanjian  Deng</span>. </span><span class="cited-content_cbyCitation_article-title">Structural comparison of ethylenediamine platinum(II) complexes containing thiourea and its di- and tetramethyl substituted derivatives. </span><span class="cited-content_cbyCitation_journal-name">Journal of Coordination Chemistry</span><span> <strong>2021,</strong> <em>74 </em>
                                    (12)
                                     , 1992-2003. <a href="https://doi.org/10.1080/00958972.2021.1923015" title="DOI URL">https://doi.org/10.1080/00958972.2021.1923015</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/00958972.2021.1923015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F00958972.2021.1923015%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Coordination%2520Chemistry%26atitle%3DStructural%252Bcomparison%252Bof%252Bethylenediamine%252Bplatinum%252528II%252529%252Bcomplexes%252Bcontaining%252Bthiourea%252Band%252Bits%252Bdi-%252Band%252Btetramethyl%252Bsubstituted%252Bderivatives%26aulast%3DBahkali%26aufirst%3DAshwaq%26date%3D2021%26date%3D2021%26volume%3D74%26issue%3D12%26spage%3D1992%26epage%3D2003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ashwaq  Bahkali</span>, <span class="hlFld-ContribAuthor ">Jacob  Wei</span>, <span class="hlFld-ContribAuthor ">Yuanjian  Deng</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and characterization of ethylenediamine platinum(II) complexes containing thiourea derivatives. X-ray crystal structures of [Pt(en)(2-imidazolidinethione)2](NO3)2 and [Pt(en)(1-phenyl-2-thiourea)2](NO3)2. </span><span class="cited-content_cbyCitation_journal-name">Inorganica Chimica Acta</span><span> <strong>2021,</strong> <em>520 </em>, 120302. <a href="https://doi.org/10.1016/j.ica.2021.120302" title="DOI URL">https://doi.org/10.1016/j.ica.2021.120302</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ica.2021.120302&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ica.2021.120302%26sid%3Dliteratum%253Aachs%26jtitle%3DInorganica%2520Chimica%2520Acta%26atitle%3DSynthesis%252Band%252Bcharacterization%252Bof%252Bethylenediamine%252Bplatinum%252528II%252529%252Bcomplexes%252Bcontaining%252Bthiourea%252Bderivatives.%252BX-ray%252Bcrystal%252Bstructures%252Bof%252B%25255BPt%252528en%252529%2525282-imidazolidinethione%2525292%25255D%252528NO3%2525292%252Band%252B%25255BPt%252528en%252529%2525281-phenyl-2-thiourea%2525292%25255D%252528NO3%2525292%26aulast%3DBahkali%26aufirst%3DAshwaq%26date%3D2021%26volume%3D520%26spage%3D120302" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Wen-Xue  Sun</span>, <span class="hlFld-ContribAuthor ">Hong-Wei  Han</span>, <span class="hlFld-ContribAuthor ">Min-Kai  Yang</span>, <span class="hlFld-ContribAuthor ">Zhong-Ling  Wen</span>, <span class="hlFld-ContribAuthor ">Yin-Song  Wang</span>, <span class="hlFld-ContribAuthor ">Jiang-Yan  Fu</span>, <span class="hlFld-ContribAuthor ">Yun-Ting  Lu</span>, <span class="hlFld-ContribAuthor ">Ming-Yue  Wang</span>, <span class="hlFld-ContribAuthor ">Jia-Xin  Bao</span>, <span class="hlFld-ContribAuthor ">Gui-Hua  Lu</span>, <span class="hlFld-ContribAuthor ">Jin-Liang  Qi</span>, <span class="hlFld-ContribAuthor ">Xiao-Ming  Wang</span>, <span class="hlFld-ContribAuthor ">Hong-Yan  Lin</span>, <span class="hlFld-ContribAuthor ">Yong-Hua  Yang</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and biological evaluation of benzoylacrylic acid shikonin ester derivatives as irreversible dual inhibitors of tubulin and EGFR. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2019,</strong> <em>27 </em>
                                    (23)
                                     , 115153. <a href="https://doi.org/10.1016/j.bmc.2019.115153" title="DOI URL">https://doi.org/10.1016/j.bmc.2019.115153</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2019.115153&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2019.115153%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bbiological%252Bevaluation%252Bof%252Bbenzoylacrylic%252Bacid%252Bshikonin%252Bester%252Bderivatives%252Bas%252Birreversible%252Bdual%252Binhibitors%252Bof%252Btubulin%252Band%252BEGFR%26aulast%3DSun%26aufirst%3DWen-Xue%26date%3D2019%26volume%3D27%26issue%3D23%26spage%3D115153" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yi-Cong  Wu</span>, <span class="hlFld-ContribAuthor ">Xin-Yue  Ren</span>, <span class="hlFld-ContribAuthor ">Guo-Wu  Rao</span>. </span><span class="cited-content_cbyCitation_article-title">Research Progress of Diphenyl Urea Derivatives as Anticancer Agents and Synthetic Methodologies. </span><span class="cited-content_cbyCitation_journal-name">Mini-Reviews in Organic Chemistry</span><span> <strong>2019,</strong> <em>16 </em>
                                    (7)
                                     , 617-630. <a href="https://doi.org/10.2174/1570193X15666181029130418" title="DOI URL">https://doi.org/10.2174/1570193X15666181029130418</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2174/1570193X15666181029130418&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2174%2F1570193X15666181029130418%26sid%3Dliteratum%253Aachs%26jtitle%3DMini-Reviews%2520in%2520Organic%2520Chemistry%26atitle%3DResearch%252BProgress%252Bof%252BDiphenyl%252BUrea%252BDerivatives%252Bas%252BAnticancer%252BAgents%252Band%252BSynthetic%252BMethodologies%26aulast%3DWu%26aufirst%3DYi-Cong%26date%3D2019%26volume%3D16%26issue%3D7%26spage%3D617%26epage%3D630" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yaling  Zhang</span>, <span class="hlFld-ContribAuthor ">Qiaoli  Hou</span>, <span class="hlFld-ContribAuthor ">Xiabing  Li</span>, <span class="hlFld-ContribAuthor ">Jiuling  Zhu</span>, <span class="hlFld-ContribAuthor ">Wei  Wang</span>, <span class="hlFld-ContribAuthor ">Baolin  Li</span>, <span class="hlFld-ContribAuthor ">Lijun  Zhao</span>, <span class="hlFld-ContribAuthor ">Haibin  Xia</span>. </span><span class="cited-content_cbyCitation_article-title">Enrichment of novel quinazoline derivatives with high antitumor activity in mitochondria tracked by its self-fluorescence. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>178 </em>, 417-432. <a href="https://doi.org/10.1016/j.ejmech.2019.06.015" title="DOI URL">https://doi.org/10.1016/j.ejmech.2019.06.015</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2019.06.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2019.06.015%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DEnrichment%252Bof%252Bnovel%252Bquinazoline%252Bderivatives%252Bwith%252Bhigh%252Bantitumor%252Bactivity%252Bin%252Bmitochondria%252Btracked%252Bby%252Bits%252Bself-fluorescence%26aulast%3DZhang%26aufirst%3DYaling%26date%3D2019%26volume%3D178%26spage%3D417%26epage%3D432" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Fatima  Arshad</span>, <span class="hlFld-ContribAuthor ">Mohemmed Faraz  Khan</span>, <span class="hlFld-ContribAuthor ">Wasim  Akhtar</span>, <span class="hlFld-ContribAuthor ">Mohammad Mumtaz  Alam</span>, <span class="hlFld-ContribAuthor ">Lalit Mohan  Nainwal</span>, <span class="hlFld-ContribAuthor ">Sumit Kumar  Kaushik</span>, <span class="hlFld-ContribAuthor ">Mymoona  Akhter</span>, <span class="hlFld-ContribAuthor ">Suhel  Parvez</span>, <span class="hlFld-ContribAuthor ">Syed Misbahul  Hasan</span>, <span class="hlFld-ContribAuthor ">Mohammad  Shaquiquzzaman</span>. </span><span class="cited-content_cbyCitation_article-title">Revealing quinquennial anticancer journey of morpholine: A SAR based review. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>167 </em>, 324-356. <a href="https://doi.org/10.1016/j.ejmech.2019.02.015" title="DOI URL">https://doi.org/10.1016/j.ejmech.2019.02.015</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2019.02.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2019.02.015%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DRevealing%252Bquinquennial%252Banticancer%252Bjourney%252Bof%252Bmorpholine%25253A%252BA%252BSAR%252Bbased%252Breview%26aulast%3DArshad%26aufirst%3DFatima%26date%3D2019%26volume%3D167%26spage%3D324%26epage%3D356" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Aslı  Türe</span>, <span class="hlFld-ContribAuthor ">Deniz Cansen  Kahraman</span>, <span class="hlFld-ContribAuthor ">Rengul  Cetin-Atalay</span>, <span class="hlFld-ContribAuthor ">Sinem  Helvacıoğlu</span>, <span class="hlFld-ContribAuthor ">Mohammad  Charehsaz</span>, <span class="hlFld-ContribAuthor ">İlkay  Küçükgüzel</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis, anticancer activity, toxicity evaluation and molecular docking studies of novel phenylaminopyrimidine—(thio)urea hybrids as potential kinase inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Computational Biology and Chemistry</span><span> <strong>2019,</strong> <em>78 </em>, 227-241. <a href="https://doi.org/10.1016/j.compbiolchem.2018.12.003" title="DOI URL">https://doi.org/10.1016/j.compbiolchem.2018.12.003</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.compbiolchem.2018.12.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.compbiolchem.2018.12.003%26sid%3Dliteratum%253Aachs%26jtitle%3DComputational%2520Biology%2520and%2520Chemistry%26atitle%3DSynthesis%25252C%252Banticancer%252Bactivity%25252C%252Btoxicity%252Bevaluation%252Band%252Bmolecular%252Bdocking%252Bstudies%252Bof%252Bnovel%252Bphenylaminopyrimidine%2525E2%252580%252594%252528thio%252529urea%252Bhybrids%252Bas%252Bpotential%252Bkinase%252Binhibitors%26aulast%3DT%25C3%25BCre%26aufirst%3DAsl%25C4%25B1%26date%3D2019%26volume%3D78%26spage%3D227%26epage%3D241" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Anna  Bielenica</span>, <span class="hlFld-ContribAuthor ">Giuseppina  Sanna</span>, <span class="hlFld-ContribAuthor ">Silvia  Madeddu</span>, <span class="hlFld-ContribAuthor ">Gabriele  Giliberti</span>, <span class="hlFld-ContribAuthor ">Joanna  Stefańska</span>, <span class="hlFld-ContribAuthor ">Anna  Kozioł</span>, <span class="hlFld-ContribAuthor ">Oleksandra  Savchenko</span>, <span class="hlFld-ContribAuthor ">Paulina  Strzyga-Łach</span>, <span class="hlFld-ContribAuthor ">Alicja  Chrzanowska</span>, <span class="hlFld-ContribAuthor ">Grażyna  Kubiak-Tomaszewska</span>, <span class="hlFld-ContribAuthor ">Marta  Struga</span>. </span><span class="cited-content_cbyCitation_article-title">Disubstituted 4-Chloro-3-nitrophenylthiourea Derivatives: Antimicrobial and Cytotoxic Studies. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2018,</strong> <em>23 </em>
                                    (10)
                                     , 2428. <a href="https://doi.org/10.3390/molecules23102428" title="DOI URL">https://doi.org/10.3390/molecules23102428</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules23102428&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules23102428%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DDisubstituted%252B4-Chloro-3-nitrophenylthiourea%252BDerivatives%25253A%252BAntimicrobial%252Band%252BCytotoxic%252BStudies%26aulast%3DBielenica%26aufirst%3DAnna%26date%3D2018%26date%3D2018%26volume%3D23%26issue%3D10%26spage%3D2428" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Francesco P.  Fiorentino</span>, <span class="hlFld-ContribAuthor ">Luigi  Bagella</span>, <span class="hlFld-ContribAuthor ">Irene  Marchesi</span>. </span><span class="cited-content_cbyCitation_article-title">A new parameter of growth inhibition for cell proliferation assays. </span><span class="cited-content_cbyCitation_journal-name">Journal of Cellular Physiology</span><span> <strong>2018,</strong> <em>233 </em>
                                    (5)
                                     , 4106-4115. <a href="https://doi.org/10.1002/jcp.26208" title="DOI URL">https://doi.org/10.1002/jcp.26208</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/jcp.26208&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fjcp.26208%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Cellular%2520Physiology%26atitle%3DA%252Bnew%252Bparameter%252Bof%252Bgrowth%252Binhibition%252Bfor%252Bcell%252Bproliferation%252Bassays%26aulast%3DFiorentino%26aufirst%3DFrancesco%2BP.%26date%3D2018%26date%3D2017%26volume%3D233%26issue%3D5%26spage%3D4106%26epage%3D4115" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Peng  Liao</span>, <span class="hlFld-ContribAuthor ">Shi-Qin  Hu</span>, <span class="hlFld-ContribAuthor ">Hong  Zhang</span>, <span class="hlFld-ContribAuthor ">Liang-Bi  Xu</span>, <span class="hlFld-ContribAuthor ">Jing-Zi  Liu</span>, <span class="hlFld-ContribAuthor ">Bin  He</span>, <span class="hlFld-ContribAuthor ">Shang-Gao  Liao</span>, <span class="hlFld-ContribAuthor ">Yong-Jun  Li</span>. </span><span class="cited-content_cbyCitation_article-title">Study on Anti-Proliferative Activity in Cancer Cells and Preliminary Structure-Activity Relationship of Pseudo-Peptide Chiral Thioureas. </span><span class="cited-content_cbyCitation_journal-name">Bulletin of the Korean Chemical Society</span><span> <strong>2018,</strong> <em>39 </em>
                                    (3)
                                     , 300-304. <a href="https://doi.org/10.1002/bkcs.11383" title="DOI URL">https://doi.org/10.1002/bkcs.11383</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/bkcs.11383&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fbkcs.11383%26sid%3Dliteratum%253Aachs%26jtitle%3DBulletin%2520of%2520the%2520Korean%2520Chemical%2520Society%26atitle%3DStudy%252Bon%252BAnti-Proliferative%252BActivity%252Bin%252BCancer%252BCells%252Band%252BPreliminary%252BStructure-Activity%252BRelationship%252Bof%252BPseudo-Peptide%252BChiral%252BThioureas%26aulast%3DLiao%26aufirst%3DPeng%26date%3D2018%26date%3D2018%26volume%3D39%26issue%3D3%26spage%3D300%26epage%3D304" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiaodong  Ma</span>, <span class="hlFld-ContribAuthor ">Xiaoqing  Lv</span>, <span class="hlFld-ContribAuthor ">Jiankang  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Exploiting polypharmacology for improving therapeutic outcome of kinase inhibitors (KIs): An update of recent medicinal chemistry efforts. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>143 </em>, 449-463. <a href="https://doi.org/10.1016/j.ejmech.2017.11.049" title="DOI URL">https://doi.org/10.1016/j.ejmech.2017.11.049</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2017.11.049&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2017.11.049%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DExploiting%252Bpolypharmacology%252Bfor%252Bimproving%252Btherapeutic%252Boutcome%252Bof%252Bkinase%252Binhibitors%252B%252528KIs%252529%25253A%252BAn%252Bupdate%252Bof%252Brecent%252Bmedicinal%252Bchemistry%252Befforts%26aulast%3DMa%26aufirst%3DXiaodong%26date%3D2018%26volume%3D143%26spage%3D449%26epage%3D463" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Tao  Jiang</span>, <span class="hlFld-ContribAuthor ">Chun  Yang</span>, <span class="hlFld-ContribAuthor ">Liyuan  Ma</span>, <span class="hlFld-ContribAuthor ">Zehua  Wu</span>, <span class="hlFld-ContribAuthor ">Ling  Ye</span>, <span class="hlFld-ContribAuthor ">Xiaoqiang  Ma</span>, <span class="hlFld-ContribAuthor ">Hai  Li</span>, <span class="hlFld-ContribAuthor ">Junwei  Fan</span>, <span class="hlFld-ContribAuthor ">Yinxue  Yang</span>, . </span><span class="cited-content_cbyCitation_article-title">Overexpression of GRK3, Promoting Tumor Proliferation, Is Predictive of Poor Prognosis in Colon Cancer. </span><span class="cited-content_cbyCitation_journal-name">Disease Markers</span><span> <strong>2017,</strong> <em>2017 </em>, 1-11. <a href="https://doi.org/10.1155/2017/1202710" title="DOI URL">https://doi.org/10.1155/2017/1202710</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1155/2017/1202710&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1155%2F2017%2F1202710%26sid%3Dliteratum%253Aachs%26jtitle%3DDisease%2520Markers%26atitle%3DOverexpression%252Bof%252BGRK3%25252C%252BPromoting%252BTumor%252BProliferation%25252C%252BIs%252BPredictive%252Bof%252BPoor%252BPrognosis%252Bin%252BColon%252BCancer%26aulast%3DJiang%26aufirst%3DTao%26date%3D2017%26volume%3D2017%26spage%3D1%26epage%3D11" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sunil  Kumar</span>, <span class="hlFld-ContribAuthor ">Pei-Heng  Ho</span>, <span class="hlFld-ContribAuthor ">Indrajeet J.  Barve</span>, <span class="hlFld-ContribAuthor ">Chung-Ming  Sun</span>. </span><span class="cited-content_cbyCitation_article-title">Enantiospecific Synthesis of Imidazoquinazolin-2-ones via Base-Catalyzed Tandem Cyclization. </span><span class="cited-content_cbyCitation_journal-name">ChemistrySelect</span><span> <strong>2017,</strong> <em>2 </em>
                                    (28)
                                     , 8917-8921. <a href="https://doi.org/10.1002/slct.201701686" title="DOI URL">https://doi.org/10.1002/slct.201701686</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/slct.201701686&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fslct.201701686%26sid%3Dliteratum%253Aachs%26jtitle%3DChemistrySelect%26atitle%3DEnantiospecific%252BSynthesis%252Bof%252BImidazoquinazolin-2-ones%252Bvia%252BBase-Catalyzed%252BTandem%252BCyclization%26aulast%3DKumar%26aufirst%3DSunil%26date%3D2017%26date%3D2017%26volume%3D2%26issue%3D28%26spage%3D8917%26epage%3D8921" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hong-Yan  Lin</span>, <span class="hlFld-ContribAuthor ">Wen-Xue  Sun</span>, <span class="hlFld-ContribAuthor ">Chao-Sai  Zheng</span>, <span class="hlFld-ContribAuthor ">Hong-Wei  Han</span>, <span class="hlFld-ContribAuthor ">Xue  Wang</span>, <span class="hlFld-ContribAuthor ">Ya-Han  Zhang</span>, <span class="hlFld-ContribAuthor ">Han-Yue  Qiu</span>, <span class="hlFld-ContribAuthor ">Cheng-Yi  Tang</span>, <span class="hlFld-ContribAuthor ">Jin-Liang  Qi</span>, <span class="hlFld-ContribAuthor ">Gui-Hua  Lu</span>, <span class="hlFld-ContribAuthor ">Rong-Wu  Yang</span>, <span class="hlFld-ContribAuthor ">Xiao-Ming  Wang</span>, <span class="hlFld-ContribAuthor ">Yong-Hua  Yang</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis, characterization and biological evaluation of formononetin derivatives as novel EGFR inhibitors via inhibiting growth, migration and inducing apoptosis in breast cancer cell line. </span><span class="cited-content_cbyCitation_journal-name">RSC Adv.</span><span> <strong>2017,</strong> <em>7 </em>
                                    (76)
                                     , 48404-48419. <a href="https://doi.org/10.1039/C7RA09825A" title="DOI URL">https://doi.org/10.1039/C7RA09825A</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C7RA09825A&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC7RA09825A%26sid%3Dliteratum%253Aachs%26jtitle%3DRSC%2520Adv.%26atitle%3DSynthesis%25252C%252Bcharacterization%252Band%252Bbiological%252Bevaluation%252Bof%252Bformononetin%252Bderivatives%252Bas%252Bnovel%252BEGFR%252Binhibitors%252Bvia%252Binhibiting%252Bgrowth%25252C%252Bmigration%252Band%252Binducing%252Bapoptosis%252Bin%252Bbreast%252Bcancer%252Bcell%252Bline%26aulast%3DLin%26aufirst%3DHong-Yan%26date%3D2017%26date%3D2017%26volume%3D7%26issue%3D76%26spage%3D48404%26epage%3D48419" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01774/20170407/images/medium/jm-2016-01774z_0016.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01774/20170407/images/large/jm-2016-01774z_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01774&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="cht1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Chart 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01774/20170407/images/medium/jm-2016-01774z_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01774/20170407/images/large/jm-2016-01774z_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Chart 1. General Structures of the Quinazoline Derivatives Selected for Screening Towards the NF-κB Inhibitory Activity</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01774/20170407/images/large/jm-2016-01774z_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01774&amp;id=cht1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01774/20170407/images/medium/jm-2016-01774z_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01774/20170407/images/large/jm-2016-01774z_0006.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 1. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01774/20170407/images/large/jm-2016-01774z_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01774&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (i) TEOF, (Ac)<sub>2</sub>O, reflux, 16 h; (ii) R-NH<sub>2</sub>, CH<sub>3</sub>COOH, reflux, 1 h; (iii) SnCl<sub>2</sub>, MeOH, reflux, 30 min; (iv) PhCH<sub>2</sub>-NCS, DMF, rt, 5 h.</p></p></figure><figure data-id="sch2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01774/20170407/images/medium/jm-2016-01774z_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01774/20170407/images/large/jm-2016-01774z_0007.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 2. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01774/20170407/images/large/jm-2016-01774z_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01774&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (i) S═CCl<sub>2</sub>, HCl (ii) Ar-NH<sub>2</sub>, DMF, rt, 5 h; (iii) R-NH<sub>2</sub>, DMF, rt, 5 h; (iv) R-NCO, DMF, rt, 5 h.</p></p></figure><figure data-id="cht2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Chart 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01774/20170407/images/medium/jm-2016-01774z_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01774/20170407/images/large/jm-2016-01774z_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Chart 2. Overview on the Modifications of Hit Compound <b>VIa</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01774/20170407/images/large/jm-2016-01774z_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01774&amp;id=cht2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01774/20170407/images/medium/jm-2016-01774z_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01774/20170407/images/large/jm-2016-01774z_0008.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 3. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01774/20170407/images/large/jm-2016-01774z_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01774&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (i) S═CCl<sub>2</sub>, HCl; (ii) Ar-NH<sub>2</sub>, DMF, rt, 5 h [used for <b>9a</b>–<b>c</b>]; (iii) PhOCSCl, Ar-NH<sub>2</sub>, DMF, 1 h “used for <b>9d</b>–<b>g</b>”.</p></p></figure><figure data-id="fig1" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01774/20170407/images/medium/jm-2016-01774z_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01774/20170407/images/large/jm-2016-01774z_0003.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Compound <b>6c</b> but not gefitinib reduces the amount of CREB-binding protein (CBP) in the NF-κB transcription complex. MDA-MB-231 cells were treated with compounds or DMSO for 12 h as indicated (in backets: concentration in μM). Then 5 μg of isolated nuclear proteins were analyzed for the specific binding to the NF-κB response element oligonucleotide on an ELISA plate. (A) CBP physically associated with bound RelA/p65 was detected using a specific primary antibody directed against CBP, followed by a HRP-coupled secondary antibody and colorimetric reaction. (B) The same nuclear extracts as in A were analyzed in parallel, however, anti-RelA/p65 was used as a primary antibody. OD450, optical density at 450 nm; Gft, gefitinib. The experiment was performed in triplicates; error bars indicate the SD values. One representative experiment out of three is shown, which essentially gave the same results.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01774/20170407/images/large/jm-2016-01774z_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01774&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01774/20170407/images/medium/jm-2016-01774z_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01774/20170407/images/large/jm-2016-01774z_0004.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Time-dependent plasma concentrations of <b>9b</b> and <b>9d</b> after subcutaneous administration to female NMRI nu/nu mice.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01774/20170407/images/large/jm-2016-01774z_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01774&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01774/20170407/images/medium/jm-2016-01774z_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01774/20170407/images/large/jm-2016-01774z_0005.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. <b>9b</b> inhibits tumor growth in a xenograft model. MDA-MB-231 tumor cells were injected in female NMRI nu/nu mice, and the treatment with the test compounds or vehicle started 5 days after the inoculation (day 1) as described under <a class="ref internalNav" href="#sec4" aria-label="Experimental Section">Experimental Section</a>. Mean values of the measured tumor sizes are shown (error bars: ±SD). The asterisks denote statistical significance compared with the vehicle-treated group: *, <i>p</i> < 0.05; **, <i>p</i> < 0.01.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01774/20170407/images/large/jm-2016-01774z_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01774&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i49">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_64328" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_64328" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 58 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">Sharma, S. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bell, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Settleman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haber, D. A.</span><span> </span><span class="NLM_article-title">Epidermal growth factor receptor mutations in lung cancer</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">169</span><span class="NLM_x">–</span> <span class="NLM_lpage">181</span><span class="refDoi"> DOI: 10.1038/nrc2088</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01774&amp;key=10.1038%2Fnrc2088" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01774&amp;key=17318210" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01774&amp;key=1%3ACAS%3A528%3ADC%252BD2sXitVGrsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2007&pages=169-181&author=S.+V.+Sharmaauthor=D.+W.+Bellauthor=J.+Settlemanauthor=D.+A.+Haber&title=Epidermal+growth+factor+receptor+mutations+in+lung+cancer&doi=10.1038%2Fnrc2088"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Epidermal growth factor receptor mutations in lung cancer</span></div><div class="casAuthors">Sharma, Sreenath V.; Bell, Daphne W.; Settleman, Jeffrey; Haber, Daniel A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">169-181</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The development and clin. application of inhibitors that target the epidermal growth factor receptor (EGFR) provide important insights for new lung cancer therapies, as well as for the broader field of targeted cancer therapies.  We review the results of genetic, biochem. and clin. studies focused on somatic mutations of EGFR that are assocd. with the phenomenon of oncogene addiction, describing 'oncogenic shock' as a mechanistic explanation for the apoptosis that follows the acute treatment of susceptible cells with kinase inhibitors.  Understanding the genetic heterogeneity of epithelial tumors and devising strategies to circumvent their rapid acquisition of resistance to targeted kinase inhibitors are essential to the successful use of targeted therapies in common epithelial cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMKw7Y4FUFM7Vg90H21EOLACvtfcHk0liRI0S0yZyRSw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXitVGrsbo%253D&md5=46219ea3ae7b9f0977e4a4b7243fd875</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1038%2Fnrc2088&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2088%26sid%3Dliteratum%253Aachs%26aulast%3DSharma%26aufirst%3DS.%2BV.%26aulast%3DBell%26aufirst%3DD.%2BW.%26aulast%3DSettleman%26aufirst%3DJ.%26aulast%3DHaber%26aufirst%3DD.%2BA.%26atitle%3DEpidermal%2520growth%2520factor%2520receptor%2520mutations%2520in%2520lung%2520cancer%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2007%26volume%3D7%26spage%3D169%26epage%3D181%26doi%3D10.1038%2Fnrc2088" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">Sequist, L. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lynch, T. J.</span><span> </span><span class="NLM_article-title">EGFR tyrosine kinase inhibitors in lung cancer: an evolving story</span> <span class="citation_source-journal">Annu. Rev. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">59</span><span class="NLM_x">, </span> <span class="NLM_fpage">429</span><span class="NLM_x">–</span> <span class="NLM_lpage">442</span><span class="refDoi"> DOI: 10.1146/annurev.med.59.090506.202405</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01774&amp;key=10.1146%2Fannurev.med.59.090506.202405" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2008&pages=429-442&author=L.+V.+Sequistauthor=T.+J.+Lynch&title=EGFR+tyrosine+kinase+inhibitors+in+lung+cancer%3A+an+evolving+story&doi=10.1146%2Fannurev.med.59.090506.202405"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1146%2Fannurev.med.59.090506.202405&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev.med.59.090506.202405%26sid%3Dliteratum%253Aachs%26aulast%3DSequist%26aufirst%3DL.%2BV.%26aulast%3DLynch%26aufirst%3DT.%2BJ.%26atitle%3DEGFR%2520tyrosine%2520kinase%2520inhibitors%2520in%2520lung%2520cancer%253A%2520an%2520evolving%2520story%26jtitle%3DAnnu.%2520Rev.%2520Med.%26date%3D2008%26volume%3D59%26spage%3D429%26epage%3D442%26doi%3D10.1146%2Fannurev.med.59.090506.202405" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">da Cunha Santos, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shepherd, F. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsao, M. S.</span><span> </span><span class="NLM_article-title">EGFR mutations and lung cancer</span> <span class="citation_source-journal">Annu. Rev. Pathol.: Mech. Dis.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">49</span><span class="NLM_x">–</span> <span class="NLM_lpage">69</span><span class="refDoi"> DOI: 10.1146/annurev-pathol-011110-130206</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01774&amp;key=10.1146%2Fannurev-pathol-011110-130206" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01774&amp;key=20887192" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01774&amp;key=1%3ACAS%3A280%3ADC%252BC3M7jvVSitg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2011&pages=49-69&author=G.+da+Cunha+Santosauthor=F.+A.+Shepherdauthor=M.+S.+Tsao&title=EGFR+mutations+and+lung+cancer&doi=10.1146%2Fannurev-pathol-011110-130206"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">EGFR mutations and lung cancer</span></div><div class="casAuthors">da Cunha Santos Gilda; Shepherd Frances A; Tsao Ming Sound</div><div class="citationInfo"><span class="NLM_cas:title">Annual review of pathology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">49-69</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Epidermal growth factor receptor (EGFR) is a transmembrane protein with cytoplasmic kinase activity that transduces important growth factor signaling from the extracellular milieu to the cell.  Given that more than 60% of non-small cell lung carcinomas (NSCLCs) express EGFR, EGFR has become an important therapeutic target for the treatment of these tumors.  Inhibitors that target the kinase domain of EGFR have been developed and are clinically active.  More importantly, such tyrosine kinase inhibitors (TKIs) are especially effective in patients whose tumors harbor activating mutations in the tyrosine kinase domain of the EGFR gene.  More recent trials have suggested that for advanced NSCLC patients with EGFR mutant tumors, initial therapy with a TKI instead of chemotherapy may be the best choice of treatment.  Therefore, mutation testing is mandatory to identify these patients, given that selection based only on clinico-pathologic characteristics is inadequate.  We review the role of EGFR mutations in the diagnosis and management of NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSWZQp6wFX2j9yzdcP07UmufW6udTcc2ebo6ceDKKHhkLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3M7jvVSitg%253D%253D&md5=2ab255110cb58879af550a86e7155c35</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1146%2Fannurev-pathol-011110-130206&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev-pathol-011110-130206%26sid%3Dliteratum%253Aachs%26aulast%3Dda%2BCunha%2BSantos%26aufirst%3DG.%26aulast%3DShepherd%26aufirst%3DF.%2BA.%26aulast%3DTsao%26aufirst%3DM.%2BS.%26atitle%3DEGFR%2520mutations%2520and%2520lung%2520cancer%26jtitle%3DAnnu.%2520Rev.%2520Pathol.%253A%2520Mech.%2520Dis.%26date%3D2011%26volume%3D6%26spage%3D49%26epage%3D69%26doi%3D10.1146%2Fannurev-pathol-011110-130206" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">Godin-Heymann, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ulkus, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brannigan, B. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDermott, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lamb, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maheswaran, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Settleman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haber, D. A.</span><span> </span><span class="NLM_article-title">The T790M ″gatekeeper″ mutation in EGFR mediates resistance to low concentrations of an irreversible EGFR inhibitor</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">874</span><span class="NLM_x">–</span> <span class="NLM_lpage">879</span><span class="refDoi"> DOI: 10.1158/1535-7163.MCT-07-2387</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01774&amp;key=10.1158%2F1535-7163.MCT-07-2387" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01774&amp;key=18413800" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01774&amp;key=1%3ACAS%3A528%3ADC%252BD1cXks1GmsLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2008&pages=874-879&author=N.+Godin-Heymannauthor=L.+Ulkusauthor=B.+W.+Branniganauthor=U.+McDermottauthor=J.+Lambauthor=S.+Maheswaranauthor=J.+Settlemanauthor=D.+A.+Haber&title=The+T790M+%E2%80%B3gatekeeper%E2%80%B3+mutation+in+EGFR+mediates+resistance+to+low+concentrations+of+an+irreversible+EGFR+inhibitor&doi=10.1158%2F1535-7163.MCT-07-2387"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">The T790M "gatekeeper" mutation in EGFR mediates resistance to low concentrations of an irreversible EGFR inhibitor</span></div><div class="casAuthors">Godin-Heymann, Nadia; Ulkus, Lindsey; Brannigan, Brian W.; McDermott, Ultan; Lamb, Jennifer; Maheswaran, Shyamala; Settleman, Jeffrey; Haber, Daniel A.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">874-879</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Patients with non-small cell lung cancer (NSCLC) harboring activating mutations in the epidermal growth factor receptor (EGFR) kinase domain tend to respond well to the tyrosine kinase inhibitors, gefitinib and erlotinib.  However, following clin. response, these patients typically relapse within a year of treatment.  In many cases, resistance is caused by an acquired secondary EGFR kinase domain mutation, T790M.  In vitro studies have shown that a new class of EGFR-irreversible inhibitors could overcome the resistance conferred by T790M.  Clin. trials are under way to examine the efficacy of one of these inhibitors, HKI-272, in patients with NSCLC who initially responded to gefitinib/erlotinib and subsequently relapsed.  To anticipate the possibility that patients who respond to irreversible inhibitors will develop secondary resistance to such inhibitors, as has been seen in other similar settings, we modeled acquired resistance to the dual EGFR/HER2-irreversible tyrosine kinase inhibitor HKI-272 in a NSCLC cell culture model.  We found that HKI-272-resistant clones fall into two biochem. groups based on the retention of EGFR phosphorylation in the presence of the drug.  Cells that retain phosphorylated EGFR have acquired the secondary mutation T790M.  Moreover, HKI-272 can overcome T790M resistance only at suprapharmacol. concns.  We further model mutations at EGFR C797 as a mechanism of resistance to irreversible EGFR inhibitors and show that although these mutants are resistant to the irreversible inhibitor, they retain erlotinib sensitivity.  Our findings suggest that HKI-272 treatment at maximally tolerated dosing may lead to the emergence of T790M-mediated resistance, whereas treatment with a more potent irreversible inhibitor could yield a resistance mutation at EGFR C797.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGra5FtRNHnlNLVg90H21EOLACvtfcHk0liRI0S0yZyRSw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXks1GmsLo%253D&md5=f71cd83bfabef2d7b2c5d8b6e5cfac6a</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-07-2387&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-07-2387%26sid%3Dliteratum%253Aachs%26aulast%3DGodin-Heymann%26aufirst%3DN.%26aulast%3DUlkus%26aufirst%3DL.%26aulast%3DBrannigan%26aufirst%3DB.%2BW.%26aulast%3DMcDermott%26aufirst%3DU.%26aulast%3DLamb%26aufirst%3DJ.%26aulast%3DMaheswaran%26aufirst%3DS.%26aulast%3DSettleman%26aufirst%3DJ.%26aulast%3DHaber%26aufirst%3DD.%2BA.%26atitle%3DThe%2520T790M%2520%25E2%2580%25B3gatekeeper%25E2%2580%25B3%2520mutation%2520in%2520EGFR%2520mediates%2520resistance%2520to%2520low%2520concentrations%2520of%2520an%2520irreversible%2520EGFR%2520inhibitor%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2008%26volume%3D7%26spage%3D874%26epage%3D879%26doi%3D10.1158%2F1535-7163.MCT-07-2387" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">Engelman, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zejnullahu, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mitsudomi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Song, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hyland, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, J. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lindeman, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gale, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kosaka, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holmes, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rogers, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cappuzzo, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mok, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cantley, L. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janne, P. A.</span><span> </span><span class="NLM_article-title">MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">316</span><span class="NLM_x">, </span> <span class="NLM_fpage">1039</span><span class="NLM_x">–</span> <span class="NLM_lpage">1043</span><span class="refDoi"> DOI: 10.1126/science.1141478</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01774&amp;key=10.1126%2Fscience.1141478" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01774&amp;key=17463250" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01774&amp;key=1%3ACAS%3A528%3ADC%252BD2sXltlOjt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=316&publication_year=2007&pages=1039-1043&author=J.+A.+Engelmanauthor=K.+Zejnullahuauthor=T.+Mitsudomiauthor=Y.+Songauthor=C.+Hylandauthor=J.+O.+Parkauthor=N.+Lindemanauthor=C.+M.+Galeauthor=X.+Zhaoauthor=J.+Christensenauthor=T.+Kosakaauthor=A.+J.+Holmesauthor=A.+M.+Rogersauthor=F.+Cappuzzoauthor=T.+Mokauthor=C.+Leeauthor=B.+E.+Johnsonauthor=L.+C.+Cantleyauthor=P.+A.+Janne&title=MET+amplification+leads+to+gefitinib+resistance+in+lung+cancer+by+activating+ERBB3+signaling&doi=10.1126%2Fscience.1141478"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling</span></div><div class="casAuthors">Engelman, Jeffrey A.; Zejnullahu, Kreshnik; Mitsudomi, Tetsuya; Song, Youngchul; Hyland, Courtney; Park, Joon Oh; Lindeman, Neal; Gale, Christopher-Michael; Zhao, Xiaojun; Christensen, James; Kosaka, Takayuki; Holmes, Alison J.; Rogers, Andrew M.; Cappuzzo, Federico; Mok, Tony; Lee, Charles; Johnson, Bruce E.; Cantley, Lewis C.; Jaenne, Pasi A.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">316</span>
        (<span class="NLM_cas:issue">5827</span>),
    <span class="NLM_cas:pages">1039-1043</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">The epidermal growth factor receptor (EGFR) kinase inhibitors gefitinib and erlotinib are effective treatments for lung cancers with EGFR activating mutations, but these tumors invariably develop drug resistance.  Here, we describe a gefitinib-sensitive lung cancer cell line that developed resistance to gefitinib as a result of focal amplification of the MET proto-oncogene. inhibition of MET signaling in these cells restored their sensitivity to gefitinib.  MET amplification was detected in 4 of 18 (22%) lung cancer specimens that had developed resistance to gefitinib or erlotinib.  We find that amplification of MET causes gefitinib resistance by driving ERBB3 (HER3)-dependent activation of PI3K, a pathway thought to be specific to EGFR/ERBB family receptors.  Thus, we propose that MET amplification may promote drug resistance in other ERBB-driven cancers as well.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr430gbvBeIoLVg90H21EOLACvtfcHk0ljoArNSpcLsKQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXltlOjt7g%253D&md5=3da9383b4acb965f57529b095f8f4686</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1126%2Fscience.1141478&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1141478%26sid%3Dliteratum%253Aachs%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26aulast%3DZejnullahu%26aufirst%3DK.%26aulast%3DMitsudomi%26aufirst%3DT.%26aulast%3DSong%26aufirst%3DY.%26aulast%3DHyland%26aufirst%3DC.%26aulast%3DPark%26aufirst%3DJ.%2BO.%26aulast%3DLindeman%26aufirst%3DN.%26aulast%3DGale%26aufirst%3DC.%2BM.%26aulast%3DZhao%26aufirst%3DX.%26aulast%3DChristensen%26aufirst%3DJ.%26aulast%3DKosaka%26aufirst%3DT.%26aulast%3DHolmes%26aufirst%3DA.%2BJ.%26aulast%3DRogers%26aufirst%3DA.%2BM.%26aulast%3DCappuzzo%26aufirst%3DF.%26aulast%3DMok%26aufirst%3DT.%26aulast%3DLee%26aufirst%3DC.%26aulast%3DJohnson%26aufirst%3DB.%2BE.%26aulast%3DCantley%26aufirst%3DL.%2BC.%26aulast%3DJanne%26aufirst%3DP.%2BA.%26atitle%3DMET%2520amplification%2520leads%2520to%2520gefitinib%2520resistance%2520in%2520lung%2520cancer%2520by%2520activating%2520ERBB3%2520signaling%26jtitle%3DScience%26date%3D2007%26volume%3D316%26spage%3D1039%26epage%3D1043%26doi%3D10.1126%2Fscience.1141478" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group">Duffy, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGowan, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crown, J.</span><span> </span><span class="NLM_article-title">Targeted therapy for triple-negative breast cancer: where are we?</span> <span class="citation_source-journal">Int. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">131</span><span class="NLM_x">, </span> <span class="NLM_fpage">2471</span><span class="NLM_x">–</span> <span class="NLM_lpage">2477</span><span class="refDoi"> DOI: 10.1002/ijc.27632</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01774&amp;key=10.1002%2Fijc.27632" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01774&amp;key=22581656" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01774&amp;key=1%3ACAS%3A528%3ADC%252BC38XotFKmurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=131&publication_year=2012&pages=2471-2477&author=M.+J.+Duffyauthor=P.+M.+McGowanauthor=J.+Crown&title=Targeted+therapy+for+triple-negative+breast+cancer%3A+where+are+we%3F&doi=10.1002%2Fijc.27632"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Targeted therapy for triple-negative breast cancer: Where are we?</span></div><div class="casAuthors">Duffy, Michael J.; McGowan, Patricia M.; Crown, John</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Cancer</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">131</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2471-2477</span>CODEN:
                <span class="NLM_cas:coden">IJCNAW</span>;
        ISSN:<span class="NLM_cas:issn">0020-7136</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">A review.  Breast cancers that are neg. for estrogen receptor (ER), progesterone receptors (PR) and HER2, using std. clin. assays, have been dubbed triple-neg. (TN).  Unlike other mol. subtypes of invasive breast cancer, validated targeted therapies are currently unavailable for patients with TN breast cancer.  Preclin. studies however, have identified several potential targets such as epidermal growth factor receptor (EGFR), SRC, MET and poly ADP ribose polymerase 1/2 (PARP1/2).  Because of tumor heterogeneity, it is unlikely that any single targeted therapy will be efficacious in all patients with TN breast cancer.  The rational way forward for treating these patients is likely to be biomarker-driven, combination targeted therapies or combination of targeted therapy with cytotoxic chemotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqnmJkW7zwQsbVg90H21EOLACvtfcHk0ljoArNSpcLsKQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XotFKmurg%253D&md5=3e09cb2672f68bc17b80bbc17253f039</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1002%2Fijc.27632&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fijc.27632%26sid%3Dliteratum%253Aachs%26aulast%3DDuffy%26aufirst%3DM.%2BJ.%26aulast%3DMcGowan%26aufirst%3DP.%2BM.%26aulast%3DCrown%26aufirst%3DJ.%26atitle%3DTargeted%2520therapy%2520for%2520triple-negative%2520breast%2520cancer%253A%2520where%2520are%2520we%253F%26jtitle%3DInt.%2520J.%2520Cancer%26date%3D2012%26volume%3D131%26spage%3D2471%26epage%3D2477%26doi%3D10.1002%2Fijc.27632" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">deFazio, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chiew, Y. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McEvoy, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watts, C. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sutherland, R. L.</span><span> </span><span class="NLM_article-title">Antisense estrogen receptor RNA expression increases epidermal growth factor receptor gene expression in breast cancer cells</span> <span class="citation_source-journal">Cell Growth Differ.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">903</span><span class="NLM_x">–</span> <span class="NLM_lpage">911</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01774&amp;key=9269899" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01774&amp;key=1%3ACAS%3A528%3ADyaK2sXlsVGgs7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=1997&pages=903-911&author=A.+deFazioauthor=Y.+E.+Chiewauthor=M.+McEvoyauthor=C.+K.+Wattsauthor=R.+L.+Sutherland&title=Antisense+estrogen+receptor+RNA+expression+increases+epidermal+growth+factor+receptor+gene+expression+in+breast+cancer+cells"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Antisense estrogen receptor RNA expression increases epidermal growth factor receptor gene expression in breast cancer cells</span></div><div class="casAuthors">Defazio, Anna; Chiew, Yoke-Eng; Mcevoy, Maryanne; Watts, Colin K. W.; Sutherland, Robert L.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Growth & Differentiation</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">903-911</span>CODEN:
                <span class="NLM_cas:coden">CGDIE7</span>;
        ISSN:<span class="NLM_cas:issn">1044-9523</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">In human breast cancer, progression to a more malignant phenotype is often accompanied by decreased expression of estrogen receptor (ER) and increased expression of epidermal growth factor receptor (EGFR).  Higher levels of this receptor tyrosine kinase are found in tumors lacking ER, and a quant., inverse relation exists between the level of ER and EGFR mRNA in human breast cell lines.  Antisense ER (ASER) RNA was used to evaluate the consequence of decreased ER expression in breast cancer cells, specifically to det. whether ER is involved in the regulation of EGFR gene expression.  ER-pos. MCF-7 human breast cancer cells were transfected with ASER, and clones constitutively expressing ASER RNA had decreased ER and up to a 3-fold increase in the expression of EGFR mRNA.  To confirm that this observation was a direct consequence of ASER expression, a metal-inducible ASER expression construct was transfected into MCF-7 cells, and transfected clones were isolated and characterized.  Northern anal. revealed an induction of ASER RNA within 1 h of the addn. of zinc, which was followed by a 4-fold increase in EGFR mRNA levels, maximal at 6-12 h.  The basal level of expression of the glucocorticoid receptor is also inversely related to that of ER among breast cancer cell lines but neither constitutive nor inducible expression of ASER affected the expression of glucocorticoid receptor.  These data support the hypothesis that the level of expression of ER specifically influences the expression of EGFR in human breast cancer cells and provides a potential link between loss of steroid sensitivity and the acquisition of autonomous growth.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrpLM5BDYb_0LVg90H21EOLACvtfcHk0ljoArNSpcLsKQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXlsVGgs7c%253D&md5=a885da2b97b609942d5825f5a4900ed3</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DdeFazio%26aufirst%3DA.%26aulast%3DChiew%26aufirst%3DY.%2BE.%26aulast%3DMcEvoy%26aufirst%3DM.%26aulast%3DWatts%26aufirst%3DC.%2BK.%26aulast%3DSutherland%26aufirst%3DR.%2BL.%26atitle%3DAntisense%2520estrogen%2520receptor%2520RNA%2520expression%2520increases%2520epidermal%2520growth%2520factor%2520receptor%2520gene%2520expression%2520in%2520breast%2520cancer%2520cells%26jtitle%3DCell%2520Growth%2520Differ.%26date%3D1997%26volume%3D8%26spage%3D903%26epage%3D911" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">Nielsen, T. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hsu, F. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jensen, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheang, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karaca, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hernandez-Boussard, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Livasy, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cowan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dressler</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Akslen, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ragaz, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gown, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilks, C. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van de Rijn, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perou, C. M.</span><span> </span><span class="NLM_article-title">Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">5367</span><span class="NLM_x">–</span> <span class="NLM_lpage">5374</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-04-0220</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01774&amp;key=10.1158%2F1078-0432.CCR-04-0220" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01774&amp;key=15328174" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01774&amp;key=1%3ACAS%3A528%3ADC%252BD2cXmvFSlt7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2004&pages=5367-5374&author=T.+O.+Nielsenauthor=F.+D.+Hsuauthor=K.+Jensenauthor=M.+Cheangauthor=G.+Karacaauthor=Z.+Huauthor=T.+Hernandez-Boussardauthor=C.+Livasyauthor=D.+Cowanauthor=+Dresslerauthor=L.+A.+Akslenauthor=J.+Ragazauthor=A.+M.+Gownauthor=C.+B.+Gilksauthor=M.+van+de+Rijnauthor=C.+M.+Perou&title=Immunohistochemical+and+clinical+characterization+of+the+basal-like+subtype+of+invasive+breast+carcinoma&doi=10.1158%2F1078-0432.CCR-04-0220"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma</span></div><div class="casAuthors">Nielsen, Torsten O.; Hsu, Forrest D.; Jensen, Kristin; Cheang, Maggie; Karaca, Gamze; Hu, Zhiyuan; Hernandez-Boussard, Tina; Livasy, Chad; Cowan, Dave; Dressler, Lynn; Akslen, Lars A.; Ragaz, Joseph; Gown, Allen M.; Gilks, C. Blake; van de Rijn, Matt; Perou, Charles M.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">5367-5374</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Expression profiling studies classified breast carcinomas into estrogen receptor (ER)+/luminal, normal breast-like, HER2 overexpressing, and basal-like groups, with the latter two assocd. with poor outcomes.  Currently, there exist clin. assays that identify ER+/luminal and HER2-overexpressing tumors, and we sought to develop a clin. assay for breast basal-like tumors.  To identify an immunohistochem. profile for breast basal-like tumors, we collected a series of known basal-like tumors and tested them for protein patterns that are characteristic of this subtype.  Next, we examd. the significance of these protein patterns using tissue microarrays and evaluated the prognostic significance of these findings.  Using a panel of 21 basal-like tumors, which was detd. using gene expression profiles, we saw that this subtype was typically immunohistochem. neg. for estrogen receptor and HER2 but pos. for basal cytokeratins, HER1, and/or c-KIT.  Using breast carcinoma tissue microarrays representing 930 patients with 17.4-yr mean follow-up, basal cytokeratin expression was assocd. with low disease-specific survival.  HER1 expression was obsd. in 54% of cases pos. for basal cytokeratins (vs. 11% of neg. cases) and was assocd. with poor survival independent of nodal status and size. c-KIT expression was more common in basal-like tumors than in other breast cancers but did not influence prognosis.  A panel of four antibodies (ER, HER1, HER2, and cytokeratin 5/6) can accurately identify basal-like tumors using std. available clin. tools and shows high specificity.  These studies show that many basal-like tumors express HER1, which suggests candidate drugs for evaluation in these patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo71vxmorFG-LVg90H21EOLACvtfcHk0lhHzR5_OYTpdw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXmvFSlt7k%253D&md5=139e2accba56257f9557ea030b6270b7</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-04-0220&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-04-0220%26sid%3Dliteratum%253Aachs%26aulast%3DNielsen%26aufirst%3DT.%2BO.%26aulast%3DHsu%26aufirst%3DF.%2BD.%26aulast%3DJensen%26aufirst%3DK.%26aulast%3DCheang%26aufirst%3DM.%26aulast%3DKaraca%26aufirst%3DG.%26aulast%3DHu%26aufirst%3DZ.%26aulast%3DHernandez-Boussard%26aufirst%3DT.%26aulast%3DLivasy%26aufirst%3DC.%26aulast%3DCowan%26aufirst%3DD.%26aulast%3DDressler%26aulast%3DAkslen%26aufirst%3DL.%2BA.%26aulast%3DRagaz%26aufirst%3DJ.%26aulast%3DGown%26aufirst%3DA.%2BM.%26aulast%3DGilks%26aufirst%3DC.%2BB.%26aulast%3Dvan%2Bde%2BRijn%26aufirst%3DM.%26aulast%3DPerou%26aufirst%3DC.%2BM.%26atitle%3DImmunohistochemical%2520and%2520clinical%2520characterization%2520of%2520the%2520basal-like%2520subtype%2520of%2520invasive%2520breast%2520carcinoma%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2004%26volume%3D10%26spage%3D5367%26epage%3D5374%26doi%3D10.1158%2F1078-0432.CCR-04-0220" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group">Corkery, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crown, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clynes, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Donovan, N.</span><span> </span><span class="NLM_article-title">Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer</span> <span class="citation_source-journal">Ann. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">862</span><span class="NLM_x">–</span> <span class="NLM_lpage">867</span><span class="refDoi"> DOI: 10.1093/annonc/mdn710</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01774&amp;key=10.1093%2Fannonc%2Fmdn710" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01774&amp;key=19150933" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01774&amp;key=1%3ACAS%3A280%3ADC%252BD1MzgvVyitw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2009&pages=862-867&author=B.+Corkeryauthor=J.+Crownauthor=M.+Clynesauthor=N.+O%E2%80%99Donovan&title=Epidermal+growth+factor+receptor+as+a+potential+therapeutic+target+in+triple-negative+breast+cancer&doi=10.1093%2Fannonc%2Fmdn710"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer</span></div><div class="casAuthors">Corkery B; Crown J; Clynes M; O'Donovan N</div><div class="citationInfo"><span class="NLM_cas:title">Annals of oncology : official journal of the European Society for Medical Oncology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">862-7</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  No proven targeted therapy is currently available for the treatment of triple-negative breast cancer (TNBC).  Epidermal growth factor receptor (EGFR) is frequently overexpressed in TNBC.  We studied the activity of EGFR antagonists alone, and in combination with chemotherapy, in TNBC cell lines.  MATERIALS AND METHODS:  EGFR and phosphorylated EGFR were measured by enzyme-linked immunosorbent assay.  Sensitivity to EGFR inhibitors alone and in combination with chemotherapy was assessed.  Effects of gefitinib on EGFR signalling and cell cycle were also examined.  RESULTS:  EGFR was overexpressed in the TNBC compared with the human epidermal growth factor receptor 2 (HER-2)-positive cell lines.  Phosphorylation of EGFR was detected in the TNBC cells in response to epidermal growth factor stimulation and was blocked by gefitinib treatment.  However, the TNBC cell lines were less sensitive to EGFR inhibition than the HER-2-positive cell lines.  Response to gefitinib was associated with reduced phosphorylation of both mitogen activated protein kinase (MAPK) and Akt and induction of G(1) arrest.  Gefitinib enhanced response to both carboplatin and docetaxel in the TNBC cells, and the triple combination of gefitinib, carboplatin and docetaxel was synergistic.  CONCLUSIONS:  Although the TNBC cells are less sensitive to EGFR inhibition than the HER-2-positive cell lines, gefitinib enhanced response to chemotherapy.  Gefitinib combined with carboplatin and docetaxel warrants further investigation in TNBC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSwDYVxbcpKC_EeosoOnpOLfW6udTcc2ea8rurklpfCY7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1MzgvVyitw%253D%253D&md5=e5e1fc85f70552c7ffafca14fe9ed491</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1093%2Fannonc%2Fmdn710&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fannonc%252Fmdn710%26sid%3Dliteratum%253Aachs%26aulast%3DCorkery%26aufirst%3DB.%26aulast%3DCrown%26aufirst%3DJ.%26aulast%3DClynes%26aufirst%3DM.%26aulast%3DO%25E2%2580%2599Donovan%26aufirst%3DN.%26atitle%3DEpidermal%2520growth%2520factor%2520receptor%2520as%2520a%2520potential%2520therapeutic%2520target%2520in%2520triple-negative%2520breast%2520cancer%26jtitle%3DAnn.%2520Oncol.%26date%3D2009%26volume%3D20%26spage%3D862%26epage%3D867%26doi%3D10.1093%2Fannonc%2Fmdn710" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">Nakai, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hung, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamaguchi, H.</span><span> </span><span class="NLM_article-title">A perspective on anti-EGFR therapies targeting triple-negative breast cancer</span> <span class="citation_source-journal">Am. J. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">1609</span><span class="NLM_x">–</span> <span class="NLM_lpage">1623</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01774&amp;key=27648353" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01774&amp;key=1%3ACAS%3A528%3ADC%252BC1cXotFers7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2016&pages=1609-1623&author=K.+Nakaiauthor=M.+C.+Hungauthor=H.+Yamaguchi&title=A+perspective+on+anti-EGFR+therapies+targeting+triple-negative+breast+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">A perspective on anti-EGFR therapies targeting triple-negative breast cancer</span></div><div class="casAuthors">Nakai, Katsuya; Hung, Mien-Chie; Yamaguchi, Hirohito</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Cancer Research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1609-1623</span>CODEN:
                <span class="NLM_cas:coden">AJCRFT</span>;
        ISSN:<span class="NLM_cas:issn">2156-6976</span>.
    
            (<span class="NLM_cas:orgname">e-Century Publishing Corp.</span>)
        </div><div class="casAbstract">Triple-neg. breast cancer (TNBC), which lacks estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2), accounts for about 15-20% of breast cancers and is the most aggressive breast cancer subtype.  There are currently no effective therapies against metastatic TNBC.  Compared with other breast cancer subtypes, EGFR is frequently overexpressed in TNBC and a potential therapeutic target for this disease.  There are two types of EGFR inhibitors, small mol. tyrosine kinase inhibitor (TKI) and monoclonal antibody (mAb), for the treatment of cancers, such as non-small cell lung cancer and colorectal cancer.  For breast cancer, however, the clin. trials of EGFR inhibitors have failed due to low response rates.  Because a small portion of patients do demonstrate response to EGFR inhibitors, it may be necessary to stratify patients to enhance the efficacy of EGFR inhibitors in TNBC and to develop the effective combination therapy for this patient population.  In this review, we describe some of the mol. mechanisms underlying EGFR inhibitor sensitivity and further discuss the possible therapeutic strategies to increase the efficacy of EGFR inhibitors in TNBC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrGYTJlhdhPhLVg90H21EOLACvtfcHk0lhHzR5_OYTpdw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXotFers7g%253D&md5=e13cf20b285b00db54350e62423f5d80</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DNakai%26aufirst%3DK.%26aulast%3DHung%26aufirst%3DM.%2BC.%26aulast%3DYamaguchi%26aufirst%3DH.%26atitle%3DA%2520perspective%2520on%2520anti-EGFR%2520therapies%2520targeting%2520triple-negative%2520breast%2520cancer%26jtitle%3DAm.%2520J.%2520Cancer%2520Res.%26date%3D2016%26volume%3D6%26spage%3D1609%26epage%3D1623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">Biswas, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cruz, A. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gansberger, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pardee, A. B.</span><span> </span><span class="NLM_article-title">Epidermal growth factor-induced nuclear factor κB activation: a major pathway of cell-cycle progression in estrogen-receptor negative breast cancer cells</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">97</span><span class="NLM_x">, </span> <span class="NLM_fpage">8542</span><span class="NLM_x">–</span> <span class="NLM_lpage">8547</span><span class="refDoi"> DOI: 10.1073/pnas.97.15.8542</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01774&amp;key=10.1073%2Fpnas.97.15.8542" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=97&publication_year=2000&pages=8542-8547&author=D.+K.+Biswasauthor=A.+P.+Cruzauthor=E.+Gansbergerauthor=A.+B.+Pardee&title=Epidermal+growth+factor-induced+nuclear+factor+%CE%BAB+activation%3A+a+major+pathway+of+cell-cycle+progression+in+estrogen-receptor+negative+breast+cancer+cells&doi=10.1073%2Fpnas.97.15.8542"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1073%2Fpnas.97.15.8542&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.97.15.8542%26sid%3Dliteratum%253Aachs%26aulast%3DBiswas%26aufirst%3DD.%2BK.%26aulast%3DCruz%26aufirst%3DA.%2BP.%26aulast%3DGansberger%26aufirst%3DE.%26aulast%3DPardee%26aufirst%3DA.%2BB.%26atitle%3DEpidermal%2520growth%2520factor-induced%2520nuclear%2520factor%2520%25CE%25BAB%2520activation%253A%2520a%2520major%2520pathway%2520of%2520cell-cycle%2520progression%2520in%2520estrogen-receptor%2520negative%2520breast%2520cancer%2520cells%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2000%26volume%3D97%26spage%3D8542%26epage%3D8547%26doi%3D10.1073%2Fpnas.97.15.8542" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Nakshatri, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhat-Nakshatri, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goulet, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sledge, G. W. J.</span><span> </span><span class="NLM_article-title">Constitutive activation of NF-kB during progression of breast cancer to hormone-independent growth</span> <span class="citation_source-journal">Mol. Cell. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">3629</span><span class="NLM_x">–</span> <span class="NLM_lpage">3639</span><span class="refDoi"> DOI: 10.1128/MCB.17.7.3629</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01774&amp;key=10.1128%2FMCB.17.7.3629" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01774&amp;key=9199297" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01774&amp;key=1%3ACAS%3A528%3ADyaK2sXktFOhtLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=1997&pages=3629-3639&author=H.+Nakshatriauthor=P.+Bhat-Nakshatriauthor=D.+A.+Martinauthor=R.+J.+Gouletauthor=G.+W.+J.+Sledge&title=Constitutive+activation+of+NF-kB+during+progression+of+breast+cancer+to+hormone-independent+growth&doi=10.1128%2FMCB.17.7.3629"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Constitutive activation of NF-κB during progression of breast cancer to hormone-independent growth</span></div><div class="casAuthors">Nakshatri, Harikrishna; Bhat-Nakshatri, Poornima; Martin, Daniel A.; Goulet, Robert J., Jr.; Sledge, George W., Jr.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Biology</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">3629-3639</span>CODEN:
                <span class="NLM_cas:coden">MCEBD4</span>;
        ISSN:<span class="NLM_cas:issn">0270-7306</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Breast cancers often progress from a hormone-dependent, nonmetastatic, antiestrogen-sensitive phenotype to a hormone-independent, antiestrogen- and chemotherapy-resistant phenotype with highly invasive and metastatic growth properties.  This progression is usually accompanied by altered function of the estrogen receptor (ER) or outgrowth of ER-neg. cancer cells.  To understand the mol. mechanisms responsible for metastatic growth of ER-neg. breast cancers, the activities of the transcription factor NF-κB (which modulates the expression of genes involved in cell proliferation, differentiation, apoptosis, and metastasis) were compared in ER-pos. (MCF-7 and T47 D) and ER-neg. (MDA-MB-231 and MDA-MB-435) human breast cancer cell lines.  NF-κB, which is usually maintained in an inactive state by protein-protein interaction with inhibitor IκBs, was found to be constitutively active in ER-neg. breast cancer cell lines.  Constitutive DNA binding of NF-κB was also obsd. with exts. from ER-neg., poorly differentiated primary breast tumors.  Progression of the rat mammary carcinoma cell line RM22-F5 from an ER-pos., nonmalignant phenotype (E phenotype) to an ER-neg., malignant phenotype (F phenotype) was also accompanied by constitutive activation of NF-κB.  Anal. of individual subunits of NF-κB revealed that all ER-neg. cell lines, including RM22-F5 cells of F phenotype, contain a unique 37-kDa protein which is antigenically related to the RelA subunit.  Cell-type-specific differences in IκBα, -β, and -γ were also obsd.  In transient-transfection expts., constitutive activity of an NF-κB-dependent promoter was obsd. in MDA-MB-231 and RM22-F5 cells of F phenotype, and this activity was efficiently repressed by cotransfected ER.  Since ER inhibits the constitutive as well as inducible activation function of NFκB in a dose-dependent manner, the authors propose that breast cancers that lack functional ER overexpress NFκB-regulated genes.  Furthermore, since recent data indicate that NF-κB protects cells from tumor necrosis factor alpha-, ionizing radiation-, and chemotherapeutic agent daunorubicin-mediated apoptosis, the results provide an explanation for chemotherapeutic resistance in ER-neg. breast cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpnMGhiNR4C7bVg90H21EOLACvtfcHk0lgbk8wVj6jJPw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXktFOhtLY%253D&md5=dd1afb1617221b6e9d1da86f1a3c88b8</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1128%2FMCB.17.7.3629&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FMCB.17.7.3629%26sid%3Dliteratum%253Aachs%26aulast%3DNakshatri%26aufirst%3DH.%26aulast%3DBhat-Nakshatri%26aufirst%3DP.%26aulast%3DMartin%26aufirst%3DD.%2BA.%26aulast%3DGoulet%26aufirst%3DR.%2BJ.%26aulast%3DSledge%26aufirst%3DG.%2BW.%2BJ.%26atitle%3DConstitutive%2520activation%2520of%2520NF-kB%2520during%2520progression%2520of%2520breast%2520cancer%2520to%2520hormone-independent%2520growth%26jtitle%3DMol.%2520Cell.%2520Biol.%26date%3D1997%26volume%3D17%26spage%3D3629%26epage%3D3639%26doi%3D10.1128%2FMCB.17.7.3629" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">Shostak, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chariot, A.</span><span> </span><span class="NLM_article-title">Chariot, A. EGFR and NF-kappaB: partners in cancer</span> <span class="citation_source-journal">Trends Mol. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">385</span><span class="NLM_x">–</span> <span class="NLM_lpage">393</span><span class="refDoi"> DOI: 10.1016/j.molmed.2015.04.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01774&amp;key=10.1016%2Fj.molmed.2015.04.001" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2015&pages=385-393&author=K.+Shostakauthor=A.+Chariot&title=Chariot%2C+A.+EGFR+and+NF-kappaB%3A+partners+in+cancer&doi=10.1016%2Fj.molmed.2015.04.001"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1016%2Fj.molmed.2015.04.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molmed.2015.04.001%26sid%3Dliteratum%253Aachs%26aulast%3DShostak%26aufirst%3DK.%26aulast%3DChariot%26aufirst%3DA.%26atitle%3DChariot%252C%2520A.%2520EGFR%2520and%2520NF-kappaB%253A%2520partners%2520in%2520cancer%26jtitle%3DTrends%2520Mol.%2520Med.%26date%3D2015%26volume%3D21%26spage%3D385%26epage%3D393%26doi%3D10.1016%2Fj.molmed.2015.04.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Bivona, T. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hieronymus, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parker, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taron, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosell, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moonsamy, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dahlman, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, V. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Costa, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hannon, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sawyers, C. L.</span><span> </span><span class="NLM_article-title">FAS and NF-kappaB signalling modulate dependence of lung cancers on mutant EGFR</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">471</span><span class="NLM_x">, </span> <span class="NLM_fpage">523</span><span class="NLM_x">–</span> <span class="NLM_lpage">526</span><span class="refDoi"> DOI: 10.1038/nature09870</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01774&amp;key=10.1038%2Fnature09870" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=471&publication_year=2011&pages=523-526&author=T.+G.+Bivonaauthor=H.+Hieronymusauthor=J.+Parkerauthor=K.+Changauthor=M.+Taronauthor=R.+Rosellauthor=P.+Moonsamyauthor=K.+Dahlmanauthor=V.+A.+Millerauthor=C.+Costaauthor=G.+Hannonauthor=C.+L.+Sawyers&title=FAS+and+NF-kappaB+signalling+modulate+dependence+of+lung+cancers+on+mutant+EGFR&doi=10.1038%2Fnature09870"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1038%2Fnature09870&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature09870%26sid%3Dliteratum%253Aachs%26aulast%3DBivona%26aufirst%3DT.%2BG.%26aulast%3DHieronymus%26aufirst%3DH.%26aulast%3DParker%26aufirst%3DJ.%26aulast%3DChang%26aufirst%3DK.%26aulast%3DTaron%26aufirst%3DM.%26aulast%3DRosell%26aufirst%3DR.%26aulast%3DMoonsamy%26aufirst%3DP.%26aulast%3DDahlman%26aufirst%3DK.%26aulast%3DMiller%26aufirst%3DV.%2BA.%26aulast%3DCosta%26aufirst%3DC.%26aulast%3DHannon%26aufirst%3DG.%26aulast%3DSawyers%26aufirst%3DC.%2BL.%26atitle%3DFAS%2520and%2520NF-kappaB%2520signalling%2520modulate%2520dependence%2520of%2520lung%2520cancers%2520on%2520mutant%2520EGFR%26jtitle%3DNature%26date%3D2011%26volume%3D471%26spage%3D523%26epage%3D526%26doi%3D10.1038%2Fnature09870" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">Blakely, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pazarentzos, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olivas, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Asthana, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yan, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hrustanovic, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neel, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Newton, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bobb, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fouts, T. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meshulam, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gubens, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jablons, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bandyopadhyay, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krogan, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bivona, T. G.</span><span> </span><span class="NLM_article-title">NF-kappaB-activating complex engaged in response to EGFR oncogene inhibition drives tumor cell survival and residual disease in lung cancer</span> <span class="citation_source-journal">Cell Rep.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">98</span><span class="NLM_x">–</span> <span class="NLM_lpage">110</span><span class="refDoi"> DOI: 10.1016/j.celrep.2015.03.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01774&amp;key=10.1016%2Fj.celrep.2015.03.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01774&amp;key=25843712" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01774&amp;key=1%3ACAS%3A528%3ADC%252BC2MXlvVCisr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2015&pages=98-110&author=C.+M.+Blakelyauthor=E.+Pazarentzosauthor=V.+Olivasauthor=S.+Asthanaauthor=J.+J.+Yanauthor=I.+Tanauthor=G.+Hrustanovicauthor=E.+Chanauthor=L.+Linauthor=D.+S.+Neelauthor=W.+Newtonauthor=K.+L.+Bobbauthor=T.+R.+Foutsauthor=J.+Meshulamauthor=M.+A.+Gubensauthor=D.+M.+Jablonsauthor=J.+R.+Johnsonauthor=S.+Bandyopadhyayauthor=N.+J.+Kroganauthor=T.+G.+Bivona&title=NF-kappaB-activating+complex+engaged+in+response+to+EGFR+oncogene+inhibition+drives+tumor+cell+survival+and+residual+disease+in+lung+cancer&doi=10.1016%2Fj.celrep.2015.03.012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">NF-κB-Activating Complex Engaged in Response to EGFR Oncogene Inhibition Drives Tumor Cell Survival and Residual Disease in Lung Cancer</span></div><div class="casAuthors">Blakely, Collin M.; Pazarentzos, Evangelos; Olivas, Victor; Asthana, Saurabh; Yan, Jenny Jiacheng; Tan, Irena; Hrustanovic, Gorjan; Chan, Elton; Lin, Luping; Neel, Dana S.; Newton, William; Bobb, Kathryn L.; Fouts, Timothy R.; Meshulam, Jeffrey; Gubens, Matthew A.; Jablons, David M.; Johnson, Jeffrey R.; Bandyopadhyay, Sourav; Krogan, Nevan J.; Bivona, Trever G.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Reports</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">98-110</span>CODEN:
                <span class="NLM_cas:coden">CREED8</span>;
        ISSN:<span class="NLM_cas:issn">2211-1247</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Although oncogene-targeted therapy often elicits profound initial tumor responses in patients, responses are generally incomplete because some tumor cells survive initial therapy as residual disease that enables eventual acquired resistance.  The mechanisms underlying tumor cell adaptation and survival during initial therapy are incompletely understood.  Here, through the study of EGFR mutant lung adenocarcinoma, we show that NF-κB signaling is rapidly engaged upon initial EGFR inhibitor treatment to promote tumor cell survival and residual disease.  EGFR oncogene inhibition induced an EGFR-TRAF2-RIP1-IKK complex that stimulated an NF-κB-mediated transcriptional survival program.  The direct NF-κB inhibitor PBS-1086 suppressed this adaptive survival program and increased the magnitude and duration of initial EGFR inhibitor response in multiple NSCLC models, including a patient-derived xenograft.  These findings unveil NF-κB activation as a crit. adaptive survival mechanism engaged by EGFR oncogene inhibition and provide rationale for EGFR and NF-κB co-inhibition to eliminate residual disease and enhance patient responses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoC125gpHJNxLVg90H21EOLACvtfcHk0lgbk8wVj6jJPw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXlvVCisr0%253D&md5=819a5e83c2ad6549a1c88e68c6b75285</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1016%2Fj.celrep.2015.03.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.celrep.2015.03.012%26sid%3Dliteratum%253Aachs%26aulast%3DBlakely%26aufirst%3DC.%2BM.%26aulast%3DPazarentzos%26aufirst%3DE.%26aulast%3DOlivas%26aufirst%3DV.%26aulast%3DAsthana%26aufirst%3DS.%26aulast%3DYan%26aufirst%3DJ.%2BJ.%26aulast%3DTan%26aufirst%3DI.%26aulast%3DHrustanovic%26aufirst%3DG.%26aulast%3DChan%26aufirst%3DE.%26aulast%3DLin%26aufirst%3DL.%26aulast%3DNeel%26aufirst%3DD.%2BS.%26aulast%3DNewton%26aufirst%3DW.%26aulast%3DBobb%26aufirst%3DK.%2BL.%26aulast%3DFouts%26aufirst%3DT.%2BR.%26aulast%3DMeshulam%26aufirst%3DJ.%26aulast%3DGubens%26aufirst%3DM.%2BA.%26aulast%3DJablons%26aufirst%3DD.%2BM.%26aulast%3DJohnson%26aufirst%3DJ.%2BR.%26aulast%3DBandyopadhyay%26aufirst%3DS.%26aulast%3DKrogan%26aufirst%3DN.%2BJ.%26aulast%3DBivona%26aufirst%3DT.%2BG.%26atitle%3DNF-kappaB-activating%2520complex%2520engaged%2520in%2520response%2520to%2520EGFR%2520oncogene%2520inhibition%2520drives%2520tumor%2520cell%2520survival%2520and%2520residual%2520disease%2520in%2520lung%2520cancer%26jtitle%3DCell%2520Rep.%26date%3D2015%26volume%3D11%26spage%3D98%26epage%3D110%26doi%3D10.1016%2Fj.celrep.2015.03.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">Shimizu, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tolcher, A. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Papadopoulos, K. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beeram, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rasco, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, L. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gunn, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smetzer, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mays, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaiser, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wick, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alvarez, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cavazos, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mangold, G. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patnaik, A.</span><span> </span><span class="NLM_article-title">The clinical effect of the dual-targeting strategy involving PI3K/AKT/mTOR and RAS/MEK/ERK pathways in patients with advanced cancer</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">2316</span><span class="NLM_x">–</span> <span class="NLM_lpage">2325</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-11-2381</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01774&amp;key=10.1158%2F1078-0432.CCR-11-2381" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01774&amp;key=22261800" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01774&amp;key=1%3ACAS%3A528%3ADC%252BC38XmsFOnurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2012&pages=2316-2325&author=T.+Shimizuauthor=A.+W.+Tolcherauthor=K.+P.+Papadopoulosauthor=M.+Beeramauthor=D.+W.+Rascoauthor=L.+S.+Smithauthor=S.+Gunnauthor=L.+Smetzerauthor=T.+A.+Maysauthor=B.+Kaiserauthor=M.+J.+Wickauthor=C.+Alvarezauthor=A.+Cavazosauthor=G.+L.+Mangoldauthor=A.+Patnaik&title=The+clinical+effect+of+the+dual-targeting+strategy+involving+PI3K%2FAKT%2FmTOR+and+RAS%2FMEK%2FERK+pathways+in+patients+with+advanced+cancer&doi=10.1158%2F1078-0432.CCR-11-2381"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">The Clinical Effect of the Dual-Targeting Strategy Involving PI3K/AKT/mTOR and RAS/MEK/ERK Pathways in Patients with Advanced Cancer</span></div><div class="casAuthors">Shimizu, Toshio; Tolcher, Anthony W.; Papadopoulos, Kyriakos P.; Beeram, Muralidhar; Rasco, Drew W.; Smith, Lon S.; Gunn, Shelly; Smetzer, Leslie; Mays, Theresa A.; Kaiser, Brianne; Wick, Michael J.; Alvarez, Cathy; Cavazos, Aracely; Mangold, Gina L.; Patnaik, Amita</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2316-2325</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">PURPOSE: This study evaluated the clin. relevance of the dual-targeting strategy involving PI3K/AKT/mTOR and RAF/MEK/ERK pathways.  Exptl. Design: We investigated safety, efficacy, and correlations between tumor genetic alterations and clin. benefit in 236 patients with advanced cancers treated with phase I study drugs targeting phosphoinositide 3-kinase (PI3K) and/or mitogen-activated protein kinase (MAPK) pathways in our Phase I Clin. Trials Program.  RESULTS: Seventy-six (32.2%) patients received a PI3K pathway inhibitor in combination with a MAPK pathway inhibitor (D), whereas 124 (52.5%) and 36 (15.3%), resp., received an inhibitor of either the PI3K or MAPK pathways (S).  The rates of drug-related grade >III adverse events were 18.1% for (S) and 53.9% for (D; P < 0.001); the rates of dose-limiting toxicities were 9.4% for (S) and 18.4% for (D; P = 0.06).  The most frequent grade >III adverse events were transaminase elevations, skin rash, and mucositis.  In our comprehensive tumor genomic anal., of 9 patients who harbored coactivation of both pathways (colorectal cancer, n = 7; melanoma, n = 2), all 5 patients treated with (D) had tumor regression ranging from 2% to 64%.  CONCLUSIONS: These results suggest that dual inhibition of both pathways may potentially exhibit favorable efficacy compared with inhibition of either pathway, at the expense of greater toxicity.  Furthermore, this parallel pathway targeting strategy may be esp. important in patients with coexisting PI3K pathway genetic alterations and KRAS or BRAF mutations and suggests that mol. profiling and matching patients with combinations of these targeted drugs will need to be investigated in depth.  Clin Cancer Res; 18(8); 2316-25.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXSSzrpJOMr7Vg90H21EOLACvtfcHk0lgwwdJ9ROsoBg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XmsFOnurk%253D&md5=553a4cfbbd2b3bb1c9a7c9afeb1c0f5e</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-11-2381&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-11-2381%26sid%3Dliteratum%253Aachs%26aulast%3DShimizu%26aufirst%3DT.%26aulast%3DTolcher%26aufirst%3DA.%2BW.%26aulast%3DPapadopoulos%26aufirst%3DK.%2BP.%26aulast%3DBeeram%26aufirst%3DM.%26aulast%3DRasco%26aufirst%3DD.%2BW.%26aulast%3DSmith%26aufirst%3DL.%2BS.%26aulast%3DGunn%26aufirst%3DS.%26aulast%3DSmetzer%26aufirst%3DL.%26aulast%3DMays%26aufirst%3DT.%2BA.%26aulast%3DKaiser%26aufirst%3DB.%26aulast%3DWick%26aufirst%3DM.%2BJ.%26aulast%3DAlvarez%26aufirst%3DC.%26aulast%3DCavazos%26aufirst%3DA.%26aulast%3DMangold%26aufirst%3DG.%2BL.%26aulast%3DPatnaik%26aufirst%3DA.%26atitle%3DThe%2520clinical%2520effect%2520of%2520the%2520dual-targeting%2520strategy%2520involving%2520PI3K%252FAKT%252FmTOR%2520and%2520RAS%252FMEK%252FERK%2520pathways%2520in%2520patients%2520with%2520advanced%2520cancer%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2012%26volume%3D18%26spage%3D2316%26epage%3D2325%26doi%3D10.1158%2F1078-0432.CCR-11-2381" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">Rewcastle, G. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Denny, W. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bridges, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cody, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McMichael, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fry, D. W.</span><span> </span><span class="NLM_article-title">Tyrosine kinase inhibitors. 5. Synthesis and structure-activity relationships for 4-[(phenylmethyl)amino]- and 4-(phenylamino)quinazolines as potent adenosine 5′-triphosphate binding site inhibitors of the tyrosine kinase domain of the epidermal growth factor receptor</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">38</span><span class="NLM_x">, </span> <span class="NLM_fpage">3482</span><span class="NLM_x">–</span> <span class="NLM_lpage">3487</span><span class="refDoi"> DOI: 10.1021/jm00018a008</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm00018a008" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=1995&pages=3482-3487&author=G.+W.+Rewcastleauthor=W.+A.+Dennyauthor=A.+J.+Bridgesauthor=H.+Zhouauthor=D.+R.+Codyauthor=A.+McMichaelauthor=D.+W.+Fry&title=Tyrosine+kinase+inhibitors.+5.+Synthesis+and+structure-activity+relationships+for+4-%5B%28phenylmethyl%29amino%5D-+and+4-%28phenylamino%29quinazolines+as+potent+adenosine+5%E2%80%B2-triphosphate+binding+site+inhibitors+of+the+tyrosine+kinase+domain+of+the+epidermal+growth+factor+receptor&doi=10.1021%2Fjm00018a008"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1021%2Fjm00018a008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00018a008%26sid%3Dliteratum%253Aachs%26aulast%3DRewcastle%26aufirst%3DG.%2BW.%26aulast%3DDenny%26aufirst%3DW.%2BA.%26aulast%3DBridges%26aufirst%3DA.%2BJ.%26aulast%3DZhou%26aufirst%3DH.%26aulast%3DCody%26aufirst%3DD.%2BR.%26aulast%3DMcMichael%26aufirst%3DA.%26aulast%3DFry%26aufirst%3DD.%2BW.%26atitle%3DTyrosine%2520kinase%2520inhibitors.%25205.%2520Synthesis%2520and%2520structure-activity%2520relationships%2520for%25204-%255B%2528phenylmethyl%2529amino%255D-%2520and%25204-%2528phenylamino%2529quinazolines%2520as%2520potent%2520adenosine%25205%25E2%2580%25B2-triphosphate%2520binding%2520site%2520inhibitors%2520of%2520the%2520tyrosine%2520kinase%2520domain%2520of%2520the%2520epidermal%2520growth%2520factor%2520receptor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1995%26volume%3D38%26spage%3D3482%26epage%3D3487%26doi%3D10.1021%2Fjm00018a008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">Smaill, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rewcastle, G. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loo, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greis, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, O. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reyner, E. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lipka, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Showalter, H. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vincent, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elliott, W. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Denny, W. A.</span><span> </span><span class="NLM_article-title">Tyrosine kinase inhibitors. 17. Irreversible inhibitors of the epidermal growth factor receptor: 4-(phenylamino)quinazoline- and 4-(phenylamino)pyrido[3,2-d]pyrimidine-6-acrylamides bearing additional solubilizing functions</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">43</span><span class="NLM_x">, </span> <span class="NLM_fpage">1380</span><span class="NLM_x">–</span> <span class="NLM_lpage">1397</span><span class="refDoi"> DOI: 10.1021/jm990482t</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm990482t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01774&amp;key=1%3ACAS%3A528%3ADC%252BD3cXhs1Crtr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2000&pages=1380-1397&author=J.+B.+Smaillauthor=G.+W.+Rewcastleauthor=J.+A.+Looauthor=K.+D.+Greisauthor=O.+H.+Chanauthor=E.+L.+Reynerauthor=E.+Lipkaauthor=H.+D.+Showalterauthor=P.+W.+Vincentauthor=W.+L.+Elliottauthor=W.+A.+Denny&title=Tyrosine+kinase+inhibitors.+17.+Irreversible+inhibitors+of+the+epidermal+growth+factor+receptor%3A+4-%28phenylamino%29quinazoline-+and+4-%28phenylamino%29pyrido%5B3%2C2-d%5Dpyrimidine-6-acrylamides+bearing+additional+solubilizing+functions&doi=10.1021%2Fjm990482t"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Tyrosine kinase inhibitors. 17. Irreversible inhibitors of the epidermal growth factor receptor: 4-(Phenylamino)quinazoline- and 4-(Phenylamino)pyrido[3,2-d]pyrimidine-6-acrylamides bearing additional solubilizing functions</span></div><div class="casAuthors">Smaill, Jeff B.; Rewcastle, Gordon W.; Loo, Joseph A.; Greis, Kenneth D.; Chan, O. Helen; Reyner, Eric L.; Lipka, Elke; Showalter, H. D. Hollis; Vincent, Patrick W.; Elliott, William L.; Denny, William A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1380-1397</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">4-Anilinoquinazoline- and 4-anilinopyrido[3,2-d]pyrimidine-6-acrylamides substituted with solubilizing 7-alkylamine or 7-alkoxyamine side chains were prepd. by reaction of the corresponding 6-amines with acrylic acid or acrylic acid anhydrides.  In the pyrido[3,2-d]pyrimidine series, the intermediate 6-amino-7-alkylamines were prepd. from 7-bromo-6-fluoropyrido[3,2-d]pyrimidine via Stille coupling with the appropriate stannane under palladium(0) catalysis.  This proved a versatile method for the introduction of cationic solubilizing side chains.  The compds. were evaluated for their inhibition of phosphorylation of the isolated EGFR enzyme and for inhibition of EGF-stimulated autophosphorylation of EGFR in A431 cells and of heregulin-stimulated autophosphorylation of erbB2 in MDA-MB 453 cells.  Quinazoline analogs with 7-alkoxyamine solubilizing groups were potent irreversible inhibitors of the isolated EGFR enzyme, with IC50[app] values from 2 to 4 nM, and potently inhibited both EGFR and erbB2 autophosphorylation in cells. 7-Alkylamino- and 7-alkoxyaminopyrido[3,2-d]pyrimidines were also irreversible inhibitors with equal or superior potency against the isolated enzyme but were less effective in the cellular autophosphorylation assays.  Both quinazoline- and pyrido[3,2-d]pyrimidine-6-acrylamides bound at the ATP site alkylating cysteine 773, as shown by electrospray ionization mass spectrometry, and had similar rates of absorptive and secretory transport in Caco-2 cells.  A comparison of two 7-propoxymorpholide analogs showed that the pyrido[3,2-d]pyrimidine-6-acrylamide had greater amide instability and higher acrylamide reactivity, being converted to glutathione adducts in cells more rapidly than the corresponding quinazoline.  This difference may contribute to the obsd. lower cellular potency of the pyrido[3,2-d]pyrimidine-6-acrylamides.  Selected compds. showed high in vivo activity against A431 xenografts on oral dosing, with the quinazolines being superior to the pyrido[3,2-d]pyrimidines. Overall, the quinazolines proved superior to previous analogs in terms of aq. soly., potency, and in vivo antitumor activity, and one example (CI 1033) has been selected for clin. evaluation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpF5L1nBGlu6rVg90H21EOLACvtfcHk0lgFOEKAxrNthA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXhs1Crtr0%253D&md5=6c569a822c398df08559abde31a1d4ac</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1021%2Fjm990482t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm990482t%26sid%3Dliteratum%253Aachs%26aulast%3DSmaill%26aufirst%3DJ.%2BB.%26aulast%3DRewcastle%26aufirst%3DG.%2BW.%26aulast%3DLoo%26aufirst%3DJ.%2BA.%26aulast%3DGreis%26aufirst%3DK.%2BD.%26aulast%3DChan%26aufirst%3DO.%2BH.%26aulast%3DReyner%26aufirst%3DE.%2BL.%26aulast%3DLipka%26aufirst%3DE.%26aulast%3DShowalter%26aufirst%3DH.%2BD.%26aulast%3DVincent%26aufirst%3DP.%2BW.%26aulast%3DElliott%26aufirst%3DW.%2BL.%26aulast%3DDenny%26aufirst%3DW.%2BA.%26atitle%3DTyrosine%2520kinase%2520inhibitors.%252017.%2520Irreversible%2520inhibitors%2520of%2520the%2520epidermal%2520growth%2520factor%2520receptor%253A%25204-%2528phenylamino%2529quinazoline-%2520and%25204-%2528phenylamino%2529pyrido%255B3%252C2-d%255Dpyrimidine-6-acrylamides%2520bearing%2520additional%2520solubilizing%2520functions%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2000%26volume%3D43%26spage%3D1380%26epage%3D1397%26doi%3D10.1021%2Fjm990482t" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">Sajan, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nimal, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mastorides, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Acevedo-Duncan, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kahn, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fields, A. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Braun, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leitges, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Farese, R. V.</span><span> </span><span class="NLM_article-title">Correction of metabolic abnormalities in a rodent model of obesity, metabolic syndrome, and type 2 diabetes mellitus by inhibitors of hepatic protein kinase C-iota</span> <span class="citation_source-journal">Metab., Clin. Exp.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">61</span><span class="NLM_x">, </span> <span class="NLM_fpage">459</span><span class="NLM_x">–</span> <span class="NLM_lpage">469</span><span class="refDoi"> DOI: 10.1016/j.metabol.2011.12.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01774&amp;key=10.1016%2Fj.metabol.2011.12.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01774&amp;key=22225955" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01774&amp;key=1%3ACAS%3A528%3ADC%252BC38XjvFKrtrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2012&pages=459-469&author=M.+P.+Sajanauthor=S.+Nimalauthor=S.+Mastoridesauthor=M.+Acevedo-Duncanauthor=C.+R.+Kahnauthor=A.+P.+Fieldsauthor=U.+Braunauthor=M.+Leitgesauthor=R.+V.+Farese&title=Correction+of+metabolic+abnormalities+in+a+rodent+model+of+obesity%2C+metabolic+syndrome%2C+and+type+2+diabetes+mellitus+by+inhibitors+of+hepatic+protein+kinase+C-iota&doi=10.1016%2Fj.metabol.2011.12.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Correction of metabolic abnormalities in a rodent model of obesity, metabolic syndrome, and type 2 diabetes mellitus by inhibitors of hepatic protein kinase C-ι</span></div><div class="casAuthors">Sajan, Mini P.; Nimal, Sonali; Mastorides, Stephen; Acevedo-Duncan, Mildred; Kahn, C. Ronald; Fields, Alan P.; Braun, Ursula; Leitges, Michael; Farese, Robert V.</div><div class="citationInfo"><span class="NLM_cas:title">Metabolism, Clinical and Experimental</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">459-469</span>CODEN:
                <span class="NLM_cas:coden">METAAJ</span>;
        ISSN:<span class="NLM_cas:issn">0026-0495</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Excessive activity of hepatic atypical protein kinase (aPKC) is proposed to play a crit. role in mediating lipid and carbohydrate abnormalities in obesity, the metabolic syndrome, and type 2 diabetes mellitus.  In previous studies of rodent models of obesity and type 2 diabetes mellitus, adenoviral-mediated expression of kinase-inactive aPKC rapidly reversed or markedly improved most if not all metabolic abnormalities.  Here, we examd. effects of 2 newly developed small-mol. PKC-ι/λ inhibitors.  We used the mouse model of heterozygous muscle-specific knockout of PKC-λ, in which partial deficiency of muscle PKC-λ impairs glucose transport in muscle and thereby causes glucose intolerance and hyperinsulinemia, which, via hepatic aPKC activation, leads to abdominal obesity, hepatosteatosis, hypertriglyceridemia, and hypercholesterolemia.  One inhibitor, 1H-imidazole-4-carboxamide, 5-amino-1-[2,3-dihydroxy-4-[(phosphonooxy)methyl]cyclopentyl-[1R-(1a,2b,3b,4a)]], binds to the substrate-binding site of PKC-λ/ι, but not other PKCs.  The other inhibitor, aurothiomalate, binds to cysteine residues in the PB1-binding domains of aPKC-λ/ι/ζ and inhibits scaffolding.  Treatment with either inhibitor for 7 days inhibited aPKC, but not Akt, in liver and concomitantly improved insulin signaling to Akt and aPKC in muscle and adipocytes.  Moreover, both inhibitors diminished excessive expression of hepatic, aPKC-dependent lipogenic, proinflammatory, and gluconeogenic factors; and this was accompanied by reversal or marked improvements in hyperglycemia, hyperinsulinemia, abdominal obesity, hepatosteatosis, hypertriglyceridemia, and hypercholesterolemia.  Our findings highlight the pathogenetic importance of insulin signaling to hepatic PKC-ι in obesity, the metabolic syndrome, and type 2 diabetes mellitus and suggest that 1H-imidazole-4-carboxamide, 5-amino-1-[2,3-dihydroxy-4-[(phosphonooxy)methyl]cyclopentyl-[1R-(1a,2b,3b,4a)]] and aurothiomalate or similar agents that selectively inhibit hepatic aPKC may be useful treatments.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo6O8rXWz2X57Vg90H21EOLACvtfcHk0ljY5-aohBXCwA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XjvFKrtrY%253D&md5=7c783772ef69767ed31689a28cad2916</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1016%2Fj.metabol.2011.12.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.metabol.2011.12.008%26sid%3Dliteratum%253Aachs%26aulast%3DSajan%26aufirst%3DM.%2BP.%26aulast%3DNimal%26aufirst%3DS.%26aulast%3DMastorides%26aufirst%3DS.%26aulast%3DAcevedo-Duncan%26aufirst%3DM.%26aulast%3DKahn%26aufirst%3DC.%2BR.%26aulast%3DFields%26aufirst%3DA.%2BP.%26aulast%3DBraun%26aufirst%3DU.%26aulast%3DLeitges%26aufirst%3DM.%26aulast%3DFarese%26aufirst%3DR.%2BV.%26atitle%3DCorrection%2520of%2520metabolic%2520abnormalities%2520in%2520a%2520rodent%2520model%2520of%2520obesity%252C%2520metabolic%2520syndrome%252C%2520and%2520type%25202%2520diabetes%2520mellitus%2520by%2520inhibitors%2520of%2520hepatic%2520protein%2520kinase%2520C-iota%26jtitle%3DMetab.%252C%2520Clin.%2520Exp.%26date%3D2012%26volume%3D61%26spage%3D459%26epage%3D469%26doi%3D10.1016%2Fj.metabol.2011.12.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group">Jones, T. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thornton, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flinn, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jackman, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Newell, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Calvert, A. H.</span><span> </span><span class="NLM_article-title">Quinazoline antifolates inhibiting thymidylate synthase: 2-desamino derivatives with enhanced solubility and potency</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1989</span><span class="NLM_x">, </span> <span class="NLM_volume">32</span><span class="NLM_x">, </span> <span class="NLM_fpage">847</span><span class="NLM_x">–</span> <span class="NLM_lpage">852</span><span class="refDoi"> DOI: 10.1021/jm00124a018</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm00124a018" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=1989&pages=847-852&author=T.+R.+Jonesauthor=T.+J.+Thorntonauthor=A.+Flinnauthor=A.+L.+Jackmanauthor=D.+R.+Newellauthor=A.+H.+Calvert&title=Quinazoline+antifolates+inhibiting+thymidylate+synthase%3A+2-desamino+derivatives+with+enhanced+solubility+and+potency&doi=10.1021%2Fjm00124a018"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1021%2Fjm00124a018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00124a018%26sid%3Dliteratum%253Aachs%26aulast%3DJones%26aufirst%3DT.%2BR.%26aulast%3DThornton%26aufirst%3DT.%2BJ.%26aulast%3DFlinn%26aufirst%3DA.%26aulast%3DJackman%26aufirst%3DA.%2BL.%26aulast%3DNewell%26aufirst%3DD.%2BR.%26aulast%3DCalvert%26aufirst%3DA.%2BH.%26atitle%3DQuinazoline%2520antifolates%2520inhibiting%2520thymidylate%2520synthase%253A%25202-desamino%2520derivatives%2520with%2520enhanced%2520solubility%2520and%2520potency%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1989%26volume%3D32%26spage%3D847%26epage%3D852%26doi%3D10.1021%2Fjm00124a018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group">Cavalli, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lizzi, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bongarzone, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brun, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luise Krauth-Siegel, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bolognesi, M. L.</span><span> </span><span class="NLM_article-title">Privileged structure-guided synthesis of quinazoline derivatives as inhibitors of trypanothione reductase</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">3031</span><span class="NLM_x">–</span> <span class="NLM_lpage">3035</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2009.04.060</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01774&amp;key=10.1016%2Fj.bmcl.2009.04.060" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=3031-3035&author=A.+Cavalliauthor=F.+Lizziauthor=S.+Bongarzoneauthor=R.+Brunauthor=R.+Luise+Krauth-Siegelauthor=M.+L.+Bolognesi&title=Privileged+structure-guided+synthesis+of+quinazoline+derivatives+as+inhibitors+of+trypanothione+reductase&doi=10.1016%2Fj.bmcl.2009.04.060"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2009.04.060&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2009.04.060%26sid%3Dliteratum%253Aachs%26aulast%3DCavalli%26aufirst%3DA.%26aulast%3DLizzi%26aufirst%3DF.%26aulast%3DBongarzone%26aufirst%3DS.%26aulast%3DBrun%26aufirst%3DR.%26aulast%3DLuise%2BKrauth-Siegel%26aufirst%3DR.%26aulast%3DBolognesi%26aufirst%3DM.%2BL.%26atitle%3DPrivileged%2520structure-guided%2520synthesis%2520of%2520quinazoline%2520derivatives%2520as%2520inhibitors%2520of%2520trypanothione%2520reductase%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26spage%3D3031%26epage%3D3035%26doi%3D10.1016%2Fj.bmcl.2009.04.060" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">Takase, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saeki, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watanabe, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adachi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Souda, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saito, I.</span><span> </span><span class="NLM_article-title">Cyclic GMP phosphodiesterase inhibitors. 2. Requirement of 6-substitution of quinazoline derivatives for potent and selective inhibitory activity</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_volume">37</span><span class="NLM_x">, </span> <span class="NLM_fpage">2106</span><span class="NLM_x">–</span> <span class="NLM_lpage">2111</span><span class="refDoi"> DOI: 10.1021/jm00039a024</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm00039a024" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=1994&pages=2106-2111&author=Y.+Takaseauthor=T.+Saekiauthor=N.+Watanabeauthor=H.+Adachiauthor=S.+Soudaauthor=I.+Saito&title=Cyclic+GMP+phosphodiesterase+inhibitors.+2.+Requirement+of+6-substitution+of+quinazoline+derivatives+for+potent+and+selective+inhibitory+activity&doi=10.1021%2Fjm00039a024"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1021%2Fjm00039a024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00039a024%26sid%3Dliteratum%253Aachs%26aulast%3DTakase%26aufirst%3DY.%26aulast%3DSaeki%26aufirst%3DT.%26aulast%3DWatanabe%26aufirst%3DN.%26aulast%3DAdachi%26aufirst%3DH.%26aulast%3DSouda%26aufirst%3DS.%26aulast%3DSaito%26aufirst%3DI.%26atitle%3DCyclic%2520GMP%2520phosphodiesterase%2520inhibitors.%25202.%2520Requirement%2520of%25206-substitution%2520of%2520quinazoline%2520derivatives%2520for%2520potent%2520and%2520selective%2520inhibitory%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1994%26volume%3D37%26spage%3D2106%26epage%3D2111%26doi%3D10.1021%2Fjm00039a024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group">Berra, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Diaz-Meco, M. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lozano, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frutos, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Municio, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sanchez, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sanz, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moscat, J.</span><span> </span><span class="NLM_article-title">Evidence for a role of MEK and MAPK during signal transduction by protein kinase C zeta</span> <span class="citation_source-journal">EMBO. J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">6157</span><span class="NLM_x">–</span> <span class="NLM_lpage">6163</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=1995&pages=6157-6163&author=E.+Berraauthor=M.+T.+Diaz-Mecoauthor=J.+Lozanoauthor=S.+Frutosauthor=M.+M.+Municioauthor=P.+Sanchezauthor=L.+Sanzauthor=J.+Moscat&title=Evidence+for+a+role+of+MEK+and+MAPK+during+signal+transduction+by+protein+kinase+C+zeta"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBerra%26aufirst%3DE.%26aulast%3DDiaz-Meco%26aufirst%3DM.%2BT.%26aulast%3DLozano%26aufirst%3DJ.%26aulast%3DFrutos%26aufirst%3DS.%26aulast%3DMunicio%26aufirst%3DM.%2BM.%26aulast%3DSanchez%26aufirst%3DP.%26aulast%3DSanz%26aufirst%3DL.%26aulast%3DMoscat%26aufirst%3DJ.%26atitle%3DEvidence%2520for%2520a%2520role%2520of%2520MEK%2520and%2520MAPK%2520during%2520signal%2520transduction%2520by%2520protein%2520kinase%2520C%2520zeta%26jtitle%3DEMBO.%2520J.%26date%3D1995%26volume%3D14%26spage%3D6157%26epage%3D6163" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group">Marugan, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zheng, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Motabar, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Southall, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldin, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Westbroek, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stubblefield, B. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sidransky, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aungst, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lea, W. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simeonov, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leister, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Austin, C. P.</span><span> </span><span class="NLM_article-title">Evaluation of quinazoline analogues as glucocerebrosidase inhibitors with chaperone activity</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">1033</span><span class="NLM_x">–</span> <span class="NLM_lpage">1058</span><span class="refDoi"> DOI: 10.1021/jm1008902</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm1008902" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=1033-1058&author=J.+J.+Maruganauthor=W.+Zhengauthor=O.+Motabarauthor=N.+Southallauthor=E.+Goldinauthor=W.+Westbroekauthor=B.+K.+Stubblefieldauthor=E.+Sidranskyauthor=R.+A.+Aungstauthor=W.+A.+Leaauthor=A.+Simeonovauthor=W.+Leisterauthor=C.+P.+Austin&title=Evaluation+of+quinazoline+analogues+as+glucocerebrosidase+inhibitors+with+chaperone+activity&doi=10.1021%2Fjm1008902"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1021%2Fjm1008902&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm1008902%26sid%3Dliteratum%253Aachs%26aulast%3DMarugan%26aufirst%3DJ.%2BJ.%26aulast%3DZheng%26aufirst%3DW.%26aulast%3DMotabar%26aufirst%3DO.%26aulast%3DSouthall%26aufirst%3DN.%26aulast%3DGoldin%26aufirst%3DE.%26aulast%3DWestbroek%26aufirst%3DW.%26aulast%3DStubblefield%26aufirst%3DB.%2BK.%26aulast%3DSidransky%26aufirst%3DE.%26aulast%3DAungst%26aufirst%3DR.%2BA.%26aulast%3DLea%26aufirst%3DW.%2BA.%26aulast%3DSimeonov%26aufirst%3DA.%26aulast%3DLeister%26aufirst%3DW.%26aulast%3DAustin%26aufirst%3DC.%2BP.%26atitle%3DEvaluation%2520of%2520quinazoline%2520analogues%2520as%2520glucocerebrosidase%2520inhibitors%2520with%2520chaperone%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D1033%26epage%3D1058%26doi%3D10.1021%2Fjm1008902" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group">Levy, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuo, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schaefer, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kitson, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheung, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Espejo, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zee, B. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tangsombatvisit, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tennen, R. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuo, A. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tanjing, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheung, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chua, K. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Utz, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prinjha, R. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garcia, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bedford, M. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tarakhovsky, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, O.</span><span> </span><span class="NLM_article-title">Bedford, M. T.; Tarakhovsky, A.; Cheng, X.; Gozani, O. Lysine methylation of the NF-kappaB subunit RelA by SETD6 couples activity of the histone methyltransferase GLP at chromatin to tonic repression of NF-kappaB signaling</span> <span class="citation_source-journal">Nat. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">29</span><span class="NLM_x">–</span> <span class="NLM_lpage">36</span><span class="refDoi"> DOI: 10.1038/ni.1968</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01774&amp;key=10.1038%2Fni.1968" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01774&amp;key=21131967" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01774&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsFajur%252FO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2011&pages=29-36&author=D.+Levyauthor=A.+J.+Kuoauthor=Y.+Changauthor=U.+Schaeferauthor=C.+Kitsonauthor=P.+Cheungauthor=A.+Espejoauthor=B.+M.+Zeeauthor=C.+L.+Liuauthor=S.+Tangsombatvisitauthor=R.+I.+Tennenauthor=A.+Y.+Kuoauthor=S.+Tanjingauthor=R.+Cheungauthor=K.+F.+Chuaauthor=P.+J.+Utzauthor=X.+Shiauthor=R.+K.+Prinjhaauthor=K.+Leeauthor=B.+A.+Garciaauthor=M.+T.+Bedfordauthor=A.+Tarakhovskyauthor=X.+Chengauthor=O.+Cheng&title=Bedford%2C+M.+T.%3B+Tarakhovsky%2C+A.%3B+Cheng%2C+X.%3B+Gozani%2C+O.+Lysine+methylation+of+the+NF-kappaB+subunit+RelA+by+SETD6+couples+activity+of+the+histone+methyltransferase+GLP+at+chromatin+to+tonic+repression+of+NF-kappaB+signaling&doi=10.1038%2Fni.1968"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Lysine methylation of the NF-κB subunit RelA by SETD6 couples activity of the histone methyltransferase GLP at chromatin to tonic repression of NF-κB signaling</span></div><div class="casAuthors">Levy, Dan; Kuo, Alex J.; Chang, Yanqi; Schaefer, Uwe; Kitson, Christopher; Cheung, Peggie; Espejo, Alexsandra; Zee, Barry M.; Liu, Chih Long; Tangsombatvisit, Stephanie; Tennen, Ruth I.; Kuo, Andrew Y.; Tanjing, Song; Cheung, Regina; Chua, Katrin F.; Utz, Paul J.; Shi, Xiaobing; Prinjha, Rab K.; Lee, Kevin; Garcia, Benjamin A.; Bedford, Mark T.; Tarakhovsky, Alexander; Cheng, Xiaodong; Gozani, Or</div><div class="citationInfo"><span class="NLM_cas:title">Nature Immunology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">29-36</span>CODEN:
                <span class="NLM_cas:coden">NIAMCZ</span>;
        ISSN:<span class="NLM_cas:issn">1529-2908</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Signaling via the methylation of lysine residues in proteins has been linked to diverse biol. and disease processes, yet the catalytic activity and substrate specificity of many human protein lysine methyltransferases (PKMTs) are unknown.  We screened over 40 candidate PKMTs and identified SETD6 as a methyltransferase that monomethylated chromatin-assocd. transcription factor NF-κB subunit RelA at Lys310 (RelAK310me1).  SETD6-mediated methylation rendered RelA inert and attenuated RelA-driven transcriptional programs, including inflammatory responses in primary immune cells.  RelAK310me1 was recognized by the ankryin repeat of the histone methyltransferase GLP, which under basal conditions promoted a repressed chromatin state at RelA target genes through GLP-mediated methylation of histone H3 Lys9 (H3K9).  NF-κB-activation-linked phosphorylation of RelA at Ser311 by protein kinase C-ζ (PKC-ζ) blocked the binding of GLP to RelAK310me1 and relieved repression of the target gene.  Our findings establish a previously uncharacterized mechanism by which chromatin signaling regulates inflammation programs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrG8M_FlbB1DbVg90H21EOLACvtfcHk0lieW3l0ExB-4A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsFajur%252FO&md5=e35e84351e9cb605a3423b3b2c98064b</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1038%2Fni.1968&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fni.1968%26sid%3Dliteratum%253Aachs%26aulast%3DLevy%26aufirst%3DD.%26aulast%3DKuo%26aufirst%3DA.%2BJ.%26aulast%3DChang%26aufirst%3DY.%26aulast%3DSchaefer%26aufirst%3DU.%26aulast%3DKitson%26aufirst%3DC.%26aulast%3DCheung%26aufirst%3DP.%26aulast%3DEspejo%26aufirst%3DA.%26aulast%3DZee%26aufirst%3DB.%2BM.%26aulast%3DLiu%26aufirst%3DC.%2BL.%26aulast%3DTangsombatvisit%26aufirst%3DS.%26aulast%3DTennen%26aufirst%3DR.%2BI.%26aulast%3DKuo%26aufirst%3DA.%2BY.%26aulast%3DTanjing%26aufirst%3DS.%26aulast%3DCheung%26aufirst%3DR.%26aulast%3DChua%26aufirst%3DK.%2BF.%26aulast%3DUtz%26aufirst%3DP.%2BJ.%26aulast%3DShi%26aufirst%3DX.%26aulast%3DPrinjha%26aufirst%3DR.%2BK.%26aulast%3DLee%26aufirst%3DK.%26aulast%3DGarcia%26aufirst%3DB.%2BA.%26aulast%3DBedford%26aufirst%3DM.%2BT.%26aulast%3DTarakhovsky%26aufirst%3DA.%26aulast%3DCheng%26aufirst%3DX.%26aulast%3DCheng%26aufirst%3DO.%26atitle%3DBedford%252C%2520M.%2520T.%253B%2520Tarakhovsky%252C%2520A.%253B%2520Cheng%252C%2520X.%253B%2520Gozani%252C%2520O.%2520Lysine%2520methylation%2520of%2520the%2520NF-kappaB%2520subunit%2520RelA%2520by%2520SETD6%2520couples%2520activity%2520of%2520the%2520histone%2520methyltransferase%2520GLP%2520at%2520chromatin%2520to%2520tonic%2520repression%2520of%2520NF-kappaB%2520signaling%26jtitle%3DNat.%2520Immunol.%26date%3D2011%26volume%3D12%26spage%3D29%26epage%3D36%26doi%3D10.1038%2Fni.1968" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group">Evans, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rittle, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bock, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DiPardo, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Freidinger, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whitter, W. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lundell, G. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Veber, D. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderson, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lotti, V. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cerino, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, T. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kling, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kunkel, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Springer, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirshfield, J.</span><span> </span><span class="NLM_article-title">Methods for drug discovery: development of potent, selective, orally effective cholecystokinin antagonists</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1988</span><span class="NLM_x">, </span> <span class="NLM_volume">31</span><span class="NLM_x">, </span> <span class="NLM_fpage">2235</span><span class="NLM_x">–</span> <span class="NLM_lpage">2246</span><span class="refDoi"> DOI: 10.1021/jm00120a002</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm00120a002" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01774&amp;key=1%3ACAS%3A528%3ADyaL1cXmtVCgurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=1988&pages=2235-2246&author=B.+E.+Evansauthor=K.+E.+Rittleauthor=M.+G.+Bockauthor=R.+M.+DiPardoauthor=R.+M.+Freidingerauthor=W.+L.+Whitterauthor=G.+F.+Lundellauthor=D.+F.+Veberauthor=P.+S.+Andersonauthor=R.+S.+Changauthor=V.+J.+Lottiauthor=D.+J.+Cerinoauthor=T.+B.+Chenauthor=P.+J.+Klingauthor=K.+A.+Kunkelauthor=J.+P.+Springerauthor=J.+Hirshfield&title=Methods+for+drug+discovery%3A+development+of+potent%2C+selective%2C+orally+effective+cholecystokinin+antagonists&doi=10.1021%2Fjm00120a002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Methods for drug discovery:  development of potent, selective, orally effective cholecystokinin antagonists</span></div><div class="casAuthors">Evans, B. E.; Rittle, K. E.; Bock, M. G.; DiPardo, R. M.; Freidinger, R. M.; Whitter, W. L.; Lundell, G. F.; Veber, D. F.; Anderson, P. S.; et al.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1988</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2235-46</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    </div><div class="casAbstract">3-(Acylamino)-5-phenyl-2H-1,4-benzodiazepines) (I, X = H or F; R1 = H, Me, CH2CO2Et, CH2CO2H; R2 = acylamino, indolylalkyl, heterocyclic contg. groups, substituted benzoyl, etc.), antagonists of the peptide hormone cholecystokinin (CCK), are described.  Developed by reasoned modification of the known anxiolytic benzodiazepines, these compds. provide highly potent, orally effective ligands selective for peripheral (CCK-A) receptors, with binding affinities approaching or equaling that of the natural ligand CCK-8.  The distinction between CCK-A receptors on the one hand and CNS (CCK-B), gastrin, and central benzodiazepine receptors on the other is demonstrated by using the structure-activity profiles of the new compds.  Details of the binding of these agents to CCK-A receptors are examd., and the method of development of these compds. is discussed in terms of its relevance to the general problem of drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrF3uSMSNckhrVg90H21EOLACvtfcHk0lieW3l0ExB-4A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL1cXmtVCgurs%253D&md5=783be926d2512ab8f67c8786afcf0276</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1021%2Fjm00120a002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00120a002%26sid%3Dliteratum%253Aachs%26aulast%3DEvans%26aufirst%3DB.%2BE.%26aulast%3DRittle%26aufirst%3DK.%2BE.%26aulast%3DBock%26aufirst%3DM.%2BG.%26aulast%3DDiPardo%26aufirst%3DR.%2BM.%26aulast%3DFreidinger%26aufirst%3DR.%2BM.%26aulast%3DWhitter%26aufirst%3DW.%2BL.%26aulast%3DLundell%26aufirst%3DG.%2BF.%26aulast%3DVeber%26aufirst%3DD.%2BF.%26aulast%3DAnderson%26aufirst%3DP.%2BS.%26aulast%3DChang%26aufirst%3DR.%2BS.%26aulast%3DLotti%26aufirst%3DV.%2BJ.%26aulast%3DCerino%26aufirst%3DD.%2BJ.%26aulast%3DChen%26aufirst%3DT.%2BB.%26aulast%3DKling%26aufirst%3DP.%2BJ.%26aulast%3DKunkel%26aufirst%3DK.%2BA.%26aulast%3DSpringer%26aufirst%3DJ.%2BP.%26aulast%3DHirshfield%26aufirst%3DJ.%26atitle%3DMethods%2520for%2520drug%2520discovery%253A%2520development%2520of%2520potent%252C%2520selective%252C%2520orally%2520effective%2520cholecystokinin%2520antagonists%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1988%26volume%3D31%26spage%3D2235%26epage%3D2246%26doi%3D10.1021%2Fjm00120a002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group">Hamed, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abou El Ella, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keeton, A. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Piazza, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engel, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hartmann, R. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abadi, A. H.</span><span> </span><span class="NLM_article-title">Quinazoline and tetrahydropyridothieno[2,3-d]pyrimidine derivatives as irreversible EGFR tyrosine kinase inhibitors: influence of the position 4 substituent</span> <span class="citation_source-journal">MedChemComm</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">1202</span><span class="NLM_x">–</span> <span class="NLM_lpage">1207</span><span class="refDoi"> DOI: 10.1039/c3md00118k</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01774&amp;key=10.1039%2Fc3md00118k" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2013&pages=1202-1207&author=M.+M.+Hamedauthor=D.+A.+Abou+El+Ellaauthor=A.+B.+Keetonauthor=G.+A.+Piazzaauthor=M.+Engelauthor=R.+W.+Hartmannauthor=A.+H.+Abadi&title=Quinazoline+and+tetrahydropyridothieno%5B2%2C3-d%5Dpyrimidine+derivatives+as+irreversible+EGFR+tyrosine+kinase+inhibitors%3A+influence+of+the+position+4+substituent&doi=10.1039%2Fc3md00118k"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1039%2Fc3md00118k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fc3md00118k%26sid%3Dliteratum%253Aachs%26aulast%3DHamed%26aufirst%3DM.%2BM.%26aulast%3DAbou%2BEl%2BElla%26aufirst%3DD.%2BA.%26aulast%3DKeeton%26aufirst%3DA.%2BB.%26aulast%3DPiazza%26aufirst%3DG.%2BA.%26aulast%3DEngel%26aufirst%3DM.%26aulast%3DHartmann%26aufirst%3DR.%2BW.%26aulast%3DAbadi%26aufirst%3DA.%2BH.%26atitle%3DQuinazoline%2520and%2520tetrahydropyridothieno%255B2%252C3-d%255Dpyrimidine%2520derivatives%2520as%2520irreversible%2520EGFR%2520tyrosine%2520kinase%2520inhibitors%253A%2520influence%2520of%2520the%2520position%25204%2520substituent%26jtitle%3DMedChemComm%26date%3D2013%26volume%3D4%26spage%3D1202%26epage%3D1207%26doi%3D10.1039%2Fc3md00118k" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group">Hamed, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abou El Ella, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keeton, A. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Piazza, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abadi, A. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hartmann, R. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engel, M.</span><span> </span><span class="NLM_article-title">6-Aryl and heterocycle quinazoline derivatives as potent EGFR inhibitors with improved activity toward gefitinib-sensitive and -resistant tumor cell lines</span> <span class="citation_source-journal">ChemMedChem</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">1495</span><span class="NLM_x">–</span> <span class="NLM_lpage">504</span><span class="refDoi"> DOI: 10.1002/cmdc.201300147</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01774&amp;key=10.1002%2Fcmdc.201300147" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01774&amp;key=23847159" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01774&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtVykurzF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2013&pages=1495-504&author=M.+M.+Hamedauthor=D.+A.+Abou+El+Ellaauthor=A.+B.+Keetonauthor=G.+A.+Piazzaauthor=A.+H.+Abadiauthor=R.+W.+Hartmannauthor=M.+Engel&title=6-Aryl+and+heterocycle+quinazoline+derivatives+as+potent+EGFR+inhibitors+with+improved+activity+toward+gefitinib-sensitive+and+-resistant+tumor+cell+lines&doi=10.1002%2Fcmdc.201300147"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">6-Aryl and Heterocycle Quinazoline Derivatives as Potent EGFR Inhibitors with Improved Activity toward Gefitinib-Sensitive and -Resistant Tumor Cell Lines</span></div><div class="casAuthors">Hamed, Mostafa M.; Abou El Ella, Dalal A.; Keeton, Adam B.; Piazza, Gary A.; Abadi, Ashraf H.; Hartmann, Rolf W.; Engel, Matthias</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1495-1504</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Anilinoquinazolinyl benzaldimines I [R = R1CH:N; R1 = 4-HOC6H4, 2,4-(HO)2C6H3, 3-O2NC6H4, 4-O2NC6H4, 2-MeOC6H4], thioureas I [R = R1NHC(:S)NH; R1 = PhCH2, 2-(4-morpholinyl)ethyl], aminoacetamides and aminopropanamides II [R = R1NHCH2CONH, R1NHCH2CH2CONH; R1 = PhCH2, 4-(2-thiazolylaminosulfonyl)phenyl], and amides [R = R1CONH; R1 = 4-H2NC6H4, 4-NCC6H4, 4-MeCONHC6H4, 4-O2NC6H4, 3,5-(O2N)2C6H3, 4-MeOC6H4, 3,4-(MeO)2C6H3, 4-morpholinyl, 2-furyl, 3-pyridinyl, 4-pyridinyl] were prepd. as inhibitors of wild-type and mutant epidermal growth factor receptor (EGFR) for potential use as antitumor agents.  Most of the compds. inhibited wild-type EGFR with IC50 values of 4-62 nM; I [R = BnNHC(:S)NH, 4-morpholinylethylaminothiocarbonylamino, R1NHCH2CH2CONH; R1 = 4-(2-thiazolylaminosulfonyl)phenyl] also retained significant activity toward the gefitinib-insensitive EGFRT790M/L858R mutant, displaying up to 24-fold greater potency than gefitinib.  The inhibition of the growth of cancer cells with wild-type and mutant EGFR was detd.; I [R = BnNHC(:S)NH, R1NHCH2CH2CONH; R1 = 4-(2-thiazolylaminosulfonyl)phenyl] inhibited cancer cell growth more effectively than the std. gefitinib.  Mol. docking calcns. of I [R = BnNHC(:S)NH, 4-morpholinylethylaminothiocarbonylamino, R1NHCH2CH2CONH; R1 = 4-(2-thiazolylaminosulfonyl)phenyl] in double mutant EGFR and of I (R = PhCH2NHCH2CONH, 2-furylcarbonylamino) in wild-type EGFR were performed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp9J8DhyAlHb7Vg90H21EOLACvtfcHk0lihyc4yPi_TgA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtVykurzF&md5=c951d913a38a5062783da74c4cf6afef</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201300147&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201300147%26sid%3Dliteratum%253Aachs%26aulast%3DHamed%26aufirst%3DM.%2BM.%26aulast%3DAbou%2BEl%2BElla%26aufirst%3DD.%2BA.%26aulast%3DKeeton%26aufirst%3DA.%2BB.%26aulast%3DPiazza%26aufirst%3DG.%2BA.%26aulast%3DAbadi%26aufirst%3DA.%2BH.%26aulast%3DHartmann%26aufirst%3DR.%2BW.%26aulast%3DEngel%26aufirst%3DM.%26atitle%3D6-Aryl%2520and%2520heterocycle%2520quinazoline%2520derivatives%2520as%2520potent%2520EGFR%2520inhibitors%2520with%2520improved%2520activity%2520toward%2520gefitinib-sensitive%2520and%2520-resistant%2520tumor%2520cell%2520lines%26jtitle%3DChemMedChem%26date%3D2013%26volume%3D8%26spage%3D1495%26epage%3D504%26doi%3D10.1002%2Fcmdc.201300147" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group">Passmore, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lukey, P. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ress, S. R.</span><span> </span><span class="NLM_article-title">The human macrophage cell line U937 as an in vitro model for selective evaluation of mycobacterial antigen-specific cytotoxic T-cell function</span> <span class="citation_source-journal">Immunology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">102</span><span class="NLM_x">, </span> <span class="NLM_fpage">146</span><span class="NLM_x">–</span> <span class="NLM_lpage">156</span><span class="refDoi"> DOI: 10.1046/j.1365-2567.2001.01164.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01774&amp;key=10.1046%2Fj.1365-2567.2001.01164.x" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=2001&pages=146-156&author=J.+S.+Passmoreauthor=P.+T.+Lukeyauthor=S.+R.+Ress&title=The+human+macrophage+cell+line+U937+as+an+in+vitro+model+for+selective+evaluation+of+mycobacterial+antigen-specific+cytotoxic+T-cell+function&doi=10.1046%2Fj.1365-2567.2001.01164.x"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1046%2Fj.1365-2567.2001.01164.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1046%252Fj.1365-2567.2001.01164.x%26sid%3Dliteratum%253Aachs%26aulast%3DPassmore%26aufirst%3DJ.%2BS.%26aulast%3DLukey%26aufirst%3DP.%2BT.%26aulast%3DRess%26aufirst%3DS.%2BR.%26atitle%3DThe%2520human%2520macrophage%2520cell%2520line%2520U937%2520as%2520an%2520in%2520vitro%2520model%2520for%2520selective%2520evaluation%2520of%2520mycobacterial%2520antigen-specific%2520cytotoxic%2520T-cell%2520function%26jtitle%3DImmunology%26date%3D2001%26volume%3D102%26spage%3D146%26epage%3D156%26doi%3D10.1046%2Fj.1365-2567.2001.01164.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group">Tobe, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Isobe, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tomizawa, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nagasaki, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takahashi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fukazawa, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hayashi, H.</span><span> </span><span class="NLM_article-title">Discovery of quinazolines as a novel structural class of potent inhibitors of NF-kappa B activation</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">383</span><span class="NLM_x">–</span> <span class="NLM_lpage">391</span><span class="refDoi"> DOI: 10.1016/S0968-0896(02)00440-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01774&amp;key=10.1016%2FS0968-0896%2802%2900440-6" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2003&pages=383-391&author=M.+Tobeauthor=Y.+Isobeauthor=H.+Tomizawaauthor=T.+Nagasakiauthor=H.+Takahashiauthor=T.+Fukazawaauthor=H.+Hayashi&title=Discovery+of+quinazolines+as+a+novel+structural+class+of+potent+inhibitors+of+NF-kappa+B+activation&doi=10.1016%2FS0968-0896%2802%2900440-6"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1016%2FS0968-0896%2802%2900440-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0968-0896%252802%252900440-6%26sid%3Dliteratum%253Aachs%26aulast%3DTobe%26aufirst%3DM.%26aulast%3DIsobe%26aufirst%3DY.%26aulast%3DTomizawa%26aufirst%3DH.%26aulast%3DNagasaki%26aufirst%3DT.%26aulast%3DTakahashi%26aufirst%3DH.%26aulast%3DFukazawa%26aufirst%3DT.%26aulast%3DHayashi%26aufirst%3DH.%26atitle%3DDiscovery%2520of%2520quinazolines%2520as%2520a%2520novel%2520structural%2520class%2520of%2520potent%2520inhibitors%2520of%2520NF-kappa%2520B%2520activation%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2003%26volume%3D11%26spage%3D383%26epage%3D391%26doi%3D10.1016%2FS0968-0896%2802%2900440-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group">Tobe, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Isobe, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tomizawa, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nagasaki, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takahashi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hayashi, H.</span><span> </span><span class="NLM_article-title">A novel structural class of potent inhibitors of NF-kappa B activation: structure-activity relationships and biological effects of 6-aminoquinazoline derivatives</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">3869</span><span class="NLM_x">–</span> <span class="NLM_lpage">3878</span><span class="refDoi"> DOI: 10.1016/S0968-0896(03)00438-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01774&amp;key=10.1016%2FS0968-0896%2803%2900438-3" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2003&pages=3869-3878&author=M.+Tobeauthor=Y.+Isobeauthor=H.+Tomizawaauthor=T.+Nagasakiauthor=H.+Takahashiauthor=H.+Hayashi&title=A+novel+structural+class+of+potent+inhibitors+of+NF-kappa+B+activation%3A+structure-activity+relationships+and+biological+effects+of+6-aminoquinazoline+derivatives&doi=10.1016%2FS0968-0896%2803%2900438-3"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1016%2FS0968-0896%2803%2900438-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0968-0896%252803%252900438-3%26sid%3Dliteratum%253Aachs%26aulast%3DTobe%26aufirst%3DM.%26aulast%3DIsobe%26aufirst%3DY.%26aulast%3DTomizawa%26aufirst%3DH.%26aulast%3DNagasaki%26aufirst%3DT.%26aulast%3DTakahashi%26aufirst%3DH.%26aulast%3DHayashi%26aufirst%3DH.%26atitle%3DA%2520novel%2520structural%2520class%2520of%2520potent%2520inhibitors%2520of%2520NF-kappa%2520B%2520activation%253A%2520structure-activity%2520relationships%2520and%2520biological%2520effects%2520of%25206-aminoquinazoline%2520derivatives%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2003%26volume%3D11%26spage%3D3869%26epage%3D3878%26doi%3D10.1016%2FS0968-0896%2803%2900438-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group">Haas, T. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Emmerich, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gerlach, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmukle, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cordier, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rieser, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feltham, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vince, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warnken, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wenger, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koschny, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Komander, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Silke, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walczak, H.</span><span> </span><span class="NLM_article-title">Recruitment of the linear ubiquitin chain assembly complex stabilizes the TNF-R1 signaling complex and is required for TNF-mediated gene induction</span> <span class="citation_source-journal">Mol. Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">36</span><span class="NLM_x">, </span> <span class="NLM_fpage">831</span><span class="NLM_x">–</span> <span class="NLM_lpage">844</span><span class="refDoi"> DOI: 10.1016/j.molcel.2009.10.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01774&amp;key=10.1016%2Fj.molcel.2009.10.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01774&amp;key=20005846" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01774&amp;key=1%3ACAS%3A528%3ADC%252BC3cXht1Cjsr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2009&pages=831-844&author=T.+L.+Haasauthor=C.+H.+Emmerichauthor=B.+Gerlachauthor=A.+C.+Schmukleauthor=S.+M.+Cordierauthor=E.+Rieserauthor=R.+Felthamauthor=J.+Vinceauthor=U.+Warnkenauthor=T.+Wengerauthor=R.+Koschnyauthor=D.+Komanderauthor=J.+Silkeauthor=H.+Walczak&title=Recruitment+of+the+linear+ubiquitin+chain+assembly+complex+stabilizes+the+TNF-R1+signaling+complex+and+is+required+for+TNF-mediated+gene+induction&doi=10.1016%2Fj.molcel.2009.10.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Recruitment of the linear ubiquitin chain assembly complex stabilizes the TNF-R1 signaling complex and is required for TNF-mediated gene induction</span></div><div class="casAuthors">Haas, Tobias L.; Emmerich, Christoph H.; Gerlach, Bjoern; Schmukle, Anna C.; Cordier, Stefanie M.; Rieser, Eva; Feltham, Rebecca; Vince, James; Warnken, Uwe; Wenger, Till; Koschny, Ronald; Komander, David; Silke, John; Walczak, Henning</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cell</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">831-844</span>CODEN:
                <span class="NLM_cas:coden">MOCEFL</span>;
        ISSN:<span class="NLM_cas:issn">1097-2765</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">TNF is a key inflammatory cytokine.  Using a modified tandem affinity purifn. approach, the authors identified HOIL-1 and HOIP as functional components of the native TNF-R1 signaling complex (TNF-RSC).  Together, they were shown to form a linear ubiquitin chain assembly complex (LUBAC) and to ubiquitylate NEMO.  The authors show that LUBAC binds to ubiquitin chains of different linkage types and that its recruitment to the TNF-RSC is impaired in TRADD-, TRAF2-, and cIAP1/2- but not in RIP1- or NEMO-deficient MEFs.  Furthermore, the E3 ligase activity of cIAPs, but not TRAF2, is required for HOIL-1 recruitment to the TNF-RSC.  LUBAC enhances NEMO interaction with the TNF-RSC, stabilizes this protein complex, and is required for efficient TNF-induced activation of NF-κB and JNK, resulting in apoptosis inhibition.  Finally, the authors demonstrate that sustained stability of the TNF-RSC requires LUBAC's enzymic activity, thereby adding a third form of ubiquitin linkage to the triggering of TNF signaling by the TNF-RSC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpouDjeBY7XcbVg90H21EOLACvtfcHk0lgkzscA9fm1iw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXht1Cjsr4%253D&md5=a4dc338f1a4185a09c8ce8533ea87084</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1016%2Fj.molcel.2009.10.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molcel.2009.10.013%26sid%3Dliteratum%253Aachs%26aulast%3DHaas%26aufirst%3DT.%2BL.%26aulast%3DEmmerich%26aufirst%3DC.%2BH.%26aulast%3DGerlach%26aufirst%3DB.%26aulast%3DSchmukle%26aufirst%3DA.%2BC.%26aulast%3DCordier%26aufirst%3DS.%2BM.%26aulast%3DRieser%26aufirst%3DE.%26aulast%3DFeltham%26aufirst%3DR.%26aulast%3DVince%26aufirst%3DJ.%26aulast%3DWarnken%26aufirst%3DU.%26aulast%3DWenger%26aufirst%3DT.%26aulast%3DKoschny%26aufirst%3DR.%26aulast%3DKomander%26aufirst%3DD.%26aulast%3DSilke%26aufirst%3DJ.%26aulast%3DWalczak%26aufirst%3DH.%26atitle%3DRecruitment%2520of%2520the%2520linear%2520ubiquitin%2520chain%2520assembly%2520complex%2520stabilizes%2520the%2520TNF-R1%2520signaling%2520complex%2520and%2520is%2520required%2520for%2520TNF-mediated%2520gene%2520induction%26jtitle%3DMol.%2520Cell%26date%3D2009%26volume%3D36%26spage%3D831%26epage%3D844%26doi%3D10.1016%2Fj.molcel.2009.10.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group">Golan-Goldhirsh, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gopas, J.</span><span> </span><span class="NLM_article-title">Plant derived inhibitors of NF-κB</span> <span class="citation_source-journal">Phytochem. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">107</span><span class="NLM_x">–</span> <span class="NLM_lpage">121</span><span class="refDoi"> DOI: 10.1007/s11101-013-9293-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01774&amp;key=10.1007%2Fs11101-013-9293-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01774&amp;key=1%3ACAS%3A528%3ADC%252BC2cXislChu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=107-121&author=A.+Golan-Goldhirshauthor=J.+Gopas&title=Plant+derived+inhibitors+of+NF-%CE%BAB&doi=10.1007%2Fs11101-013-9293-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Plant derived inhibitors of NF-κB</span></div><div class="casAuthors">Golan-Goldhirsh, Avi; Gopas, Jacob</div><div class="citationInfo"><span class="NLM_cas:title">Phytochemistry Reviews</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">107-121</span>CODEN:
                <span class="NLM_cas:coden">PRHEBS</span>;
        ISSN:<span class="NLM_cas:issn">1568-7767</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  Plant secondary metabolites (natural products) have been a source for many of our medicines.  Their functions in plants remain often unknown, but in recent years there are more and more new compds. isolated and identified and their medicinal potential investigated.  The major classes of plant natural products and various derivs. thereof are: phenolics, terpenoids, alkaloids and lignans.  The major transcription factor, nuclear factor-κB (NF-κB) is a central downstream regulator of inflammation, cell proliferation and apoptosis that controls the expression of more than 500 genes.  It plays an essential role in several aspects of human health including the development of innate and adaptive immunity.  The deregulation of NF-κB is assocd. with many ailments including cancer and chronic inflammatory diseases.  In spite of a vast literature describing NF-κB inhibitors from many natural or synthetic sources, such modulators have not been fully tapped for therapeutic purposes and the search for effective and specific inhibitors for therapeutic use and minimal side effects is still relevant and ongoing.  Plant-derived phytochems. are promising lead compds. to develop potent and safe inhibitors for cancer and inflammatory disorders driven by NF-κB.  We briefly review the recent knowledge on plant derived phytochems. and their major NF-κB mol. targets.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpO4RD0fDWWE7Vg90H21EOLACvtfcHk0lgkzscA9fm1iw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXislChu7s%253D&md5=387be35abe847685ee286394a8447bc4</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1007%2Fs11101-013-9293-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11101-013-9293-5%26sid%3Dliteratum%253Aachs%26aulast%3DGolan-Goldhirsh%26aufirst%3DA.%26aulast%3DGopas%26aufirst%3DJ.%26atitle%3DPlant%2520derived%2520inhibitors%2520of%2520NF-%25CE%25BAB%26jtitle%3DPhytochem.%2520Rev.%26date%3D2014%26volume%3D13%26spage%3D107%26epage%3D121%26doi%3D10.1007%2Fs11101-013-9293-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group">Fan, W. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, Y. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deng, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ge, X. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, P. H.</span><span> </span><span class="NLM_article-title">EGFR antisense RNA blocks expression of the epidermal growth factor receptor and partially reverse the malignant phenotype of human breast cancer MDA-MB-231 cells</span> <span class="citation_source-journal">Cell Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">63</span><span class="NLM_x">–</span> <span class="NLM_lpage">71</span><span class="refDoi"> DOI: 10.1038/cr.1998.7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01774&amp;key=10.1038%2Fcr.1998.7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01774&amp;key=9570018" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01774&amp;key=1%3ACAS%3A280%3ADyaK1c3jtFGgtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=1998&pages=63-71&author=W.+H.+Fanauthor=Y.+L.+Luauthor=F.+Dengauthor=X.+M.+Geauthor=S.+Liuauthor=P.+H.+Tang&title=EGFR+antisense+RNA+blocks+expression+of+the+epidermal+growth+factor+receptor+and+partially+reverse+the+malignant+phenotype+of+human+breast+cancer+MDA-MB-231+cells&doi=10.1038%2Fcr.1998.7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">EGFR antisense RNA blocks expression of the epidermal growth factor receptor and partially reverse the malignant phenotype of human breast cancer MDA-MB-231 cells</span></div><div class="casAuthors">Fan W H; Lu Y L; Deng F; Ge X M; Liu S; Tang P H</div><div class="citationInfo"><span class="NLM_cas:title">Cell research</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">63-71</span>
        ISSN:<span class="NLM_cas:issn">1001-0602</span>.
    </div><div class="casAbstract">The effects of human EGFR to the malignant phenotype of human breast cancer cell line MDA-MB-231 were investigated experimentally.  A retroviral vector containing a 5'1350bp fragment of the human EGFR cDNA in the antisense orientation was transfected into targeted cells by lipofectamine.  The effects on cell proliferation, cell cycle and adherent ability to extracellular matrix (ECM) components were studied after the expression of antisense transcripts to EGFR 5'1350bp fragment in target cells.  In vitro studies showed that the growth ability of the transfected cells was partially inhibited in comparison to parental cells and to cells transfected with the plasmid containing the neomycin resistance gene only.  It was found that EGF (10 ng/ml) had an argumenation effect on the growth of transfected MDA-AS10 cells but not MDA-MB-231 cells.  Flow cytometric analysis showed that the cell cycle of the transfected cells was abnormal with a decrease of cells in G2/M and S phases and an increase of cells in G1 phase, indicating a blockage in phase G1.  Immunofluorescence of EGFR expression in transfectants stained with an anti-EGFR antibody was decreased and their growth in soft agarose was also severely impaired.  The transfected cells showed less adherence to laminin (LN) and fibronectin (FN).  In short, EGFR antisense RNA decreases the expression of EGFR on MDA-MB-231 cells and partially reverses their malignant phenotype as well.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQPXKIOPAgUKs-crCu0nI_sfW6udTcc2ebkKe5_ws-rurntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK1c3jtFGgtQ%253D%253D&md5=6d62c7311813bfacbbd54a8774cfd467</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1038%2Fcr.1998.7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fcr.1998.7%26sid%3Dliteratum%253Aachs%26aulast%3DFan%26aufirst%3DW.%2BH.%26aulast%3DLu%26aufirst%3DY.%2BL.%26aulast%3DDeng%26aufirst%3DF.%26aulast%3DGe%26aufirst%3DX.%2BM.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DTang%26aufirst%3DP.%2BH.%26atitle%3DEGFR%2520antisense%2520RNA%2520blocks%2520expression%2520of%2520the%2520epidermal%2520growth%2520factor%2520receptor%2520and%2520partially%2520reverse%2520the%2520malignant%2520phenotype%2520of%2520human%2520breast%2520cancer%2520MDA-MB-231%2520cells%26jtitle%3DCell%2520Res.%26date%3D1998%26volume%3D8%26spage%3D63%26epage%3D71%26doi%3D10.1038%2Fcr.1998.7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group">Ferrer-Soler, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vazquez-Martin, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brunet, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Menendez, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Llorens, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colomer, R.</span><span> </span><span class="NLM_article-title">An update of the mechanisms of resistance to EGFR-tyrosine kinase inhibitors in breast cancer: gefitinib (Iressa) -induced changes in the expression and nucleo-cytoplasmic trafficking of HER-ligands (Review)</span> <span class="citation_source-journal">Int. J. Mol. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">3</span><span class="NLM_x">–</span> <span class="NLM_lpage">10</span><span class="refDoi"> DOI: 10.3892/ijmm.20.1.3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01774&amp;key=10.3892%2Fijmm.20.1.3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01774&amp;key=17549382" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01774&amp;key=1%3ACAS%3A528%3ADC%252BD2sXot1Kqt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2007&pages=3-10&author=L.+Ferrer-Solerauthor=A.+Vazquez-Martinauthor=J.+Brunetauthor=J.+A.+Menendezauthor=R.+De+Llorensauthor=R.+Colomer&title=An+update+of+the+mechanisms+of+resistance+to+EGFR-tyrosine+kinase+inhibitors+in+breast+cancer%3A+gefitinib+%28Iressa%29+-induced+changes+in+the+expression+and+nucleo-cytoplasmic+trafficking+of+HER-ligands+%28Review%29&doi=10.3892%2Fijmm.20.1.3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">An update of the mechanisms of resistance to EGFR-tyrosine kinase inhibitors in breast cancer: gefitinib (Iressa)-induced changes in the expression and nucleo-cytoplasmic trafficking of HER-ligands (Review)</span></div><div class="casAuthors">Ferrer-Soler, Laura; Vazquez-Martin, Alejandro; Brunet, Joan; Menendez, Javier A.; De Llorens, Rafael; Colomer, Ramon</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Molecular Medicine</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">3-10</span>CODEN:
                <span class="NLM_cas:coden">IJMMFG</span>;
        ISSN:<span class="NLM_cas:issn">1107-3756</span>.
    
            (<span class="NLM_cas:orgname">International Journal of Molecular Medicine</span>)
        </div><div class="casAbstract">A review.  Intrinsic resistance to the epidermal growth factor receptor (EGFR; HER1) tyrosine kinase inhibitor (TKI) gefitinib, and more generally to EGFR TKIs, is a common phenomenon in breast cancer.  The availability of mol. criteria for predicting sensitivity to EGFR-TKIs is, therefore, the most relevant issue for their correct use and for planning future research.  Though it appears that in non-small-cell lung cancer (NSCLC) response to gefitinib is directly related to the occurrence of specific mutations in the EGFR TK domain, breast cancer patients cannot be selected for treatment with gefitinib on the same basis as such EGFR mutations have been reported neither in primary breast carcinomas nor in several breast cancer cell lines.  Alternatively, there is a general agreement on the hypothesis that the occurrence of mol. alterations that activate transduction pathways downstream of EGFR (i.e., MEK1/MEK2 → ERK1/2 MAPK and PI-3'K → AKT growth/survival signaling cascades) significantly affect the response to EGFR TKIs in breast carcinomas.  However, there are no studies so far addressing a role of EGF-related ligands as intrinsic breast cancer cell modulators of EGFR TKI efficacy.  We recently monitored gene expression profiles and sub-cellular localization of HER-1/-2/-3/-4 related ligands (i.e., EGF, amphiregulin, transforming growth factor-α, β-cellulin, epiregulin and neuregulins) prior to and after gefitinib treatment in a panel of human breast cancer cell lines.  First, gefitinib-induced changes in the endogenous levels of EGF-related ligands correlated with the natural degree of breast cancer cell sensitivity to gefitinib.  While breast cancer cells intrinsically resistant to gefitinib (IC50 ≥15 μM) markedly up-regulated (up to 600 times) the expression of genes codifying for HER-specific ligands, a significant down-regulation (up to 106 times) of HER ligand gene transcription was found in breast cancer cells intrinsically sensitive to gefitinib (IC50 ≤1 μM).  Second, loss of HER1 function differentially regulated the nuclear trafficking of HER-related ligands.  While gefitinib treatment induced an active import and nuclear accumulation of the HER ligand NRG in intrinsically gefitinib-resistant breast cancer cells, an active export and nuclear loss of NRG was obsd. in intrinsically gefitinib-sensitive breast cancer cells.  In summary, through in vitro and pharmacodynamic studies we have learned that, besides mutations in the HER1 gene, oncogenic changes downstream of HER1 are the key players regulating gefitinib efficacy in breast cancer cells.  It now appears that pharmacol. inhibition of HER1 function also leads to striking changes in both the gene expression and the nucleo-cytoplasmic trafficking of HER-specific ligands, and that this response correlates with the intrinsic degree of breast cancer sensitivity to the EGFR TKI gefitinib.  The relevance of this previously unrecognized intracrine feedback to gefitinib warrants further studies as cancer cells could bypass the antiproliferative effects of HER1-targeted therapeutics without a need for the overexpression and/or activation of other HER family members and/or the activation of HER-driven downstream signaling cascades.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqwSC5Rsb6FG7Vg90H21EOLACvtfcHk0ljkyGIRd8NO2g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXot1Kqt74%253D&md5=6ef1ec64a3e1aea5a13b2e7d088947e5</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.3892%2Fijmm.20.1.3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3892%252Fijmm.20.1.3%26sid%3Dliteratum%253Aachs%26aulast%3DFerrer-Soler%26aufirst%3DL.%26aulast%3DVazquez-Martin%26aufirst%3DA.%26aulast%3DBrunet%26aufirst%3DJ.%26aulast%3DMenendez%26aufirst%3DJ.%2BA.%26aulast%3DDe%2BLlorens%26aufirst%3DR.%26aulast%3DColomer%26aufirst%3DR.%26atitle%3DAn%2520update%2520of%2520the%2520mechanisms%2520of%2520resistance%2520to%2520EGFR-tyrosine%2520kinase%2520inhibitors%2520in%2520breast%2520cancer%253A%2520gefitinib%2520%2528Iressa%2529%2520-induced%2520changes%2520in%2520the%2520expression%2520and%2520nucleo-cytoplasmic%2520trafficking%2520of%2520HER-ligands%2520%2528Review%2529%26jtitle%3DInt.%2520J.%2520Mol.%2520Med.%26date%3D2007%26volume%3D20%26spage%3D3%26epage%3D10%26doi%3D10.3892%2Fijmm.20.1.3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group">Sovak, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bellas, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zanieski, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rogers, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Traish, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sonenshein, G. E.</span><span> </span><span class="NLM_article-title">Aberrant nuclear factor-kappaB/Rel expression and the pathogenesis of breast cancer</span> <span class="citation_source-journal">J. Clin. Invest.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">100</span><span class="NLM_x">, </span> <span class="NLM_fpage">2952</span><span class="NLM_x">–</span> <span class="NLM_lpage">2960</span><span class="refDoi"> DOI: 10.1172/JCI119848</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01774&amp;key=10.1172%2FJCI119848" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=100&publication_year=1997&pages=2952-2960&author=M.+A.+Sovakauthor=R.+E.+Bellasauthor=D.+W.+Kimauthor=G.+J.+Zanieskiauthor=A.+E.+Rogersauthor=A.+M.+Traishauthor=G.+E.+Sonenshein&title=Aberrant+nuclear+factor-kappaB%2FRel+expression+and+the+pathogenesis+of+breast+cancer&doi=10.1172%2FJCI119848"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1172%2FJCI119848&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI119848%26sid%3Dliteratum%253Aachs%26aulast%3DSovak%26aufirst%3DM.%2BA.%26aulast%3DBellas%26aufirst%3DR.%2BE.%26aulast%3DKim%26aufirst%3DD.%2BW.%26aulast%3DZanieski%26aufirst%3DG.%2BJ.%26aulast%3DRogers%26aufirst%3DA.%2BE.%26aulast%3DTraish%26aufirst%3DA.%2BM.%26aulast%3DSonenshein%26aufirst%3DG.%2BE.%26atitle%3DAberrant%2520nuclear%2520factor-kappaB%252FRel%2520expression%2520and%2520the%2520pathogenesis%2520of%2520breast%2520cancer%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D1997%26volume%3D100%26spage%3D2952%26epage%3D2960%26doi%3D10.1172%2FJCI119848" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group">Anastassiadis, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deacon, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Devarajan, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peterson, J. R.</span><span> </span><span class="NLM_article-title">Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity</span> <span class="citation_source-journal">Nat. Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">1039</span><span class="NLM_x">–</span> <span class="NLM_lpage">1045</span><span class="refDoi"> DOI: 10.1038/nbt.2017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01774&amp;key=10.1038%2Fnbt.2017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01774&amp;key=22037377" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01774&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtlyisL7E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2011&pages=1039-1045&author=T.+Anastassiadisauthor=S.+W.+Deaconauthor=K.+Devarajanauthor=H.+Maauthor=J.+R.+Peterson&title=Comprehensive+assay+of+kinase+catalytic+activity+reveals+features+of+kinase+inhibitor+selectivity&doi=10.1038%2Fnbt.2017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity</span></div><div class="casAuthors">Anastassiadis, Theonie; Deacon, Sean W.; Devarajan, Karthik; Ma, Haiching; Peterson, Jeffrey R.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1039-1045</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Small-mol. protein kinase inhibitors are widely used to elucidate cellular signaling pathways and are promising therapeutic agents.  Owing to evolutionary conservation of the ATP-binding site, most kinase inhibitors that target this site promiscuously inhibit multiple kinases.  Interpretation of expts. that use these compds. is confounded by a lack of data on the comprehensive kinase selectivity of most inhibitors.  Here we used functional assays to profile the activity of 178 com. available kinase inhibitors against a panel of 300 recombinant protein kinases.  Quant. anal. revealed complex and often unexpected interactions between protein kinases and kinase inhibitors, with a wide spectrum of promiscuity.  Many off-target interactions occur with seemingly unrelated kinases, revealing how large-scale profiling can identify multitargeted inhibitors of specific, diverse kinases.  The results have implications for drug development and provide a resource for selecting compds. to elucidate kinase function and for interpreting the results of expts. involving kinase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpUljWIhZGPkrVg90H21EOLACvtfcHk0ljkyGIRd8NO2g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtlyisL7E&md5=b2f705509b0e09afa46b01d4669f0515</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1038%2Fnbt.2017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt.2017%26sid%3Dliteratum%253Aachs%26aulast%3DAnastassiadis%26aufirst%3DT.%26aulast%3DDeacon%26aufirst%3DS.%2BW.%26aulast%3DDevarajan%26aufirst%3DK.%26aulast%3DMa%26aufirst%3DH.%26aulast%3DPeterson%26aufirst%3DJ.%2BR.%26atitle%3DComprehensive%2520assay%2520of%2520kinase%2520catalytic%2520activity%2520reveals%2520features%2520of%2520kinase%2520inhibitor%2520selectivity%26jtitle%3DNat.%2520Biotechnol.%26date%3D2011%26volume%3D29%26spage%3D1039%26epage%3D1045%26doi%3D10.1038%2Fnbt.2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group">Beharry, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zemskova, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mahajan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xia, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lilly, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kraft, A. S.</span><span> </span><span class="NLM_article-title">Novel benzylidene-thiazolidine-2,4-diones inhibit Pim protein kinase activity and induce cell cycle arrest in leukemia and prostate cancer cells</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">1473</span><span class="NLM_x">–</span> <span class="NLM_lpage">1483</span><span class="refDoi"> DOI: 10.1158/1535-7163.MCT-08-1037</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01774&amp;key=10.1158%2F1535-7163.MCT-08-1037" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01774&amp;key=19509254" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01774&amp;key=1%3ACAS%3A528%3ADC%252BD1MXntVKgsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2009&pages=1473-1483&author=Z.+Beharryauthor=M.+Zemskovaauthor=S.+Mahajanauthor=F.+Zhangauthor=J.+Maauthor=Z.+Xiaauthor=M.+Lillyauthor=C.+D.+Smithauthor=A.+S.+Kraft&title=Novel+benzylidene-thiazolidine-2%2C4-diones+inhibit+Pim+protein+kinase+activity+and+induce+cell+cycle+arrest+in+leukemia+and+prostate+cancer+cells&doi=10.1158%2F1535-7163.MCT-08-1037"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Novel benzylidene-thiazolidine-2,4-diones inhibit Pim protein kinase activity and induce cell cycle arrest in leukemia and prostate cancer cells</span></div><div class="casAuthors">Beharry, Zanna; Zemskova, Marina; Mahajan, Sandeep; Zhang, Fengxue; Ma, Jian; Xia, Zuping; Lilly, Michael; Smith, Charles D.; Kraft, Andrew S.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1473-1483</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The Pim protein kinases play important roles in cancer development and progression, including prostate tumors and hematol. malignancies.  To investigate the potential role of these enzymes as anticancer drug targets, we have synthesized novel benzylidene-thiazolidine-2,4-diones that function as potent Pim protein kinase inhibitors.  With IC50 values in the nanomolar range, these compds. block the ability of Pim to phosphorylate peptides and proteins in vitro and, when added to DU145 prostate cancer cells overexpressing Pim, inhibit the ability of this enzyme to phosphorylate a known substrate, the BH3 protein BAD.  When added to prostate cancer cell lines, including PC3, DU145, and CWR22Rv1, and human leukemic cells, MV4;11, K562, and U937 cells, these compds. induce G1-S cell cycle arrest and block the antiapoptotic effect of the Pim protein kinase.  The cell cycle arrest induced by these compds. is assocd. with an inhibition of cyclin-dependent kinase 2 and activity and translocation of the Pim-1 substrate p27Kip1, a cyclin-dependent kinase 2 inhibitory protein, to the nucleus.  Furthermore, when added to leukemic cells, these compds. synergize with the mammalian target of rapamycin inhibitor rapamycin to decrease the phosphorylation level of the translational repressor 4E-BP1 at sites phosphorylated by mammalian target of rapamycin.  Combinations of rapamycin and the benzylidene-thiazolidine-2,4-diones synergistically block the growth of leukemic cells.  Thus, these agents represent novel Pim inhibitors and point to an important role for the Pim protein kinases in cell cycle control in multiple types of cancer cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrLAvby3We1JbVg90H21EOLACvtfcHk0ljKUrp34UrwnA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXntVKgsb8%253D&md5=7a66bb477cc0e5372d620fb0921c3262</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-08-1037&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-08-1037%26sid%3Dliteratum%253Aachs%26aulast%3DBeharry%26aufirst%3DZ.%26aulast%3DZemskova%26aufirst%3DM.%26aulast%3DMahajan%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DF.%26aulast%3DMa%26aufirst%3DJ.%26aulast%3DXia%26aufirst%3DZ.%26aulast%3DLilly%26aufirst%3DM.%26aulast%3DSmith%26aufirst%3DC.%2BD.%26aulast%3DKraft%26aufirst%3DA.%2BS.%26atitle%3DNovel%2520benzylidene-thiazolidine-2%252C4-diones%2520inhibit%2520Pim%2520protein%2520kinase%2520activity%2520and%2520induce%2520cell%2520cycle%2520arrest%2520in%2520leukemia%2520and%2520prostate%2520cancer%2520cells%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2009%26volume%3D8%26spage%3D1473%26epage%3D1483%26doi%3D10.1158%2F1535-7163.MCT-08-1037" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group">Palombella, V. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rando, O. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldberg, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maniatis, T.</span><span> </span><span class="NLM_article-title">The ubiquitin-proteasome pathway is required for processing the NF-kB1 precursor protein and the activation of NF-kB</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_volume">78</span><span class="NLM_x">, </span> <span class="NLM_fpage">773</span><span class="NLM_x">–</span> <span class="NLM_lpage">785</span><span class="refDoi"> DOI: 10.1016/S0092-8674(94)90482-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01774&amp;key=10.1016%2FS0092-8674%2894%2990482-0" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=1994&pages=773-785&author=V.+J.+Palombellaauthor=O.+J.+Randoauthor=A.+L.+Goldbergauthor=T.+Maniatis&title=The+ubiquitin-proteasome+pathway+is+required+for+processing+the+NF-kB1+precursor+protein+and+the+activation+of+NF-kB&doi=10.1016%2FS0092-8674%2894%2990482-0"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1016%2FS0092-8674%2894%2990482-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0092-8674%252894%252990482-0%26sid%3Dliteratum%253Aachs%26aulast%3DPalombella%26aufirst%3DV.%2BJ.%26aulast%3DRando%26aufirst%3DO.%2BJ.%26aulast%3DGoldberg%26aufirst%3DA.%2BL.%26aulast%3DManiatis%26aufirst%3DT.%26atitle%3DThe%2520ubiquitin-proteasome%2520pathway%2520is%2520required%2520for%2520processing%2520the%2520NF-kB1%2520precursor%2520protein%2520and%2520the%2520activation%2520of%2520NF-kB%26jtitle%3DCell%26date%3D1994%26volume%3D78%26spage%3D773%26epage%3D785%26doi%3D10.1016%2FS0092-8674%2894%2990482-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group">Montagut, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rovira, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gascon, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ross, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Albanell, J.</span><span> </span><span class="NLM_article-title">Preclinical and clinical development of the proteasome inhibitor bortezomib in cancer treatment</span> <span class="citation_source-journal">Drugs Today</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">41</span><span class="NLM_x">, </span> <span class="NLM_fpage">299</span><span class="NLM_x">–</span> <span class="NLM_lpage">315</span><span class="refDoi"> DOI: 10.1358/dot.2005.41.5.893706</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01774&amp;key=10.1358%2Fdot.2005.41.5.893706" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01774&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtV2itr7J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2005&pages=299-315&author=C.+Montagutauthor=A.+Roviraauthor=P.+Gasconauthor=J.+S.+Rossauthor=J.+Albanell&title=Preclinical+and+clinical+development+of+the+proteasome+inhibitor+bortezomib+in+cancer+treatment&doi=10.1358%2Fdot.2005.41.5.893706"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical and clinical development of the proteasome inhibitor bortezomib in cancer treatment</span></div><div class="casAuthors">Montagut, C.; Rovira, A.; Mellado, B.; Gascon, P.; Ross, J. S.; Albanell, J.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs of Today</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">299-315</span>CODEN:
                <span class="NLM_cas:coden">MDACAP</span>;
        ISSN:<span class="NLM_cas:issn">0025-7656</span>.
    
            (<span class="NLM_cas:orgname">Prous Science</span>)
        </div><div class="casAbstract">A review.  The proteasome is a ubiquitous enzyme complex that plays a crit. role in the degrdn. of many proteins involved in cell cycle regulation, apoptosis and angiogenesis.  Since these pathways are fundamental for cell survival and proliferation, particularly in cancer cells, the inhibition of proteasome is an attractive potential anticancer therapy.  The present review will focus on the proteasome inhibitor bortezomib (Velcade, formerly PS-341; Millennium Pharmaceuticals, Inc., Cambridge, MA, USA).  Bortezomib is an extremely potent and selective proteasome inhibitor that shows strong activity in in vitro and in vivo lab. studies against many solid and hematol. tumor types.  Moreover, bortezomib, mainly by inhibition of the NF-κB pathway, has a chemosensitizing effect when administered together with other antitumoral drugs.  Based on these results, bortezomib entered clin. phase I trials, alone or in combination with chemotherapy, that showed good tolerance at doses that achieved a desired degree of proteasome inhibition.  Phase II studies showed high response rates in refractory multiple myeloma patients, which led to the accelerated approval of bortezomib by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMEA) for this indication.  A phase III trial comparing bortezomib with dexamethasone in refractory/relapsed multiple myeloma patients had to be halted due to a survival advantage in the bortezomib arm.  Addnl. studies are focusing on the potential benefit of bortezomib in newly diagnosed multiple myeloma patients.  In other solid and hematol. malignancies, phase II studies with bortezomib alone or in combination with other agents are ongoing.  Encouraging results, particularly in lung cancer and lymphoma, have been obsd.  The crit. mols. or genes responsible for tumor sensitivity to bortezomib continue to be evaluated using novel technologies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq1vSaOr12debVg90H21EOLACvtfcHk0ljKUrp34UrwnA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtV2itr7J&md5=9f863821579e7dac2fa1d831a522b376</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1358%2Fdot.2005.41.5.893706&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1358%252Fdot.2005.41.5.893706%26sid%3Dliteratum%253Aachs%26aulast%3DMontagut%26aufirst%3DC.%26aulast%3DRovira%26aufirst%3DA.%26aulast%3DGascon%26aufirst%3DP.%26aulast%3DRoss%26aufirst%3DJ.%2BS.%26aulast%3DAlbanell%26aufirst%3DJ.%26atitle%3DPreclinical%2520and%2520clinical%2520development%2520of%2520the%2520proteasome%2520inhibitor%2520bortezomib%2520in%2520cancer%2520treatment%26jtitle%3DDrugs%2520Today%26date%3D2005%26volume%3D41%26spage%3D299%26epage%3D315%26doi%3D10.1358%2Fdot.2005.41.5.893706" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group">Berkers, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verdoes, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lichtman, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fiebiger, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kessler, B. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderson, K. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ploegh, H. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ovaa, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galardy, P. J.</span><span> </span><span class="NLM_article-title">Activity probe for in vivo profiling of the specificity of proteasome inhibitor bortezomib</span> <span class="citation_source-journal">Nat. Methods</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">357</span><span class="NLM_x">–</span> <span class="NLM_lpage">362</span><span class="refDoi"> DOI: 10.1038/nmeth759</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01774&amp;key=10.1038%2Fnmeth759" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01774&amp;key=15846363" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01774&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjsVyls70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2005&pages=357-362&author=C.+R.+Berkersauthor=M.+Verdoesauthor=E.+Lichtmanauthor=E.+Fiebigerauthor=B.+M.+Kesslerauthor=K.+C.+Andersonauthor=H.+L.+Ploeghauthor=H.+Ovaaauthor=P.+J.+Galardy&title=Activity+probe+for+in+vivo+profiling+of+the+specificity+of+proteasome+inhibitor+bortezomib&doi=10.1038%2Fnmeth759"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Activity probe for in vivo profiling of the specificity of proteasome inhibitor bortezomib</span></div><div class="casAuthors">Berkers, Celia R.; Verdoes, Martijn; Lichtman, Eben; Fiebiger, Edda; Kessler, Benedikt M.; Anderson, Kenneth C.; Ploegh, Hidde L.; Ovaa, Huib; Galardy, Paul J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Methods</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">357-362</span>CODEN:
                <span class="NLM_cas:coden">NMAEA3</span>;
        ISSN:<span class="NLM_cas:issn">1548-7091</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Proteasome inhibitors, such as the dipeptide boronic acid bortezomib, are emerging as important tools in the treatment of the fatal hematol. malignancy multiple myeloma.  Despite the recent US Food and Drug Administration approval of bortezomib (PS341, Velcade) for the treatment of refractory multiple myeloma, many of the basic pharmacol. parameters of bortezomib and its mode of action on myeloma cells remain to be detd.  We describe the synthesis and use of a cell-permeant active site-directed probe, which allows profiling of proteasomal activities in living cells.  When we compared proteasome activity patterns in cultured cells and crude cell exts. with this probe, we obsd. substantial differences, stressing the importance for bioassays compatible with live cells to ensure accuracy of such measurements.  Using this probe, we investigated the in vivo subunit specificities of bortezomib and another inhibitor, MG132.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGomPqiElUEWtLVg90H21EOLACvtfcHk0ljKUrp34UrwnA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjsVyls70%253D&md5=5055e0a80ecfd5ea8272e6b38f0c73bc</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1038%2Fnmeth759&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnmeth759%26sid%3Dliteratum%253Aachs%26aulast%3DBerkers%26aufirst%3DC.%2BR.%26aulast%3DVerdoes%26aufirst%3DM.%26aulast%3DLichtman%26aufirst%3DE.%26aulast%3DFiebiger%26aufirst%3DE.%26aulast%3DKessler%26aufirst%3DB.%2BM.%26aulast%3DAnderson%26aufirst%3DK.%2BC.%26aulast%3DPloegh%26aufirst%3DH.%2BL.%26aulast%3DOvaa%26aufirst%3DH.%26aulast%3DGalardy%26aufirst%3DP.%2BJ.%26atitle%3DActivity%2520probe%2520for%2520in%2520vivo%2520profiling%2520of%2520the%2520specificity%2520of%2520proteasome%2520inhibitor%2520bortezomib%26jtitle%3DNat.%2520Methods%26date%3D2005%26volume%3D2%26spage%3D357%26epage%3D362%26doi%3D10.1038%2Fnmeth759" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group">Hayden, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghosh, S.</span><span> </span><span class="NLM_article-title">Signaling to NF-kappaB</span> <span class="citation_source-journal">Genes Dev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">2195</span><span class="NLM_x">–</span> <span class="NLM_lpage">2224</span><span class="refDoi"> DOI: 10.1101/gad.1228704</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01774&amp;key=10.1101%2Fgad.1228704" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01774&amp;key=15371334" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01774&amp;key=1%3ACAS%3A528%3ADC%252BD2cXnslCntbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2004&pages=2195-2224&author=M.+S.+Haydenauthor=S.+Ghosh&title=Signaling+to+NF-kappaB&doi=10.1101%2Fgad.1228704"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Signaling to NF-κB</span></div><div class="casAuthors">Hayden, Matthew S.; Ghosh, Sankar</div><div class="citationInfo"><span class="NLM_cas:title">Genes & Development</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">2195-2224</span>CODEN:
                <span class="NLM_cas:coden">GEDEEP</span>;
        ISSN:<span class="NLM_cas:issn">0890-9369</span>.
    
            (<span class="NLM_cas:orgname">Cold Spring Harbor Laboratory Press</span>)
        </div><div class="casAbstract">A review.  The transcription factor NF-κB has been the focus of intense investigation for nearly two decades.  Over this period, considerable progress has been made in detg. the function and regulation of NF-κB, although there are nuances in this important signaling pathway that still remain to be understood.  The challenge now is to reconcile the regulatory complexity in this pathway with the complexity of responses in which NF-κB family members play important roles.  In this review, authors provide an overview of established NF-κB signaling pathways with focus on the current state of research into the mechanisms that regulate IKK activation and NF-κB transcriptional activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqGn6Te9a4IB7Vg90H21EOLACvtfcHk0lhAr1SP8DKSbA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXnslCntbY%253D&md5=59ac1691d86e059c8f4b62d8629729dd</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1101%2Fgad.1228704&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1101%252Fgad.1228704%26sid%3Dliteratum%253Aachs%26aulast%3DHayden%26aufirst%3DM.%2BS.%26aulast%3DGhosh%26aufirst%3DS.%26atitle%3DSignaling%2520to%2520NF-kappaB%26jtitle%3DGenes%2520Dev.%26date%3D2004%26volume%3D18%26spage%3D2195%26epage%3D2224%26doi%3D10.1101%2Fgad.1228704" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group">Yang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, W. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, J. C.</span><span> </span><span class="NLM_article-title">CBP knockdown inhibits angiotensin II-induced vascular smooth muscle cells proliferation through downregulating NF-kB transcriptional activity</span> <span class="citation_source-journal">Mol. Cell. Biochem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">340</span><span class="NLM_x">, </span> <span class="NLM_fpage">55</span><span class="NLM_x">–</span> <span class="NLM_lpage">62</span><span class="refDoi"> DOI: 10.1007/s11010-010-0400-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01774&amp;key=10.1007%2Fs11010-010-0400-2" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=340&publication_year=2010&pages=55-62&author=J.+Yangauthor=H.+Jiangauthor=S.+S.+Chenauthor=J.+Chenauthor=S.+K.+Xuauthor=W.+Q.+Liauthor=J.+C.+Wang&title=CBP+knockdown+inhibits+angiotensin+II-induced+vascular+smooth+muscle+cells+proliferation+through+downregulating+NF-kB+transcriptional+activity&doi=10.1007%2Fs11010-010-0400-2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1007%2Fs11010-010-0400-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11010-010-0400-2%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DJiang%26aufirst%3DH.%26aulast%3DChen%26aufirst%3DS.%2BS.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DXu%26aufirst%3DS.%2BK.%26aulast%3DLi%26aufirst%3DW.%2BQ.%26aulast%3DWang%26aufirst%3DJ.%2BC.%26atitle%3DCBP%2520knockdown%2520inhibits%2520angiotensin%2520II-induced%2520vascular%2520smooth%2520muscle%2520cells%2520proliferation%2520through%2520downregulating%2520NF-kB%2520transcriptional%2520activity%26jtitle%3DMol.%2520Cell.%2520Biochem.%26date%3D2010%26volume%3D340%26spage%3D55%26epage%3D62%26doi%3D10.1007%2Fs11010-010-0400-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group">Ma, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fey, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hottiger, M. O.</span><span> </span><span class="NLM_article-title">WNT/beta-catenin signaling inhibits CBP-mediated RelA acetylation and expression of proinflammatory NF-kappaB target genes</span> <span class="citation_source-journal">J. Cell Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">128</span><span class="NLM_x">, </span> <span class="NLM_fpage">2430</span><span class="NLM_x">–</span> <span class="NLM_lpage">2436</span><span class="refDoi"> DOI: 10.1242/jcs.168542</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01774&amp;key=10.1242%2Fjcs.168542" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01774&amp;key=26021349" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01774&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsVamsLfN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=128&publication_year=2015&pages=2430-2436&author=B.+Maauthor=M.+Feyauthor=M.+O.+Hottiger&title=WNT%2Fbeta-catenin+signaling+inhibits+CBP-mediated+RelA+acetylation+and+expression+of+proinflammatory+NF-kappaB+target+genes&doi=10.1242%2Fjcs.168542"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">WNT/β-catenin signaling inhibits CBP-mediated RelA acetylation and expression of proinflammatory NF-κB target genes</span></div><div class="casAuthors">Ma, Bin; Fey, Monika; Hottiger, Michael O.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cell Science</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">128</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">2430-2436</span>CODEN:
                <span class="NLM_cas:coden">JNCSAI</span>;
        ISSN:<span class="NLM_cas:issn">0021-9533</span>.
    
            (<span class="NLM_cas:orgname">Company of Biologists Ltd.</span>)
        </div><div class="casAbstract">The discovery of functional crosstalk between WNT and nuclear factor κB (NF-κB) signaling has established a more complex role for these two pathways in inflammation and cancer.  However, the mol. mechanisms of the crosstalk and its biol. consequences are largely unknown.  Here, we show that WNT/β-catenin signaling selectively inhibits the expression of a proinflammatory subset of IL-1β-induced NF-κB target genes.  WNT/β-catenin signaling does not affect nuclear translocation of the RelA subunit of NF-κB or its assocn. with CBP (also known as CREBBP), but reduces CBP-mediated acetylation and chromatin recruitment of RelA.  Thus, β-catenin selectively regulates NF-κB gene expression through its neg. effects on RelA acetylation.  This anti-inflammatory effect may be relevant for cancer treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpvPgHrhvl7Z7Vg90H21EOLACvtfcHk0lhAr1SP8DKSbA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsVamsLfN&md5=9994710454a8600497fd4fd6ac4594e9</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1242%2Fjcs.168542&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1242%252Fjcs.168542%26sid%3Dliteratum%253Aachs%26aulast%3DMa%26aufirst%3DB.%26aulast%3DFey%26aufirst%3DM.%26aulast%3DHottiger%26aufirst%3DM.%2BO.%26atitle%3DWNT%252Fbeta-catenin%2520signaling%2520inhibits%2520CBP-mediated%2520RelA%2520acetylation%2520and%2520expression%2520of%2520proinflammatory%2520NF-kappaB%2520target%2520genes%26jtitle%3DJ.%2520Cell%2520Sci.%26date%3D2015%26volume%3D128%26spage%3D2430%26epage%3D2436%26doi%3D10.1242%2Fjcs.168542" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group">Hua, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tamamori-Adachi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luo, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tamura, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morioka, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fukuda, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tanaka, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kitajima, S.</span><span> </span><span class="NLM_article-title">A splice variant of stress response gene ATF3 counteracts NF-kappaB-dependent anti-apoptosis through inhibiting recruitment of CREB-binding protein/p300 coactivator</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">281</span><span class="NLM_x">, </span> <span class="NLM_fpage">1620</span><span class="NLM_x">–</span> <span class="NLM_lpage">1629</span><span class="refDoi"> DOI: 10.1074/jbc.M508471200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01774&amp;key=10.1074%2Fjbc.M508471200" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=281&publication_year=2006&pages=1620-1629&author=B.+Huaauthor=M.+Tamamori-Adachiauthor=Y.+Luoauthor=K.+Tamuraauthor=M.+Moriokaauthor=M.+Fukudaauthor=Y.+Tanakaauthor=S.+Kitajima&title=A+splice+variant+of+stress+response+gene+ATF3+counteracts+NF-kappaB-dependent+anti-apoptosis+through+inhibiting+recruitment+of+CREB-binding+protein%2Fp300+coactivator&doi=10.1074%2Fjbc.M508471200"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M508471200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M508471200%26sid%3Dliteratum%253Aachs%26aulast%3DHua%26aufirst%3DB.%26aulast%3DTamamori-Adachi%26aufirst%3DM.%26aulast%3DLuo%26aufirst%3DY.%26aulast%3DTamura%26aufirst%3DK.%26aulast%3DMorioka%26aufirst%3DM.%26aulast%3DFukuda%26aufirst%3DM.%26aulast%3DTanaka%26aufirst%3DY.%26aulast%3DKitajima%26aufirst%3DS.%26atitle%3DA%2520splice%2520variant%2520of%2520stress%2520response%2520gene%2520ATF3%2520counteracts%2520NF-kappaB-dependent%2520anti-apoptosis%2520through%2520inhibiting%2520recruitment%2520of%2520CREB-binding%2520protein%252Fp300%2520coactivator%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2006%26volume%3D281%26spage%3D1620%26epage%3D1629%26doi%3D10.1074%2Fjbc.M508471200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group">Mukherjee, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Behar, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Birnbaum, H. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoffmann, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wright, P. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghosh, G.</span><span> </span><span class="NLM_article-title">Analysis of the RelA:CBP/p300 interaction reveals its involvement in NF-kappaB-driven transcription</span> <span class="citation_source-journal">PLoS Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">e1001647</span><span class="refDoi"> DOI: 10.1371/journal.pbio.1001647</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01774&amp;key=10.1371%2Fjournal.pbio.1001647" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2013&pages=e1001647&author=S.+P.+Mukherjeeauthor=M.+Beharauthor=H.+A.+Birnbaumauthor=A.+Hoffmannauthor=P.+E.+Wrightauthor=G.+Ghosh&title=Analysis+of+the+RelA%3ACBP%2Fp300+interaction+reveals+its+involvement+in+NF-kappaB-driven+transcription&doi=10.1371%2Fjournal.pbio.1001647"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pbio.1001647&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pbio.1001647%26sid%3Dliteratum%253Aachs%26aulast%3DMukherjee%26aufirst%3DS.%2BP.%26aulast%3DBehar%26aufirst%3DM.%26aulast%3DBirnbaum%26aufirst%3DH.%2BA.%26aulast%3DHoffmann%26aufirst%3DA.%26aulast%3DWright%26aufirst%3DP.%2BE.%26aulast%3DGhosh%26aufirst%3DG.%26atitle%3DAnalysis%2520of%2520the%2520RelA%253ACBP%252Fp300%2520interaction%2520reveals%2520its%2520involvement%2520in%2520NF-kappaB-driven%2520transcription%26jtitle%3DPLoS%2520Biol.%26date%3D2013%26volume%3D11%26spage%3De1001647%26doi%3D10.1371%2Fjournal.pbio.1001647" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group">Tilstra, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gaddy, D. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dave, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niedernhofer, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Plevy, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robbins, P. D.</span><span> </span><span class="NLM_article-title">Pharmacologic IKK/NF-kappaB inhibition causes antigen presenting cells to undergo TNFalpha dependent ROS-mediated programmed cell death</span> <span class="citation_source-journal">Sci. Rep.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">3631</span><span class="refDoi"> DOI: 10.1038/srep03631</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01774&amp;key=10.1038%2Fsrep03631" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01774&amp;key=24406986" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01774&amp;key=1%3ACAS%3A528%3ADC%252BC2cXjslCjurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2014&pages=3631&author=J.+S.+Tilstraauthor=D.+F.+Gaddyauthor=J.+Zhaoauthor=S.+H.+Daveauthor=L.+J.+Niedernhoferauthor=S.+E.+Plevyauthor=P.+D.+Robbins&title=Pharmacologic+IKK%2FNF-kappaB+inhibition+causes+antigen+presenting+cells+to+undergo+TNFalpha+dependent+ROS-mediated+programmed+cell+death&doi=10.1038%2Fsrep03631"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacologic IKK/NF-κB inhibition causes antigen presenting cells to undergo TNFα dependent ROS-mediated programmed cell death</span></div><div class="casAuthors">Tilstra, Jeremy S.; Gaddy, Daniel F.; Zhao, Jing; Dave, Shaival H.; Niedernhofer, Laura J.; Plevy, Scott E.; Robbins, Paul D.</div><div class="citationInfo"><span class="NLM_cas:title">Scientific Reports</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">3631/1-3631/11</span>CODEN:
                <span class="NLM_cas:coden">SRCEC3</span>;
        ISSN:<span class="NLM_cas:issn">2045-2322</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Monocyte-derived antigen presenting cells (APC) are central mediators of the innate and adaptive immune response in inflammatory diseases.  As such, APC are appropriate targets for therapeutic intervention to ameliorate certain diseases.  APC differentiation, activation and functions are regulated by the NF-κB family of transcription factors.  Herein, the authors examd. the effect of NF-κB inhibition, via suppression of the IκB Kinase (IKK) complex, on APC function.  Murine bone marrow-derived macrophages and dendritic cells (DC), as well as macrophage and DC lines, underwent rapid programmed cell death (PCD) after treatment with several IKK/NF-κB inhibitors through a TNFα-dependent mechanism.  PCD was induced proximally by reactive oxygen species (ROS) formation, which causes a loss of mitochondrial membrane potential and activation of a caspase signaling cascade.  NF-κB-inhibition-induced PCD of APC may be a key mechanism through which therapeutic targeting of NF-κB reduces inflammatory pathologies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrGEhCbne7HD7Vg90H21EOLACvtfcHk0lhd_2mBuoVR5A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXjslCjurY%253D&md5=f40f14d2c4db3e170a8f50e42c82c540</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1038%2Fsrep03631&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsrep03631%26sid%3Dliteratum%253Aachs%26aulast%3DTilstra%26aufirst%3DJ.%2BS.%26aulast%3DGaddy%26aufirst%3DD.%2BF.%26aulast%3DZhao%26aufirst%3DJ.%26aulast%3DDave%26aufirst%3DS.%2BH.%26aulast%3DNiedernhofer%26aufirst%3DL.%2BJ.%26aulast%3DPlevy%26aufirst%3DS.%2BE.%26aulast%3DRobbins%26aufirst%3DP.%2BD.%26atitle%3DPharmacologic%2520IKK%252FNF-kappaB%2520inhibition%2520causes%2520antigen%2520presenting%2520cells%2520to%2520undergo%2520TNFalpha%2520dependent%2520ROS-mediated%2520programmed%2520cell%2520death%26jtitle%3DSci.%2520Rep.%26date%3D2014%26volume%3D4%26spage%3D3631%26doi%3D10.1038%2Fsrep03631" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group">Verstrepen, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beyaert, R.</span><span> </span><span class="NLM_article-title">Receptor proximal kinases in NF-kappaB signaling as potential therapeutic targets in cancer and inflammation</span> <span class="citation_source-journal">Biochem. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">92</span><span class="NLM_x">, </span> <span class="NLM_fpage">519</span><span class="NLM_x">–</span> <span class="NLM_lpage">29</span><span class="refDoi"> DOI: 10.1016/j.bcp.2014.10.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01774&amp;key=10.1016%2Fj.bcp.2014.10.017" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=92&publication_year=2014&pages=519-29&author=L.+Verstrepenauthor=R.+Beyaert&title=Receptor+proximal+kinases+in+NF-kappaB+signaling+as+potential+therapeutic+targets+in+cancer+and+inflammation&doi=10.1016%2Fj.bcp.2014.10.017"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1016%2Fj.bcp.2014.10.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bcp.2014.10.017%26sid%3Dliteratum%253Aachs%26aulast%3DVerstrepen%26aufirst%3DL.%26aulast%3DBeyaert%26aufirst%3DR.%26atitle%3DReceptor%2520proximal%2520kinases%2520in%2520NF-kappaB%2520signaling%2520as%2520potential%2520therapeutic%2520targets%2520in%2520cancer%2520and%2520inflammation%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2014%26volume%3D92%26spage%3D519%26epage%3D29%26doi%3D10.1016%2Fj.bcp.2014.10.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group">Enzler, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sano, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choo, M. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cottam, H. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karin, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsao, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, J. M.</span><span> </span><span class="NLM_article-title">Cell-selective inhibition of NF-kappaB signaling improves therapeutic index in a melanoma chemotherapy model</span> <span class="citation_source-journal">Cancer Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">496</span><span class="NLM_x">–</span> <span class="NLM_lpage">507</span><span class="refDoi"> DOI: 10.1158/2159-8290.CD-11-0143</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01774&amp;key=10.1158%2F2159-8290.CD-11-0143" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2011&pages=496-507&author=T.+Enzlerauthor=Y.+Sanoauthor=M.+K.+Chooauthor=H.+B.+Cottamauthor=M.+Karinauthor=H.+Tsaoauthor=J.+M.+Park&title=Cell-selective+inhibition+of+NF-kappaB+signaling+improves+therapeutic+index+in+a+melanoma+chemotherapy+model&doi=10.1158%2F2159-8290.CD-11-0143"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-11-0143&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-11-0143%26sid%3Dliteratum%253Aachs%26aulast%3DEnzler%26aufirst%3DT.%26aulast%3DSano%26aufirst%3DY.%26aulast%3DChoo%26aufirst%3DM.%2BK.%26aulast%3DCottam%26aufirst%3DH.%2BB.%26aulast%3DKarin%26aufirst%3DM.%26aulast%3DTsao%26aufirst%3DH.%26aulast%3DPark%26aufirst%3DJ.%2BM.%26atitle%3DCell-selective%2520inhibition%2520of%2520NF-kappaB%2520signaling%2520improves%2520therapeutic%2520index%2520in%2520a%2520melanoma%2520chemotherapy%2520model%26jtitle%3DCancer%2520Discovery%26date%3D2011%26volume%3D1%26spage%3D496%26epage%3D507%26doi%3D10.1158%2F2159-8290.CD-11-0143" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group">Aggarwal, B. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sung, B.</span><span> </span><span class="NLM_article-title">NF-kappaB in cancer: a matter of life and death</span> <span class="citation_source-journal">Cancer Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">469</span><span class="NLM_x">–</span> <span class="NLM_lpage">471</span><span class="refDoi"> DOI: 10.1158/2159-8290.CD-11-0260</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01774&amp;key=10.1158%2F2159-8290.CD-11-0260" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2011&pages=469-471&author=B.+B.+Aggarwalauthor=B.+Sung&title=NF-kappaB+in+cancer%3A+a+matter+of+life+and+death&doi=10.1158%2F2159-8290.CD-11-0260"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-11-0260&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-11-0260%26sid%3Dliteratum%253Aachs%26aulast%3DAggarwal%26aufirst%3DB.%2BB.%26aulast%3DSung%26aufirst%3DB.%26atitle%3DNF-kappaB%2520in%2520cancer%253A%2520a%2520matter%2520of%2520life%2520and%2520death%26jtitle%3DCancer%2520Discovery%26date%3D2011%26volume%3D1%26spage%3D469%26epage%3D471%26doi%3D10.1158%2F2159-8290.CD-11-0260" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group">Picaud, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fedorov, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thanasopoulou, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leonards, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meier, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olzscha, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Monteiro, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Philpott, M.-.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tumber, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Filippakopoulos, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yapp, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wells, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Che, K. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bannister, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robson, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kumar, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parr, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lugo, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jeffrey, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vecellio, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bountra, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brennan, P.-.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Mahony, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Velichko, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Müller, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hay, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Daniels, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Urh, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">La Thangue, N. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kouzarides, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prinjha, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwaller, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knapp, S.</span><span> </span><span class="NLM_article-title">Generation of a selective small molecule inhibitor of the CBP/p300 bromodomain for leukemia therapy</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">75</span><span class="NLM_x">, </span> <span class="NLM_fpage">5106</span><span class="NLM_x">–</span> <span class="NLM_lpage">5119</span><span class="refDoi"> DOI: 10.1158/0008-5472.CAN-15-0236</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01774&amp;key=10.1158%2F0008-5472.CAN-15-0236" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01774&amp;key=26552700" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01774&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvFensrzN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2015&pages=5106-5119&author=S.+Picaudauthor=O.+Fedorovauthor=A.+Thanasopoulouauthor=K.+Leonardsauthor=K.+Jonesauthor=J.+Meierauthor=H.+Olzschaauthor=O.+Monteiroauthor=S.+Martinauthor=M.-.+Philpottauthor=A.+Tumberauthor=P.+Filippakopoulosauthor=C.+Yappauthor=C.+Wellsauthor=K.+H.+Cheauthor=A.+Bannisterauthor=S.+Robsonauthor=U.+Kumarauthor=N.+Parrauthor=K.+Leeauthor=D.+Lugoauthor=P.+Jeffreyauthor=S.+Taylorauthor=L.+M.+Vecellioauthor=C.+Bountraauthor=P.-.+Brennanauthor=A.+O%E2%80%99Mahonyauthor=S.+Velichkoauthor=S.+M%C3%BCllerauthor=D.+Hayauthor=D.+L.+Danielsauthor=M.+Urhauthor=N.+B.+La+Thangueauthor=T.+Kouzaridesauthor=R.+Prinjhaauthor=J.+Schwallerauthor=S.+Knapp&title=Generation+of+a+selective+small+molecule+inhibitor+of+the+CBP%2Fp300+bromodomain+for+leukemia+therapy&doi=10.1158%2F0008-5472.CAN-15-0236"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Generation of a Selective Small Molecule Inhibitor of the CBP/p300 Bromodomain for Leukemia Therapy</span></div><div class="casAuthors">Picaud, Sarah; Fedorov, Oleg; Thanasopoulou, Angeliki; Leonards, Katharina; Jones, Katherine; Meier, Julia; Olzscha, Heidi; Monteiro, Octovia; Martin, Sarah; Philpott, Martin; Tumber, Anthony; Filippakopoulos, Panagis; Yapp, Clarence; Wells, Christopher; Che, Ka Hing; Bannister, Andrew; Robson, Samuel; Kumar, Umesh; Parr, Nigel; Lee, Kevin; Lugo, Dave; Jeffrey, Philip; Taylor, Simon; Vecellio, Matteo L.; Bountra, Chas; Brennan, Paul E.; O'Mahony, Alison; Velichko, Sharlene; Mueller, Susanne; Hay, Duncan; Daniels, Danette L.; Urh, Marjeta; La Thangue, Nicholas B.; Kouzarides, Tony; Prinjha, Rab; Schwaller, Juerg; Knapp, Stefan</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">75</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">5106-5119</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The histone acetyltransferases CBP/p300 are involved in recurrent leukemia-assocd. chromosomal translocations and are key regulators of cell growth.  Therefore, efforts to generate inhibitors of CBP/p300 are of clin. value.  We developed a specific and potent acetyl-lysine competitive protein-protein interaction inhibitor, I-CBP112, that targets the CBP/p300 bromodomains.  Exposure of human and mouse leukemic cell lines to I-CBP112 resulted in substantially impaired colony formation and induced cellular differentiation without significant cytotoxicity.  I-CBP112 significantly reduced the leukemia-initiating potential of MLL-AF9+ acute myeloid leukemia cells in a dose-dependent manner in vitro and in vivo.  Interestingly, I-CBP112 increased the cytotoxic activity of BET bromodomain inhibitor JQ1 as well as doxorubicin.  Collectively, we report the development and preclin. evaluation of a novel, potent inhibitor targeting CBP/p300 bromodomains that impairs aberrant self-renewal of leukemic cells.  The synergistic effects of I-CBP112 and current std. therapy (doxorubicin) as well as emerging treatment strategies (BET inhibition) provide new opportunities for combinatorial treatment of leukemia and potentially other cancers.  Cancer Res; 75(23); 5106-19. ©2015 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWk5dMbmC6K7Vg90H21EOLACvtfcHk0lgzW5i7T-WLcQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvFensrzN&md5=da936fa34139ba27abc748db5f78c95e</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-15-0236&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-15-0236%26sid%3Dliteratum%253Aachs%26aulast%3DPicaud%26aufirst%3DS.%26aulast%3DFedorov%26aufirst%3DO.%26aulast%3DThanasopoulou%26aufirst%3DA.%26aulast%3DLeonards%26aufirst%3DK.%26aulast%3DJones%26aufirst%3DK.%26aulast%3DMeier%26aufirst%3DJ.%26aulast%3DOlzscha%26aufirst%3DH.%26aulast%3DMonteiro%26aufirst%3DO.%26aulast%3DMartin%26aufirst%3DS.%26aulast%3DPhilpott%26aufirst%3DM.-.%26aulast%3DTumber%26aufirst%3DA.%26aulast%3DFilippakopoulos%26aufirst%3DP.%26aulast%3DYapp%26aufirst%3DC.%26aulast%3DWells%26aufirst%3DC.%26aulast%3DChe%26aufirst%3DK.%2BH.%26aulast%3DBannister%26aufirst%3DA.%26aulast%3DRobson%26aufirst%3DS.%26aulast%3DKumar%26aufirst%3DU.%26aulast%3DParr%26aufirst%3DN.%26aulast%3DLee%26aufirst%3DK.%26aulast%3DLugo%26aufirst%3DD.%26aulast%3DJeffrey%26aufirst%3DP.%26aulast%3DTaylor%26aufirst%3DS.%26aulast%3DVecellio%26aufirst%3DL.%2BM.%26aulast%3DBountra%26aufirst%3DC.%26aulast%3DBrennan%26aufirst%3DP.-.%26aulast%3DO%25E2%2580%2599Mahony%26aufirst%3DA.%26aulast%3DVelichko%26aufirst%3DS.%26aulast%3DM%25C3%25BCller%26aufirst%3DS.%26aulast%3DHay%26aufirst%3DD.%26aulast%3DDaniels%26aufirst%3DD.%2BL.%26aulast%3DUrh%26aufirst%3DM.%26aulast%3DLa%2BThangue%26aufirst%3DN.%2BB.%26aulast%3DKouzarides%26aufirst%3DT.%26aulast%3DPrinjha%26aufirst%3DR.%26aulast%3DSchwaller%26aufirst%3DJ.%26aulast%3DKnapp%26aufirst%3DS.%26atitle%3DGeneration%2520of%2520a%2520selective%2520small%2520molecule%2520inhibitor%2520of%2520the%2520CBP%252Fp300%2520bromodomain%2520for%2520leukemia%2520therapy%26jtitle%3DCancer%2520Res.%26date%3D2015%26volume%3D75%26spage%3D5106%26epage%3D5119%26doi%3D10.1158%2F0008-5472.CAN-15-0236" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group">Dancy, B. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cole, P. A.</span><span> </span><span class="NLM_article-title">Protein lysine acetylation by p300/CBP</span> <span class="citation_source-journal">Chem. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">115</span><span class="NLM_x">, </span> <span class="NLM_fpage">2419</span><span class="NLM_x">–</span> <span class="NLM_lpage">2452</span><span class="refDoi"> DOI: 10.1021/cr500452k</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cr500452k" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01774&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtVCiu7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=115&publication_year=2015&pages=2419-2452&author=B.+M.+Dancyauthor=P.+A.+Cole&title=Protein+lysine+acetylation+by+p300%2FCBP&doi=10.1021%2Fcr500452k"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Protein Lysine Acetylation by p300/CBP</span></div><div class="casAuthors">Dancy, Beverley M.; Cole, Philip A.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Reviews (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">115</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2419-2452</span>CODEN:
                <span class="NLM_cas:coden">CHREAY</span>;
        ISSN:<span class="NLM_cas:issn">0009-2665</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The human protein lysine acetyltransferase encoded by the paralogous p300 and CBP genes is involved in regulating the expression of genes.  In this capacity, p300/CBP controls several basic cellular processes such as proliferation and homeostasis, and plays a role in a variety of human diseases, particularly solid tumors.  This review summarizes information related to the current understanding of p300/CBP, including the novel technologies that have co-evolved with p300/CBP research.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpYgTImMiuo7rVg90H21EOLACvtfcHk0lgzW5i7T-WLcQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtVCiu7Y%253D&md5=40a46cf68990f4a7d11a338c54081628</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1021%2Fcr500452k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcr500452k%26sid%3Dliteratum%253Aachs%26aulast%3DDancy%26aufirst%3DB.%2BM.%26aulast%3DCole%26aufirst%3DP.%2BA.%26atitle%3DProtein%2520lysine%2520acetylation%2520by%2520p300%252FCBP%26jtitle%3DChem.%2520Rev.%26date%3D2015%26volume%3D115%26spage%3D2419%26epage%3D2452%26doi%3D10.1021%2Fcr500452k" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group">Naruse, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohmori, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fukumoto, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuroki, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mori, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saijo, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nishio, K.</span><span> </span><span class="NLM_article-title">Antitumor activity of the selective epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) Iressa® (ZD1839) in an EGFR-expressing multidrug-resistant cell line in vitro and in vivo</span> <span class="citation_source-journal">Int. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">98</span><span class="NLM_x">, </span> <span class="NLM_fpage">310</span><span class="NLM_x">–</span> <span class="NLM_lpage">315</span><span class="refDoi"> DOI: 10.1002/ijc.10173</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01774&amp;key=10.1002%2Fijc.10173" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01774&amp;key=11857424" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01774&amp;key=1%3ACAS%3A528%3ADC%252BD38XhsVSku7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=98&publication_year=2002&pages=310-315&author=I.+Naruseauthor=T.+Ohmoriauthor=Y.+Aoauthor=H.+Fukumotoauthor=T.+Kurokiauthor=M.+Moriauthor=N.+Saijoauthor=K.+Nishio&title=Antitumor+activity+of+the+selective+epidermal+growth+factor+receptor-tyrosine+kinase+inhibitor+%28EGFR-TKI%29+Iressa%C2%AE+%28ZD1839%29+in+an+EGFR-expressing+multidrug-resistant+cell+line+in+vitro+and+in+vivo&doi=10.1002%2Fijc.10173"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Antitumor activity of the selective epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) Iressa (ZD1839) in an EGFR-expressing multidrug-resistant cell line in vitro and in vivo</span></div><div class="casAuthors">Naruse, Ichiro; Ohmori, Tohru; Ao, Yoko; Fukumoto, Hisao; Kuroki, Toshio; Mori, Masatomo; Saijo, Nagahiro; Nishio, Kazuto</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Cancer</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">98</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">310-315</span>CODEN:
                <span class="NLM_cas:coden">IJCNAW</span>;
        ISSN:<span class="NLM_cas:issn">0020-7136</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">Selective tyrosine kinase inhibitors are regarded as promising antitumor agents for cancer treatment.  Iressa (ZD1839) is an orally active, selective EGFR-TKI (epidermal growth factor receptor-tyrosine kinase inhibitor) that blocks signal transduction pathways implicated in cancer cell proliferation, survival and other host-dependent processes promoting cancer growth.  The cellular mechanisms of ZD1839 action against human malignant cells and drug-resistant cells were evaluated in vitro.  Among the cell lines tested, ZD1839 showed a strong growth-inhibitory effect in vitro on human leukemic cells resistant to phorbol ester.  This cell line, K562/TPA, shows a non-P-glycoprotein-mediated multidrug-resistant phenotype.  The IC50 value of ZD1839 on K562/TPA was approx. 400-fold lower than that on the parental K562 cell (K562 = 12 ± 2 μM; K562/TPA = 0.025 ± 0.002 μM) in vitro as detd. by a dye formation assay.  The expression of EGFR and EGFR mRNA was clearly present in K562/TPA but not in parental K562 cells as detd. by Western blotting and RT-PCR.  EGFR was autophosphorylated in K562/TPA detected by the antiphosphotyrosine antibody.  The in vivo antitumor effects of ZD1839 on K562 and K562/TPA cells were also investigated in BALB/c nude mice.  K562/TPA cells transplanted s.c. into mice disappeared completely with ZD1839 treatment (20 mg/kg/day, days 3-9).  This was not the case in K562 cells.  These results suggest that ZD1839 is highly active against tumor cells with non-P-glycoprotein-mediated multidrug resistance that express EGFR.  Iressa is a trademark of AstraZeneca (Cheshire, UK).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqWYzrtWh_34rVg90H21EOLACvtfcHk0lgzW5i7T-WLcQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XhsVSku7w%253D&md5=665a402587212a4b02b794a69a1755c7</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1002%2Fijc.10173&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fijc.10173%26sid%3Dliteratum%253Aachs%26aulast%3DNaruse%26aufirst%3DI.%26aulast%3DOhmori%26aufirst%3DT.%26aulast%3DAo%26aufirst%3DY.%26aulast%3DFukumoto%26aufirst%3DH.%26aulast%3DKuroki%26aufirst%3DT.%26aulast%3DMori%26aufirst%3DM.%26aulast%3DSaijo%26aufirst%3DN.%26aulast%3DNishio%26aufirst%3DK.%26atitle%3DAntitumor%2520activity%2520of%2520the%2520selective%2520epidermal%2520growth%2520factor%2520receptor-tyrosine%2520kinase%2520inhibitor%2520%2528EGFR-TKI%2529%2520Iressa%25C2%25AE%2520%2528ZD1839%2529%2520in%2520an%2520EGFR-expressing%2520multidrug-resistant%2520cell%2520line%2520in%2520vitro%2520and%2520in%2520vivo%26jtitle%3DInt.%2520J.%2520Cancer%26date%3D2002%26volume%3D98%26spage%3D310%26epage%3D315%26doi%3D10.1002%2Fijc.10173" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group">Barker, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gibson, K. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grundy, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Godfrey, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barlow, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Healy, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woodburn, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ashton, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curry, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scarlett, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Henthorn, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richards, L.</span><span> </span><span class="NLM_article-title">Studies leading to the identification of ZD1839 (IressaTM): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">1911</span><span class="NLM_x">–</span> <span class="NLM_lpage">1914</span><span class="refDoi"> DOI: 10.1016/S0960-894X(01)00344-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01774&amp;key=10.1016%2FS0960-894X%2801%2900344-4" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2001&pages=1911-1914&author=A.+J.+Barkerauthor=K.+H.+Gibsonauthor=W.+Grundyauthor=A.+A.+Godfreyauthor=J.+J.+Barlowauthor=M.+P.+Healyauthor=J.+R.+Woodburnauthor=S.+E.+Ashtonauthor=B.+J.+Curryauthor=L.+Scarlettauthor=L.+Henthornauthor=L.+Richards&title=Studies+leading+to+the+identification+of+ZD1839+%28IressaTM%29%3A+an+orally+active%2C+selective+epidermal+growth+factor+receptor+tyrosine+kinase+inhibitor+targeted+to+the+treatment+of+cancer&doi=10.1016%2FS0960-894X%2801%2900344-4"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1016%2FS0960-894X%2801%2900344-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0960-894X%252801%252900344-4%26sid%3Dliteratum%253Aachs%26aulast%3DBarker%26aufirst%3DA.%2BJ.%26aulast%3DGibson%26aufirst%3DK.%2BH.%26aulast%3DGrundy%26aufirst%3DW.%26aulast%3DGodfrey%26aufirst%3DA.%2BA.%26aulast%3DBarlow%26aufirst%3DJ.%2BJ.%26aulast%3DHealy%26aufirst%3DM.%2BP.%26aulast%3DWoodburn%26aufirst%3DJ.%2BR.%26aulast%3DAshton%26aufirst%3DS.%2BE.%26aulast%3DCurry%26aufirst%3DB.%2BJ.%26aulast%3DScarlett%26aufirst%3DL.%26aulast%3DHenthorn%26aufirst%3DL.%26aulast%3DRichards%26aufirst%3DL.%26atitle%3DStudies%2520leading%2520to%2520the%2520identification%2520of%2520ZD1839%2520%2528IressaTM%2529%253A%2520an%2520orally%2520active%252C%2520selective%2520epidermal%2520growth%2520factor%2520receptor%2520tyrosine%2520kinase%2520inhibitor%2520targeted%2520to%2520the%2520treatment%2520of%2520cancer%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2001%26volume%3D11%26spage%3D1911%26epage%3D1914%26doi%3D10.1016%2FS0960-894X%2801%2900344-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group">Choi, S. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gout, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Collins, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span> </span><span class="NLM_article-title">Lessons from patient-derived xenografts for better in vitro modeling of human cancer</span> <span class="citation_source-journal">Adv. Drug Delivery Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">79–80</span><span class="NLM_x">, </span> <span class="NLM_fpage">222</span><span class="NLM_x">–</span> <span class="NLM_lpage">237</span><span class="refDoi"> DOI: 10.1016/j.addr.2014.09.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01774&amp;key=10.1016%2Fj.addr.2014.09.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01774&amp;key=25305336" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01774&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhslGnsb7F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79%E2%80%9380&publication_year=2014&pages=222-237&author=S.+Y.+Choiauthor=D.+Linauthor=P.+W.+Goutauthor=C.+C.+Collinsauthor=Y.+Xuauthor=Y.+Wang&title=Lessons+from+patient-derived+xenografts+for+better+in+vitro+modeling+of+human+cancer&doi=10.1016%2Fj.addr.2014.09.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Lessons from patient-derived xenografts for better in vitro modeling of human cancer</span></div><div class="casAuthors">Choi, Stephen Yiu Chuen; Lin, Dong; Gout, Peter W.; Collins, Colin C.; Xu, Yong; Wang, Yuzhuo</div><div class="citationInfo"><span class="NLM_cas:title">Advanced Drug Delivery Reviews</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">79-80</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">222-237</span>CODEN:
                <span class="NLM_cas:coden">ADDREP</span>;
        ISSN:<span class="NLM_cas:issn">0169-409X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The development of novel cancer therapeutics is often plagued by discrepancies between drug efficacies obtained in preclin. studies and outcomes of clin. trials.  The inconsistencies can be attributed to a lack of clin. relevance of the cancer models used for drug testing.  While commonly used in vitro culture systems are advantageous for addressing specific exptl. questions, they are often gross, fidelity-lacking simplifications that largely ignore the heterogeneity of cancers as well as the complexity of the tumor microenvironment.  Factors such as tumor architecture, interactions among cancer cells and between cancer and stromal cells, and an acidic tumor microenvironment are crit. characteristics obsd. in patient-derived cancer xenograft models and in the clinic.  By mimicking these crucial in vivo characteristics through use of 3D cultures, co-culture systems and acidic culture conditions, an in vitro cancer model/microenvironment that is more physiol. relevant may be engineered to produce results more readily applicable to the clinic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXoTBcCs2UHbVg90H21EOLACvtfcHk0ljoo12A41m5ow"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhslGnsb7F&md5=9b1d3ad6233457db04bab2dd6c88e891</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1016%2Fj.addr.2014.09.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.addr.2014.09.009%26sid%3Dliteratum%253Aachs%26aulast%3DChoi%26aufirst%3DS.%2BY.%26aulast%3DLin%26aufirst%3DD.%26aulast%3DGout%26aufirst%3DP.%2BW.%26aulast%3DCollins%26aufirst%3DC.%2BC.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DY.%26atitle%3DLessons%2520from%2520patient-derived%2520xenografts%2520for%2520better%2520in%2520vitro%2520modeling%2520of%2520human%2520cancer%26jtitle%3DAdv.%2520Drug%2520Delivery%2520Rev.%26date%3D2014%26volume%3D79%25E2%2580%259380%26spage%3D222%26epage%3D237%26doi%3D10.1016%2Fj.addr.2014.09.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group">Fry, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kraker, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McMichael, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ambroso, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nelson, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leopold, W. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Connors, R. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bridges, A. J.</span><span> </span><span class="NLM_article-title">A specific inhibitor of the epidermal growth factor receptor tyrosine kinase</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_volume">265</span><span class="NLM_x">, </span> <span class="NLM_fpage">1093</span><span class="NLM_x">–</span> <span class="NLM_lpage">1095</span><span class="refDoi"> DOI: 10.1126/science.8066447</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01774&amp;key=10.1126%2Fscience.8066447" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01774&amp;key=8066447" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01774&amp;key=1%3ACAS%3A528%3ADyaK1cXjvFyisA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=265&publication_year=1994&pages=1093-1095&author=D.+W.+Fryauthor=A.+J.+Krakerauthor=A.+McMichaelauthor=L.+A.+Ambrosoauthor=J.+M.+Nelsonauthor=W.+R.+Leopoldauthor=R.+W.+Connorsauthor=A.+J.+Bridges&title=A+specific+inhibitor+of+the+epidermal+growth+factor+receptor+tyrosine+kinase&doi=10.1126%2Fscience.8066447"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">A specific inhibitor of the epidermal growth factor receptor tyrosine kinase</span></div><div class="casAuthors">Fry, David W.; Kraker, Alan J.; McMichael, Amy; Ambroso, Linda A.; Nelson, James M.; Leopold, Wilbur R.; Connors, Richard W.; Bridges, Alexander J.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, D. C.)</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">265</span>
        (<span class="NLM_cas:issue">5175</span>),
    <span class="NLM_cas:pages">1093-1095</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">A small mol. called PD 153035 inhibited the epidermal growth factor (EGF) receptor tyrosine kinase with a 5-pM inhibition const.  The inhibitor was specific for the EGF receptor tyrosine kinase and inhibited other purified tyrosine kinases only at micromolar or higher concns.  PD 153035 rapidly suppressed autophosphorylation of the EGF receptor at low nanomolar concns. in fibroblasts or in human epidermoid carcinoma cells and selectively blocked EGF-mediated cellular processes including mitogenesis, early gene expression, and oncogenic transformation.  PD 153035 demonstrates an increase in potency over that of other tyrosine kinase inhibitors of four to five orders of magnitude for inhibition of isolated EGF receptor tyrosine kinase and three to four orders of magnitude for inhibition of cellular phosphorylation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpsdxz-fMjijrVg90H21EOLACvtfcHk0ljoo12A41m5ow"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXjvFyisA%253D%253D&md5=5c0599c2e75f0f086313ce2cef8eacef</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1126%2Fscience.8066447&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.8066447%26sid%3Dliteratum%253Aachs%26aulast%3DFry%26aufirst%3DD.%2BW.%26aulast%3DKraker%26aufirst%3DA.%2BJ.%26aulast%3DMcMichael%26aufirst%3DA.%26aulast%3DAmbroso%26aufirst%3DL.%2BA.%26aulast%3DNelson%26aufirst%3DJ.%2BM.%26aulast%3DLeopold%26aufirst%3DW.%2BR.%26aulast%3DConnors%26aufirst%3DR.%2BW.%26aulast%3DBridges%26aufirst%3DA.%2BJ.%26atitle%3DA%2520specific%2520inhibitor%2520of%2520the%2520epidermal%2520growth%2520factor%2520receptor%2520tyrosine%2520kinase%26jtitle%3DScience%26date%3D1994%26volume%3D265%26spage%3D1093%26epage%3D1095%26doi%3D10.1126%2Fscience.8066447" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group">Frohner, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lopez-Garcia, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neimanis, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weber, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Navratil, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maurer, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stroba, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Biondi, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engel, M.</span><span> </span><span class="NLM_article-title">4-Benzimidazolyl-3-phenylbutanoic acids as novel PIF-pocket-targeting allosteric inhibitors of protein kinase PKCzeta</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">6714</span><span class="NLM_x">–</span> <span class="NLM_lpage">6723</span><span class="refDoi"> DOI: 10.1021/jm2005892</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm2005892" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=6714-6723&author=W.+Frohnerauthor=L.+A.+Lopez-Garciaauthor=S.+Neimanisauthor=N.+Weberauthor=J.+Navratilauthor=F.+Maurerauthor=A.+Strobaauthor=H.+Zhangauthor=R.+M.+Biondiauthor=M.+Engel&title=4-Benzimidazolyl-3-phenylbutanoic+acids+as+novel+PIF-pocket-targeting+allosteric+inhibitors+of+protein+kinase+PKCzeta&doi=10.1021%2Fjm2005892"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1021%2Fjm2005892&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm2005892%26sid%3Dliteratum%253Aachs%26aulast%3DFrohner%26aufirst%3DW.%26aulast%3DLopez-Garcia%26aufirst%3DL.%2BA.%26aulast%3DNeimanis%26aufirst%3DS.%26aulast%3DWeber%26aufirst%3DN.%26aulast%3DNavratil%26aufirst%3DJ.%26aulast%3DMaurer%26aufirst%3DF.%26aulast%3DStroba%26aufirst%3DA.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DBiondi%26aufirst%3DR.%2BM.%26aulast%3DEngel%26aufirst%3DM.%26atitle%3D4-Benzimidazolyl-3-phenylbutanoic%2520acids%2520as%2520novel%2520PIF-pocket-targeting%2520allosteric%2520inhibitors%2520of%2520protein%2520kinase%2520PKCzeta%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D6714%26epage%3D6723%26doi%3D10.1021%2Fjm2005892" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit58"><span><span class="NLM_contrib-group">Schmitt, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kail, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mariano, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Empting, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weber, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paul, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hartmann, R. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engel, M.</span><span> </span><span class="NLM_article-title">Design and synthesis of a library of lead-like 2,4-bisheterocyclic substituted thiophenes as selective Dyrk/Clk inhibitors</span> <span class="citation_source-journal">PLoS One</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">e87851</span><span class="refDoi"> DOI: 10.1371/journal.pone.0087851</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01774&amp;key=10.1371%2Fjournal.pone.0087851" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&pages=e87851&author=C.+Schmittauthor=D.+Kailauthor=M.+Marianoauthor=M.+Emptingauthor=N.+Weberauthor=T.+Paulauthor=R.+W.+Hartmannauthor=M.+Engel&title=Design+and+synthesis+of+a+library+of+lead-like+2%2C4-bisheterocyclic+substituted+thiophenes+as+selective+Dyrk%2FClk+inhibitors&doi=10.1371%2Fjournal.pone.0087851"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0087851&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0087851%26sid%3Dliteratum%253Aachs%26aulast%3DSchmitt%26aufirst%3DC.%26aulast%3DKail%26aufirst%3DD.%26aulast%3DMariano%26aufirst%3DM.%26aulast%3DEmpting%26aufirst%3DM.%26aulast%3DWeber%26aufirst%3DN.%26aulast%3DPaul%26aufirst%3DT.%26aulast%3DHartmann%26aufirst%3DR.%2BW.%26aulast%3DEngel%26aufirst%3DM.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520a%2520library%2520of%2520lead-like%25202%252C4-bisheterocyclic%2520substituted%2520thiophenes%2520as%2520selective%2520Dyrk%252FClk%2520inhibitors%26jtitle%3DPLoS%2520One%26date%3D2014%26volume%3D9%26spage%3De87851%26doi%3D10.1371%2Fjournal.pone.0087851" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2ITY" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2ITY','PDB','2ITY'); return false;">PDB: 2ITY</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i45"><a href="/doi/suppl/10.1021/acs.jmedchem.6b01774">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_88557"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a class="ext-link" href="/">ACS Publications website</a> at DOI: <a class="ext-link" href="/doi/abs/10.1021/acs.jmedchem.6b01774">10.1021/acs.jmedchem.6b01774</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Complete set of screened compounds; kinase inhibition selectivity profile for compound <b>6c</b>, IC<sub>50</sub> for compound <b>6c</b> against EGFR, Mnk2, and Pim-1, percent inhibition in the NF-κB reporter gene assay by SIM-4a (Pim-1 inhibitor) and gefitinib at different concentrations, determination of water solubility, kinase inhibition selectivity profile for compound <b>9b</b>; NF-κB translocation assay, compound <b>6c</b> does not impair DNA binding of NF-κB/p65, LCMS data of compounds <b>6c</b>, <b>6h</b>, <b>9b</b>, and <b>9d</b>; experimental details. (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.6b01774/suppl_file/jm6b01774_si_001.pdf">PDF</a>)</p></li><li><p class="inline">Molecular formula strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.6b01774/suppl_file/jm6b01774_si_002.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.6b01774/suppl_file/jm6b01774_si_001.pdf">jm6b01774_si_001.pdf (1.23 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.6b01774/suppl_file/jm6b01774_si_002.csv">jm6b01774_si_002.csv (3.7 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.6b01774&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.6b01774%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2017.60.issue-7" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.6b01774" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                3MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"67994092fe7a3de3","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
